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Abstract 
Class IA phosphoinositide 3-kinases (PI3Ks) are a family of enzymes with key roles in the 
regulation of signalling pathways, many of which are mediated through Akt. The PI3K/Akt 
pathway has a critical role in the regulation of key cellular functions such as cell survival, 
growth, proliferation, migration and metabolism and is involved in several diseases. 
Advances in mass spectrometry and separation sciences have revolutionized the field of 
proteomics. Techniques based on mass spectrometry are now the first choice for protein 
identification and are increasingly important for their quantitative analysis. The 
development of phosphoproteomics has also permitted the global quantitative analysis of 
signalling activity.  
The aim of this project was to contribute to our understanding of the activity and 
regulation of the PI3K/Akt signalling pathway from a proteomics perspective. Novel 
approaches based on mass spectrometry were designed, developed and applied to the 
investigation of this signalling pathway.  
Firstly, we investigated the hypothesis that PI3K activity may be regulated by dynamic 
protein interactions. We designed an affinity purification mass spectrometry strategy to 
identify proteins interacting dynamically with PI3K. Our study revealed that calpain small 
subunit 1 interacts dynamically with PI3K. Further investigation demonstrated that active 
calpain heterodimers associate dynamically with PI3K, thereby regulating PI3K stability and 
activity.  
Secondly, we characterized phosphorylation events downstream of Akt, a major 
downstream effector of PI3K. We used global shotgun phosphoproteomics of a cell line 
expressing an inducible construct encoding constitutively active Akt to identify 
phosphorylation events downstream of Akt in vivo. In addition, we also developed an in 
vitro kinase assay which, when coupled to global shotgun phosphoproteomics, enables the 
quantification of Akt1 activity in addition to the identification of downstream 
phosphorylation sites. Furthermore, we found that this in vitro approach may be used as a 
method suitable for the global profiling of endogenous kinase activities. 
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1. Introduction 
1.1. Phosphoinositide 3-kinases (PI3Ks) 
The phosphoinositide 3-kinases (PI3Ks) are a family of enzymes with key roles in cell 
signalling, regulating essential cellular functions including survival, growth, migration and 
metabolism. Their major biological roles are carried out through their lipid kinase activity by 
which PI3Ks phosphorylate the 3-hydroxyl group on phosphatidylinositol lipids, which act as 
membrane docks for downstream effector signalling proteins.   
1.1.1. Classification of PI3Ks 
PI3Ks can be broadly classified into 3 groups based on their structure and lipid substrate 
specificity: class I, II & III (Fig. 1.1.) [1, 2].  
 
 
Figure 1.1. Summary of PI3K activity. Adapted from [2]. Upstream activating signals are relatively 
well-characterized for class I PI3K but are less well-understood for classes II and III. The three PI3K 
classes utilise distinct lipid substrates and, thus, generate different lipid products, all phosphorylated 
on position 3 of the inositol ring. Each lipid product recruits proteins with specific lipid-binding 
domains.  
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Yeast express solely the class III isoform but higher eukaryotes express at least one 
representation of each of the other classes [1, 2]. Class I PI3K is relatively well-characterized, 
however much remains to be discovered about classes II and III. 
1.1.1.1. Class I PI3K 
The ubiquitously expressed class I PI3Ks signal downstream of receptor tyrosine kinases 
(RTKs), G-protein coupled receptors (GPCRs) and Ras small GTPases (Ras) [2, 3]. They 
phosphorylate the lipid substrate phosphatidylinositol 4, 5-bisphosphate (PIP2) to generate 
phosphatidylinositol 3, 4, 5-triphosphate (PIP3) in vivo [4] and have been shown to have key 
roles in the regulation of cellular functions such as cell survival, growth, proliferation, 
migration and metabolism [2, 3].  
This project will be focusing on the signalling downstream of Class I PI3K therefore this 
group will subsequently be discussed in further detail.  
1.1.1.2. Class II PI3K 
Class II PI3Ks are widely but not ubiquitously expressed in mammalian tissues and can be 
further subdivided into 3 isoforms: PI3K-C2α, PI3K-C2β and PI3K-C2γ [2]. All isoforms are 
composed of a single catalytic subunit and their activity is thought to be modulated through 
the N- or C- terminal domains, which are extended compared to other PI3K classes [2].  
Although the mechanism remains unclear, class II PI3Ks have been shown to be 
activated downstream of RTKs and GPCRs, possibly due to compartment re-localization 
caused by recruitment to the membrane [5, 6]. Interaction partners that have been 
identified for class II PI3K, e.g. epidermal growth factor receptor (EGFR), clathrin and GRB2, 
may mediate this re-localization [2]. 
The in vivo lipid substrate of class II PI3K is thought to be phosphoinositide (PI) [7, 8], 
however it has been shown to additionally phosphorylate phosphatidylinositol 4-phosphate 
(PI4P) in vitro [9]. The phosphatidylinositol 3-phosphate (PI3P) product thought to be 
generated by class II PI3K is mainly found in endosomes [10] and recruits proteins 
containing PX or FYVE domains, e.g. protein kinase SGK3 [11]. Such proteins are highly 
conserved and have been found to have roles in endocytic membrane trafficking, 
phagosome maturation, signalling and microbial killing [11]. 
Chapter 1: Introduction 
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Class II PI3Ks were discovered through their homology to classes I and III PI3K and much 
remains to be discovered about their functional physiological roles and downstream 
effectors. They have, however, been implicated through cell and knockout animal studies in 
the regulation of apoptosis, migration, metabolism, exocytosis and smooth muscle 
contraction [2, 6].  
1.1.1.3. Class III PI3K 
Class III PI3K is comprised of a single isoform, Vps34, and is highly conserved from yeast 
through to mammals [2]. Vps34 is generally found in the endosomal compartment and it 
binds constitutively to Vps15 with which it forms 3 distinct multi-protein complexes in yeast 
[12] and a further 3 in mammals [13]. The composition of multi-protein Vps34 complexes 
determines biological output [2].  
Vps15 is myristyolated, i.e. contains a hydrophobic myristyol group on the N-terminus, 
therefore it permanently tethers the Vps15-Vps34 complex to the intracellular membrane 
[2, 13]. There is some evidence that Vps34 is additionally regulated downstream of amino 
acid stimulation [14] and activated GPCRs [12], however the mechanisms for these activities 
remain unclear.  
Class III PI3K phosphorylates PI to generate PI3P [15]. Thus it recruits effector proteins 
containing PX or FYVE domains although it is unclear if these downstream substrates 
overlap with those of class II PI3K [2]. Vps34 also interacts with other proteins that do not 
carry these characteristic domains, suggesting that class III PI3K may also have a scaffold 
function [2]. 
Vps34 regulates essential cellular functions and homozygous deletion of the gene is 
lethal in yeast and flies [2]. The biological functions of class III PI3K are mediated through 
regulation of vesicular trafficking and include regulation of autophagy, endocytosis and 
phagocytosis [2, 13]. 
1.1.2. Structure and characterization of class I PI3Ks 
Class I PI3Ks catalyze the formation of the second messenger phosphatidylinositol 3, 4, 
5-triphosphate (PIP3) from phosphatidylinositol 4, 5-bisphosphate (PIP2) in vivo [4]. This class 
Chapter 1: Introduction 
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of heterodimeric proteins can be further subdivided into class IA and class IB, depending on 
the type of regulatory subunit that associates with the p110 catalytic subunit (Fig 1.2.). 
 
 
Figure 1.2. Summary of the structure of Class I PI3K subunits. Each class I p110 catalytic subunit 
forms a heterodimer with a regulatory subunit, the type of which further subdivides class I into class 
IA and class IB. The structure of p110 isoforms is highly conserved. Figure adapted from [16]. 
The p110 catalytic subunits are comprised of a C2 domain, a helical domain and a 
catalytic domain, which form the core of all PI3K proteins [16]. The p110 subunits in 
addition have a regulatory subunit-binding domain and a Ras-binding domain, indicating 
that all PI3K subunits have the potential to be activated by Ras. The p85 regulatory subunits 
of class IA PI3K contain Src homology (SH2) domains, which bind phosphorylated tyrosine. In 
addition, they have proline-rich domains and may also have BCR homology (BH) and SH3 
domains, all of which may contribute to additional regulation of class IA PI3K activity 
although mechanisms remain unclear [17, 18]. Class IB regulatory subunits are poorly 
understood and have no known homology to other proteins or recognizable domain 
structures [2].  
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Class I PI3Ks form stable heterodimers in vivo [19]. The various class IA p85 regulatory 
subunits, which have no known preference for the different p110 isoforms, act to inhibit 
p110 catalytic activity and to stabilize the p110 protein when the complex is free in the 
cytosol [20]. The X-ray crystal structure for p85-bound p110α has been resolved and shows 
that there are multiple interaction sites between the two proteins [21]. The structure of the 
p110β-p85β complex also revealed multiple interaction sites between the subunits, 
revealing a dual mechanism for inhibition of p110β catalytic activity [22]. Studies of p110δ 
structure have recently revealed that overall p110δ most closely resembles p110α 
structurally, although it is more flexible upon the binding of inhibitors [23]. Investigations 
into the crystal structure of p110γ revealed that interaction of p110 with the membrane is 
likely to be mediated by the C2 domain [24] but the binding to regulatory subunits was 
unclear. 
Class IA PI3Ks have been shown by absolute quantification to be present only as 
heterodimers under basal conditions [19]. Furthermore, both the p110 catalytic subunit and 
p85 regulatory subunit have been shown to be unstable when free as monomers [20, 25]. 
However, some groups suggest that free p85 exists and has a role in the regulation of insulin 
signalling as it acts as a competitive inhibitor of PI3K [26].  The possibility that the 
expression of either the p85 or the p110 subunit could be transiently regulated cannot be 
excluded. 
Within the class I PI3Ks, p110α and p110β are ubiquitously expressed, whereas p110δ 
and p110γ are enriched in leukocytes [27] and isoform-specific roles have been determined 
for the various p110 catalytic subunits (discussed further below). Within the p85 subunits, 
p85α and β are ubiquitously expressed whereas the other isoforms appear to show more 
restricted distributions [27]. Detailed investigation of the relative tissue distribution levels of 
the different isoforms have been hampered so far by the lack of high specificity tools, such 
as isoform-specific antibodies suitable for immunohistochemistry [27].  
1.1.3. Activation of class I PI3K 
Class I PI3Ks are activated by a variety of mechanisms (Fig. 1.3.). All p110 isoforms have 
a Ras-binding domain and activation of class I PI3K by Ras has been demonstrated in a 
variety of in vitro studies and is thought to be an ancient mechanism for PI3K activation [2]. 
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However, a high degree of variability has been demonstrated in the response depending on 
the Ras GTPase and p110 isoform investigated [28] and the contribution of Ras in PI3K 
regulation remains unclear. In vivo studies have however demonstrated that the interaction 
between Ras and p110α is essential for normal response to growth factors and Ras-driven 
tumourogenesis [29, 30].  
Class IA PI3Ks are also activated in response to receptor tyrosine kinase (RTK) 
stimulation by extracellular stimuli, such as growth factors, hormones and inflammatory 
mediators. The SH2 domain of the p85 regulatory subunit is recruited by the dimerized, 
phosphorylated receptor producing a conformational change in the PI3K complex, which 
leads to the release of p85’s inhibitory effect on catalytic p110. The single class IB PI3K is 
activated in response to G protein-coupled receptor (GPCR) stimulation by chemokines, 
which results in the release of the Gβγ subunit from the receptor. This mechanism of PI3K 
activation is less well characterized but it is known that Gβγ mediates the recruitment of the 
PI3K heterodimer to the membrane via interaction with p101/p84 [31]. p110γ thereby 
becomes active, although it is not clear whether Gβγ interacts with p101/p84 alone or with 
both p101/p84 and p110γ to mediate this [31, 32]. Recent work has also demonstrated that 
p110β signals downstream of GPCRs, through mechanisms which remain unclear, and that 
this class IA isoform has only a minor role in signalling in response to tyrosine kinase 
stimulation [33, 34]. Furthermore, GPCRs have been shown to transactivate RTKs which may 
represent an indirect method for PI3K activation by GPCRs [35].  
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Figure 1.3. Summary of the upstream activation of class I PI3Ks. Class IA PI3Ks are recruited and 
activated by phosphorylated receptor tyrosine kinases (RTK). Class IA p110β and class IB p110γ have 
also been shown to be activated downstream of G-protein coupled receptors (GPCRs). All class I 
p110 isoforms have Ras-binding domains and are thought to be regulated by this protein. 
1.1.4. Regulation of class IA PI3K 
p85 has a key role in the regulation of PI3K through inhibition of the catalytic activity 
of p110. This conformational inhibition is mediated by the binding of p85 to the N-terminal 
of p110 and abrogated by the binding of p85 to phosphorylated residues on tyrosine kinase 
receptors [20]. In addition, p85 binding stabilizes the p110 protein and protects it from 
thermal stress when the complex is free in the cytosol [20]. Furthermore, it has been shown 
that p85 binding to p110 prevents its activation by Ras and that this inhibitory role is 
relieved by the binding of p85 to tyrosine kinases [36]. Thus, p85 has a dual inhibitory role 
on p110 activity.  
It has been reported that the efficiency of p110 inhibition varies between p85 isoforms 
therefore expression levels of the distinct p85 isoforms may regulate PI3K activity [37]. It 
has also been proposed that free, non-p110 associated p85 may negatively regulate PI3K 
activity by competing for docking sites on phosphorylated tyrosine kinases [38, 39]. 
However, absolute quantitation of all isoforms of p85 and p110 by mass spectrometry found 
them to be present in equimolar ratios and therefore argues against this theory [19]. 
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A further key mechanism for the regulation of PI3K is the activity of lipid phosphatases 
that de-phosphorylate the PIP3 lipid product of PI3K. Phosphatase and tensin homolog 
deleted on chromosome 10 (PTEN) de-phosphorylates 3-phosphorylated 
phophatidylinositols [4] and therefore acts as a PIP3 phosphatase [40]. PTEN is a 
ubiquitously expressed protein that has both protein and lipid phosphatase properties [41] 
and its high level of lipid phosphatase activity is thought to be regulated through membrane 
translocation [42]. Interestingly, it has been shown that p110δ negatively regulates PTEN 
activity via the inhibition of RhoA and therefore negatively controls itself via this feedback 
loop [43]. 
Another type of lipid phosphatase, SH2 domain containing inositol phosphatase (SHIP), 
de-phosphorylates 5-phosphoryated phosphatidylinositols and preferentially uses PIP3 as a 
substrate [4]. SHIPs are also thought to be regulated by subcellular localization [44]. The 
activities of these different phosphatases will result in the generation of distinct lipid 
products, which may have implications for further regulation of signalling activity. 
Another mechanism important for the regulation of PI3K is the activation of negative 
feedback loops. Negative feedback loops result from the activity of signalling proteins that 
are activated downstream of PI3K and that act to terminate the activation signal. The most 
well-characterized example of such a regulatory mechanism is the activation of mammalian 
target of rapamycin (mTOR) downstream of PI3K, the activity of which results in 
phosphorylation and subsequent degradation of insulin receptor substrate 1 (IRS1), 
resulting in impaired insulin signalling [45, 46]. mTOR activity has also been shown to down-
regulate RTK levels, such as the PDGF receptor [47]. 
PI3K signalling can also be regulated by cross-talk from other pathways. For example, 
over-expression of mutant Ras represses PTEN transcription through the activation of 
mitogen-activated protein (MAP) kinase [48]. Similarly, PTEN expression was down-
regulated by over-expression of MAP kinase 4 [49]. 
Another potential mechanism of kinase regulation, which has not been extensively 
investigated for PI3K, is regulation by interaction with binding partners. In addition to 
transient interactions with proteins that regulate PI3K activity through known mechanisms, 
such as RTKs, phosphatases and Ras, there are reports of other proteins binding PI3K and 
regulating activity through alternative mechanisms. For example, X-box binding protein-1 
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has been reported to bind p85, thus increasing its nuclear translocation and regulating the 
unfolded protein response [50, 51]. p85α has also been reported to bind directly with PTEN, 
enhancing its lipid phosphatase activity, thus regulating PI3K activity through negative 
feedback [52]. Gα16 was also found to bind class IA PI3K complexes inhibiting EGF-induced 
Akt phosphorylation [53]. However, despite these studies the roles of interaction partners in 
the regulation of class I PI3K signalling remains poorly understood and under-explored. 
1.1.5. Signalling downstream of class IA PI3K 
The PIP3 second messenger generated by class I PI3K activity recruits signalling proteins 
with plekstrin homology (PH) domains, which interact with phospholipids [54], to the cell 
membrane. Such proteins include protein kinases, such as Akt and PDK1; adaptor and 
scaffold  proteins, such as Gab1, Dos, myosinX, and Sbf1 [55], and small GTPase regulators 
(GEFs and GAPs) [56, 57]. Membrane recruitment and cellular re-localisation regulates the 
activity of these downstream signalling proteins. 
One of the most well characterized signalling molecules downstream of class I PI3K is the 
serine/threonine kinase Akt, also known as protein kinase B (PKB). Translocation of Akt to 
the cell membrane permits its phosphorylation and activation, thereby initiating a cascade 
of downstream effects. The downstream signalling of this effector protein will subsequently 
be discussed in more detail. 
In addition, it has been proposed that PI3K may provide a scaffolding role for other 
proteins. p110γ has been shown to bind phosphodiesterase and some isoforms of protein 
kinase C forming an important component of their respective protein complexes and 
regulating their activity [58, 59]. It has also been proposed that other PI3K isoforms may 
have scaffolding roles but no specific binding partners have been identified to date [2]. 
The wide range of downstream effectors of PI3K contributes to the key role of this 
signalling pathway in essential functions such as cell growth, proliferation, survival, 
metabolism and migration [2, 60, 61].  
1.1.6. Tools for the investigation of PI3K activity 
The investigation of PI3K signalling and isoform-specific roles is not straightforward, 
however in recent decades a number of tools have become available to enable research in 
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this field. The first PI3K inhibitor identified was the microbial product wortmannin, which 
acts as a non-competitive, irreversible inhibitor of all isoforms of the PI3K family [62, 63]. 
Although this compound was a useful early resource its lack of specificity and poor stability 
mean that its use is now limited. The compound LY294002, a synthetic chromone, was 
found to reversibly inhibit PI3K but not PI4K or other tested protein and lipid kinases [64], 
thus providing a clear advantage over wortmannin. However, LY294002, like wortmannin, 
was later found to inhibit mTOR when used at doses nearly identical to those required to 
inhibit PI3K [65]. 
In time PI3K isoform-selective inhibitors were also developed. IC87114, a p110δ 
selective inhibitor was identified from a chemical library screen and shows relatively good 
specificity towards p110δ [66]. TGX221, a p110β selective inhibitor, was designed and 
developed working from the structure of LY294002 structure and exhibits good specificity 
towards p110β [67]. Inhibitors with dual specificity for p110δ and p110γ have also been 
designed for the specific targeting of immunological cells [68]. The development of p110α 
selective inhibitors has been more problematic and although compounds are available, such 
as PI103, their utility is limited by a lack of specificity. 
Gene-targeted mice have been of great importance in the investigation of PI3K activity. 
There are two main strategies for kinase gene-targeting: the “knock-out” approach, where 
the gene is deleted and therefore the kinase is not expressed, and the “knock-in” approach, 
where single base pair changes result in inactivation of kinase activity but expression levels 
are largely unaffected. Where possible, the “knock-in” approach is preferable as complete 
lack of expression of a gene product may result in compensatory mechanisms that mask the 
true phenotype of the protein under investigation. 
A number of p85 and p110 isoform selective “knock-out” models have been described 
(reviewed in [17]). Although a lot of useful information was obtained from the use of these 
models, our emerging understanding of compensatory mechanisms in signalling pathways 
means that results from these systems should be interpreted with caution. A number of 
“knock-in” mouse models were later developed for the investigation of PI3K activity. Mice 
that were homozygous for kinase-dead p110γ or kinase-dead p110δ, both isoforms of 
restricted expression, were found to be viable and fertile [69, 70]. Mice that are 
homozygous for kinase-dead p110α were found to be embryonic lethal but heterozygotes 
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were viable and fertile [34, 71]. Mice that were homozygous for inactive p110β were fertile, 
although partial lethality that has not yet been explained was observed [33]. All of these 
models have been successfully applied to investigate isoform-selective roles of PI3K.  
1.1.7. Non-redundant roles of class IA PI3K isoforms 
Genetic and pharmacological isoform-selective inhibition of PI3K showed that cell 
survival and proliferation can be sustained with minimal levels of PI3K activity produced by 
isoforms expressed at very low levels, indicating key redundant functions [72]. However, 
distinct biological roles have also been determined for the different class I PI3K isoforms.  
Studies using mice heterozygous for kinase-dead p110α revealed that this isoform was 
critical for growth and normal glucose metabolism [71]. In addition, p110α has been 
demonstrated to be the PI3K isoform necessary for endothelial cell migration, in response to 
VEGF, during angiogenesis [34]. The use of the isoform-selective inhibitor TGX221 showed 
that p110β was critical for normal thrombus formation initiated by platelets [67].  
Both p110δ and p110γ are enriched in leukocytes, however they demonstrate largely 
non-overlapping immune phenotypes [16]. The 110γ mouse model showed that this isoform 
was crucial for macrophage accumulation during inflammation [69]. Studies using the 
“knock-in” p110δ mice model showed that antigen receptor signalling in B and T cells was 
defective and that consequentially in vivo immune responses were attenuated [70]. Later, 
this model was also used to show p110δ to be the only PI3K isoform to mediate mast cell 
allergic response upon IgE receptor stimulation [73, 74]. IC87114, the p110δ selective 
inhibitor, was also used to show that this isoform was essential for directional chemotaxis 
[66].  
It was also found that the different PI3K regulatory and catalytic isoforms have distinct 
roles in the regulation of cell motility [25, 61]. Different isoforms of p110 have been shown 
to regulate distinct functions in primary macrophages downstream of the same tyrosine 
kinase stimulation [75], suggesting that isoform-specific roles are not regulated solely by 
selective activation. In addition, different immortalised macrophage cell lines show variable 
dependence on the different isoforms of p110 downstream of CSF-1 receptor stimulation 
[75].  
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The basis for these distinct biological roles is unclear and various theories have been 
proposed. For example, differential tissue expression and activity levels of the different 
catalytic and regulatory isoforms may contribute to the reported variability of their 
biological effects [75]. It has also been suggested that subcellular localization of the PI3K 
complex may play an important role in the regulation of its activity [37]. Variable activity of 
PI3K in different cell types may be independent of the intrinsic lipid kinase activity of PI3K 
and therefore regulated by the cellular environment, such as small GTPase activity levels 
[75]. A further theory, which this project aims to investigate, is that unknown interaction 
partners may regulate PI3K activity, potentially in an isoform-specific manner [37].  
1.2. Akt 
Akt is a serine/threonine protein kinase that is activated downstream of class I PI3K 
activity. It is the most highly characterized downstream effector of class I PI3K and, as such, 
has been implicated in the regulation of key cellular functions including growth, survival, 
metabolism, proliferation and migration [60]. This kinase is thought to be one of the most 
important signalling nodes in higher eukaryotes [60]. 
There are 3 known isoforms of the protein kinase Akt: Akt1, Akt2 and Akt3, all of 
which are highly conserved and have extensive homology with other members of the AGC 
kinase family. Akt1 and Akt2 are ubiquitously expressed whereas Akt3 expression has a 
more selective distribution [60].  
1.2.1. Activation of Akt 
The key step in the activation of Akt is recruitment of the kinase to the cell membrane 
through the binding of its PH domain with PIP3 [76, 77], produced from PIP2 by the lipid 
kinase activity of PI3K. In fact, an intact PH domain was shown to be crucial for activation of 
Akt in response to PIP3 levels [77].  
The translocation of the kinase to the membrane enables the phosphorylation of Akt, 
at the residue Thr308, by PDK1 (phosphoinositide-dependent kinase 1) [78], which is also 
recruited and activated by PI3K activity [79]. It has recently been shown that interaction 
with membrane phosphatidylinositols is not necessary for Akt activation but it is likely to 
have a functional role in enabling the physical interaction between Akt and PDK1 [80].  
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Maximal activation of Akt requires further phosphorylation at Ser473, which was some 
years later found to be mediated by the mTORC2 complex [81]. Mutational analysis revealed 
that phosphorylation of the Thr308 site was crucial to enable Akt activity, however 
membrane-localized Akt that lacked Ser473 phosphorylation was still able to signal through 
mTOR [82]. 
PIP3 levels, the direct product of PI3K activity, determine membrane association of Akt 
and correlate with phosphorylation of Akt at Thr308 [83]. Thus, Akt phosphorylation is 
widely used as a surrogate indirect measure of PI3K activity.  
1.2.2. Regulation of Akt 
The key regulatory factors of Akt activity are membrane localization and 
phosphorylation, which are determined by the balance of PIP2 and PIP3 at the cell 
membrane [83]. This is in turn regulated by the lipid kinase activity of PI3K and the lipid 
phosphatase activity of PTEN and SHIP.  
Akt activity is also down-regulated by dephosphorylation of its activating 
phosphorylation sites. Protein phosphatase 2A (PP2A) dephosphorylates both the Thr308 
and Ser473 sites [84, 85]. Furthermore, the Ser473 site is also dephosphorylated by PH 
domain leucine-rich repeat protein phosphatase (PHLPP). 
In addition, it has recently been revealed that mTORC2 activity has a further role in 
the regulation of Akt. mTORC2 not only mediates the phosphorylation of Akt at Ser473, 
which enables full activation of the kinase [81], but furthermore promotes 
polyubiquitination and subsequent proteasomal degradation of Akt [86]. 
In addition to the regulatory processes described it is also likely that Akt activity is 
affected by specific stimuli, subcellular localization and substrate availability, mechanisms 
that are likely to affect the activity of all kinases although they may not be well 
characterized for specific cases [60]. 
1.2.3. Signalling downstream of Akt 
Fully active Akt phosphorylates substrates at the consensus motif R-X-R-X-X-S/T-X, 
where X is any amino acid [87, 88]. The critical requirement for arginine residues at the -3 
and -5 positions is the most distinctive feature of the motif. Phosphorylation of Akt 
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substrates can result in positive or negative regulation of protein activity and Akt substrates 
carry out a wide range of cellular functions, performing critical roles in the regulation of cell 
survival, growth, proliferation, metabolism and migration (Fig. 1.4.). 
Cell survival is mediated by Akt through the negative regulation of pro-apoptotic 
proteins. For example, Akt directly phosphorylates, and thereby inactivates, the pro-
apoptotic protein BAD [89]. Furthermore, Akt phosphorylates some transcription factors, 
such as FOXO and p53, which results in their translocation out of the nucleus and thereby 
reduces the expression of pro-apoptotic proteins [90]. A further indirect mechanism is the 
phosphorylation of MDM2 by Akt, which results in nuclear translocation and subsequent 
inhibition of p53-mediated transcription of pro-apoptotic proteins [91]. Akt also 
phosphorylates glycogen synthase kinase 3 (GSK3), resulting in inhibition of the pro-
apoptotic protein MCL-1 [92]. 
mTOR complex 1 (mTORC1) has a critical role in cell growth, mediated through the 
control of translation initiation and ribosome biosynthesis, and is regulated by Akt. Akt 
phosphorylates tuberous sclerosis complex 2 (TSC2) thereby inhibiting its activity, which in 
turn enables the activation of mTORC1 by rheb-GTP, which is negatively regulated by TSC2 
[93]. In an alternative mechanism, Akt phosphorylates proline-rich Akt substrate (PRAS40), 
resulting in activation of mTORC1 by this protein [94]. mTOR-independent mechanisms for 
control of cell growth downstream of Akt have also been described. Sterol-regulatory-
element-binding-protein (SREBP) has been shown to have a role in transcriptional regulation 
of lipogenesis genes, downstream of Akt and GSK3, leading to control of cell and organ size 
in vivo [95]. 
Akt has a dual role in the regulation of cell proliferation as it promotes cell growth, 
through mTORC1, and regulates cell division. The major role of Akt in the control of cell 
proliferation is mediated through the negative regulation of p27, which represses cell cycle 
progression, by direct phosphorylation [96]. Akt also indirectly inhibits p27 through the 
phosphorylation and inhibition of FOXO transcription factors [97]. In addition, Akt regulates 
cyclin-dependent kinases, which control cell-cycle progression, through GSK3β-mediated 
regulation of cyclins [98]. 
Akt regulates metabolism by mediating the translocation of glucose-transporter 4 
(Glut4) [99], although the mechanisms for this association remain unclear and may involve 
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the Rab-GAP AS160 [100]. Phosphorylation and inhibition of GSK3 results in the activation of 
glycogen synthase [101]. Akt also indirectly regulates metabolism through mTORC1 
mediated transcription of Glut1 [102]. 
The exact mechanisms for the role of Akt in cell migration remain poorly understood 
but is thought to exhibit striking isoform-selectivity and to involve cross-talk with other 
signalling pathways [60]. 
There are many more reported substrates than those described here, some of which 
have not yet been fully validated in vivo. 
 
 
 
 
 
Figure 1.4. Overview of signalling downstream of Akt: targets and biological outcome. 
Phosphorylation of Akt substrates can result in positive or negative regulation of protein activity. Akt 
substrates carry out a wide range of cellular functions, performing critical roles in the regulation of 
cell survival, growth, proliferation, metabolism and migration through a complex signalling network. 
Some of the most well-characterized roles are illustrated in this figure. 
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1.2.4. Non-redundant isoform specific roles of Akt isoforms 
The different isoforms of Akt are highly conserved, particularly in the kinase domain, 
thus it is unlikely that they have distinguishable substrate specificities [60]. Knockout models 
for the different Akt isoforms have demonstrated overlapping roles in key functions, such as 
growth [103]; however some isoform specific functions have been identified [104]. For 
example, Akt1, but not Akt2, is responsible for stimulating Glut4 translocation in adipocytes 
[105]. Isoform specific roles of Akt have been of particular interest in the investigation of 
cancer. It has been found that the different isoforms of Akt have distinct, complex roles in 
the regulation of cell transformation and metastasis in breast cancer. In one study, Akt1 was 
found to promote mammary tumour induction whereas Akt2 was found to have a key role 
in cell metastasis [106]. The actin-bundling protein palladin was identified as a substrate 
specific to Akt1 that may contribute towards these observed differences  in breast cancer 
cell migration [107].                                                                                                                                                                                                                                                                                                                                                                                
As for PI3K class IA, it is unclear how these isoform specific roles are regulated as the 
protein isoforms are extensively homologous. It has been suggested that expression levels 
and cytoplasmic location may regulate the activity of the different isoforms. It has also been 
proposed that regulation of Akt activity by PHLPP may produce isoform specific roles. 
PHLPP1 and PHLPP2 both dephosphorylate Akt at the same residue but PHLPP1 modulates 
Akt2 activity whereas PHLPP2 modulates Akt3 activity, therefore regulating distinct 
downstream substrates due to compartmentalization of the two complexes [108].  
1.3. PI3K/Akt signalling in disease 
Given the number of key cellular functions attributed to the PI3K/Akt pathway it is 
unsurprising that deregulation of this axis is implicated in a number of diseases. For 
example, the PI3K/Akt pathway is activated by inflammatory stimuli and thus has a role in 
the pathophysiology of inflammatory diseases, such as allergies [73]. 
PI3K/Akt activity is important in insulin signalling therefore this pathway is also 
implicated in metabolic diseases, such as diabetes mellitus. Elevated p85 levels have been 
detected in skeletal muscle from some patients with type 2 condition [109]. This is in line 
with in vitro data that proposed that free p85 down-regulates insulin-dependent PI3K 
signalling through competition with PI3K heterodimers [37]. Polymorphisms of the p85 gene 
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have also been found in patients, however the mechanisms for these genetic alterations on 
the development of disease have not been determined [110]. As a consequence of these 
alterations, attenuation of class IA PI3K signalling downstream of IRS-1 is known to be a 
significant feature of type 2 diabetes [111]. In addition, insulin-stimulated glucose uptake by 
the transporter Glut4 is impaired in adipocytes [105] and glucose production is increased in 
the liver [112] upon inhibition of PI3K signalling.  
Despite interest in the diabetes field, the role of the PI3K/Akt pathway in cancer is the 
most comprehensive area of investigation of the effects of this signalling pathway on 
disease. PI3K/Akt signalling has key roles in cell proliferation, growth and survival, therefore 
upregulation of this pathway can contribute to uncontrolled cell growth and malignant 
transformation. Indeed, it is the most frequently mutated signalling pathway found in 
cancer [16, 113]. The role of PI3K/Akt in the regulation of cell motility also plays an 
important role in tumour cell invasion and metastasis. The role of PI3K/Akt signalling in 
inflammation is also important and can contribute to tumour inhibition or promotion. 
1.3.1. Characterised mutations in the PI3K/Akt pathway 
The investigation into PI3K/Akt pathway mutations has mostly been focused on the 
investigation of cancer. The most frequently encountered mutations in the PI3K/Akt 
pathway are loss of function or loss of expression of PTEN [16]. Such genetic alterations 
result in the accumulation of PIP3 at the membrane and thus result in constitutive activation 
of the pathway. Recently, PTEN-deficient cancers were observed to be dependent on p110β 
signalling in PC3, BT549 and U87MG cancer cell lines [114]. This dependency has also been 
supported by a study that found p110β inhibition was important for the efficacy of PI3K 
inhibitors in inhibiting the PI3K/Akt pathway in PTEN-negative tumour xenografts [115]. 
Other authors have more recently suggested that p110δ activity is required, in addition to 
p110β, to mediate RTK-independent PI3K activity in PTEN-deficient prostate cancer cells 
[116]. 
Activating mutations were later identified in the PIK3CA gene, which encodes for the 
p110α catalytic isoform [117, 118]. Such mutations were shown to have little effect on the 
growth of colorectal cancer cells in vitro, however it was shown to reduce dependence on 
growth factors, attenuate apoptosis and facilitate invasion [119]. The effects of nine 
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different PIK3CA mutations were investigated in the transformation of MCF10A cells and 
found to have different effects on morphogenesis, invasion and inhibition of cell growth by 
LY294002 [120]. p110α is mutated in around 30% of prostate, breast, cervical and 
endometrium tumours, most frequently caused by a single amino acid change in the helical 
or kinase domain, which results in up-regulation of the pathway [121]. Helical domain 
mutant p110α activity is independent of p85 binding but requires interaction with Ras-GTP 
whereas catalytic domain mutant p110α activity is highly dependent on p85 association but 
does not require Ras-GTP binding [121].  
Many of the mutations have been shown to occur at the p85-p110 interaction 
interface, which are likely to result in a loss of the regulatory effect of p85 or intrinsic 
changes to p110 catalytic activity, thus providing some clues into the mechanisms of such 
mutations [21, 122]. Indeed, sequence analysis has shown that the p110α mutant N345K is 
homologous to wild-type p110β and that this sequence in the C2 domain interface with p85 
accounts for the oncogenic potential of over-expressed p110β [123]. Amplification 
mutations of PI3K genes have also been found in head and neck cancers, squamous cell lung 
carcinoma and cervical and gastric cancers [111].  
In some PIK3CA mutants, where Akt has been shown to be minimally activated, PDK1 
has been implicated in Akt-independent oncogenic events [124]. Mutations have not yet 
been identified in other class IA PI3K catalytic isoforms; however they are often 
differentially expressed in cancers [16, 121]. p110γ over-expression has recently been 
implicated in the progression of pancreatic cancer through mechanisms that remain unclear 
[125]. Mutations have also been identified in the inter-SH2 domain of the p85α regulatory 
subunit of PI3K, although at much lower frequency than other pathway aberrations [126, 
127]. In this context, p85 retains its p110 stabilizing role but its inhibitory effect is abrogated 
therefore promoting anchorage-independent growth, potentially through all expressed 
p110 isoforms [127]. 
The E17K activating mutation of Akt1 has been found in a variety of solid tumours, 
including breast, lung, colorectal and ovarian cancers [128]. This mutation causes 
constitutive activation of Akt1 and has also been shown to induce the development of 
leukaemia in mice models [128]. Other mutations that upregulate the PI3K/Akt pathway 
include activating mutations on Ras [30] and RTKs, such as EGFR or HER2.  
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Multiple mutations often co-exist, which is in line with the widely held view that initial, 
transforming mutations, known as “driver” mutations, increase the propensity of cancer 
cells to develop further mutations, known as “passenger” mutations. The existence of 
mutations in multiple signalling pathways within a cancer cell may enable them to evade 
regulatory feedback responses induced by the primary mutation [129]. PI3KCA mutations 
have been found to frequently co-exist with other PI3K-pathway altering mutations, such as 
RAS or PTEN, in a variety of solid tumours [130] and with alterations in other signalling 
pathways [129]. 
1.3.2. Use of PI3K/Akt inhibitors in disease 
Many kinds of PI3K inhibitors, both isoform-specific and pan-isoform, have been 
developed and evaluated with varying degrees of success in both in vitro and in vivo studies. 
Most of them are small molecule inhibitors, which act by binding competitively to the ATP-
binding pocket of the p110 catalytic domain. Due to the highly conserved nature of this 
domain specificity problems are a challenge in the development of these drugs, however 
selectivity is achievable through the exploitation of differences in flexibility between 
isoforms and sequence divergence in residues around the ATP-binding pocket [23].  
Mammalian cells can proliferate and survive with very low levels (<10%) of PI3K 
activity [72]. In vitro studies show that there is little correlation between PTEN status and 
inhibition of growth by PI3K inhibitors in human breast cancer cell lines [131]. Furthermore, 
it has been shown that PI3K activity levels in cancer cell lines do not correlate well with 
PIK3CA mutation status [132]. It is possible that constitutive PI3K pathway activation results 
in compensatory feedback loops that affect PI3K activity. Cross-talk between signalling 
pathways can also account for unexpected results on pathway activity. Full understanding of 
the signalling pathways that modulate PI3K activity may be key to the effectiveness of 
targeting this pathway. Most of the data in favour of the use of PI3K inhibitors in the 
treatment of disease is derived from cell line and xenograft studies; therefore it remains to 
be seen if such successes can be replicated in vivo in the much more complex and often 
multifactorial setting of disease. 
Despite such uncertainty, at least 195 clinical trials targeting the PI3K/Akt pathway 
have been initiated [41]. A number of PI3K inhibitors have reached Phase I clinical trials, for 
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use as single agents or in combination with existing therapies for solid tumours in cancer 
[16, 122]. The high incidence of tumours with multiple mutations affecting the pathway 
suggests that the latter approach may be the most effective [133].  For example, in lung 
adenocarcinoma models, driven by a PI3KCA mutation, tumours were found to decrease 
upon treatment with a dual PI3K and mTOR inhibitor [133]. However, combination 
treatments should be approached with care as PI3K inhibitors have shown to induce chemo-
resistance in various human cancer cell lines in vitro [134] and feedback loops and pathway 
cross-talk could result in undesirable activation of other pathway elements [46]. However, 
side-effects from PI3K inhibition treatment have thus far proven to be tolerable [122]. 
Isoform-selective p110δ inhibitors are in early trials for haematological malignancies 
and promising results have been reported for B-cell lymphoma patients [135]. These 
compounds have not yet been tested for allergy or inflammation, although in principle they 
show great promise in these applications.  
In accordance with its role as an important downstream effector of PI3K, several Akt 
inhibitors have been developed. The compound perifosine has had little effect as a single 
agent; however other compounds, such as MK2206, are currently under clinical 
investigation as part of a combination therapy [136]. Nevertheless, our emerging 
understanding of compensatory mechanisms following Akt inhibition may raise concerns 
about further use of kinase inhibitors. It has recently been reported that Akt inhibition 
activates a recovery mechanism, through mTOR inhibition and consequent FOXO activation, 
that results in expression and phosphorylation of RTKs [137]. It has also been shown that 
the ATP-competitive Akt inhibitor A-443654 induces hyperphosphorylation of Akt at Thr308 
and Ser473 through conformational changes that facilitate PH domain binding to PIP3 and 
the reactivity of phosphorylation sites [138]. Worryingly, Akt was found to be extremely 
active following inhibitor disassociation. This is the first time such a phenomenon, termed 
“inhibitor hijacking”, has been described, however should it turn out to be a common 
phenomenon, it may have serious implications for the use of kinase inhibitors. 
The mTOR inhibitor rapamycin, and more recent analogues, are the compounds that 
have advanced the furthest clinically to date [41, 136]. Clinical trials using these compounds, 
in single or combination therapies, for the treatment of solid tumours have shown 
encouraging results but a clear improvement in survival has not been found [136]. Our 
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emerging understanding of the importance of mTOR regulated feedback loops in the 
regulation of PI3K, by which inhibition of mTOR results in an activation of PI3K, may account 
for the disappointing results encountered so far. 
Improved understanding of the PI3K/Akt pathway activity and regulation is necessary 
to predict the efficacy of inhibitors in the treatment of disease. Distinct, sometimes 
opposing roles, for elements of this pathway are continually emerging, thus demonstrating 
the need to be cautious when using these drugs. Inhibition of multiple pathways may also 
become an important strategy as the importance of cross-talk emerges [136]. The 
identification of the specific pathway deregulation or biomarker panel in each patient, using 
high-throughput methods, would permit most efficient use of targeted drug treatment 
[139]. 
1.4. Proteomics 
1.4.1. Principles of proteomic analysis using mass spectrometry 
Mass spectrometry is an analytical technique used to determine the chemical 
composition of a sample by measuring the mass to charge ratio (m/z) of constituent 
molecules, after they have been converted to gas-phase ions. The technique is extremely 
specific and provides unbiased analysis, permitting diverse applications in a wide variety of 
fields in biology and chemistry. All mass spectrometers have the same basic structure, 
although there are a variety of different types for each component depending on the 
application. The key components are as follows: 
ION SOURCE     →  MASS ANALYZER    →  DETECTOR 
The ion source produces gas-phase ions from the molecules in the sample, which are 
then separated by the mass analyzer according to their m/z, a physical property of great 
diagnostic value. The final component is the detector, which measures the relative 
abundance of the separated ions. 
The relative intensity of the ions detected from a compound can be plotted against 
their m/z to generate a unique mass spectrum, which can be used for identification. The 
charge of each ion can be determined from the mass spectrum and therefore its mass can 
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be calculated from the m/z. This data can be used to identify the molecular composition of 
the sample and intensity of ion peaks can be used to generate quantitative data. 
Mass spectrometry has been applied extensively to the field of proteomics over the 
last decade. The technique can be applied to identify and quantify proteins present in a 
sample, to identify post-translational modifications, to sequence newly identified proteins 
and to elucidate protein structure. The major advantage of mass spectrometry over other 
techniques is that it can be used to profile the protein composition of a sample in depth 
without the need for targeting; i.e. without having a prior preconception of what molecules 
may be present in the sample and at what abundance.  
Proteomic analysis by mass spectrometry is becoming increasingly important through 
its application to large-scale, global studies. Traditionally, genomic approaches, such as 
mRNA microarray analysis and large-scale sequencing projects, have been used for global 
characterization of cells or disease states. However, the impact of multiple levels of post-
transcriptional and post-translational regulation of gene expression cannot be fully taken 
into account using these approaches. Global proteomics can overcome these limitations and 
is key to the understanding of complex biological systems, such as signalling pathways.  
1.4.2. Protein sample preparation for mass spectrometry analysis 
Sample preparation for mass spectrometry is a critical stage for successful protein 
analysis. The majority of protein analysis using mass spectrometry is carried out on peptide 
solutions resulting from proteolytic digestion of the protein mixture, using the so-called 
“bottom-up” approach [140]. In this approach, qualitative and quantitative data is 
generated for the peptides and extrapolated to give information about the whole protein 
[140].  
Many different approaches for proteolytic digestion of biological samples prior to 
“bottom up” mass spectrometry proteomic analysis have been described (reviewed in 
[141]). An important consideration of all such methods is that many detergents and 
reducing agents used in the harvesting of protein from cells or tissue can inhibit protease 
activity. Accordingly, one approach to proteolytic digestion is to first immobilize proteins in 
a solid support, for example using polyacrylamide gel electrophoresis (PAGE). Proteins 
embedded in gels can then be washed clean of interfering substances before digestion and 
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subsequent elution of resulting peptides. A variation of this approach is filter-assisted 
sample preparation (FASP), a technique in which proteins are immobilized on a solid filter 
support [142]. An alternative method that is also widely used is to carry out proteolytic 
digestion of proteins in solution. In such an approach, samples are diluted after protein 
extraction to reduce the impact of interfering substances on digestion.  
Selection of the most appropriate protease for proteolytic digestion is also important in 
mass spectrometry based proteomics. Trypsin, which cleaves proteins at the carboxyl 
terminus of arginine and lysine residues, is the most widely used protease for this purpose 
[141]. Other proteases used include: chymotrypsin, which cleaves proteins at tyrosine, 
tryptophan or phenylalanine; Lys-C, which cleaves proteins at the carboxyl terminus of 
lysine; and Asp-N, which cleaves proteins at the N-terminal side of aspartic acid.  Protease 
choice should be influenced by the type of experiment that is being performed and it should 
be noted that a combination of proteases is likely to result in more complete protein 
digestion. In addition, the use of multiple proteases in parallel experiments produces 
complementary sequences, resulting in greater coverage of the proteome.  
In the so-called “top down” proteomic approach intact proteins are analyzed by the 
mass spectrometer. Using this method more information can in principle be obtained about 
a protein’s primary structure as sequence coverage can be very high, approaching 100% for 
proteins up to 30 kDa in size [143]. Precise information about isoform variations and post-
translational modifications can also be obtained. The method can also be applied for the 
investigation of protein-protein interactions to estimate binding affinities of proteins in 
solution [144]. Due to the complexity of fragmentation patterns from whole proteins “top 
down” proteomics is not suitable for the analysis of complex mixtures, such as those 
present in typical biological samples. However, the development of high resolution hybrid 
instruments like FT-ICR and LTQ-Orbitrap has enabled advances in this field in recent years 
[143]. 
Regardless of the proteomic approach used, biological protein solutions are typically 
very complex mixtures and some degree of sample separation is often required prior to 
mass spectrometry analysis [141]. Mass spectrometry may be coupled to traditional protein 
analysis methods, such as electrophoresis or chromatography, to fractionate the proteins in 
the sample to yield less complex mixtures [141]. Alternatively, the sample may undergo a 
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purification step, such as affinity purification or phosphopeptide enrichment, to enrich the 
sample for proteins of analytical interest. After proteolytic digestion, peptide samples are 
often further separated prior to mass spectrometry analysis by high or ultra performance 
liquid chromatography [141]. This last step is usually carried out on chromatography 
systems which are coupled to the mass spectrometer, with column eluents feeding directly 
into the analyzer.  
1.4.3. Types of mass spectrometer used for proteomic analysis 
The development of ionization methods that facilitated the formation of charged, gas-
phase ions from an aqueous peptide or protein solution was the major breakthrough that 
allowed progress in the field of protein analysis by mass spectrometry. The two ionization 
methods currently used in protein analysis are electrospray ionization (ESI) and matrix-
assisted laser desorption/ionization (MALDI), although the former is most widely employed. 
In ESI, a high voltage is applied to the sample, in liquid phase, as it passes through a silica or 
metallic capillary, thereby dispersing it into a charged aerosol which rapidly evaporates, 
producing gas phase ions [145]. In MALDI, a laser beam is used to vaporize and ionize the 
sample, which is crystallized in the solid phase [146]. Both techniques are known as “soft” 
ionization methods, as the peptides molecules are unlikely to fragment, but differ in that ESI 
tends to produce more multiply charged ions than MALDI. Another difference is that ESI is 
more readily coupled with LC than MALDI. MALDI is also less suited to quantitative 
investigation as signal intensity is dependent on analyte-matrix crystallization conditions 
[147]. 
Commonly used mass analyzers for protein mass spectrometry include quadrupole, 
time of flight (TOF), 3D and linear ion traps, Fourier transform ion cyclotron resonance (FT-
ICR) and orbitrap instruments. In quadrupole analyzers, radiofrequency and electrical fields 
are created through which ions move at a speed and trajectory determined by their m/z. 
The conditions of the fields are manipulated to filter the ions and select those required. In 
TOF analyzers, ions are initially accelerated by an electrical field and then left to drift in a 
free-field, wherein they separate according to m/z as this determines the speed at which 
they travel. Ion trap analyzers, 3D and linear, trap ions in an oscillating electrical field, which 
can then be manipulated to sequentially eject the ions from the trap according to their m/z. 
Chapter 1: Introduction 
38 
 
In FT-ICR instruments, the ions are trapped within a magnetic field and excited by an 
electrical field. The speed and movement of the ions in the trap is determined by the m/z, 
which can be calculated by Fourier transformation from the measurement of ion motion. 
Orbitrap analyzers work in a similar way to FT-ICR instruments, trapping ions in an electrical 
field causing them to oscillate around a central electrode. The m/z is determined by Fourier 
transformation of the measured frequency of ion oscillations. 
Ions separated by quadrupole, TOF and ion trap instruments are most frequently 
detected by the physical impact of the ion on a detector, such as a conversion dynode or a 
micro-channel plate. The signal detected is then amplified using an electron multiplier. In 
FT-ICR and orbitrap analyzers detection is carried out by a pair of metal plate detectors 
between which a weak current is produced by the movement of the ions. 
TOF, ion trap, FT-ICR and orbitrap analyzers all offer a wide range for mass detection; 
however orbitrap and FT-ICR instruments offer greater mass accuracy and resolution. Many 
applications of mass spectrometry in protein analysis require the use of hybrid instruments, 
which are composed of two or three of the mass analyzers described coupled together, to 
permit more complex analysis.  
1.4.4. Qualitative protein analysis 
Qualitative mass spectrometry analysis can be applied in a targeted manner. One 
example of such an application is the identification of a protein that has been found to be 
differentially expressed using traditional methods, such as affinity purification and SDS-
PAGE [81, 148, 149]. However, the greatest strength of proteomic analysis using mass 
spectrometry lies in its application to global approaches. Current technology enables the 
identification of thousands of peptides or proteins and their post-translational modifications 
within a relatively short period of analysis time.  
Qualitative analysis for the identification of peptides and proteins is usually carried out 
using tandem mass spectrometry (MS/MS) analysis (Fig. 1.5.). In the first and second stages 
of MS/MS analysis, peptide ions are selected and fragmented, usually along peptide bonds, 
generating daughter, fragment ions that are separated and detected by the third stage of 
analysis. The mass spectra generated for the daughter ions enable peptide identification by 
comparison to reference databases or by de novo amino acid sequencing. MS/MS can be 
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carried out using hybrid instruments, with the various stages of analysis carried out in 
multiple mass analyzers (MS/MS in space), or in a single ion storage analyzer, with the 
various stages of analysis carried out using an appropriate series of conditions (MS/MS in 
time).  
 
 
Figure 1.5. Illustration of the principles of MS and MS/MS proteomic analysis. In MS proteomic 
analysis the intensity of a peptide ion with a given m/z in detected (MS scan). In MS/MS analysis, 
peptide ions are selected and fragmented, usually along peptide bonds, generating daughter, 
fragment ions that are separated and detected by the third stage of analysis (MS/MS spectra). 
Peptide fragmentation is typically induced by subjecting charged ions to collision with 
other particles. The kinetic energy of the collision is internalised and results in the rupture of 
the weakest bonds, which are typically the peptide backbone amide bonds. Thus, low-
energy collision conditions result in fragmentation of peptides along the amino acid 
backbone [150-152]. However, peptide fragmentation patterns are complex and influenced 
by amino acid composition, molecule size and excitation method, amongst other factors 
[151]. Thus conditions must be optimized to ensure efficient fragmentation in order to 
obtain useful information.  
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Collision-induced dissociation (CID) is the most popular form of gas phase 
fragmentation. Charged peptides are accelerated within a vacuum in the collision cell and 
are bombarded with inert neutral gas, such as helium, nitrogen or argon and the resulting 
energy internalised. Higher energy collision dissociation (HCD) is similar in principle to CID 
carried out in quadrupoles but in hybrid linear ion trap-orbitrap instruments it is used to 
avoid the low mass cut-off typical of ion trap fragmentation and to enable the use of high 
resolution detection in the Orbitrap to improve resolution of fragments ions [153]. In 
electron-transfer dissociation (ETD) and electron-capture dissociation (ECD), peptides are 
fragmented by bombardment with electrons. In addition to MS/MS analysis of peptides, 
CID, ECD and ETD are also used for protein fragmentation in “top down” proteomic 
approaches [143]. 
MS/MS spectra resulting from peptide fragmentation can be used for de novo amino 
acid sequencing. As peptides fragment along the amino acid backbone they form 
structurally informative sequence ions (amino acid chains) and non-sequence small neutral 
ions, such as water and ammonia [154]. Fragments derived from the N-terminus of the 
peptide are designated as b ions and fragments derived from the C-terminus of the peptide 
are known as y ions [154]. In de novo sequencing, amino acid residues are identified by 
calculation of the mass difference between successive fragment ions of the same type i.e. b 
or y [151, 154]. Thus peptides, and by extrapolation proteins, can be sequenced with no 
prior knowledge of the sample. This process can be automated using software, however it 
remains a relatively time consuming method for routine peptide identification. 
The mass spectra generated by daughter ion fragmentation can also be compared to 
databases of predicted fragments for known peptides generated by in silico digestion and 
fragmention of all known proteins present in databases to enable the identification of 
peptides and, by extrapolation, proteins. This process, more commonly used than de novo 
sequencing, can be highly automated using software programmes that are used as search 
engines, examples of which include MASCOT and SEQUEST. The major advantage of this 
approach is that peptide identifications in large-scale datasets can be obtained rapidly. 
However, there is a significant disadvantage associated with this approach in that false-
positive matches are likely to occur by chance in a large dataset. It has been estimated that 
there are 3.8 million theoretical tryptic peptides in the widely used IPI human database, of 
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which 2 million are shared between 2 or more proteins thus potentially resulting in 
ambiguous protein identification [155]. Complex algorithms can be used to estimate the 
probability of an accurate identification [156] and thus the stringency of a match can be set 
by the user to generate low or high confidence results. Improved understanding of peptide 
fragmentation patterns would enable the generation of better in silico databases, resulting 
in more accurate results [151]. Improvements in this area are likely to occur as the method 
matures. 
It should be noted that regardless of the peptide identification method used, the 
phenomenon of “under-sampling” remains a limitation of MS/MS analysis of complex 
samples. In MS/MS analysis, a limited number of high-abundance peptide ions are isolated 
for fragmentation; thus many low-abundance peptides in a complex mixture are not 
identified. This restricted analysis of complex mixtures is termed “under-sampling” and is a 
common phenomenon in MS/MS. The most influential factors on under-sampling are: target 
peptide ion intensity, sequencing speed (duty cycle), instrument sensitivity and precursor 
ion isolation [157]. It has been estimated that more than 100,000 peptide features can be 
eluted in a 100 min gradient elution using an LTQ Orbitrap Velos but only around 16% of 
these ions are selected for MS/MS [157]. One approach to combat this limitation is to 
analyze the same sample in multiple technical replicates as this has been demonstrated to 
increase the numbers of peptide identifications produced [158]. As the resolution and, more 
importantly, duty cycles of instruments improve the impact of under-sampling will gradually 
be reduced but it currently remains one of the greatest challenges for mass-spectrometry 
based proteomics. 
1.4.5. Quantitative protein analysis 
The capability for quantitative global analysis is the greatest strength of mass 
spectrometry in the field of proteomics. Qualitative proteomic analysis is an important tool 
in biological research, however the utility of the data obtained is limited as quantitative 
information is key to the understanding of biochemical processes. In quantitative analysis, 
mass spectrometry is unrivalled by any other proteomic tool, which are all reliant on the 
targeted analysis of a relatively small number of proteins. Current technology permits the 
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simultaneous identification and quantitation of hundreds or thousands of proteins per 
experiment [159-161]. 
1.4.5.1. Label-based approaches 
One approach to quantitative proteomics is to label protein samples that are to be 
compared with tags of different isotopic mass. The samples can then be pooled, digested 
and analysed by LC-MS and LC-MS/MS. Proteins in the samples are identified and the 
relative abundance in the different samples can be obtained by comparing the peak heights 
for the different isotopic variants of the tag. The isotopic labelling of proteins can be carried 
out at various stages in the workflow process. In one approach, known as isotope-coded 
affinity tag (ICAT), the proteins are labelled after they have been harvested from cells. The 
ICAT has a cysteine reactive group, a “heavy” or “light” isotope linker and a biotin affinity 
tag [162]. Cell lysates are incubated with the ICAT reagent, digested and then the labelled 
peptides are isolated by affinity purification prior to LC-MS analysis [162]. Variations on this 
approach are isobaric tag for relative and absolute quantitation (iTRAQ) and tandem mass 
tag (TMT), which label amino groups with a tag that generates a specific reporter ion upon 
peptide fragmentation [163]. Limitations include variability of labelling efficiency between 
samples, isotopic impurities, e.g. from manufacturers, and interference of mixed MS/MS 
contributions during precursor ion selection [164]. Furthermore, it has recently been shown 
that isobarically labelled phosphopeptides result in significantly greater charging during ESI, 
which results in reduced fragmentation and identification efficiency [165]. This 
phenomenon was estimated to reduce phosphopeptide identification numbers by 50% even 
when using optimized MS/MS conditions [165]. 
An alternative labelling approach is to incorporate the isotopic tag in vivo during 
protein synthesis. The most widely used example of this approach, termed stable isotope 
labelling by amino acids in cell culture (SILAC), involves the addition of isotopically labelled 
amino acids to cell culture medium, thereby labelling the proteins more comprehensively 
and without affinity issues as may be encountered with alternative labelling approaches 
[166]. The cell lysates are then mixed prior to digestion and LC-MS and LC-MS/MS analysis. 
However, a key restriction of this approach is that in vivo labelling may be challenging, for 
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example if an animal tissue was under investigation, or indeed completely impracticable, for 
example if a human patient was under investigation. 
The Mann group, which pioneered the SILAC method, have also developed solutions to 
overcome these limitations and broaden its applicability to more sample types or greater 
sample numbers. More recent work showed that in vivo isotopic labelling can be performed 
at the organism level by developing a SILAC-labelled mouse, thus enabling the use of tissue 
for proteomic studies [167]. Mice were labelled over 4 generations to obtain 100% labelling, 
although 93% labelling was obtained after a single generation [167]. Another strategy was 
also developed to enable the application of SILAC to human investigations. SILAC-labelled 
cell lines, termed “Super-SILAC” mix, were created to represent the proteome of the tissue 
type under investigation [168]. These lysates were then used as internal standards to enable 
the relative quantification peptides and phosphopeptides in cancer cell lines [169] and 
human tumour tissue samples [170]. This approach assumes that cell lines express the same 
repertoire of proteins and the same phosphorylation sites as primary tissues. 
Despite the many advances in recent years, the major limitation of label-based 
proteomics is that only a small number of samples can be compared in any given 
experiment due to the limited number of isotopic labels available. These methods also tend 
to be more expensive due to the requirement for specific, labelled reagents. Despite these 
limitations, iTRAQ and SILAC quantitation methods are frequently used for global proteomic 
studies with great success. 
1.4.5.2. “Label-free” approaches 
Many label-free methods for the quantitation of proteins using mass spectrometry 
have also been developed. One approach, known as spectral counting, is to use the number 
of unique peptide spectra identified in a data-dependent LC-MS/MS experiment for a 
particular protein as an indicator of its abundance. Spectral counting has been reported to 
provide a simple and reliable index of protein abundance [171]. The number of peptides 
that are identified for a protein do indeed correlate with protein abundance, however the 
relationship between these measurements is complex as factors such as peptide size, 
ionization efficiency and sampling difference between runs are also implicated [147, 171, 
172]. To overcome these limitations, labelled internal standards may be incorporated into 
Chapter 1: Introduction 
44 
 
the samples or mathematical corrections can be used to take these factors into account. 
One example of the latter approach is absolute protein expression measurement (APEX), 
which corrects the observed spectral count using learned probabilities for sampling depth 
and confidence of peptide identification [172]. Although spectral counting has been 
successfully applied for many large scale proteomic studies [160, 172], it should be noted 
that extensive normalization and statistical analysis are required to obtain accurate and 
reliable quantification [171].  
Alternative approaches use the measurement of ion peak area or height as a measure 
of peptide abundance, which can then be extrapolated as a measure of protein abundance. 
Selective reaction monitoring (SRM), also known as multiple reaction monitoring (MRM), 
uses the peak intensity of a small number (3-6) of the most abundant and proteotypic 
daughter ions from the MS/MS fragmentation of a peptide as a measure of abundance. SRM 
has been shown to be sensitive and specific [173], however the number of proteins that can 
be quantitated in a single analysis is limited by the duty cycle of the mass analyzer. 
Alternative strategies to SRM, which measure the intensity or area of the parent peptide 
ion, are not limited in this way and can quantitate a much larger number of proteins in each 
run. Thousands of peptides, and thus hundreds of proteins, can be easily quantified in a 
single experiment [159, 174]. 
Label-free methods for protein quantitation by mass spectrometry offer many 
advantages over labelling approaches. The most notable benefit is that a potentially 
unlimited number of samples can be compared in a single experiment. In addition, such 
methods tend to be cheaper, require less complex sample processing and can be applied to 
any sample type. The limitations are that mass spectrometry and data analysis can be more 
complex and the resolution and reproducibility of the analyzers can affect the quality of 
results. However, as the precision and resolution of mass spectrometry instruments 
continue to improve and data processing software is developed these issues are likely to 
become of limited impact. A study evaluating label-fee methods for quantitative proteomics 
found that linearity and reproducibility were within a 95% confidence limit for a spectral 
counting approach and for the measurement of peak area intensity [175]. The authors 
noted that spectral counting is the more sensitive method however peak area intensity 
provides more accurate quantitations [175]. Furthermore, peak areas and heights on 
Chapter 1: Introduction 
45 
 
peptide elution profiles (extracted ion chromatograms - XICs) have been shown to correlate 
well with abundance across samples [159, 171, 176].  
However, there are important factors to be considered when using peak measurement 
for peptide quantitation approaches. Some argue that quantitation of parent ion peaks 
requires confident assigned MS/MS spectra in each sample for peak matching, which, due to 
the phenomenon of “under-sampling”, greatly reduces the number of quantifiable peptides 
in an experiment [147, 177]. However, modern high mass accuracy and resolution enables 
the confident identification of correct peaks using RT, m/z and isotopic distribution [159, 
177]. A greater problem is that the XICs of different peptides within a protein may be very 
different, however the average of the three most abundant has been shown to provide an 
accurate estimate in most cases [171]. In addition, low resolution data may result in 
multiple or overlapping candidate peaks (pseudopeaks), however in such cases MS/MS can 
be used to identify the correct peak [175]. Experimental drifts in retention time (RT) and 
mass-to-charge ratio (m/z) can also complicate analysis and increase inaccuracy, however, 
again, improvements in the technology make this less relevant [171]. A rapid increase in the 
development of bioinformatic tools to assist label-free quantification has supported 
developments in this method [171]. 
Despite existing concerns, many validation studies have demonstrated the suitability 
of label-free ion peak measurement for peptide quantification. In a method termed “Serac”, 
intensity of XICs was measured across multiple samples after normalization and background 
subtraction [175]. The data revealed that peak height exhibited a linear relationship with 
protein abundance and that reproducibility of quantification was within 95% confidence 
limits when more than three peptides were used [175]. Another approach, “SEMI” 
(sequence, elution time, mass-to-charge and internal standard) was applied to quantify 
peptides, identified in at least one but not every sample, across multiple samples [177]. This 
method used algorithms for retention time alignment and cross-referenced across multiple 
runs for confident peak assignment [177]. Further work with this method estimated 
quantitative accuracy at around 6% error and reproducibility at 34% relative SD [178].  
Furthermore, work by this group has demonstrated the suitability of a label-free 
quantification method that uses a computer program named Pescal, which was developed 
in-house [159], for the quantification of peptides. Retention time, mass-to-charge ratio, 
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charge and isotopic distribution data, obtained from a single MS/MS event, is used to 
confidently identify peptide peaks in MS scans across multiple samples [159, 179]. Further 
work developed a validation method that demonstrated the ability of Pescal to quantitate 
peptides across a wide dynamic range with a mean accuracy variation of 22% for over 80% 
of the ions quantified [179]. 
1.4.5.3. Absolute quantification 
Most investigations performed using both labelled and label-free mass-spectrometry 
based quantification are focused on the relative quantification of peptides or proteins 
between different experimental conditions. However, absolute quantification of peptides 
and proteins may also be of great interest and may be performed using either method. 
Many methods for absolute quantification rely upon the use of labelled internal 
standards. The most straight-forward approach to absolute quantification of proteins is the 
so-called “Top 3 method”. In this approach, the average MS signal response of the three 
most intense tryptic peptides is measured per mole of internal standard protein [180]. This 
information is used to calculate a universal signal response factor that is then applied to 
quantify unknown proteins using the mean MS signal response of their three most intense 
tryptic peptides [180]. This method was shown to be applicable to complex mixtures [180] 
and to demonstrate a linearity of 0.98 across a wide dynamic range [181]. 
A similar approach identified proteotypic peptides representing an array of proteins 
across a wide dynamic range (40 – 15000 copies/cell) [182]. Absolute abundance levels were 
then determined for these proteins by measuring the median ion intensity for the three 
most abundant peptides using labelled reference standards [182]. These selected proteins 
were used as calibration points and the proteome of the pathogen Leptospira interrogans 
was quantified [182]. 
Although both of these methods make use of labelled internal standards these 
references serve primarily as calibration points and therefore extrapolation is necessary for 
the quantification of the thousands of proteins quantified in a proteome. An alternative 
approach, which aims to overcome this limitation is the QconCat method [183]. In QconCat 
technology, artificial genes that encode combinations of proteotypic tryptic fragments of 
multiple proteins are designed and expressed in bacteria using isotopic labelling [183, 184]. 
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Known amounts of these artificial proteins are then used as internal standards for the 
absolute quantification of the selected proteins in a sample [183, 184]. This workflow is 
repeated to represent all the proteins in a proteome under investigation, providing high 
confidence absolute quantification of every protein using its own internal standard [184]. 
Alternative approaches for absolute quantification using label-free methods have also 
been developed in addition to the “top-three” method described above. In absolute protein 
expression profiling (APEX), spectral counting and mathematical algorithms based on 
learned probabilities are used to quantify proteins [172]. The abundance of a particular 
protein is quantified by measuring the spectral count and correcting for the prior 
expectation of observing each peptide, determined by in silico analysis [172].  Another label-
free method, intensity based absolute quantification (iBAQ), uses the sum of peptide peak 
intensities divided by the number of theoretically observable tryptic peptides to quantify a 
protein [185]. 
Although absolute quantification of proteins is feasible but it remains a more complex, 
time-consuming and expensive method than relative quantification. Thus, its application is 
not as widespread as many questions in biology are often adequately addressed by the use 
of relative quantitation. 
1.4.6. Affinity purification coupled to mass spectrometry: analysis of protein-protein 
interactions 
One of the major applications of proteomics is in the field of mapping protein-protein 
interactions. The importance of protein-protein interactions and protein complexes in 
biological processes, such as cell signalling, is being increasingly recognized and mass 
spectrometry is facilitating such advances. Protein-protein interaction studies may be 
targeted, e.g. with the aim of identifying binding partners of a particular protein, or of a 
global, networked approach with the aim of characterizing the interaction network of an 
entire pathway or cell type. 
The traditional proteomic approach for the identification of protein-protein 
interactions is the yeast 2-hybrid system (Y2H). This method, developed some decades ago, 
uses a “bait” protein and a “prey” protein, fused with a DNA binding domain and an 
activation domain of a reporter gene respectively, which are co-expressed in yeast [186]. 
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Expression of the reporter gene indicates interaction between the “bait” and the “prey” in 
the yeast cell. This method has been used to identify thousands of stable and transient 
protein-protein interactions but the method is limited in that it can only identify binary 
interactions. Furthermore, Y2H has been shown to result in a high false positive rate and 
does not account for the influences of cellular localization, different cell environments, post-
translational modifications and basal expression levels [187]. Despites its limitations, 
stringent, high-throughput Y2H strategies are suitable for the investigation of binary 
interactions cells [188] and have been used to begin to map the human interactome [189] 
and to comprehensively map those of S. cerevisiae, C. elegans, and D. melanogaster [190].  
Affinity purification of protein complexes followed by proteomic analysis by mass 
spectrometry has more recently emerged as the method of choice for the identification of 
protein-protein interactions in protein complexes. In this technique the “bait” protein, 
which is the protein central to the complex of interest, is isolated from total cell lysate using 
affinity purification techniques, such as immunoprecipitation (IP) or epitope tag affinity 
chromatography. It is crucial that this affinity purification step is carried out under 
conditions that do not disrupt protein-protein interactions, for example low ionic strength 
solutions and mild detergents should be used. The isolated protein complex is then analyzed 
by mass spectrometry to facilitate the identification and quantitation of the constituent 
proteins, thus identifying interaction partners. This strategy has been successfully applied to 
a number of protein interaction studies in yeast and mammalian cells [191-193]. 
 The advantages of affinity purification-mass spectrometry (AP-MS) are multiple and 
overcome many of the limitations of Y2H. Firstly, the technique can be applied to cells or 
tissues grown under physiological conditions, therefore permitting the study of dynamic 
changes in protein complexes by the manipulation of growth conditions. Another advantage 
of AP-MS is that post-translational modifications are not usually affected, thus providing 
further valuable information with regards to the regulation of protein complexes. Finally, 
AP-MS permits the identification of multi-protein complexes as it is not restricted by binary 
relationships. The inherent qualities of mass spectrometry are also important for making AP-
MS the method of choice. Mass spectrometry analysis is sensitive and specific; it permits 
qualitative and quantitative analysis and permits the unbiased identification of proteins 
present in a sample. 
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The abundance of the “bait” protein is an important factor in the effectiveness of AP-
MS as interacting partners may not be present in equimolar ratios. High amounts of “bait” 
protein may be required to ensure sufficient recovery of binding partners and the method 
can be biased towards high-abundance proteins [194].  
However, the major consideration for AP-MS is that the technique is limited by the 
specificity of the affinity purification technique, as non-specific interactions will complicate 
the identification of true binding partners. A “one size fits all” AP-MS strategy is an unlikely 
proposition; it is necessary to optimize affinity-purification for the application required. 
Immunoprecipitation using monoclonal antibodies is an attractive approach as it is specific 
and does not require modification of the “bait” protein, however such tools are often 
unavailable [187]. An alternative approach, in which the “bait” protein is tagged is more 
widely used. Nonetheless, the use of artificially transfected “bait” proteins should be 
approached with care as expression levels of transfected proteins can be up to double basal 
concentrations [187] and it has also been shown that some tags, such as green fluorescent 
protein, can affect subcellular localization  [194, 195], thereby increasing the likelihood of 
false-positives. 
A consistent problem with AP-MS is the incidence of false-positives resulting from 
interactions of the “bait” with abundant house-keeping proteins that also have high affinity 
for purification reagents [194]. Tandem affinity purification approaches (TAP) were 
developed in an attempt to overcome such limitations [196]. In TAP, “bait” protein 
complexes are purified using two successive rounds of complimentary affinity purification 
[196]. This approach reduces the number of false positive results, however it can also result 
in decreased sensitivity due to sample losses during multiple rounds of purification [194, 
197]. An innovative variation on this strategy, parallel affinity capture (iPAC), was more 
recently described [197]. In iPAC, cells are transfected with a transposable element that 
results in the production of endogenous proteins triple-tagged with FLAG-StrepII-YFP [197]. 
Parallel FLAG and StrepII purification steps are then performed, which results in lower 
protein losses than sequential purification steps [197]. Interactors are identified as proteins 
that are present in the complexes isolated using both purification systems but not found in 
the negative control wild type cell line purification products [197].  
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Computational methods have also been developing at an impressive pace to enable 
the advances in AP-MS that have been produced. Bioinformatic resources are crucial for 
managing the large datasets produced by this method and de-convoluting the data to 
identify protein-protein interactions within multi-protein complexes and larger networks 
[194]. Bioinformatics also has an important role in reducing the incidences of false-positive 
results in AP-MS studies. Control affinity purification samples can be used to generate a 
database of non-specific interactors with the affinity reagents; a so-called “beadome”. In 
silico analysis can then be used to discard such data from experimental samples [193, 197]. 
Quantitative proteomics also has an important role in AP-MS.  Quantitative strategies 
can be used to differentiate non-specific interactors from dynamic binding partners 
following AP-MS. In such an approach, unlabelled or SILAC-labelled cells were stimulated 
with EGF or left untreated prior to affinity purification against the phosphorylated EGF 
receptor [198]. Proteins interacting with the phosphorylated EGF receptor were then 
identified as those purified in different abundance under the two conditions [198]. There 
are several advantages to this approach for targeted studies, such as the reduced likelihood 
of false positives, due to the use of endogenous, untagged proteins, and the potential to 
investigate the dynamics of protein-protein interactions at multiple time points [198]. 
However, such an approach is unlikely to be practical for proteome-wide interaction studies. 
The analysis of protein interactions requires further consideration of protein complex 
topology and structure, as well as composition [199]. Other emerging mass spectrometry 
methods, such as drift cell and travelling wave ion mobility, are likely to become increasingly 
important in this area. 
1.4.7. Phosphoproteomics 
Phosphoproteomics is the subfield of proteomics that is dedicated to the 
characterisation of protein phosphorylation. Phosphorylation is a reversible post-
translational modification that has a key role in the regulation of protein function [200-202]. 
Phosphorylation occurs upon serine, threonine or tyrosine residues in eukaryotes [202] and 
has the potential to induce conformational changes in proteins, thereby enabling regulation 
of activity [203]. In addition, phosphorylation can also mediate recognition of proteins by 
interaction partners and affect subcellular localization. Protein phosphorylation is tightly 
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regulated by kinases, which phosphorylate proteins, and phosphatases, which 
dephosphorylate proteins [200, 204] and proteins may be phosphorylated on multiple sites, 
each event potentially resulting in a distinct biological output.  
Protein phosphorylation has a fundamental role in signal transduction and, therefore, is 
a key regulator of essential cellular processes including metabolism, growth, cell cycle 
progression, migration and apoptosis [200-202]. As discussed in the previous section, the 
disruption of signalling pathways is associated with the pathology of many diseases 
including cancer, diabetes, autoimmune diseases and neurodegenerative conditions [200]. 
Hence, understanding the activity of signal transduction pathways can lead to the 
identification of novel therapeutic targets and biomarkers. 
 Phosphoproteins can be detected and quantified using immunochemical techniques. 
However, global mass spectrometry analysis of protein phosphorylation is emerging as a 
more powerful method for the investigation of signalling pathway activity [203, 205]. MS-
based phosphoproteomic techniques enable the identification and quantification of 
thousands of phosphoproteins and phosphorylation sites in a single experiment. Thus, the 
method is inherently multiplexed (provides high content information) and a further 
advantage is that it is unbiased, requiring no prior knowledge of the proteins involved in the 
processes under investigation.  
The mass spectrometry techniques previously described are all applicable to 
phosphoproteomic analysis although there are some additional considerations to be 
undertaken. Phosphorylation is a dynamic modification [200] and samples must be handled 
accordingly to prevent loss of phosphate groups due to phosphatase activity as these are 
efficient and robust enzymes [206, 207]. Therefore, cells or tissues must be lysed in the 
presence of phosphatase inhibitors to minimize phosphate hydrolysis [207, 208].  
Mass spectrometry is a very sensitive technique, however its range of detection is 
limited due to the phenomenon of “under-sampling” discussed above. Large-scale 
proteomics experiments do not typically identify a significant number of phosphorylated 
peptides as phosphoproteins are usually present in very low stochiometry compared to their 
non-phosphorylated counterparts and are therefore less likely to be identified.  
This issue is further compounded by the fact that MS/MS fragmentation methods 
frequently result in the neutral loss of the relatively labile phosphate and/or phosphoric acid 
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groups from phosphopeptides rather than backbone fragmentation, thereby reducing 
resulting sequence information [152, 209]. Another challenge is that phosphorylated 
peptides have been found to ionize less efficiently than non-phosphorylated peptides, using 
both ESI and MALDI [210].  
Due to these phenomena, methods to enrich phosphorylated proteins prior to analysis 
are required in order to successfully perform MS-based phosphoproteomics experiments. A 
large number of techniques for the enrichment of phosphoproteins have emerged in recent 
years and been instrumental in the development and success of phosphoproteomics. These 
techniques can be divided into two groups: those that perform the enrichment at the 
protein level (Fig. 1.6.A) and those that enrich phosphopeptides after digestion of whole cell 
lysates by proteases (Fig. 1.6.B).  
These methods will be subsequently discussed in detail and it should be noted that there 
are many different formats in which they may be applied. Methods for enriching 
phosphopeptides may be “on-line”, where the enrichment method is coupled directly to the 
mass spectrometer, or “off-line”. A wide range of affinity purification reagent solid phases is 
also available and includes beads, columns, tips and nanoparticles.  
 
Figure 1.6. Summary of enrichment strategies commonly used for phosphoproteins (A) and 
phosphopeptides (B).  
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1.4.7.1. Affinity purification: inorganic species 
Phosphorylated peptides or proteins can be purified by exploiting the affinity of 
negatively charged phosphate groups towards positively charged species bound to solid 
affinity matrices. The most widely used of these techniques are Immobilized Metal Affinity 
Chromatography (IMAC) and Metal Oxide Affinity Chromatography (MOAC) (Fig. 1.7. A). 
IMAC exploits the affinity of phosphate groups for transition metal ions, which include 
Cu2+ (copper), Ni2+ (nickel), Zn2+ (zinc), Fe3+ (iron), Co2+ (cobalt), Al3+ (aluminium) and Ga2+ 
(gallium). The interaction occurs due to the formation of coordinate bonds between the 
electron donor groups of oxygen in the negatively charged phosphate group and positively 
charged metal ions [211]. Transition metals also have affinity for nitrogen and sulphur 
therefore many amino acids also bind metal ions, which reduces the specificity of IMAC for 
phospho enrichment. The binding efficiency of metal ions for each interaction species varies 
greatly; Fe3+ has a high affinity for phosphate groups [212] and thus is most frequently used 
for phosphopeptide enrichment [213].  
IMAC can be used for the enrichment of both full length phosphoproteins and 
phosphopeptides and its use has been extensively demonstrated since the first application 
by Neville et al. [213-219]. 
The major limitation in the application of IMAC for phosphopeptide enrichment is that 
its specificity is limited by co-purification of acidic peptides. Solvent concentrations are an 
important factor in regulating specificity of IMAC and a higher concentration of acetonitrile 
was shown to improve the affinity and specificity of IMAC for phosphopeptides [220]. 
Interaction pH is also an important factor and acidic pH, between 2.5 and 3.5, has been 
shown to be optimal for phosphopeptide binding [221]. The choice of acid used is also 
influential and formic acid has been demonstrated to enhance IMAC specificity as it 
competes with non-phosphorylated peptides for binding [221, 222]. Elution conditions are 
another variable that can strongly influence efficiency and specificity. Phosphopeptides can 
be eluted from Fe3+ IMAC material under acidic or basic conditions [220, 222] and efficiency 
has been shown to be higher for mono- and multiply-phosphorylated peptides respectively 
[222]. Time is also an important factor and acidic and multiply-phosphorylated peptides 
have been demonstrated to elute more rapidly than non-acidic mono-phosphorylated 
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peptides [220]. Despite wide application, the characteristics of IMAC result in a systematic 
bias for multiply-phosphorylated peptides [220, 222]. 
An alternative method of affinity chromatography for phosphopeptide isolation exploits 
the interaction between phosphate groups and metal oxides, a method sometimes referred 
to as MOAC. This method is based on the affinity of negatively charged oxygen present in 
the phosphate group for metal atoms. Titanium dioxide (TiO2) is the chemical species most 
frequently used for MOAC as it has the highest efficiency for this application [223]. TiO2 
affinity purification of phosphopeptides has been extensively demonstrated since its utility 
was first demonstrated by Pinkse et al [203, 223-226].  
As with IMAC, the non-specific binding of acidic residues to TiO2 reduces specificity for 
phosphopeptides. It has been shown that the addition of organic acids to solvents minimizes 
non-specific binding of acidic residues and improves specificity [223, 227]. Trifluoroacetic 
acid has been shown to be the best choice for reducing the binding of non-phosphorylated 
peptides [223]. Non-phosphopeptide excluders, acids that bind metal more weakly than 
phosphate groups but more strongly than carboxyl groups (e.g. glycolic acid), can also be 
used to improve the recovery of phosphopeptides [223, 228, 229]. Phosphopeptides are 
typically eluted using basic solutions, such as NH4OH, as acidic eluents were found to be less 
efficient [223]. The recovery of phosphopeptides using MOAC has also been shown to be 
improved by applying multiple rounds of enrichment to a single sample [225, 230, 231]. TiO2 
affinity purification typically results in a bias towards mono-phosphorylated peptides as 
multiply-phosphorylated species bind with a very high affinity and are difficult to elute [223, 
228, 229].  
Despite their limitations, IMAC and MOAC are very efficient enrichment methods in 
phosphoproteomics and therefore they are widely used. It has been shown that TiO2 MOAC 
is more selective and sensitive than IMAC in the enrichment of phosphopeptides, however 
more multiply phosphorylated peptides can be identified using the former [223, 228]. Our 
group has optimized the application of TiO2 affinity chromatography for quantitative 
phosphoproteomics and demonstrated its suitability for this application [232]. 
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Figure 1.7. Principles of commonly used phosphopeptide enrichment methods. 
1.4.7.2. Affinity purification: antibodies 
Antibody-based affinity purification is based upon the selective enrichment of peptides 
or proteins that contain phosphorylated residues that are recognized by specific antibodies 
(Fig. 1.7.B). These methods are therefore limited by the specificity of the antibody tools 
available. There are many antibodies that claim specificity against phosphorylated serine 
(pS) and threonine (pT) residues, however few have been demonstrated to be suitable for 
phospho enrichment of peptides or proteins [233]. More success has been found for the 
enrichment of peptides and proteins phosphorylated on tyrosine residues, most likely 
because phosphorylation of this site is typically found at very low levels compared to serine 
and threonine. In fact, the distribution of phosphorylation sites has been estimated to be 
86.4% on serine, 11.8% on threonine and 1.8% on tyrosine residues [203]. Thus, methods 
that are not specific for tyrosine-phosphorylation result in the enrichment of very low 
numbers of this modification relative to other phosphopeptides. Therefore, antibody 
purification methods specific for phosphorylated tyrosine have demonstrated better results 
than other methods. In addition, there are a number of available antibodies that are highly 
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efficient for the immunoprecipitation of peptides and proteins containing phosphorylated 
tyrosine [234], possibly because the aromatic ring of tyrosine is highly amenable to antibody 
recognition. 
Antibody purification has been extensively used in global phosphoproteomic studies for 
the enrichment of peptides and proteins; most frequently in studies that are focused on 
tyrosine phosphorylation [160, 235-238].  
1.4.7.3. Chemical derivatization 
Phosphopeptide enrichment using chemical derivatization involves the selective 
modification of the phosphate group to enable selective enrichment of these peptides or 
proteins (Fig. 1.7.C). An important rationale of this method is that sensitivity and sequence 
coverage of phosphopeptides may be improved by removal of the phosphate group, which 
therefore results in greater fragmentation efficiency upon MS/MS. In addition, ionization 
efficiency is likely to be improved by the removal of negatively charged groups. The most 
common chemical derivatization method involves β-elimination of the phosphate group, 
using a reducing agent, followed by Michael addition with a stable chemical tag.  
Limitations of this method include sample losses during multiple reaction steps and 
unavoidable side reactions. However, the method has been successfully applied for the 
enrichment of both phosphoproteins and phosphopeptides [239]. An additional feature of 
chemical derivitization is that sample labelling for quantification can be incorporated into 
the phosphopeptide enrichment workflow [219, 240]. 
1.4.7.4. Other chromatographic methods 
Alternative forms of chromatography have also been applied for phosphopeptide 
enrichment. Strong cation exchange (SCX) chromatography separates molecules based on 
their charge (Fig. 1.7.D). The stationary phase is negatively charged and thus retains cations, 
which can be sequentially eluted by displacement using an increasing gradient of salt or pH. 
Strong anion exchange (SAX) chromatography is based on the same principles but the 
polarities of the reaction are reversed (Figure 1.7.D). SCX chromatography has been used 
under acidic conditions for the selective enrichment of phosphopeptides [241], however 
further studies have suggested that sensitivity and specificity is poor due to retention of 
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highly hydrophobic phosphopeptides and co-elution of acidic non-phosphorylated peptides 
[242, 243]. SAX chromatography was later proposed as a more suitable method for the 
enrichment of negatively charged phosphopeptides, providing greater scope for elution 
control. The method does enable the selective enrichment of phosphopeptides from a 
complex mixture [244], however sensitivity and specificity issues persist [243]. 
Hydrophilic interaction chromatography (HILIC) has also been applied to 
phosphopeptide enrichment (Figure 1.7.D). HILIC is based on the hydrogen-bonding 
interaction between charged ions and the neutral, hydrophilic stationary phase. The 
strength of this interaction increases with the degree of polarity and molecules can be 
eluted using an increasingly polar elution solvent. As phosphopeptides are more hydrophilic 
than non-phosphorylated peptides they are retained more strongly by the column and thus 
can be separated from a complex mixture. However, the sensitivity and specificity of this 
method are poor when used in isolation for the enrichment of phosphopeptides [245].  
Accumulated data indicate that, on their own, HILIC, SCX and SAX are not suitable for 
phosphopeptide enrichment as they do not have sufficient specificity [243, 245-247], 
however they are powerful separation techniques and are useful in combination with other 
enrichment techniques in “coupled” approaches. 
1.4.7.5. “Coupled” methods 
Chromatography methods may be combined to provide multidimensional 
chromatographic separation for phosphopeptide enrichment. The rationale behind 
multidimensional chromatography is that the use of multiple orthogonal chromatographic 
methods (i.e. methods that produce non-overlapping separation) will result in 
comprehensive fractionation of a peptide mixture. Such strategies were not specifically 
designed for phosphopeptide enrichment, however comprehensive sample separation 
results in increased identification of low abundance peptides such as phosphopeptides.  
In addition to SCX, SAX and HILIC, reverse phase (RP) chromatography has also been 
used for multidimensional chromatography. RP chromatography is based upon the 
interaction between charged molecules and the non-polar stationary phase, which can then 
be eluted according to polarity using a polar organic mobile phase. SCX, SAX and HILIC are 
orthogonal to RP, however HILIC and RP at high pH produce a more even fractionation of 
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peptides and thus are more useful for multidimensional chromatography [245, 248]. This 
technique has been applied for phosphoproteomic experiments [242, 249] and the major 
advantage of this strategy over other phosphopeptide enrichment techniques is that there 
is no loss of unmodified peptides, which provides additional informative data. 
The combination of chromatographic separation with affinity purification methods can 
improve phospho enrichment efficiency as reduction of sample complexity can improve the 
sensitivity and specificity of affinity purification methods. Such approaches are reported to 
greatly enhance phosphoproteomic coverage [226, 243, 245, 246].  
More specific phosphopeptide enrichment techniques have also been coupled to 
increase phosphopeptide enrichment efficiency. As discussed, MOAC and IMAC are 
complimentary methods with biases towards different populations of phosphopeptides. 
These methods have been coupled, in a method termed sequential elution from IMAC 
(SIMAC), to double the number of phosphopeptides identified using MOAC alone [222]. This 
method was further enhanced by combining it further with SCX [250]. In addition, antibody 
affinity purification and IMAC have been combined with chemical derivitization to improve 
specificity and sensitivity of phospho enrichment [251, 252]. 
1.4.7.6. Bioinformatic considerations  
In addition to the use of phospho-enrichment methods prior to analysis in 
phosphoproteomics, there are important considerations to be made during mass 
spectrometry and bioinformatic analysis. 
MS/MS analysis can be optimized to improve the likelihood and efficiency of 
phosphopeptide fragmentation using a method known as multi-stage activation. In this 
approach, collision energy conditions are selected to produce neutral loss of phosphoric 
acid, corresponding to losses of 80 or 98 kDa, and peptide backbone fragmentation [253]. 
Multi-stage activation increases the quantity and intensity of peptide fragment ions and 
therefore results in improved sequence coverage and confidence of identification [152, 
254].  
The fragmentation method used can also improve phosphopeptide fragmentation. ETD 
and HCD have been proposed as more suitable fragmentation methods for 
phosphoproteomics as they result in increased phosphopeptide sequence coverage than the 
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more widely used CID method [153, 209, 255]. The type of instrument used can also affect 
phosphopeptide fragmentation. It has been shown that CID performed in quadrupoles and 
linear ion traps produce complementary information and therefore the combination of 
datasets enhances phosphopeptide identification [158].  
Additional consideration must be given during bioinformatic analysis in 
phosphoproteomic experiments. Such studies not only aim to identify the presence of 
phosphorylation but also the exact location within the peptide, which is not a trivial task 
[152, 177]. Serine, threonine or tyrosine account for 16% of the amino acids in the NCBI 
peptide database, therefore the potential for multiple candidate phosphorylation sites in a 
single peptide is high [152]. The confident localization of a phosphosite requires the 
identification of specific diagnostic backbone fragments; i.e. residues with intact phosphate 
ion and unmodified residues must both be present [152, 256]. When proton mobility is low, 
i.e. neutral loss most likely, some phosphopeptides may induce a charge-remote cleavage 
pathway that results in a higher than expected intensity for the C-terminal y-ion of the 
phosphorylated residue, therefore making it easier to detect [257]. However, during gas 
phase in MS/MS phosphate groups may be re-arranged and transferred prior to 
fragmentation leading to false localization [258]. 
Peptide identification software, such as MASCOT or Sequest, calculates the probability 
for all the different potential phosphorylation sites and the highest score is the most likely 
candidate, although not necessarily the correct one. Using Sequest for peptide 
identification, the A score, which is based on the presence of site-determining ions in the 
MS/MS spectra, can be used to measure the likelihood that a phosphorylation site 
localization is correct and when this was tested in a large-scale phosphoproteomics study 
the false positive rate was found to be 1.3% [259]. Similarly, the MASCOT Delta Score, which 
is based on the difference between scores for different phosphosite assignments, can be 
used to identify which phosphosite is the most likely [260]. This approach was reported to 
be as sensitive and specific as using A score but has the additional advantage that it does 
not require additional complex computational processing following peptide identification 
analysis [260]. Musite is a computational tool that was designed to perform large-scale 
predictions of phosphorylation site localization [261]. Prediction models are trained using 
phosphoproteomics data from multiple organisms and the programme then uses local 
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sequence similarities, protein disorder scores and amino acid frequencies to determine 
phosphorylation sites [261]. An additional consideration for bioinformatic analysis is that 
several features of phosphorylated peptides can impair the efficiency of trypsin digestion, 
therefore appropriate consideration should be given to peptides with missed cleavage sites 
during identification and, if appropriate, quantification [262].  
There are also specific considerations to be made with regards to phosphopeptide 
quantification as there are practical difficulties in obtaining highly reproducible data due to 
the complexity of many phosphoproteomics workflows [177]. Although much work has 
been performed in the evaluation of phosphopeptide enrichment methods, an assessment 
of their practicality for quantitative analysis is often overlooked. Our group has attempted 
to address this issue and has validated that our optimized TiO2 affinity chromatography 
phosphopeptide enrichment method is reproducible and suitable for label-free quantitative 
phosphoproteomics [179, 232].  
1.5. Project aims 
As discussed above, the PI3K/Akt pathway has a key role in the regulation of essential 
cellular functions including cell growth, survival and metabolism. As such, the deregulation 
of this pathway is implicated in the aetiology of a number of diseases, including cancer. 
Although investigation into the PI3K/Akt pathway has been extensive there are still a 
number of questions that remain to be addressed. 
Mass spectrometry based proteomics is emerging as an important novel tool for 
biological research. Mass spectrometry analysis is inherently sensitive, specific, quantitative 
and, crucially, untargeted. Thus, it enables global scale analysis and discovery investigation 
that was not previously possible with other methods.  
This project aims to apply mass spectrometry to investigate PI3K/Akt signalling from a 
proteomics standpoint and to answer questions that have not been addressed using 
traditional molecular biology techniques.  
One key area in the field of PI3K/Akt signalling that remains underexplored is the likely 
role of interacting proteins in the regulation of PI3K activity. Our understanding of protein-
protein interactions continues to reveal the importance of this mechanism in the regulation 
of enzymatic activity [263, 264]. Of particular relevance are the findings that protein-protein 
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interactions regulate the signalling activity of other kinases, including Erk [265], Akt [266] 
and mTOR [267, 268]. All p110 isoforms have a Ras-binding domain and activation of class I 
PI3K by Ras has been demonstrated in a variety of in vitro studies [2]; however to date, no 
further interaction partners with a clear role in the modification of the activity of Class IA 
PI3Ks have been identified, most likely due to limitations in available technology. In the 
absence of AP-MS, targeted investigation for interaction partners, requiring prior 
knowledge, is the only approach to investigate this area. This project aimed to utilise 
emerging AP-MS techniques to perform an untargeted, unbiased screen to identify dynamic 
interaction partners of class IA PI3K and to characterise their role in the regulation of this 
kinase. 
Another area in the field of PI3K/Akt signalling that has not been comprehensively 
investigated is the dynamics of signalling activity downstream of Akt. Although many 
downstream substrates have been identified it is not clear how the different biological roles 
dependent on this kinase are mediated. Mass spectrometry based phosphoproteomics 
enables the global investigation of signalling activity, in contrast to traditional proteomic 
methods for phosphorylation investigation which are targeted towards pathways for which 
good phosphospecific antibodies are available. This project aimed to apply global, 
quantitative phosphoproteomics to investigate signalling events downstream of Akt. For this 
purpose, we also developed a novel in vitro assay for the identification of kinase substrates 
and broad, untargeted quantification of kinase activity. 
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2. Materials and Methods 
2.1. Antibodies 
Table 2.1. Antibody reagents and concentration of experimental use. 
Target Specification Manufacturer 
Product 
Number 
Western Blot 
(WB) Conc. 
Immuno 
precipitation 
(IP) Conc. 
α-tubulin Mouse mAb Sigma-Aldrich T6074 1:10000  
Akt Rabbit pAb Cell Signalling 9272 1:5000  
P-Akt Ser473 Rabbit pAb Cell Signalling 9271 1:1000  
P-Akt Thr308 Rabbit pAb Cell Signalling 9275 1:1000  
Akt P-Sub Rabbit mAb Cell Signalling 9614 1:1000 1:75 
Calpain Rabbit pAb Santa Cruz sc-30064 1:1000 1:100* 
Calpain 2 Rabbit pAb Cell Signalling 2539 1:1000 1:100* 
LC3 Rabbit pAb MBL PM036 1:1000  
p110α Rabbit mAb Cell Signalling 4249 1:1000  
p110α Rabbit pAb In-House SK214+215  1:200 
p110β Rabbit pAb Santa Cruz sc-602 1:1000  
p110β Rabbit pAb In-House p110b2.1+2.2  1:100 
p110δ Rabbit pAb Santa Cruz sc-7176 1:1000  
p110δ Rabbit pAb Abcam ab1678  1:333 
p85 Rabbit pAb Millipore 06-195 1:10000 1:1000* 
p85 Rabbit pAb Millipore 06-497 1:10000 1:1000* 
P-PRAS40 
Ser246 
Rabbit pAb Cell Signalling 2640 1:1000  
P-S6 Ser 
240/244 
Rabbit pAb Cell Signalling 2215 1:1000  
P-S6K Thr389 Rabbit pAb Cell Signalling 9202 1:1000  
Total IgG Rabbit pAb Sigma-Aldrich I5006  1:2000 
Vinculin Mouse mAb Sigma-Aldrich V9131 1:5000  
 
*Best IP results obtained when used in conjunction with other antibodies for same target. 
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2.2. Other materials and reagents 
Table 2.2. Other materials and reagents. 
Reagent Manufacturer Product Number Use 
Nano ACQUITY UPLC 
BEH C18 Column 
Waters 186003546 UPLC 
Akt1 (recombinant, 
active, human) 
Millipore 14-276 In vitro protein kinase assay. 
Aktide (synthetic 
peptide) 
Millipore 123900 Substrate for in vitro Akt assay 
ALLN (Calpain Inhibitor 
1) 
Sigma-Aldrich A6185 
Calpain inhibitor 
ATP Sigma-Aldrich A0770 
Substrate for in vitro protein kinase 
assays 
[γ-33P] ATP Perkin Elmer BLU002001MC 
Substrate for in vitro PI3K lipid kinase 
assay 
Bradford Reagent BioRad 500-0205 
Protein quantification 
Calpain 1 (purified, 
porcine) 
EMD 208712 
In vitro calpain assay 
Calpain 2 (recombinant, 
rat) 
EMD 208718 
In vitro calpain assay 
Calpain Activity Assay 
Kit, Flurogenic 
EMD QIA120 
In vitro assay for the measurement of 
calpain activity 
CAPNS1 ON_TARGET 
plus SMARTpool 
Thermo 
Scientific 
L-048840-01-
0005 
siRNA transfection 
CellTiter 96® 
AQueousNon-
Radioactive Cell 
Proliferation Assay 
Promega G5421 
Cell viability assay 
Cholera toxin Sigma-Aldrich C-8052 
Cell culture medium supplement 
D030/IC87114 Intellikin Gift 
PI3K p110δ inhibitor 
DharmaFECT 1 siRNA 
Transfection Reagent 
Thermo 
Scientific 
T-2001-01 
siRNA transfection 
DMEM/F12 (1:1) Invitrogen 11965-118 
Cell culture medium 
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Dulbecco’s modified 
eagle’s medium 
(DMEM) 
PAA E15-843 
Cell culture medium 
Dynabeads SCX Invitrogen 105-13D 
Aktide assay sample purification 
EGF (recombinant, 
human) 
Peprotech AF-100-15 
Cell culture medium supplement and 
growth factor pathway stimulation 
Eppendorf LoBind 
Microcentrifuge Tubes 
Sigma-Aldrich Z666505 
Sample preparation for LC-MS/MS 
analysis 
Foetal bovine serum 
(FBS) 
PAA A15-104 
Cell culture medium supplement 
FITC Annexin V 
Apoptosis Detection Kit 
II 
BD Pharmingen 556570 
FACS apoptosis assay 
G418 (Geneticin) Invitrogen 10131019 
Cell culture medium supplement - 
selection 
Horse serum Invitrogen 16050-122 
Cell culture medium supplement 
Hydrocortisone Sigma-Aldrich H-0888 
Cell culture medium supplement 
ImmobiliumTM-P Millipore IPVH00010 
Polyvinylidene fluoride (PVDF) membrane 
for WB 
Insulin Sigma I-1882 
Cell culture medium supplement and 
growth factor pathway stimulation 
L-α-
phosphatidylinositol 
Sigma-Aldrich P2517 
PI3K lipid kinase assay substrate 
Lambda protein 
phosphatase 
NEB P0753 
In vitro protein dephosphorylation 
LY294002 Merck 681676 
PI3K inhibitor 
Microcon YM-10 Filters Millipore 42421 
Filter-aided sample preparation (FASP) 
OASIS HLB 1cc 
Extraction cartridges 
Waters WAT094225 
Reverse-phase protein extraction 
ON-TARGET plus Non-
targeting siRNA #2 
Thermo 
Scientific 
D-001810-02-20 
siRNA transfection 
PD Minitrap Column GEHealthcare 28-9180-07 
Size exclusion protein chromatography 
Penicillin/Streptomycin PAA P11-010 
Cell culture medium supplement 
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PepClean C18 Spin 
columns 
Thermo 
Scientific 
89870 
Reverse phase protein extraction and 
TiO2 affinity chromatography 
Phosphate buffered 
saline (PBS) 
PAA H15-002 
Cell culture 
PI-103 Cayman 10009209 
PI3K p110α inhibitor 
Propidium Iodide Sigma-Aldrich P4864 
FACS cell cycle analysis 
Puromycin Sigma-Aldrich P-8833 
Cell culture medium supplement - 
selection 
Ribonuclease A Sigma-Aldrich R5125 
FACS cell cycle analysis 
Roswell Park Memorial 
Institute medium 
(RPMI-1640) 
PAA E15-842 
Cell culture medium 
TGX221 Astra-Zeneca Gift 
PI3K p110β inhibitor 
Titansphere TiO2 beads 
(10 micron) 
Capital HPLC ltd 5020-75010 
TiO2 affinity chromatography 
TPCK-Trypsin 
(immobilized) 
Thermo 
Scientific 
20230 
In-solution protein digestion 
Trypsin (sequence 
grade) 
Promega V511A 
In-gel protein digestion 
Trypsin-EDTA PAA L11-004 
Cell culture 
U016 Tocris 1144 
MEK inhibitor 
Vydac C18 HPLC 
Column 
LC Packing 
MBO-15-05-
C18P3 
HPLC 
 
2.3. Cell culture 
All cell handling procedures were performed under a laminar flow hood using aseptic 
techniques and sterile materials.   
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2.3.1. Cell Lines 
Table 2.3. Immortalized cell lines and corresponding medium. 
Cell Line Cell Type Species 
Growth  
Medium 
Starvation 
Medium 
Comments 
IC-21 
Peritoneal 
macrophages 
Mouse 
RPMI-1640 
supplemented with 
10% FBS, 100 
units/ml 
Pen/Strep, 1% 
NaPyruvate, 1% 
Non-Essential 
Amino Acids and 
50 μM β-
mercaptoethanol 
N/A  
Kasumi-1 
Acute 
Myeloid 
Leukaemia 
(AML) 
Human 
RPMI-1640 
supplemented with 
10% FBS, 100 
units/ml Pen/Strep 
and 50 μM β-
mercaptoethanol 
N/A  
MCF10A 
Breast 
epithelium 
Human 
DMEM:F12 
supplemented with 
5% horse serum, 
100 units/mL of 
Pen/Strep, 20 
ng/ml EGF, 0.5 
μg/ml 
hydrocortisone, 
100 ng/ml cholera 
toxin and 10 μg/ml 
insulin. 
DMEM:F12 
supplemented 
with 100 units/mL 
of Pen/Strep 
Parental cells and 
cells stably 
transfected with 
the myrAktER 
construct or 
control empty 
vector were used.  
NIH-3T3 
Embryonic 
fibroblasts 
Mouse 
DMEM 
supplemented with 
10% FBS and 100 
units/ml Pen/Strep 
DMEM 
supplemented 
with 100 units/ml 
Pen/Strep 
 
P31/Fuj 
Acute 
Myeloid 
Leukaemia 
(AML) 
Human 
RPMI-1640 
supplemented with 
10% FBS, 100 
units/ml Pen/Strep 
and 50 μM β-
mercaptoethanol 
N/A  
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RAW 
264.7 
Leukaemic 
monocytic 
macrophages 
Mouse 
DMEM 
supplemented with 
10% FBS and 100 
units/ml Pen/Strep 
N/A  
 
2.3.2. Cryopreservation 
Cells (2 x 106 – 8 x 106) were collected by centrifugation at 1300 rpm for 3 min and re-
suspended in 1 ml of 10% Dimethyl sulfoxide (DMSO) in FBS. The cells were then transferred 
into cryovials, which were placed in isopropanol tanks, and cooled slowly (1oC/min) for 18 h 
in a -80oC freezer. Cell vials were then transferred to liquid nitrogen tanks (-196oC) for long-
term storage. Cells were recovered from liquid nitrogen storage by rapid thawing in a water 
bath at 37oC. Cells were then transferred to a tissue culture flask and diluted in appropriate 
growth medium.  
2.3.3. Growth maintenance 
All cells were grown in humidified incubators kept at 37oC with 5% CO2. Growth media 
used for each cell type is described in Table 2.3.. 
Adherent cells (IC-21, MCF10A, NIH-3T3 and RAW 264.7) were passaged when they 
reached 80 – 90% confluency. Cells were washed with PBS and detached using 0.05% EDTA-
trypsin, before inactivation of the trypsin by addition of growth medium (in a minimum of 5 
fold excess to trypsin). Cells were then diluted in growth medium in a fresh tissue culture 
flask. Suspension cells (Kasumi-1 and P31/Fuj) were maintained between 0.5 and 2 x 106 
cells/mL and diluted in growth medium in a fresh tissue culture flask as required. 
2.3.4. Seeding for experiments 
For adherent cells, cells were washed with PBS and detached using 0.05% EDTA-
trypsin, before inactivation of the trypsin by addition of growth medium (in a minimum of 5 
fold excess to trypsin). Cells were then counted and seeded at the required density, with 
fresh growth medium added as required, on tissue culture plates. For suspension cells, cells 
were counted and collected by centrifugation at 1300 rpm for 3 min. 50 x 106 cells were 
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then re-suspended in fresh growth medium and seeded at a density of 0.5 x 106 cells/mL in 
fresh tissue culture flasks. All cells were counted using the Innovatis CASY Cell Counter.  
2.3.5. Serum-starvation 
Serum starvation of cells was carried out by first seeding cells in growth medium at the 
required density. After 18 h, the cells were washed with PBS and the medium was changed 
to starvation medium (as indicated in Table 2.3.). Starvation was carried out for 18 h 
(overnight).  
2.3.6. Inhibitor treatments 
Table 2.4. Inhibitors and treatment conditions used. 
Compound 
Target Treatment 
Concentration 
Treatment 
Time (h) 
Cell Lines Treated 
ALLN  Calpain 50 µM 1 NIH-3T3 
  10 µM 48 NIH-3T3 
D030/IC87114 PI3K p110δ 100 nM 1 NIH-3T3 
LY294002 PI3K (pan) 5 µM 1 
MCF10A  
and NIH-3T3 
  5 µM 48 NIH-3T3 
PI-103 PI3K p110α 10 nM 1 NIH-3T3 
TGX221 PI3K p110β 100 nM 1 NIH-3T3 
U0126 MEK 1/2 10 µM 1 
MCF10A  
and NIH-3T3 
 
2.3.7. Signalling pathway stimulation 
All growth factor mediated signalling pathway stimulations were carried out after 18 h 
starvation and indicated inhibitor treatments. NIH-3T3 cells were stimulated with 10% FBS 
and MCF10A cells were stimulated with 100 ng/ml EGF. The Akt signalling pathway was 
activated in MCF10A myrAktER cells by treatment with 4-hydroxytamoxinfen (4-OHT) as 
indicated. 
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2.4. Cell viability assay  
CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay (Promega), or MTS 
assay, for cell viability was carried out following the manufacturer’s instructions. Cells were 
seeded in 96 well plates at densities of 5 x 103 – 2 x 104 per well, depending on cell type and 
assay conditions. After the required period of growth and treatment, 20 μl of MTS-PMS 
solution was added to each well and the plates were incubated in humidified incubators at 
37oC with 5% CO2 for 1 - 3 h. The reduced reaction product, produced by viable cells, is then 
quantified by spectrophotometric absorbance at 492 nm using a TECAN plate reader. Where 
indicated, 96-well plate wells were pre-coated with poly-HEMA by adding 200 μl of sterile 
poly-HEMA solution (10 mg/ml in ethanol) to each well and leaving on the plates to dry 
overnight. 
2.5. FACS analysis 
Fluorescence-activated cell sorting (FACS) analysis was used to investigate cell cycle 
progression and apoptosis. Cell cycle progression was investigated by using FACS to detect 
propidium iodide (PI) staining of DNA. 1 x 106 cells were collected and washed twice with 
PBS. The cells were then re-suspended in 70% ethanol and fixed at -20oC for 1 h – 1 week. 
The cells were then washed again twice with PBS and treated with RNase, prior to DNA 
staining with PI. PI staining was quantified using blue laser excitation and an emission filter 
of 695 nm on a BD Fortessa FACS analyzer.   
Apoptosis was investigated by using FITC Annexin V Apoptosis Detection Kit II and FACS 
analysis. Annexin V staining of external phosphatidylserine indicates loss of plasma 
membrane integrity, an early marker of apoptosis, and PI staining of DNA indicates dead 
and damaged cells. 1 x 106 cells were collected and re-suspended in assay binding buffer. 
The intact cells were then stained with Annexin V and PI. The dyes were measured using FL3 
and FL1 channels on a Dako CyAn ADP FACS analyzer. 
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2.6. Cell lysate preparation 
 2.6.1. Cell Lysis 
Table 2.5. Lysis buffers and indicated use. 
Lysis Buffer Composition Indicated Use 
50 mM Tris HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA and 1% Triton X-100. 
Supplemented with protease inhibitors (0.05 TIU/mg aprotinin, 10 µM 
leupeptin, 0.7 mM pepstatin A, 27 µM TLCK, 1 mM DTT and 1 mM PMSF) 
and phosphatase inhibitors if required (50 mM NaF, 1 mM Na3VO4 and 1 
µM okadaic acid). 
Aktide assay, IP and 
WB 
50 mM Tris HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA and 0.3% CHAPS. 
Supplemented with protease inhibitors (0.05 TIU/mg aprotinin, 10 µM 
leupeptin, 0.7 mM pepstatin A, 27 µM TLCK, 1 mM DTT and 1 mM PMSF). 
Co-IP 
40 mM Tris-HCl (pH 7.4), 1% Triton X-100 and 2.5 mM EDTA.  
Supplemented with protease inhibitors (0.05 TIU/mg aprotinin, 10 µM 
leupeptin, 0.7 mM pepstatin A, 27 µM TLCK, 1 mM DTT and 1 mM PMSF) 
and phosphatase inhibitors (50 mM NaF, 1 mM Na3VO4 and 1 µM okadaic 
acid). 
In vitro protein 
kinase assay 
8 M urea, 20 mM HEPES (pH 8.0) 
Supplemented with phosphatase inhibitors (1 mM Na3VO4, 1 mM NaF, 2.5 
mM Na4P2O7, 1mM ß-glycerol-phosphate). 
Phosphoproteomics 
 
Adherent cells were lysed directly on tissue culture plates and suspension cells were 
collected by centrifugation at 1300 rpm for 3 min prior to lysis. Plates or tubes were kept on 
ice throughout the procedure. Cells were washed twice with ice-cold PBS, supplemented 
with phosphatase inhibitors (1 mM NaVO4 and 1 mM NaF) for phosphoproteomic 
experiments. Lysis buffer, as required for subsequent investigation (Table 2.5.), was then 
added to the cells. Adherent lysed cells were then scraped and collected into tubes. Cell 
lysates were vortexed, or for phosphoproteomic experiments sonicated, and incubated on 
ice for 30 minutes. Soluble proteins were then clarified by centrifugation at 13,000 rpm for 
10 min at 4oC.  
2.6.2. Determination of protein concentration 
Protein concentration was determined using the Bradford assay. Lysis buffer was used 
as a blank sample and BSA solutions of 0.5, 1.25, 2.5 and 5 µg/µl were used to construct a 
calibration curve. All blank, calibration standard and analytical samples were dispensed into 
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wells on a 96-well plate and 200 µl of Bradford reagent was added. The colour change 
produced by the binding of Coomassie Brilliant Blue G-250 to protein in the sample was 
then measured by spectrophotometric absorbance at 595 nm on a TECAN plate reader. A 
calibration curve was constructed using the known standards and linear regression was used 
to calculate the protein concentration of samples. 
2.7. Immunoprecipitation (IP)  
Cell lysates were pre-cleared by incubation with 10-50 µl of Protein G Sepharose, 
which had previously been washed 3 times in lysis buffer, for 2 h at 4oC with mixing. 
Samples were then centrifuged at 2000 rpm for 1 min and the cleared sample retained. The 
required antibodies were added (see Table 2.1. for details of concentrations used) and the 
samples incubated for 2 - 18 h at 4oC with mixing. 15 – 50 µl of washed Protein G Sepharose 
were then added and samples incubated for a further 2 h at 4oC with mixing. Samples were 
then centrifuged for 1 min and the beads retained and washed 5 times with lysis buffer. The 
beads were then re-suspended in the appropriate buffer for subsequent analysis. 
2.8. SDS-PAGE 
5 x Sample Buffer (156.25 mM Tris HCl pH 6.8, 5% SDS, 25% glycerol, 0.0025% 
bromophenol blue and 250 mM DTT) was added to total cell lysate and IP protein samples  
(minimum 1:5 dilution). Proteins were then denatured by incubation at 100oC for 5 min and 
separated by size using sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE). 
8 – 15% acrylamide SDS-PAGE gels (acrylamide as indicated, 375 mM Tris pH 8.8, 0.1% 
SDS, 0.1% ammonium persulphate) were cast between 10 x 8 cm glass plates, with a gel 
thickness of 1.5 mm, or between 20 x 22 cm plates, with a gel thickness of 3 mm. Once the 
gel had polymerized, a layer of stacking gel (5% acrylamide, 375 mM Tris pH 8.8, 0.1% SDS, 
0.1% ammonium persulphate) was also cast using a comb to produce sample wells. The gels 
were transferred to tanks containing running buffer (0.025 M Tris, 0.192 M glycine, 0.1% 
SDS (pH 8.3.)) and samples loaded into the wells. Electrophoresis was then performed at 60 
V or 15 min and 100 – 120 V for 2 h for mini-gels or 50 V overnight for large gels. 
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2.8.1. Western blotting 
For WB analysis, separated proteins were transferred onto ImmobiliumTM-P 
polyvinylidine fluoride (PVDF) membranes using electroblotting. The PVDF membrane was 
activated by incubation in ethanol for 1 min. The membrane and gel were then equilibrated 
in transfer buffer (48 mM Tris-HCl (pH 8.5.), 0.39 M glycine, 0.1% SDS, 20% ethanol). For 
“wet” transfer the membrane and gel were sandwiched between two sponges and two 
pieces of Whatman 3 mm paper (also pre-equilibrated in transfer buffer). The case was then 
placed in a blotting tank filled with transfer buffer 
(anode>protection>membrane>gel>protection>cathode) and electroblotting was 
performed at 75 V for 1.5 h or 100 V for 1 h at 4oC.  For “semi-dry” transfer using the BioRad 
Trans-Blot Turbo Blot System, the membrane and gel were sandwiched between four pieces 
of Whatman 3 mm paper (also pre-equilibrated in transfer buffer) directly upon the anode 
(anode>filter>membrane>gel>filter>cathode). Excess buffer was absorbed and transfer was 
performed at 25 V for 30 min. 
Following electroblotting, the membranes were then blocked by incubation with 5% 
milk in TBS-T (Tris-buffered saline (TBS; 0.15 M NaCl, 0.05 M Tris-HCl (pH 7.6.)) 
supplemented with 0.1% Tween-20) for 30 min. The membranes were then incubated 
overnight at 4oC with primary antibody (primary antibodies prepared in 5% BSA, 0.05% 
NaN3, TBS-T; see Table 2.1. for details of concentrations used). After primary antibody 
incubation, the membranes were washed with TBS-T for 3 x 5 min prior to incubation with 
secondary antibody (anti-rabbit or anti-mouse Ig conjugated to horseradish peroxidase; 
prepared in 5% milk, TBS-T) for 1 h at room temperature.  Membranes were then washed 
again with TBS-T for 3 x 5 min. Antibody binding was visualized using X-ray film after 
membrane incubation with homemade electro-chemiluminescence (ECL) reagent (20 mM 
Tris-HCl (pH 8.5.), 0.0096% H2O2, 0.1 mM coumaric acid, 0.75 mM 3-aminophtalhydrazide) 
for 2 – 3 min. 
2.8.2. Colloidal Coomassie blue staining 
To visualize separated proteins, SDS-PAGE gels were stained using Colloidal Coomassie 
blue G-250. Gels were first fixed by incubation with 50% ethanol with 2% phosphoric acid 
for 3 – 18 h at room temperature. The gels were then washed for 3 x 30 min in H2O and 
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equilibrated in 34% methanol, 17% ammonium sulphate and 3% phosphoric acid for 30 min. 
0.5% (w/v) Colloidal Coomassie Blue G-250 was then added and gels were stained for 18 h. 
Following staining, the gels were washed in H2O and de-stained using 35% methanol, 7.5% 
acetic acid if required. 
2.9. In vitro calpain activity assay 
Calpain activity was measured using a Flurogenic Calpain Activity Assay Kit following 
the manufacturer’s instructions. Total cell lysate (50 µl) or IP (from 1 mg starting protein) 
protein samples were incubated with a synthetic peptide substrate in the presence of a 
Ca2+-containing reaction buffer for 15 min at room temperature. Cleavage of the peptide by 
calpain present in the sample results in the release of an AMC fluorophore, the abundance 
of which was detected fluorometrically using a FLUOstar OPTIMA plate reader, with an 
excitation filter of 350 nm and an emission filter of 450 nm. 
2.10. In vitro PI3K lipid kinase assay 
PI3K activity in IP protein samples was measured using an in vitro lipid kinase assay 
[269]. Samples were incubated with 10 µl L-α-phosphatidylinositol (PI) lipid substrate in the 
presence of 10 µl [γ-33] ATP and 20 µl kinase assay buffer (20 mM Tris-HCl (pH 7.4.), 200 mM 
NaCl, 1mM EDTA) for 30 – 60 min at room temperature with mixing. The reaction was then 
stopped by the addition of 100 µl of 1 M HCl.  
Phospholipids were then extracted by vigorous vortexing with 200 µl of 
chloroform:methanol (1:1) followed by retention of the organic (lower) layer. 80 µl of 
methanol:1M HCl (1:1) was then added to the sample, which was vortexed again, followed 
by retention of the phospholipid-containing organic (lower). Thin layer chromatography 
(TLC), developed in 65% propanol-1, 2% acetic acid, was then performed and PIP3, the lipid 
product of PI3K, was detected using autoradiography of the TLC plate using a STORM 
Imaging System. 
2.11. In vitro “Aktide” assay 
Akt protein kinase activity in total cell lysate protein samples was measured using the 
“Aktide” assay [270, 271], in which Akt active in the sample phosphorylates a synthetic 
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substrate peptide, which is subsequently quantified by LC-MS. A volume of 2.5 µl of total 
cell lysate were mixed with 5 µl of reaction mix (150 µM Aktide (peptide sequence: 
RPRAATF), 4 mM Tris (pH 7.4.), 0.2 mM NaVO4, 5 mM β-glycerol-phosphate, 15 mM MgCl2, 
0.15 mM ATP) and incubated at 37oC for 10 min with shaking. The reaction was stopped by 
the addition of 100 µl of 0.05 µM internal standard (IS) peptide (RP*RAApTF, where P* 
designates isotopically labelled heavy L-proline (13C5, 
15N)) in 20% acetonitrile (ACN), 0.1 % 
trifluoroacetic acid (TFA).  
Substrate and IS peptides were then extracted by strong cation exchange as follows. 
Samples were incubated with 10 µl of Dynabeads SCX in loading solution (25% ACN, 0.1% 
TFA, 0.01% Tween-20) for 45 min at room temperature. The beads were then washed twice 
with loading solution and once with wash solution (25% ACN, 0.1% TFA) before peptides 
were eluted by incubation with 20 µl of 150 mM Ammonium Bicarbonate (AmBic), 5% ACN, 
0.1% TFA for 10 min at room temperature. The eluents were then dried under vacuum at 
room temperature using a CHRIST Rotational Vacuum Concentrator and stored at -20oC until 
analysis. 
Selected Reaction Monitoring (SRM) analysis was performed on a Thermofisher TSQ-
Vantage (see 2.14.2. and 2.15.3. for details of instrument operation). The peak areas of the 
product fragment ion transitions of the Aktide peptide (parent ion mass to charge ratio 
(m/z) = 449.767, product fragment ion m/z = 400.685) and IS peptide (parent ion m/z = 
452.772, product fragment ion m/z = 403.699) were quantified. Sample Akt activity was 
expressed as the ratio of Aktide peak intensity to IS peak intensity. Aktide quality control 
samples of low (50 nM) and high (500 nM) concentrations were analyzed with each sample 
batch to assess instrument performance. 
2.12. In vitro protein kinase assay 
2.12.1. Akt1 protein kinase activity assay 
An in vitro assay, which uses intact dephosphorylated proteins as the reaction 
substrate, was designed to evaluate Akt1 protein kinase activity. Total cell lysate was 
harvested as described in 2.6.1. and subjected to a protein dephosphorylation treatment. To 
perform size exclusion chromatography, the lysate was loaded onto Sephadex G-25 columns 
Chapter 2: Materials and Methods 
75 
 
and proteins were eluted with 40 mM Tris-HCl (pH 7.0), 1 mM DTT, 0.1 mM EGTA, 0.1% 
Triton X-100, thus depleting the lysate of small molecules (including ATP). The lysate was 
then incubated at 30oC for 20 minutes to allow endogenous phosphatases to de-
phosphorylate proteins [272]. Protease inhibitors (0.05 TIU/mg aprotinin, 10 µM leupeptin, 
0.7 mM pepstatin A, 27 µM TLCK, 1 mM DTT and 1 mM PMSF) and phosphatase inhibitors 
(50 mM NaF, 1 mM Na3VO4 and 1 µM okadaic acid) were then added to the 
dephosphorylated lysate and total protein concentration was re-quantified (see  2.6.2.). 
In an alternative approach, the lysate was dephosphorylated using exogenous lambda 
protein phosphatase. Total cell lysate was harvested omitting EDTA and phosphatase 
inhibitors from the lysis buffer. Lambda protein phosphatase, in activating buffer containing 
1 mM MnCl2, was then added to the lysate, at a concentration of 10,000 units per mg of 
protein in lysate, and the mixture was incubated at 37oC for 1 h. Size exclusion 
chromatography was performed, protease and phosphatase inhibitors were added to the 
dephosphorylated lysate and total protein concentration was re-quantified, as described 
above. 
Following dephosphorylation treatment, lysate containing 500 µg of protein was 
diluted 1:1 in 2 x reaction buffer to reach a final concentration of 50 mM Tris-HCl (pH 7.5), 1 
mM EGTA, 1 mM DTT, 10 mM MgCl2 and ATP as indicated (0 - 500 μM) [273]. Recombinant, 
active protein kinase Akt1 was then added, as indicated, and the mixture was incubated at 
30oC for 5 min. The reaction was stopped by the addition of solid urea to a final 
concentration of 8 M. The samples were then subjected to in-solution trypsin digestion (see 
2.13.1.4) and phosphopeptide enrichment (see 2.13.2) prior to LC-MS/MS analysis for 
phosphopeptide identification and quantification (see 2.14.1., 2.15.2. and 2.16.1. for 
details).  
2.12.2. Endogenous protein kinase activity assay 
An in vitro assay, which uses intact native proteins as the reaction substrate, was 
designed to investigate the endogenous protein kinase activity of cell lines. Total cell lysate 
was harvested as described in 2.6.1., omitting EDTA from the lysis buffer. Lysate containing 
various concentrations of protein, 5 – 500 µg, was then diluted 1:1 in 2 x reaction buffer to 
reach a final concentration of 50 mM Tris-HCl (pH 7.5), 1 mM EGTA, 1 mM DTT, 10 mM 
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MgCl2 and ATP as indicated (0 - 500 μM). The mixture was then incubated at 30
oC for 5 min 
and the reaction was stopped by the addition of urea to a final concentration of 8 M. The 
samples were then subjected to in-solution trypsin digestion (see 2.13.1.4) and 
phosphopeptide enrichment (see 2.13.2) prior to LC-MS/MS analysis for phosphopeptide 
identification and quantification (see 2.14.1., 2.15.2. and 2.16.1. for details).  
2.13. Preparation of samples for LC-MS/MS analysis 
2.13.1. Trypsin digestion 
Prior to LC-MS/MS analysis all protein samples were subjected to protease digestion 
using trypsin. The method used was dependent on sample type and is specified for each 
experiment. Lo-Bind Eppendorf tubes were used throughout sample processing to minimize 
the loss of peptides due to binding to plastic surfaces. 
2.13.1.1. In-gel digestion 
In-gel digestion was used to digest proteins following SDS-PAGE (see 2.8.). Once 
proteins were visualized by Colloidal Coomassie Blue staining (see 2.8.2.), the individual 
sample lanes were cut out from the gel and split into 5 -10 fractions, which were the same 
across all the samples. Each gel piece was then cut up into small pieces, of around 1 mm2, 
and collected into a tube for trypsin digestion. The gel pieces were washed 3 times with 50% 
methanol and once with 100% methanol and dried under vacuum at room temperature 
using a CHRIST Rotational Vacuum Concentrator. Proteins were then reduced, by incubation 
with 10 mM DTT in 25 mM AmBic (pH 8.0) at 50oC for 45 min, and alkylated, by incubation 
with 50 mM iodoacetamide (IAM) in 25 mM AmBic (pH 8.0) in the dark for 1 h. The gel 
pieces were then washed twice with 50% methanol and dried again.  100 – 500 ng of 
sequence-grade trypsin in 25 mM AmBic (pH 8.0; quantity dependent on protein content of 
gel piece but in a minimum ratio of 1:50 trypsin:protein) was then added to each sample, 
which was then incubated at 37oC for 18 h with mixing. Peptides were then extracted from 
the gel pieces by sequential elution with 50% methanol, 1% formic acid (FA) and 100 mM 
AmBic (pH 8.0.). The gel extracts were pooled, dried under vacuum at room temperature 
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using a CHRIST Rotational Vacuum Concentrator and stored at -20oC. Dried peptide samples 
were re-constituted in 10 – 15 µl 0.1% TFA immediately prior to LC-MS/MS analysis. 
2.13.1.2. In-tube gel polymerization and in-gel digestion 
Protein samples were denatured as described for SDS-PAGE (see 2.8.). 100 µl of 
denatured protein sample was then incorporated into a polyacrylamide gel in a tube by the 
addition of 51 µl of acrylamide (30%), 5 µl ammonium persulphate (10%) and 2 µl of TEMED 
[274]. In-gel protein digestion was then performed as described previously. 
2.13.1.3. Filter-aided sample preparation (FASP)  
Filter-aided sample preparation (FASP) was performed as described by Wisniewski et al 
[142]. Protein samples were denatured in 4% SDS, 0.1 M DTT, 100 mM Tris-HCl (pH 7.6) and 
loaded onto a Microcon YM-10 10 kDa filter unit, which retains proteins greater than 10 kDa 
in size upon centrifugation at 14,000 x g. Proteins were then washed with 8 M urea, 0.1 M 
Tris-HCl (pH 8.5) and alkylated by incubation with 0.05 M IAM in 8 M urea, 0.1 M Tris-HCl 
(pH 8.5) for 20 min at room temperature. The proteins were then sequentially washed with 
8 M urea, 0.1 M Tris-HCl (pH 8.5) and 50 mM AmBic (pH 8.0) and incubated with sequence-
grade trypsin in 25 mM AmBic (pH 8.0; quantity dependent on protein amount but in a 
minimum ratio of 1:50 trypsin:protein) for 18 h at 37oC in a wet chamber. Peptides were 
eluted by the addition of 50 µl of 0.5 M NaCl and centrifugation at 14,000 x g for 20 min. 
 The resulting peptide solutions were then desalted and concentrated by solid-phase 
extraction using PepClean C18 spin columns. Sample buffer was added 1:4 to reach a final 
concentration of 5% ACN, 0.5% TFA and the solutions were loaded onto columns, which 
were pre-washed with 50% methanol followed by 5% ACN, 0.5% TFA. The columns were 
centrifuged at 2,000 rpm for 1 min to allow peptide binding. The columns were then washed 
twice with 5% ACN, 0.5% TFA and peptides were eluted with 20 µl of 50% ACN, 0.1% TFA. 
Peptide solutions were then dried under vacuum at room temperature using a CHRIST 
Rotational Vacuum Concentrator and stored at -20oC. Dried peptide samples were re-
constituted in 10 – 15 µl 0.1% TFA immediately prior to LC-MS/MS analysis. 
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2.13.1.4. In-solution digestion 
Protein samples were lysed or denatured in 8 M urea in 20 mM HEPES (pH 8.0). Proteins 
were then reduced, by incubation with 10 mM DTT for 15 min at room temperature in the 
dark, and alkylated, by incubation with 16.6 mM IAM for 15 min at room temperature in the 
dark. The samples were then diluted 1 in 4 with 20 mM HEPES, to reduce the urea 
concentration to < 2M, and incubated with immobilized TLCK-trypsin for 18 h at 37oC with 
mixing. Trypsin was inactivated by the addition of TFA to 1% of the final digest volume and 
the beads were discarded.  
The resulting peptide solutions were then de-salted and concentrated by solid-phase 
extraction using OASIS HLB 1cc Extraction cartridges. The cartridges, which were in a 
vacuum manifold at pressure <20 inHg, were washed with 100% ACN and equilibrated with 
2% ACN, 0.1% TFA. The peptide samples were then loaded onto the column and 
subsequently washed with 2% ACN, 0.1% TFA. Peptides were then eluted in 500 µl of 1M 
glycolic acid, 80% ACN, 5% TFA. Peptide solutions were then subjected to phosphopeptide 
enrichment, using TiO2 affinity chromatography (see 2.13.2.), or dried under vacuum at 
room temperature using a CHRIST Rotational Vacuum Concentrator and stored at -20oC. 
Dried peptide samples were re-constituted in 10 – 15 µl 0.1% TFA immediately prior to LC-
MS/MS analysis. 
2.13.2. Phosphopeptide enrichment: TiO2 affinity chromatography  
TiO2 affinity chromatography was used to enrich peptide samples for phosphopeptides 
as described by Montoya et al [232]. PepClean C18 spin columns were used as a solid phase 
support during TiO2 Affinity Chromatography. Peptides, in solution in 1M glycolic acid, 80% 
ACN, 5% TFA following solid-phase extraction de-salting, were incubated with Titansphere 
TiO2 beads (10 µm) for 5 min at room temperature with mixing. The samples were then 
loaded onto the columns, which were pre-washed with 1M glycolic acid, 80% ACN, 5% TFA. 
TiO2-bound peptides were then washed sequentially with 1M glycolic acid, 80% ACN, 5% 
TFA; 50% ACN and 50% ACN, 20 mM ammonium acetate (pH 6.8). TiO2-bound peptides 
were then eluted three times with 50 µl 50% ACN, 5 % NH4OH (pH 11.0). The TiO2 eluents 
were pooled and acidified by the addition of FA to a final sample volume of 10%. The 
peptide samples were then dried under vacuum at room temperature using a CHRIST 
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Rotational Vacuum Concentrator and stored at -20oC. Dried peptide samples were re-
constituted in 10 – 15 µl 0.1% TFA immediately prior to LC-MS/MS analysis. 
2.14. Liquid chromatography 
2.14.1. Ultra performance liquid chromatography (UPLC) 
The Waters Micromass Q-TOF Premier and ThermoFisher LTQ-Orbitrap XL mass 
spectrometers were coupled to Waters NanoAcquity UPLC systems. Peptide separations 
were performed using a Waters BEH130 (Ethylene Bridged Hybrid) C18 reverse-phase 
column (inner diameter = 100 µm, length = 100 mm, particle size = 1.7 µm, pore size = 300 
Å). 4 µl of sample were loaded at a flow rate of 2 μL/min for 8 min followed by a gradient 
elution at 400 nL/min, during which the instrument operated with a back pressure of around 
3,000 psi. Gradient elution was from 99% A (A = 0.1% FA in LC-MS grade H2O), 1% B (B = 
0.1% FA in LC-MS grade ACN) to 65% A, 35% B in 45 or 100 min, followed by a 10 min wash 
at 15% A, 85% B and a 10 min equilibration step at 99% A, 1% B. 
2.14.2. High performance liquid chromatography (HPLC) 
The ThermoFisher TSQ-Vantage was coupled to a ThermoFisher Accela LC system. 
Peptide separations were performed using a Vydac C18 reverse-phase column (inner 
diameter = 0.8 mm, length = 150 mm, particle size = 5 µm, pore size = 300 Å). 10 µl of 
sample were loaded at a flow rate of 480 μL/min followed by a gradient elution at 200 
µL/min, during which the instrument operated with a back pressure of around 200 bar. 
Gradient elution was from 99% A (A = 0.1% FA in LC-MS grade H2O), 1% B (B = 0.1% FA in LC-
MS grade ACN) to 65% A, 35% B in 6.5 min, followed by a 5 min wash at 99% A, 1% B. 
2.15. Mass spectrometry analysis 
2.15.1. Waters Micromass Q-TOF Premier mass spectrometer 
The Waters Micromass Q-TOF Premier is a quadrupole-TOF hybrid instrument (Fig. 
2.1.).  
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Figure 2.1. Schematics of the ion optics of the Waters Micromass Q-TOF Premier (Image 
reproduced from Operator User Manual). 
This instrument type was specifically designed for the purpose of biomolecule 
sequencing [275]. As peptides are eluted from the UPLC system they are subjected to 
electrospray ionization and directed into the mass spectrometer. Ion lenses direct the flow 
of gas phase ions into the quadrupole analyzer, which consists of 4 parallel metal rods. Each 
pair of rods is connected electrically and a current is applied between them, creating an 
electrical field in the centre of the analyzer. This electrical field can be manipulated to direct 
all ions or only ions with a selected m/z through the analyzer. The quadrupole is followed by 
a hexapole gas collision cell, which can be used to fragment ions by bombardment with 
neutral gas molecules in a process known as collision induced disassociation (CID). The TOF 
analyzer, which follows, uses a high voltage pulse to accelerate the ions down the flight tube 
towards the detector, whereby they separate as ions with different m/z travel at different 
speeds. The incorporation of two reflectrons, which are metal plates, allows the beam of 
ions to traverse the flight tube twice and increases resolution by correcting the kinetic 
energy distribution of the different ions and by increasing the flight path length. A micro-
channel plate at the end of the flight path detects the ion separation. 
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Quadrupole
Collision Cell
Ion Lenses
Detector
Reflectrons
Fragmentation
MS and MS/MS     
Analysis
Ion Source
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Quantitative data was obtained using MS mode. In this mode, the quadrupole and 
collision cell function to focus the stream of ions into the time of flight analyzer (TOF), 
where the peptide ions are separated according to m/z ratio before detection. Qualitative 
analysis was obtained using data directed acquisition (DDA) mode, which combines MS and 
MS/MS analysis. In MS/MS analysis, peptide ions of interest are selected for by the 
quadrupole and directed to the collision cell, where they are fragmented by CID. The 
fragment ions are then separated by the TOF analyzer before detection. In DDA, the 
instrument switches between MS and MS/MS modes depending on the ions detected by the 
MS scan.  
In the DDA method used, a full MS survey scan (m/z 350 – 1800; Fig. 2.2. A) was 
performed every 0.5 s and if ions of interest, i.e. multiply charged ions likely to be peptides, 
were detected the 3 most abundant were automatically mass-selected and fragmented in 
the quadrupole (collision energy 35 V) prior to MS/MS analysis in the TOF analyzer (m/z 50 – 
2000; Fig 2.2. B). The length of time the instrument takes to complete an MS survey scan 
and any required MS/MS scans is known as the duty cycle, which for the DDA cycle used was 
around 3.5 s. Due to the length of the duty cycle of the Q-TOF, this DDA method is not 
advisable for the acquisition of quantitative data as the most intense parent ion signal may 
be missed between MS scans. 
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Figure 2.2. Illustration of Waters Micromass Q-TOF Premier data output.  
A. Examples of a total ion chromatogram (TIC) and an MS survey scan taking at a given retention 
time (RT). B. Example of an MS/MS spectrum for a parent ion with a given m/z. 
 
 
2.15.2. ThermoFisher LTQ-Orbitrap XL mass spectrometer 
The ThermoFisher LTQ-Orbitrap XL is a linear (2D) quadrupole ion trap (LTQ) and 
orbitrap hybrid instrument (Figure 2.3.).  
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Figure 2.3. Schematic of the ion optics of the ThermoFisher LTQ-Orbitrap XL (Image taken from 
Operator User Manual) 
 
In this instrument the orbitrap functions as a high accuracy and high resolution mass 
detection system and the LTQ carries out ion selection and fragmentation. As peptides are 
eluted from the UPLC, they are subjected to electrospray ionization and directed into the 
mass spectrometer. The ion optics focus the stream of gas phase ions and direct them into 
the LTQ, which consists of a triple-sectored hyperbolic rod quadrupole. Voltages are applied 
to the rods creating an electrical field that can be manipulated to trap ions axially and 
radially [276], i.e. they cannot exit and orbit within the trap at a frequency determined by 
their m/z. One function of the LTQ is to collect a required number of ions before sending 
them to the orbitrap for mass analysis. The c-trap is an important element of this process as 
it ensures that the ions efficiently transfer to the orbitrap. The LTQ can also select ions of 
interest by sequentially ejecting all other ions from the trap by manipulation of the electrical 
field. In addition, the LTQ functions as a collision cell, permitting CID of selected ions. Ions 
for detection are ejected laterally from the LTQ and detected by a conversion dynode 
coupled to an electron multiplier.  
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The orbitrap consists of a central, spindle-shaped, electrode, around which the ions 
oscillate at a frequency determined by their m/z, and an outer electrode, which creates an 
electrostatic field with the central electrode. The orbitrap derives the m/z of an ion based 
on the frequency of its oscillations along the axis of the central electrode [277], which is 
measured by a Fourier transform.  
In MS mode, packets of ions are collected by the LTQ and sent to the orbitrap, via the 
c-trap, for high accuracy and high resolution mass analysis. In MS/MS mode, ions of interest, 
i.e. multiply charged ions likely to be peptides, are isolated by the LTQ and fragmented 
there by CID. The fragment ions are then sequentially ejected from the LTQ and detected. In 
DDA, the instrument switches between MS and MS/MS modes depending on the ions 
detected in the MS survey scan.  
In the DDA method used, a full MS survey scan (m/z 375 – 1800) was performed at 
resolution of 30,000 at m/z = 400. If any multiply charged ions of interest were detected, 
the 5 most abundant were automatically mass-selected, fragmented by CID (normalized 
collision energy 35%) and analyzed by MS/MS in the LTQ (m/z 50 – 2000; Fig. 2.4. A). 
Multistage activation, which enhances peptide backbone fragmentation, was used for 
phosphoproteomic experiments. Dynamic exclusion was enabled, thereby excluding the 
repeat analysis of the same ion, with the exclusion list restricted to 500 entries, exclusion 
duration of 40 s and mass window of 10 ppm. Unlike the Q-TOF, the orbitrap performs MS 
and MS/MS scans in separate analyzers and therefore can move more rapidly between 
these functions as there is no requirement to wait for the orbitrap to empty before 
commencing MS/MS scans. As scans are faster and the instrument can move before 
functions more rapidly, the duty cycle of the DDA method used was around 2 s, therefore 
quantitative MS and qualitative MS/MS data was obtained from a single analysis. An 
additional advantage over the Q-TOF analyzer is that the MS and MS/MS data obtained 
from the LTQ-Orbitrap has a higher degree of mass accuracy and resolution.  
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Figure 2.4. Illustration of ThermoFisher LTQ-Orbitrap XL data output.  
A. Examples of a total ion chromatogram (TIC) and an MS survey scan taking at a given retention 
time (RT). B. Example of an MS/MS spectrum for a parent ion with a given m/z. 
 
2.15.3. ThermoFisher TSQ-Vantage mass spectrometer 
The ThermoFisher TSQ-Vantage is a triple stage quadrupole mass spectrometer (Fig. 
2.5.), an instrument that is optimal for high sensitivity quantitative analysis of peptides and 
small molecules, e.g. metabolites and drugs. 
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Figure 2.5. Schematic of a typical triple quadrupole instrument. 
 
As peptides are eluted from the HPLC system they are subjected to electrospray 
ionization and directed into the analyzer. Each quadrupole consists of 4 parallel metal rods 
that are connected electrically and a current is applied between them, creating an electrical 
field in the centre of the analyzer. Ion lenses direct the flow of ions into the first quadrupole 
analyzer (Q1), where the electrical field can be manipulated to direct all ions or only ions 
with a selected m/z through the analyzer. The flow of ions is then directed into Q2, which 
functions as a gas collision cell where ions are fragmented by CID. Finally, Q3 acts as a 
second ion filter directing the required ions towards the electron multiplier detector. 
This triple quadrupole instrument was coupled to a HPLC system and used for the SRM 
analysis of small peptides produced by the Aktide assay (see 2.11.). Parent ions were 
selected in Q1 and directed to Q2, where they were fragmented by CID (collision energy = 
16/17 V). Q3 was then used as a second ion filter to direct selected product fragment ions 
towards the detector (Fig. 2.6.). 
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Figure 2.6. Illustration of ThermoFisher TSQ-Vantage SRM data output. 
TIC showing the peak of the product fragment ion of a given parent ion, as selected by Q3. 
 
2.16. Data analysis 
2.16.1 Mass spectrometry data analysis 
MassLynx (Waters) and XCalibur (ThermoFisher) software were used to view mass 
spectrometry data. ProteinProspector was used in conjunction with XCalibur for the manual 
verification of MS/MS data. XCalibur was also used for the quantification of ion peaks for 
Aktide SRM analysis (see 2.11. and 2.15.3.) and to manually verify peptide quantifications 
derived by other methods.  
Mascot Daemon (v2.2.2; Matrix Science, London, UK) was used to automate the 
analysis of data. This software automates the use of Mascot Distiller (v2.3.2.), to smooth 
and centroid the MS/MS data, and Mascot search engine (v2.2.02), to search the processed 
files against all entries in the peptide sequence library of the IPI Mouse database 
(ipi.MOUSE.v3.56.fasta) or the human Swiss Prot database (downloaded on 03/03/2010 
containing 23000 entries) [156]. For LTQ-orbitrap data search parameters included: enzyme, 
trypsin; number of missed cleavages permitted, 2; fixed modification, Carbamidomethyl (C); 
variable modifications, Gln->pyro-Glu (N-term Q), Oxidation (M), Phospho (ST), Phospho (Y); 
mass tolerance for precursor ions, 8 ppm; mass tolerance for fragment ions, 0.8 Da. The 
data output includes the identification of the peptide (amino acid sequence), parent protein 
m/z,  RT and confidence scores for these identifications based on probability [156]. Peptide 
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hits were considered significant when they had an Expectation value < 0.05 (as returned by 
Mascot) and protein scores were considered significant if they had a MASCOT score > 40, 
with a minimum of three peptides identified. Phosphorylation site assignments were made 
by MASCOT using the Delta score to determine confidence. 
Peptides and proteins were quantitated using Pescal (Peak Statistic Calculator), a 
software created by Dr Pedro Cutillas [159] that automates the generation of extracted ion 
chromatograms (XIC) and subsequent quantification of peak height and area. Pescal was 
used to extract the chromatographic peaks for the first three isotopes of a given peptide 
from MS data using m/z, retention time (RT) and isotopic charge distribution information 
derived from the MS scan and MS/MS spectrum (Fig. 2.7.). The restrictions of an m/z 
window of 7 ppm, RT window of 2 – 5 min (dependent on gradient length) and a coefficient 
of variation >0.95 between the observed and theoretical isotope distribution were used to 
ensure the quantification of the correct peak. Peak height and area quantification data was 
parsed into Excel for normalization and further analysis. Peptide intensities were normalized 
to the total ion chromatogram intensity for each sample. For protein quantitation, peptide 
abundance data was averaged to give an estimation of protein abundance. Quantitative 
data from experimental samples were compared using the Student’s t-test function in Excel.  
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Figure 2.7. Illustration of Pescal. 
A. MS and MS/MS data is used to generate identification information for the Enolase 1 peptide 
AVDDFLISLDGTANK. B. Identifying information is used to generate an XIC and identify the correct ion 
peak, although it should be noted that for the majority of peptides only one candidate is found 
within the RT window. The peptide abundance is expressed as peak height and peak area. 
2.16.2. Other data analysis 
GraphPad Prism was used to illustrate quantitative data and to compare data sets 
using the Student’s t-test (two-tailed). All FACS data was analyzed using FlowJo. 
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3. Affinity Purification – Mass Spectrometry Screen for Dynamic 
Interaction Partners of Class IA PI3K 
3.1. Introduction and aim of study 
Class IA PI3Ks regulate essential cellular functions including growth, survival, metabolism 
and motility [2, 60], therefore the PI3K/Akt pathway activity is tightly regulated by a number 
of well-characterized mechanisms. Lipid phosphatases, such as PTEN and SHIP, 
dephosphorylate PIP3, the lipid product of class IA PI3Ks, thereby terminating signal 
transduction [278]. The pathway is also regulated by downstream protein phosphatases, for 
example PP2A, which dephosphorylates and inactivates the effector protein Akt [85], and by 
negative feedback loops that terminate the activation signal, for example mTORC1-
mediated phosphorylation and subsequent degradation of IRS1 [46]. 
Signalling activity is often regulated by the formation of multi-protein complexes, which 
can modulate enzymatic activity [263, 264]. The regulation of signalling processes by 
protein-protein interactions has been described for several signalling pathways, including 
Erk [265], Akt [266] and mTOR [267, 268], and many large-scale protein-protein interaction 
studies are currently underway to expand our knowledge in this area. 
Our knowledge of the effects of protein-protein interactions on the activity of PI3K 
enzymes is currently under-explored. It is known that binding of p85 to p110 leads to an 
increase in stability and a decrease in lipid kinase activity of p110 in vitro [20]. However, 
whether p85 regulates p110 activity dynamically in vivo is not clear as this interaction is very 
strong and both subunits are constitutively bound in cells [19].  Ras binding to the p110α 
subunit is known to regulate some PI3K functions [29, 279] however the full implications of 
this relationship on other isoforms are not clear. A number of other proteins have also been 
reported to bind p85, including SHIP [280], ezrin [281], Src family members [282] and the 
PTEN-associated complex [283]. However, the potential roles, if any, of these binding 
partners in the regulation of PI3K signalling activity have not been investigated extensively.  
The aim of the work presented in this Chapter was to identify novel, dynamic interaction 
partners of class IA PI3K with a functional role in controlling the activity of the pathway. We 
reasoned that binding partners with an active role in signal modulation would bind PI3K at 
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different stoichiometries in cells with an active pathway relative to those in which the 
pathway was inactive. Accordingly, an affinity purification mass spectrometry (AP-MS) 
strategy, inspired by that described for the identification of EGFR signalosomes [284], was 
designed to quantify binding partners of class IA PI3K in starved cells relative to cells treated 
with serum (Fig. 3.1.). This approach was selected as we wished to investigate interaction 
partners of endogenous PI3K without the need to over-express the protein bait. 
 
 
 
 
Figure 3.1. Strategy of AP-MS screen for dynamic interaction partners of PI3K. Total cell lysate 
samples were taken from NIH-3T3 cells that were serum-starved for 18 h (resulting in low levels of 
pathway activity) or serum-starved for 18 h followed by a 5 min treatment with 10% FBS (resulting in 
high levels of pathway activity). PI3K protein complexes were purified from both samples using 
immunoprecipitation directed against the p85 regulatory subunit of PI3K. The purified protein 
complexes were then separated by SDS-PAGE and subjected to in-gel trypsin digestion followed by 
LC-MS and LC-MS/MS analysis for quantitative and qualitative proteomic analysis. 
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3.2. Optimization of AP-MS conditions 
An initial series of experiments were conducted to optimize the conditions to be used in 
the AP-MS screen for dynamic interaction partners of PI3K. Mouse embryonic fibroblast 
NIH-3T3 cells were selected as the model for the screen as they are well characterized cells 
and PI3K expression and activity levels have been thoroughly investigated [19]. An 
additional advantage of using these cells is that follow-up investigation could potentially be 
transferred to mouse genetic models with relative ease. 
3.2.1. Effects of detergent on the stability of protein-protein interactions. 
The variable effects of different detergents and their concentrations on affinity 
purification of protein complexes are well known. For example, Sarbassov et al 
demonstrated that the rictor-mTOR protein complex could only be affinity-purified from 
total cell lysate using CHAPS-containing buffers [268]. Buffers containing stronger 
detergents, such as Triton X-100, can disrupt weak protein-protein interactions [193]. 
An experiment was carried out to compare the effects of CHAPS and Triton X-100 
containing buffers on the immunoprecipitation of p85 protein complexes. Total cell lysate, 
containing 1 mg of total protein, from NIH-3T3 and IC-21 cells was subjected to IP of PI3K 
p85 protein complexes. Cell lysis and all IP bead washes were carried out using lysis buffer 
containing 1% Triton X-100 or 0.3% CHAPS and the resulting IP products were fractionated 
using SDS-PAGE and the gel stained for all proteins using Colloidal Coomassie blue staining 
(Fig. 3.2.).  
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Figure 3.2. The use of 0.3% CHAPS in buffers preserves more protein-protein interactions than the 
use of 1% Triton X-100. PI3K p85 protein complexes were immunoprecipitated from NIH-3T3 and IC-
21 cells using 0.3% CHAPS or 1% Triton X-100 in buffers throughout the purification process. The 
purified proteins were then separated by SDS-PAGE and visualized using Colloidal Coomassie blue 
staining. 
The results demonstrated that a higher number and abundance of proteins were 
isolated from total cell lysate when 0.3% CHAPS lysis buffer was used (Fig. 3.2.), thus 
indicating that this detergent preserves more p85 interactors and/or non-specific 
interactors than Triton X-100. This is in line with expected findings as a mild detergent, such 
as CHAPS, should preserve weaker protein-protein interactions than a stronger detergent, 
such as Triton X-100, thus increasing the number of proteins isolated by affinity purification. 
However, it should be noted that that weak, non-specific interactions between proteins and 
with the antibody are also likely to be preserved, thus increasing the number of unspecific 
proteins present in the AP-MS screen. 
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3.2.2. Effects of detergent type and concentration on total protein yield. 
The effects of the two different detergents on cell lysis were then examined in further 
detail to establish the implications of their use for the recovery of total protein from cells. 6-
well plates were seeded with equal numbers of NIH-3T3 cells (0.7 x 106 per well) and the 
cells were harvested using 200 µl of lysis buffer containing various concentrations of CHAPS 
or Triton X-100. The experiment was performed in triplicate. The total protein content of 
the lysates was measured using the Bradford assay (Fig. 3.3). 
 
 
Figure 3.3. Total protein yield is decreased at lower detergent concentrations. Equal numbers of 
NIH-3T3 cells were lysed in 200 µl of buffer containing various concentrations of CHAPS or Triton X-
100 detergent (n = 3). Total protein concentration of each sample was determined using the 
Bradford assay. Data expressed as mean +/- standard error of the mean (SEM). 
 
These data showed that total protein yield was comparable for both detergents at 
most concentrations (Fig. 3.3.). The results also showed that total protein yield decreased as 
the concentration of detergent in the lysis buffer was reduced (Fig. 3.3.). However, this 
effect was negligible for Triton X-100 lysis buffers containing less than 1% detergent. In 
contrast, the effect was more pronounced for CHAPS-containing lysis buffer, and protein 
yield was found to be considerably decreased when this detergent was used at a 
concentration of 0.2%.  
3.2.3. Effects of detergent type and concentration on PI3K p85 yield. 
The effects of the two different detergents on cell lysis were then further investigated 
to determine their effects on the recovery of PI3K from cells. 6-well plates were seeded with 
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equal numbers of NIH-3T3 cells (0.7 x 106 per well) and the cells were harvested using 200 µl 
of lysis buffer containing various concentrations of CHAPS or Triton X-100. The experiment 
was performed in triplicate. 30 µl of each lysate was subjected to SDS-PAGE and 
quantitative WB analysis of p85 (Fig. 3.4.). 
 
 
Figure 3.4. PI3K p85 protein yield does not correlate with detergent type or concentration. Equal 
numbers of NIH-3T3 cells were lysed in 200 µl of buffer containing various concentrations of CHAPS 
or Triton X-100 detergent (n = 3). A. Representative blot image obtained by analysing 30 µl samples 
subjected to WB analysis for p85. B. Densitometry analysis of p85 WB results. Band intensity was 
normalized to the mean band intensity across the experiment. C. p85 quantification was normalized 
to TP concentration. Data expressed as mean +/- SEM. 
 
The results of this experiment revealed that the quantity of PI3K p85 harvested did not 
correlate well with the type or concentration of detergent used in the lysis buffer (Fig. 3.4.). 
In general the discrepancy between replicates was high, which is likely to be a reflection of 
the limited use of western blots for quantitative analysis. PI3K p85 recovery was lower in 
the samples with the lowest concentration of detergent (Fig. 3.4. A and B), however when 
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recovery was normalised to the total protein yield for the corresponding sample, relative 
p85 recovery was not greatly affected (Fig. 3.4. C).  
The combined results of these experiments (3.2.2. and 3.2.3.) led to the selection of 
0.3% CHAPS lysis buffer for use in the AP-MS protocol. This lysis buffer was shown to 
increase the number of proteins purified by IP from total cell lysate (Fig. 3.2.), thus 
increasing the likelihood that weak protein-protein interactions were preserved. Although 
the use of 0.3% CHAPS lysis buffer resulted in a reduction in total protein yield (Fig. 3.3.), 
p85 recovery was not significantly affected (Fig. 3.4.) and thus this was not considered to be 
a concern.  
3.2.4. Optimization of PI3K p85 IP.  
A p85 (pan isoform) antibody was selected for affinity purification of PI3K protein 
complexes as it has been previously observed in this laboratory to have strong affinity for all 
isoforms of p85 [19]. The use of a pan p85 antibody would also overcome the problem of 
the presence of multiple PI3K p110 isoforms as all will be immunoprecipitated by targeting 
this subunit. 
Two p85 (pan) antibodies were in routine use in the laboratory: Millipore 06-195 
(antisera, raised against intact p85 and N-terminal SH2 domain) and Millipore 06-497 
(purified antibody, raised against intact p85). Experiments were carried out to evaluate the 
affinity for p85 of the two different antibodies and to determine the optimum concentration 
for IP yield. NIH-3T3 total cell lysate was subjected to IP using antibody 06-497, 06-195 or a 
50:50 mix of the two at various ratios of antibody to total protein. The resulting IP products, 
along with total cell lysate samples and an equivalent volume of supernatant from each IP, 
were run by SDS-PAGE for WB analysis of p85 (Fig 3.5.). 
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Figure 3.5. A combination of antibodies results in most efficient purification of PI3K p85. NIH-3T3 
cell lysates, containing 1 mg protein, were subjected to IP of PI3K p85 using the indicated antibodies 
at ratios of 1:500, 1:750, 1:1000 or 1:2000 (µl antibody:µg TP). Total cell lysate (TCL), 
immunoprecipitates (IP) and residual supernatant (SNT) were subjected to WB analysis for p85. 
 
The results showed that antibody 06-195 had a greater affinity for p85 than 06-497, as 
in the latter there was significant amounts of p85 residual in the IP supernatant relative to 
p85 in the IP (Fig 3.5.). This is in line with results reported in this laboratory that suggest that 
06-195 does not have high affinity for p85β, the predominant p85 isoform expressed in this 
cell line [19]. However, it should be noted that this greater affinity for p85 may also be due 
to differences in antibody concentration in the stock solution rather than in absolute 
epitope affinity. The best result, i.e. highest recovery of p85 in IP and lowest residual p85 in 
IP supernatant, was obtained using a combination of the two antibodies at a ratio of 1:500 
(µl antibody: µg TP) (Fig. 3.5.). These are the IP conditions that were selected for subsequent 
experiments. 
3.3. AP-MS screen results 
3.3.1. SDS-PAGE comparison of PI3K p85 protein complexes affinity purified from NIH-
3T3 cells. 
Following the principles of the strategy previously outlined (Fig. 3.1.), we proceeded to 
compare the composition of PI3K p85 complexes in starved and stimulated NIH-3T3 cells 
using SDS-PAGE and Colloidal Coomassie blue staining. 
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PI3K p85 protein complexes were immunoprecipitated from approximately 8 x 106 NIH-
3T3 cells (yielding around 10 mg of protein) using a mixture of two antibodies (06-195 and 
06-497) against the p85 regulatory subunit of PI3K. Samples were taken from cells treated 
with 18 h serum-starvation (resulting in low pathway activity) or with 18 h serum-starvation 
followed by 5 min stimulation with 10% FBS (resulting in high pathway activity). A control 
sample, a pool of the experimental samples, was subjected to IP using total rabbit IgG for 
assessment of non-specific interactions with rabbit IgG, protein G and the sepharose bead 
support. Mild cell lysis conditions (0.3% CHAPS) were used to maximize the chances of 
retaining weak protein-protein interactions. Purified PI3K protein complexes were then 
fractionated using SDS-PAGE and proteins were visualized by Colloidal Coomassie blue 
staining (Fig. 3.6.). 
 
 
Figure 3.6. SDS-PAGE analysis does not reveal any clear candidate interaction partners dynamically 
regulated by serum. Total cell lysate samples were taken from NIH-3T3 cells that were serum-
starved for 18 h (resulting in low levels of pathway activity) or serum-starved for 18 h followed by a 5 
min treatment with 10% FBS (resulting in high levels of pathway activity). PI3K protein complexes 
were purified from both samples using immunoprecipitation directed against the p85 regulatory 
subunit of PI3K. The purified protein complexes were then separated by SDS-PAGE and resolved by 
Colloidal Coomassie blue staining for visual comparison. 
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Colloidal Coomassie blue staining of isolated PI3K protein complexes failed to identify 
any obvious differences between the starved and stimulated cell conditions, thus 
demonstrating that this method is unlikely to be useful in the identification of interaction 
partners (Fig. 3.6.). The visual comparison of p85 IPs isolated from starved and stimulated 
samples did however demonstrate the complexity of the IP products, partly due to the likely 
presence of high numbers of non-specific interactors. The control sample (IgG IP) illustrated 
the limitations of affinity purification by highlighting the large number of non-specific 
interactors with the affinity reagents (Fig 3.6.).  
3.3.2. AP-MS analysis of PI3K p85 protein complexes from NIH-3T3 cells. 
We then proceeded to use a mass-spectrometry based quantitative approach to identify 
candidate binding partners of PI3K (Fig 3.1.). We reasoned that proteins present in equal 
abundance in IPs under both conditions were likely to be non-specific or constitutive 
interactors and therefore were not investigated further. We focused our attention on 
proteins that interacted dynamically with PI3K upon serum-induced pathway activation as 
we considered that they may have potential functional roles in the regulation of PI3K 
signalling.  
PI3K p85 protein complexes were isolated from NIH-3T3 cells and fractionated by SDS-
PAGE as described in 3.3.1. Following Colloidal Coomassie blue staining, sample lanes were 
divided into 5 – 10 fractions (dependent on gel size) that were then subjected to in gel-
trypsin digestion followed by LC-MS and LC-MS/MS analysis on the ThermoFisher LTQ 
Orbitrap XL. Three biologically independent experiments were performed and two technical 
replicates of each were analyzed. 
 Hundreds of proteins were identified and quantified across the study, with an average 
of 193 proteins found per experiment. Of these, 81 proteins were identified and quantified 
in all three replicates (Appendix 1). We used rigorous criteria for both protein identification 
and quantification to identify potential dynamic binding partners of PI3K. First, proteins had 
to be identified in IPs with a minimum of 3 peptides per protein and a MASCOT score > 40. 
Second, proteins had to be identified and quantified across all three of the independent 
replicates. Third, the average log2 fold difference of protein abundance in IPs obtained from 
starved and stimulated cells had to be <-1 or >1 (i.e. two-fold). Finally, the quantitative 
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difference had to be statistically significant (p<0.05 as assessed by the Student’s t-test). 
Three proteins met these criteria (Fig. 3.7. and Table 3.1.). 
 
 
 
 
 
 
 
Figure 3.7.  AP-MS screen identifies CAPNS1, FN1 and VIM as candidate dynamic interaction 
partners of Class IA PI3K. Volcano plot illustrating mean relative quantification of proteins identified 
in all three experiments (n = 81). Total cell lysate samples were taken from NIH-3T3 cells that were 
serum-starved for 18 h (resulting in low levels of pathway activity) or serum-starved for 18 h 
followed by a 5 min treatment with 10% FBS (resulting in high levels of pathway activity). PI3K 
protein complexes were purified from both samples using immunoprecipitation directed against the 
p85 regulatory subunit of PI3K and subjected to quantitative proteomic analysis (n = 3). Relative 
protein abundance between starved and stimulated conditions is expressed as log2 fold and 
statistical significance was evaluated using the Student’s t-test. 
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Table 3.1. Summary of AP-MS results for proteins of interest (PI3K proteins and candidate dynamic 
interaction partners). 
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p85α IPI00263878 
Phosphatidylinositol 
3-kinase regulatory 
subunit alpha 932 29 1.0 1.0 1.0 0.0 0.1 0.663 
p85β IPI00117159 
Phosphatidylinositol 
3-kinase regulatory 
subunit beta 934 27 1.0 1.0 1.0 0.0 0.2 0.951 
p110α IPI00309224 
Phosphatidylinositol-
4,5-bisphosphate 3-
kinase catalytic 
subunit alpha 
isoform 417 14 0.9 1.1 0.8 -0.3 0.6 0.445 
p110β IPI00136110 
Phosphatidylinositol-
4,5-bisphosphate 3-
kinase catalytic 
subunit beta isoform 261 10 0.8 1.2 0.7 -0.5 0.5 0.239 
CAPNS1 IPI00130992 
Calpain small 
subunit 1 145 7 1.5 0.5 2.7 1.4 0.3 0.010 
FN1 IPI00352163 
Putative 
uncharacterized 
protein (fibronectin 
1) 191 14 0.5 1.5 0.3 -1.8 0.3 0.007 
VIM IPI00227299 Vimentin 222 6 0.3 1.7 0.2 -2.6 2.1 0.031 
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The PI3K subunits p85α, p85β, p110α and p110β were identified and quantified in all 
three experiments and, as expected, were found to be present in equal abundance under 
both conditions (Table 3.1. and Fig. 3.8.A). CAPNS1, FN1 and VIM were also identified and 
quantified in PI3K protein complexes in all three experiments (Table 3.1. and Appendix 1). 
CAPNS1 was found at lower abundance in serum-stimulated cells relative to starved cells, 
with a mean log2 fold difference of 1.45 (SD = 0.3; p = 0.010) (Table 3.1. and Fig. 3.8.B). FN1 
and VIM were found at higher abundance in serum-simulated cells relative to starved cells, 
with mean log2 fold differences of -1.8 (SD = 0.3; p = 0.007) and -2.6 (SD = 2.1; p = 0.031) 
respectively (Table 3.1. and Fig. 3.8.B).   
 
 
Figure 3.8. AP-MS screen identifies CAPNS1, FN1 and VIM as candidate dynamic interaction 
partners of Class IA PI3K. Relative protein quantifications of PI3K subunits (A) and candidate 
interaction partners (B) in serum-starved and stimulated cells. Total cell lysate samples were taken 
from NIH-3T3 cells that were serum-starved for 18 h (resulting in low levels of pathway activity) or 
serum-starved for 18 h followed by a 5 min treatment with 10% FBS (resulting in high levels of 
pathway activity). PI3K protein complexes were purified from both samples using 
immunoprecipitation directed against the p85 regulatory subunit of PI3K and subjected to 
quantitative proteomic analysis. Relative protein abundance was expressed as mean ± SEM (n = 3 
independent experiments) relative to basal sample.*, p<0.05; **, p < 0.01; ns, non-significant. 
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3.4. Verification of AP-MS screen results 
3.4.1. Manual verification of MASCOT identification of candidate interaction partners. 
MASCOT identifications of candidate PI3K interaction partners were partially verified 
by manual sequencing of an identified peptide for CAPNS1, FN1 and VIM. Predicted ion 
fragments for each peptide were obtained from ProteinProspector 
(http://prospector.ucsf.edu/prospector/mshome.htm) and fragment ions were identified in 
the MS/MS spectra for that peptide (Fig. 3.9.).  
 
 
Figure 3.9. A . Manual verification supports MASCOT identification of candidate interaction 
partners. Manually annotated MS/MS spectra confirming MASCOT sequence results for 
representative peptide of CAPNS1 (A). Predicted ion fragments for each peptide were obtained from 
ProteinProspector (http://prospector.ucsf.edu/prospector/mshome.htm) and fragment ions were 
identified in the MS/MS spectra for that peptide. The MASCOT confidence score for the 
identification of each peptide is also shown. MASCOT peptide identifications were confirmed thus 
supporting the AP-MS screen results. 
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Figure 3.9. B - C. Manual verification supports MASCOT identification of candidate interaction 
partners. Manually annotated MS/MS spectra confirming MASCOT sequence results for 
representative peptides of FN1 (B) and  VIM (C). Predicted ion fragments for each peptide were 
obtained from ProteinProspector (http://prospector.ucsf.edu/prospector/mshome.htm) and 
fragment ions were identified in the MS/MS spectra for that peptide. The MASCOT confidence score 
for the identification of each peptide is also shown. MASCOT peptide identifications were confirmed 
thus supporting the AP-MS screen results. 
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3.4.2. Manual verification of Pescal quantification of candidate interaction partners. 
Pescal quantitation results for p85β and for candidate PI3K binding partners CAPNS1, 
FN1 and VIM were validated by visual inspection of the extracted ion chromatograms of a 
selection of peptides (Fig. 3.10. A – D). 
 
Figure 3.10. A. Manual validation supports Pescal quantification of p85β and candidate interaction 
partners. Extracted ion chromatograms (XICs) generated by Pescal were manually validated in the 
MS scan for representative peptides of p85β (A) in starved and stimulated samples. Panel (i) shows 
the XIC s generated by Pescal (peaks shown on normalized scale). Panel (ii) shows the XIC generated 
in XCalibur (peaks shown relative to most abundance peak in scan). The peak corresponding to the 
peptide of interest (indicated by arrow) was identified by retention time and verified in XCalibur 
using the isotopic distribution.  
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Figure 3.10. B – C. Manual validation supports Pescal quantification of p85β and candidate 
interaction partners. Extracted ion chromatograms (XICs) generated by Pescal were manually 
validated in the MS scan for representative peptides of CAPNS1 (B) and FN1 (C) in starved and 
stimulated samples. Panel (i) shows the XIC s generated by Pescal (peaks shown on normalized 
scale). Panel (ii) shows the XIC generated in XCalibur (peaks shown relative to most abundance peak 
in scan). The peak corresponding to the peptide of interest (indicated by arrow) was identified by 
retention time and verified in XCalibur using the isotopic distribution.  
0
100000
200000
300000
400000
500000
600000
52 57
Time (min)
1st Isotope
2nd Isotope
3rd Isotope
B. CAPNS1 – LGFEEFK (m/z = 435.22438 +/- 7 ppm; RT = 55.65)
i) ii)
RT:0.00 - 115.00SM:7G
0 10 20 30 40 50 60 70 80 90 100 110
Time (min)
0
10
20
30
40
50
60
70
80
90
100
0
10
20
30
40
50
60
70
80
90
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
55.79
33.67
26.3225.54 56.4034.50 76.5412.35 114.1410.20 75.2751.24 70.0838.95 43.80 94.45 97.013.54 93.0783.38 105.7419.12
33.76
33.53
56.22
12.55
2.05
26.15
34.42 108.35
25.45 40.8213.546.03 113.1548.2726.84 51.07 71.7058.93 68.46 81.7773.46 88.8324.86 107.8399.4892.29
NL:
4.88E5
m/z= 
435.22133-
435.22743  
MS 
b627p118Q
35A5
NL:
1.25E5
m/z= 
435.22133-
435.22743  
MS 
b627p118q
35b5
Base peak = 4.88E5
Base peak = 1.25E5
0
100000
200000
300000
400000
500000
600000
52 57
Time (min)
1st Isotope
2nd Isotope
3rd Isotope
C. FN1 – APITGYIIR (m/z = 502.30093 +/- 7 ppm; RT = 54.66)
RT:0.00 - 114.99 SM:7G
0 10 20 30 40 50 60 70 80 90 100 110
Time (min)
0
10
20
30
40
50
60
70
80
90
100
0
10
20
30
40
50
60
70
80
90
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
74.33
51.08
74.11
56.49
73.91 78.65
23.40
78.86
23.58 85.54
73.42 107.6024.89 85.27
53.29 73.25
30.41 85.9833.3122.13 97.8938.38 103.1297.0542.30 70.9257.66 62.22
75.63
56.18
74.25
80.25
74.01
80.52
22.31 73.64
69.0350.4822.87 42.01 81.04 109.01107.5889.5421.33 28.92 58.59 67.69 90.3318.316.79 39.60
NL:
1.33E5
m/z= 
502.29741-
502.30445  
MS 
b627p118Q
35A1
NL:
1.33E5
m/z= 
502.29741-
502.30445  
MS 
b627p118q
35b1
Base peak = 1.33E5
Base peak = 1.33E5
0
100000
200000
300000
400000
500000
600000
51 56
Time (min)
1st Isotope
2nd Isotope
3rd Isotope
12 00
1 00
8 00
60000
20000
40000
0
100000
200000
300000
400000
500000
600000
51 56
Time (min)
1st Isotope
2nd Isotope
3rd Isotope
12
1
8
60000
20000
40000
i) ii)
Chapter 3: AP-MS Screen for PI3K Interaction Partners 
107 
 
 
Figure 3.10. D. Manual validation supports Pescal quantification of p85β and candidate interaction 
partners. Extracted ion chromatograms (XICs) generated by Pescal were manually validated in the 
MS scan for representative peptides of VIM (D) in starved and stimulated samples. Panel (i) shows 
the XIC s generated by Pescal (peaks shown on normalized scale). Panel (ii) shows the XIC generated 
in XCalibur (peaks shown relative to most abundance peak in scan). The peak corresponding to the 
peptide of interest (indicated by arrow) was identified by retention time and verified in XCalibur 
using the isotopic distribution.  
Several peptides were validated for each protein quantitation from each experiment. 
The results of visual examination correlated with Pescal quantitation results, thus 
supporting the AP-MS screen results. These data verify that, whilst p85β was present in 
equal abundance in p85 IP samples from starved and stimulated cells, CAPNS1 was more 
strongly associated with the PI3K complex under starved conditions and FN1 and VIM were 
more strongly associated with PI3K under stimulated conditions. 
3.5. Conclusions 
We designed an AP-MS strategy to identify candidate dynamic interaction partners of 
Class IA PI3K. Our strategy (Fig. 3.1.) was designed to compare the composition of the PI3K 
protein complex in cells that were serum-starved, resulting in low pathway activity, or 
serum-stimulated, resulting in high pathway activity. We hypothesized that proteins present 
in equal abundance under both conditions were likely to be non-specific interactors or 
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constitutive binders, whereas proteins present in different abundance under the two 
conditions were likely to have an active role in signalling.  
We initially conducted a series of experiments to optimize our affinity purification 
approach. We found that the use of a mild detergent, 0.3% CHAPS, during the sample 
processing resulted in the purification of a higher number of proteins compared to a 
stronger detergent, 1% Triton X-100 (Fig. 3.2.). These results demonstrate, in accordance 
with the findings of others [268], that the use of weak detergent for affinity purification is 
beneficial as it increases the retention of weak protein-protein interactions. This was of 
particular importance in our study as our targets of interest were likely to be transient, 
dynamic interactors forming relatively weak interactions with PI3K. 
Further investigations were performed to investigate the effects of the detergents 
CHAPS and Triton X-100 on cell lysis in more detail. Our results showed that, whilst total 
protein yield was inversely proportional to the concentration of either detergent (Fig. 3.3.), 
p85 recovery did not correlate well with detergent type or concentration (Fig. 3.4.). These 
results suggested that the use of low concentration of 0.3% CHAPS in the affinity 
purification process would not negatively impact the recovery of PI3K. Therefore, 0.3% 
CHAPS was the detergent and concentration selected for all further experiments. 
A series of experiments were also performed to optimize the purification of PI3K 
complexes by IP. We chose to use antibodies with affinity for all isoforms of the p85 
regulatory subunit of PI3K (p85 pan) as these reagents have previously been demonstrated 
by our laboratory to be efficient affinity reagents [19]. An additional advantage to this 
approach is that the different isoforms of the p110 catalytic subunits expressed in cells will 
all be isolated by this antibody. Our investigation revealed that, whilst both antibodies 
tested had a high affinity for p85, a combination of the two used at a ratio of 1:500 (µl 
antibody:µg protein) effectively depleted PI3K p85 from the sample (Fig. 3.5.). These were 
the IP conditions selected for the AP-MS screen. 
PI3K p85 protein complexes were isolated from approximately 8 x 106 cells (yielding 
around 10 mg total protein) that were serum-starved for 18 h (“starved”) or serum-starved 
for 18 h followed by stimulation with 10% FBS for 5 min (“stimulated”). SDS-PAGE 
separation and Colloidal Coomassie blue staining revealed the complexity of the 
immunoprecipitation products isolated and failed to identify any clear differences between 
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the samples (Fig. 3.6.). These results supported the requirement for a quantitative mass 
spectrometry approach to identify candidate interaction partners. 
To complete the AP-MS screen for dynamic interaction partners of Class IA PI3K, three 
independent biological experiments were performed. Hundreds of proteins were identified 
and quantified across the study, however we focused our attention on the 81 proteins that 
were found in all three replicates (Appendix 1). We then employed strict criteria for protein 
identification and quantification to identify proteins that were interacting dynamically with 
PI3K. Critically, candidates were required to be identified to a high degree of confidence in 
all three experiments and the criteria to be considered quantitatively different between the 
two conditions was for a minimum of a two-fold change in relative abundance, which was 
statistically significant as assessed by the Student’s t-test. 
PI3K proteins were found to be present in equal abundance under both conditions in all 
three experiments. In contrast, CAPNS1 was found to be more strongly associated with PI3K 
in starved cells whereas FN1 and VIM were found to be more strongly associated with PI3K 
in stimulated cells (Fig. 3.7. - 3.8. and Table 3.1.). Qualitative and quantitative analysis of 
mass spectrometry data was manually assessed leading to the conclusive validation of the 
results (Fig. 3.9. – 3.10.). 
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4. Regulation of Class IA PI3K stability and signalling activity by 
calpain 
4.1. Introduction and aim of study 
The AP-MS study reported in Chapter 3 revealed that calpain small subunit 1 (CAPNS1) 
interacts dynamically with Class IA PI3K. CAPNS1 was consistently found to be more 
abundant (by around 3-fold) in PI3K complexes isolated from serum-starved cells (low 
pathway activity) compared to serum-stimulated cells (high pathway activity). Although 
other candidate dynamic interaction partners revealed by the AP-MS screen (FN1 and VIM) 
showed higher fold changes between the two conditions evaluated, CAPNS1 was of 
immediate interest due to its known role in the cleavage of other signalling proteins [285] 
and its implication in Akt signalling [286-288]. Calpains have also been implicated in the 
regulation of multiple biological processes, including apoptosis, autophagy, proliferation and 
migration [285, 289-291].  
 Calpains are a family of highly-conserved calcium-dependent cysteine proteases [292-
294]. There are many calpain isoforms ubiquitously expressed, however calpain 1 and 
calpain 2 (also known as µ-calpain and m-calpain respectively) are the most extensively 
studied members of the family [291, 293]. Both calpain 1 and calpain 2 are heterodimers 
comprised of a common 28 kDa regulatory subunit (CAPNS1), thought to act as a chaperone 
[295], and an 80 kDa catalytically active subunit [291, 293]. The activation and regulation of 
calpain activity in vivo is not well understood [296], although it is an abundant protein with 
limited proteolytic activity and therefore it is thought to be tightly regulated [289]. Calcium 
binding is known to induce conformational changes to the molecule by disrupting the 
electrostatic interactions between the sub domains of the catalytic unit [292]. However, 
such conformational changes are thought to be insufficient alone to induce activity [285, 
296]. In addition, the calcium levels shown to be required for calpain 2 activation in vitro are 
supraphysiological, indicating the requirement for additional regulatory mechanisms [285, 
296, 297]. For example, binding of calpain 2 to PIP2 has been shown to be required for 
activation of the protease [297, 298]. The sub-cellular localization of calpain is complex and 
variable, suggesting that this too may be a mechanism for regulation [285, 297]. A major 
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regulator of calpain activity is the endogenous inhibitor calpastatin, which is also calcium-
dependent, although the mechanisms that control the dynamics are very complex [291, 293, 
299].  
Calpains are thought to cleave proteins at highly-specific recognition sites, however no 
consensus cleavage sequence has been identified and secondary structural features are 
thought to be more important recognition factors for the protease [285, 291, 293]. Calpain 
activity most frequently results in the production of large polypeptide fragments, suggesting 
that it is more likely to have a role in substrate activity regulation than in substrate digestion 
[285, 292]. More than a hundred in vitro substrates for calpain have been described; 
including cytoskeletal proteins, transmembrane receptors, transcription factors and 
signalling enzymes [285, 291]. Reflecting the diversity of their substrates, calpains have been 
implicated in the regulation of multiple biological processes including apoptosis, autophagy, 
proliferation and migration [289, 290]. Calpain 1 and 2 are known to have different calcium 
requirements for activation in vitro, however it is not clear if the isoforms have distinct roles 
in vivo. Knockout mice for calpain 1 show no obvious phenotype [300], however knockout of 
calpain 2 and calpain small subunit 1 are embryonic lethal [301, 302], indicating non-
redundant roles of the two isoforms during pre-implantation embryonic development [303]. 
However, no differences in substrate specificity have been reported for calpain isoforms 1 
and 2 [291]. 
The aims of the work presented in this Chapter were: (i) to validate the interaction 
between CAPNS1 and Class IA PI3K; (ii) to investigate the nature of the relationship between 
the two proteins and (iii) to establish if calpain had an active role in the regulation of PI3K 
signalling activity. 
Pharmacological and genetic tools were used to investigate the interaction between 
PI3K and calpain. Notably, the pan calpain inhibitor N-Acetyl-L-leucyl-L-leucyl-L-norleucinal 
(ALLN; also known as calpain inhibitor 1), a cell-permeable peptide inhibitor that blocks the 
active site of the protease was used to inhibit calpain activity in vivo [304]. Similarly, 
LY294002, a small molecule kinase inhibitor that targets PI3K and mTOR was used to 
investigate the contribution of PI3K in vivo in undertaken studies [64, 65]. Genetic tools 
were also used to inhibit calpain activity. Specifically, small interfering RNA (siRNA) for 
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CAPNS1 was used to down-regulate CAPNS1 expression, which led to a reduction in the 
expression of active calpain catalytic subunits and overall calpain activity (Fig. 4.1.) 
 
 
Figure 4.1. siRNA against CAPNS1 reduces the expression of calpain 2 and total calpain activity. 
NIH-3T3 cells were treated with scrambled siRNA (50 nM) or CAPNS1 siRNA (as indicated) for 48 h. A. 
Calpain 2 expression was measured by WB analysis. B. Total calpain activity was measured using an 
in vitro calpain activity assay (n = 2). Data expressed as mean+/- SEM.  
 
Data showed that siRNA knockdown of CAPNS1 significantly reduced the expression of 
the catalytic subunit calpain 2, which is consistent with the down-regulation in expression of 
the regulatory subunit CAPNS1 [305] (Fig. 4.1. A). Furthermore, this treatment also resulted 
in approximately a 5-fold reduction of total calpain activity (Fig. 4.1. B). 
4.2. Validation of the interaction between calpain and Class IA PI3K 
4.2.1. Investigation of calpain activity in PI3K IPs. 
We initially sought to confirm the presence of CAPNS1 in PI3K p85 IPs by a mass 
spectrometry independent method and, furthermore, to investigate if active calpain 
catalytic subunits were also present in the PI3K protein complex. Due to the limited 
sensitivity of the available antibodies against calpains for immunoblotting, published studies 
A B
CAPNS1 siRNA
CAPNS1 siRNA
WB:
Calpain 2
Vinculin
0
20
40
60
80
100
To
ta
l C
al
p
ai
n
 A
ct
iv
it
y
(%
 o
f 
co
n
tr
o
l)
0
20
40
60
80
100
C
al
p
ai
n
 2
 B
an
d
 D
e
b
si
ty
(%
 o
f U
n
tr
ea
te
d
 C
o
n
tr
o
l)
Chapter 4: Regulation of Class IA PI3K stability and signalling activity by calpain 
113 
 
have used activity assays to investigate calpain expression in cells [305, 306]. We thus 
pursued this strategy to test the PI3K – calpain interaction further. 
PI3K was immunoprecipitated from 1 mg of protein harvested from starved and serum-
stimulated NIH-3T3 cells using antibodies against the p85 regulatory subunit of PI3K (as 
previously described). Total cell lysate (TCL; 25 µg) and PI3K immunoprecipitates (IPs) were 
then subjected to an in vitro assay for calpain protease activity (Fig. 4.2.).  
 
Figure 4.2. Active calpain heterodimers associate dynamically with Class IA PI3K. Total cell lysates 
(A; n = 3) and purified PI3K p85 protein complexes (B; n = 4) were subjected to an in vitro protease 
assay for calpain activity after serum-starvation for 18 h followed by stimulation with 10% FBS for 
the indicated times. Data expressed as mean+/- SEM. *below, below limit of assay detection; ns, not 
significant; *, p < 0.05. 
Calpain activity was detectable in both total cell lysates and p85 IPs. Calpain activity 
levels were not found to be significantly different in starved or stimulated NIH-3T3 total cell 
lysate samples (Fig. 4.2. A). In contrast, calpain activity in p85 IPs was found to be decreased 
upon serum stimulation (Fig. 4.2. B). These results confirm the findings of the AP-MS study 
(Fig. 3.8. B) and, in addition, demonstrate that the calpain heterodimers associated with 
Class IA PI3K in the isolated complex are catalytically active. 
4.2.2. Investigation of PI3K activity in calpain IPs. 
To further validate the interaction between calpain and PI3K we proceeded to evaluate 
the PI3K lipid kinase activity of protein complexes purified by immunoprecipitation against 
calpain proteins. Calpain was immunoprecipitated from 1 mg of total cell lysate harvested 
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from serum-starved and serum-stimulated NIH-3T3 cells using antibodies against calpain 
catalytic subunit proteins, including calpain 1 and calpain 2. Purified proteins were then 
subjected to an in vitro lipid kinase assay for PI3K activity [269] (Fig. 4.3.). 
 
Figure 4.3. Class IA PI3K associates dynamically with calpain. A. An in vitro lipid kinase assay was 
used to detect PI3K activity in calpain immunoprecipitates from  cells that were serum-starved for 18 
h followed by serum-stimulation as indicated. One representative  autoradiograph is shown 
alongside the quantification data for all experiments performed (n = 3). B. The same assay was used 
to detect PI3K activity in calpain immunoprecipitates from cells that were serum-starved for 8 or 18 
h (n = 2). Data expressed as mean+/- SEM. **, p < 0.01.  
 
PI3K activity was detectable in calpain IPs from cells serum-starved for 18 h and was 
found to be reduced by over 2-fold upon serum stimulation (Fig. 4.3. A). Furthermore, PI3K 
activity in calpain protein complexes was found to be higher after 18 h serum-starvation 
compared to 8 h serum-starvation (Fig. 4.3. B). Thus, in line with observations from the AP-
MS study (Fig. 3.8. B), these results indicate that the interaction between calpain and PI3K is 
enhanced in response to serum-starvation and decreased upon cell stimulation that leads to 
the activation of PI3K signalling.  
4.2.3. Investigation into calpain activity of serum-starved cells. 
We proceeded to investigate the effects of serum-starvation on total calpain activity in 
cells. Total cell lysate was taken from NIH-3T3 cells growing in complete cell medium (in the 
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presence of FBS) or medium free from serum for 18 h. Samples containing around 25 µg of 
total protein were then subjected to an in vitro assay for calpain activity (Fig. 4.4.). 
 
Figure 4.4. Serum-starvation increases calpain activity in NIH-3T3 cells. Total cell lysates (n = 3) 
taken from NIH-3T3 cells growing exponentially (+ serum in medium) or serum-starved for 18 h (- 
serum in medium) were subjected to an in vitro protease assay for calpain activity. Data expressed 
as mean+/- SEM. **, p < 0.01. 
The results of this experiment showed that serum-starvation for 18 h dramatically 
increased calpain activity, by over 2-fold, in these cells (Fig. 4.4.). These results suggest that 
serum-starvation triggers a response in cells that results in increased calpain activity, which 
appears to correlate with an increase in calpain and PI3K association. 
4.3. Investigations into the effects of calpain activity on PI3K stability and 
enzymatic activity. 
Since calpain is a protease, we next proceeded to investigate if PI3K proteins were 
substrates of calpain and to evaluate the effects of the association on PI3K stability and lipid 
kinase activity. 
4.3.1. Effects of calpain activity on PI3K stability in vitro. 
PI3K proteins were immunoprecipitated from 1 mg of total protein obtained from NIH-
3T3 and IC-21 cells using antibodies against the p85 regulatory subunit. The isolated 
proteins were then used as substrates for an in vitro calpain activity assay and purified 
calpain 1 and calpain 2 proteins were used as the protease source. Western blot (WB) 
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analysis was then used to evaluate the stability of the different PI3K subunits as a function 
of incubation with calpains (Fig. 4.5.)  
 
Figure 4.5. Calpain 1 and 2 cleave p110α completely and p110β, p110δ and p85 partially in vitro. 
PI3K subunits were immunoprecipitated from NIH-3T3 (A) and RAW 264.7 (B) cells and used as 
substrates for an in vitro protease digestion using 2 µg of purified calpain isoforms 1 or 2. WB 
analysis was used to investigate the stability of the different PI3K isoforms (one representative 
experiment of three shown). 
The results revealed that calpain 1 and calpain 2 cleaved p110α extensively, whereas 
p110δ and p85 were only partially cleaved by both calpain 1 and calpain 2 (Fig. 4.5.). 
Conversely, the effect of calpain activity on the stability of p110β was negligible (Fig. 4.5. A). 
These results demonstrate that calpain can cleave PI3K proteins in vitro and suggest that 
calpain may have a role in p110α stability in vivo.  
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4.3.2. Effects of calpain activity on PI3K lipid kinase activity in vitro. 
We next investigated the activity of calpain-cleaved PI3K proteins. PI3K proteins were 
immunoprecipitated from 1 mg of total protein obtained from NIH-3T3 cells, using 
antibodies against the p85 regulatory subunit, and subjected to an in vitro protease 
digestion using purified calpain followed by a lipid kinase assay for PI3K activity (Fig. 4.6.).  
 
 
Figure 4.6. Calpain-cleavage of PI3K proteins reduces their lipid kinase activity. PI3K subunits were 
immunoprecipitated from NIH-3T3 cells and used as substrates for an in vitro protease digestion 
using 2 µg of purified calpain 1. An in vitro lipid kinase assay was then performed to measure the 
activity of digested PI3K subunits. One representative autoradiograph is shown alongside the 
quantification data for all experiments performed (n = 4) expressed as mean+/- SEM. **, p <0.01. 
Results of this experiment demonstrated that cleavage of PI3K proteins resulted in a 
decrease in lipid kinase activity of approximately 2-fold (Fig. 4.6.). These results therefore 
indicate that cleavage of p110α by calpains results in a decrease of its lipid kinase activity.  
4.3.3. Effects of calpain activity on PI3K stability in vivo. 
We next set out to evaluate the effects of endogenous calpain activity on the stability of 
PI3K proteins in vivo. Calpain activity in serum-starved NIH-3T3 cells was inhibited for 48 h 
with the calpain inhibitor ALLN or with siRNA for CAPNS1. WB analysis was then performed 
to evaluate the stability of PI3K proteins (Fig. 4.7.). 
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Figure 4.7. Calpain regulates the stability of p110α in vivo. Calpain activity in NIH-3T3 cells was 
inhibited for 48 h using A. the calpain inhibitor ALLN (10 µM; n = 3)) or B. siRNA for CAPNS1 (50 nM; 
n = 3). p85, p110α and p110β levels were measured by WB. One representative blot is shown 
alongside quantitative data for all experiments performed (n = 3), shown as mean ± SEM (normalized 
to α-tubulin). *, p <0.05; ***, p<0.0001; ns, not significant. 
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WB analysis revealed that the reduction in calpain activity produced by both treatments 
resulted in a significant increase in p110α levels of approximately 1.5-fold compared to 
control cells (Fig. 4.7.). In contrast, p110β levels were unaffected by either treatment (Fig. 
4.7.). p85 levels were found to be slightly decreased following siRNA treatment (Fig. 4.7. B, 
however upon ALLN treatment p85 levels remained unchanged (Fig. 4.7. A). These results 
are consistent with the notion that calpains have a role in regulating p110α levels in vivo.  
4.4. Investigations into the effects of calpain activity on PI3K signalling 
activity. 
Following on from the discovery that PI3K proteins are calpain substrates, we next 
proceeded to evaluate the effects of calpain activity on PI3K/Akt signalling. 
4.4.1. Effects of calpain on the phosphorylation of Akt. 
In order to evaluate the effects of calpain activity on the modulation of PI3K/Akt 
signalling, NIH-3T3 cells were serum-starved for 18 h and then treated with the calpain 
inhibitor ALLN for 1 h prior to stimulation with 10% FBS for different lengths of time. WB 
analysis was then used to evaluate Akt phosphorylation levels (Fig. 4.8.).  
 
Figure 4.8. Calpain negatively regulates Akt phosphorylation downstream of serum stimulation. 
NIH-3T3 cells were serum-starved for 18 h followed by a 1 h treatment with DMSO (control) or ALLN 
(50 µM). The cells were then stimulated with 10% FBS for the indicated time and phosphorylation of 
Akt was determined by WB analysis. One representative blot and quantification of three is shown. 
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The results of this experiment revealed that the kinetics of serum-induced Akt 
phosphorylation, on both sites investigated, were faster in cells treated with ALLN relative 
to DMSO-treated control cells (Fig. 4.8.).  In addition, cells treated with ALLN showed a 
larger magnitude of both basal and serum-induced Akt phosphorylation relative to cells 
treated with vehicle (Fig. 4.8.). These results indicate that calpain negatively regulated Akt 
phosphorylation. 
4.4.2. PI3K-dependent effects of calpain on Akt phosphorylation. 
Further experiments were performed to investigate the interplay between calpain 
activity and PI3K/Akt signalling in more detail. NIH-3T3 cells were serum-starved for 18 h 
and treated for 1 h with DMSO control, the calpain inhibitor ALLN, the PI3K/mTOR inhibitor 
LY294002 or a combination of the two inhibitors. One set of cells was then stimulated with 
10% FBS for 5 min as indicated. WB analysis was then used to evaluate Akt phosphorylation 
(Fig. 4.9.). 
 
Figure 4.9. Calpain inhibition-induced Akt phosphorylation is dependent upon PI3K/mTOR. NIH-
3T3 cells were serum-starved for 18 h followed by a 1 h treatment with DMSO (control), ALLN (50 
µM), LY294002 (5 µM) or a combination of the two inhibitors. The cells were then stimulated with 
10% FBS for 5 min (where indicated) and phosphorylation of Akt was determined by WB analysis. 
One representative blot of three is shown. 
 
Consistent with previous data, treatment of cells with ALLN resulted in an increase of 
Akt phosphorylation at both Ser473 and Thr308 relative to vehicle-treated cells in both un-
stimulated and stimulated cells (Fig. 4.9.). As expected, LY294002 treatment decreased Akt 
phosphorylation on both Akt sites (Fig. 4.9.). Interestingly, the observed increases in Akt 
phosphorylation upon calpain inhibition were not detected when cells were also treated 
Chapter 4: Regulation of Class IA PI3K stability and signalling activity by calpain 
121 
 
with LY294002 (Fig. 4.9.). These results show that increased phosphorylation of Akt as a 
result of decreased calpain activity (Fig. 4.8. and 4.9.) is dependent on the LY294002 targets 
PI3K and/or mTOR. 
4.4.3. Effects of calpain on Akt activity. 
In order to further investigate the effects of calpain on PI3K/Akt signalling, an Aktide 
assay was performed to quantify Akt activity [270, 271]. NIH-3T3 cells were serum-starved 
for 18 h and treated with DMSO control, calpain inhibitor ALLN, PI3K/mTOR inhibitor 
LY294002 or a combination of the two inhibitors for 1 h. One set of cells were then 
stimulated with 10% FBS for 5 min as indicated. Akt activity was then measured using the 
Aktide assay (Fig. 4.10.). 
 
Figure 4.10. Calpain negatively regulates Akt activity. NIH-3T3 cells were serum-starved for 18 h 
followed by a 1 h treatment with DMSO (control), ALLN (50 µM), LY294002 (5 µM) or a combination 
of the two inhibitors. Cells were then left with no further treatment (A) or stimulated with 10% FBS 
for 5 min (B) and Akt activity was quantified using the Aktide assay (n = 3). Data expressed as mean 
+/- SEM. ns, not significant; *, p<0.05; **, p < 0.01. 
Consistent with WB data (Fig. 4.9.), treatment of cells with ALLN resulted in a significant 
increase of Akt activity relative to vehicle-treated cells in un-stimulated cells (Fig. 4.10.). A 
slight increase, which was not found to be significant, was also observed for ALLN treated 
stimulated cells. As expected, LY294002 treatment decreased Akt activity under both 
stimulated and un-stimulated conditions (Fig. 4.10.). As previously detected by Akt 
phosphorylation, the observed increases in Akt activity upon calpain inhibition were not 
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detected when the cells were also treated with LY294002 (Fig. 4.10.), further supporting the 
conclusion that this phenomenon is dependent upon PI3K/mTOR. 
4.4.4. Effects of calpain on signalling downstream of Akt. 
In order to further verify the finding that calpain negatively regulates PI3K/Akt signalling, 
an experiment was performed to investigate the phosphorylation of the downstream target 
p70 ribosomal S6K (S6K). NIH-3T3 cells were serum-starved for 18 h and then treated with 
the calpain inhibitor ALLN for 1 h prior to stimulation with 10% FBS for different lengths of 
time. WB analysis was then used to evaluate S6K phosphorylation levels (Fig. 4.11.).  
 
 
Figure 4.11. Calpain negatively regulates S6K phosphorylation downstream of Akt activity. NIH-3T3 
cells were serum-starved for 18 h followed by a 1 h treatment with DMSO (control) or ALLN (50 µM). 
The cells were then stimulated with 10% FBS for the indicated time and phosphorylation of S6K was 
determined by WB analysis. One representative blot of three is shown. 
 
WB analysis results showed that S6K phosphorylation was increased upon calpain 
inhibition (Fig. 4.11.). These results demonstrate that the increased PI3K/Akt signalling as a 
result of inhibiting calpain activity previously observed (Fig 4.8., 4.9. and 4.10.) was 
effectively propagated to downstream effectors of the pathway. 
4.4.5. Effects of calpain on PI3K/Akt signalling confirmed by siRNA treatment. 
In order to verify the findings obtained with the inhibitor ALLN we also tested the impact 
of siRNA knockdown of CAPNS1 on PI3K/Akt pathway activity. NIH-3T3 cells were 
transfected with scrambled or CAPNS1 siRNA and 48 h later subjected to 18 h of serum-
starvation. Cells were then stimulated with 10% FBS, as indicated, followed by WB analysis 
(Fig. 4.12.).  
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Figure 4.12. siRNA study supports the notion that calpain negatively regulates PI3K/Akt signalling. 
NIH-3T3 cells were transfected with scrambled or CAPNS1 siRNA (50 nM) followed by 18 h of serum-
starvation and stimulation with 10% FBS, as indicated, 48 h post-transfection. Akt phosphorylation, 
S6 phosphorylation, p110α expression and calpain 2 expression were then assessed by WB analysis. 
One representative blot of three is shown. 
 
In line with the pharmacological data (Fig. 4.8., 4.9. and 4.11.), Akt phosphorylation on 
Ser473 and Thr308 and S6 on Ser240/244 were enhanced in cells with reduced calpain 
expression (Fig. 4.12.). Furthermore, in agreement with the data in Fig. 4.7. B, p110α levels 
were found to be increased upon calpain inhibition with CAPNS1 siRNA. Calpain 2 
expression levels confirmed the efficacy of the siRNA treatment, as previously observed (Fig. 
4.1. A). Taken together, these results reinforce the notion that calpain negatively modulates 
PI3K/Akt signalling activity in vivo. 
4.5. Investigations into the effects of calpain activity on cell growth and 
survival. 
Having established that calpain has a role in the regulation of PI3K/Akt signalling, we 
next proceeded to evaluate the functional impact of this phenomenon in terms of cell 
growth and survival. 
4.5.1. Effects of calpain on the viability of serum-starved cells. 
We initially investigated the effects of calpain activity in serum-starved cells, as this was 
the condition where calpain inhibition was found to have the most pronounced effect on 
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PI3K/Akt signalling (Fig. 4.9. and 4.10.). NIH-3T3 cells were serum-starved for 48 h, during 
which calpain and PI3K/mTOR activities were inhibited using pharmacological inhibitors 
(ALLN and LY294002) or siRNA knockdown. Cell viability was assessed using an MTS assay 
(Fig. 4.13.). 
 
Figure 4.13. Inhibition of calpain increases cell viability during serum-starvation.  NIH-3T3 cells 
were starved of serum for 48 h. The impact of calpain activity was investigated by concurrent 
treatment with A. DMSO control, ALLN (10 µM), LY294002 (5 µM) or a combination of the two 
inhibitors for 48 h or B. scrambled siRNA, CAPNS1 siRNA (50 nM), LY294002 (5 µM) or a combination 
of siRNA and PI3K inhibitor. Cell viability was then assessed using an MTS assay. Data expressed as 
mean ± SEM (n = 3).*, p < 0.05; **, p < 0.01; ***, p < 0.001. 
Inhibition of calpain by ALLN resulted in an approximately 2-fold increase in the number 
of viable cells (Fig. 4.13.A), whilst siRNA treatment increased cell numbers by approximately 
1.5-fold (Fig. 4.13.B). As expected, treatment with LY294002 reduced cell viability (Fig. 
4.13.). Interestingly, inhibition of calpain activity, with either ALLN or with CAPNS1 siRNA, in 
conjunction with LY294002 treatment opposed the effects of calpain inhibition in increasing 
viability (Fig. 4.13.).These data thus suggest that the effects of calpain in modulating 
proliferative signals are at least partly dependent on PI3K/mTOR. These results also indicate 
that calpain has a role in the negative regulation of PI3K/mTOR-dependent growth and 
survival during serum-starvation. 
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4.5.2. Effects of calpain on the viability of growing cells. 
We also investigated the role of calpain activity in the regulation of growth and survival 
in exponentially growing cells. NIH-3T3 cells, in complete growth medium, were treated 
with the calpain inhibitor ALLN or siRNA against CAPNS1 in the presence or absence of the 
PI3K/mTOR inhibitor LY294002. Cell viability was assessed using an MTS assay (Fig. 4.14.). 
 
Figure 4.14. Inhibition of calpain does not significantly affect the viability of exponentially growing 
cells. NIH-3T3 cells were treated with A. DMSO control, ALLN (10 µM), LY294002 (5 µM) or a 
combination of the two inhibitors or B. scrambled siRNA, CAPNS1 siRNA (50 nM), LY294002 (5 µM) 
or a combination of siRNA and inhibitor for 48 h. Cell viability was then assessed using an MTS assay. 
Data expressed as mean ± SEM (n = 3). ns, not significant; *, p < 0.05; ***, p < 0.001. 
 
Inhibition of calpain, by either approach, did not significantly affect cell viability, 
although a slight decrease was observed (Fig. 4.14.). As expected, treatment with LY294002 
reduced cell viability and concurrent treatment with ALLN was not found to affect this 
inhibitory effect (Fig. 4.14.). These results suggest that calpain has no significant impact on 
the regulation of cell growth and survival under standard cell culture growth conditions. 
4.5.3. Effects of calpain on the cell cycle progression of serum-starved cells. 
Having established that calpain has a significant impact on cell viability during serum-
starvation, we next proceeded to investigate the underlying mechanisms for this 
phenomenon. We first investigated the effects of calpain activity on cell cycle progression. 
NIH-3T3 cells were serum-starved and treated with the calpain inhibitor ALLN and/or the 
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PI3K/mTOR inhibitor LY294002 for 48 h. Cell cycle progression was then evaluated using 
FACS analysis of PI stained cells (Fig. 4.15.). 
 
 
Figure 4.15. Calpain inhibition promotes cell cycle arrest in a PI3K-independent manner. NIH-3T3 
cells were serum-starved and treated with DMSO control, ALLN (10 µM), LY294002 (5 µM) or a 
combination of the two inhibitors for 48 h. Cells were then fixed using ethanol and stained with PI 
prior to FACS cell cycle analysis. FACS output for one representative experiment and quantitative 
data for all experiments performed (n = 2) is shown. Data expressed as mean ± SEM.  
 
FACS analysis revealed that PI3K/mTOR inhibition resulted in a considerable decrease in 
the percentage of cells in G1/G0 and S phases (by around 2-fold), whereas the fraction of 
cells in G2/M was only slightly decreased (Fig. 4.15.). In contrast, calpain inhibition resulted 
in no change in the percentage of cells in G1/G0 phase, whereas the fraction of cells in S and 
G2/M phases was reduced (Fig. 4.15.), indicating that the cells were more arrested 
compared to control cells. However, when PI3K/mTOR was also inhibited the effects of 
calpain inhibition were not opposed, indicating that these effects were unlikely to be 
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PI3K/mTOR dependent. These results therefore suggest that the calpain-PI3K interaction 
does not significantly affect cell cycle progression. 
4.5.4. Effects of calpain on apoptosis in serum-starved cells. 
We next investigated the effects of calpain on apoptosis in serum-starved cells. NIH-3T3 
cells were serum-starved and treated with the calpain inhibitor ALLN and/or the PI3K/mTOR 
inhibitor LY294002 for 48 h. Apoptosis was then evaluated using FACS analysis of Annexin V 
and PI stained cells (Fig. 4.16.). 
 
 
Figure 4.16. Calpain and PI3K inhibition promote apoptosis via complementary mechanisms. NIH-
3T3 cells were serum-starved and treated with DMSO control, ALLN (10 µM), LY294002 (5 µM) or a 
combination of the two inhibitors for 48 h. Cells were then stained with Annexin V and PI prior to 
FACS analysis for apoptotic and necrotic markers. FACS output for one representative experiment 
and quantitative data for all experiments performed (n = 2) is shown. Data expressed as mean ± 
SEM.  
FACS analysis revealed that both calpain and PI3K/mTOR inhibition increased the 
percentage of cells undergoing apoptosis (Fig. 4.16.). The combined effects of the two 
inhibitors were cumulative (Fig. 4.16.), indicating that the mechanisms were complimentary. 
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These data thus suggest that the calpain-PI3K interaction does not affect apoptosis outcome 
upon serum-starvation. 
4.5.5. Effects of calpain on autophagy in serum-starved cells. 
Finally, we investigated the effects of calpain on autophagy, as this process is strongly 
implicated in cell growth and survival. NIH-3T3 cells were serum-starved and treated with 
the calpain inhibitor ALLN and/or the PI3K/mTOR inhibitor LY294002 for 48 h. The cells were 
then subjected to WB analysis of the autophagic marker LC3 [307](Fig. 4.17.). 
 
 
Figure 4.17. Calpain inhibition reduces autophagy in a PI3K-dependent manner.  NIH-3T3 cells were 
serum-starved and treated with DMSO control, ALLN (10 µM), LY294002 (5 µM) or a combination of 
the two inhibitors for 48 h. Cells were then subjected to WB analysis for the autophagic marker LC3. 
One representative blot and quantification of LC3-II:LC3-I ratio of three is shown. 
The LC3-II to LC3-I ratio, a quantitative marker of autophagy [290], indicated that calpain 
inhibition reduced autophagic activity by over 2 fold (Fig. 4.17.). PI3K inhibition also resulted 
in a reduction of autophagy, however the use of the two inhibitors in combination reversed 
the effects of calpain inhibition (Fig. 4.17.). These data suggest that calpain has a role in the 
regulation of autophagy that is mediated through PI3K/mTOR. These results may provide 
some insight into the mechanism for increased cell viability upon calpain inhibition in 
serum-starved cells. 
4.6. Conclusions 
We initially sought to confirm the finding described in Chapter 3 from the AP-MS screen 
indicating that CAPNS1 interacts with Class IA PI3K. Furthermore, we sought to investigate if 
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the active calpain heterodimer was part of the PI3K complex and what the implications of 
this association were for the regulation of PI3K activity. 
We isolated PI3K protein complexes from starved and stimulated NIH-3T3 cells and used 
an in vitro calpain activity assay to confirm the presence of active calpain heterodimers in 
the complex (Fig. 4.2.). Furthermore, we demonstrated that, in line with the AP-MS findings, 
the association between PI3K and calpain was higher in serum-starved cells compared to 
serum-stimulated cells (Fig. 4.2.). To further validate the findings from the AP-MS study, we 
also isolated calpain protein complexes and used an in vitro lipid kinase assay to confirm the 
presence of PI3K in the protein complex (Fig. 4.3.) and showed, again, that the association 
was higher in serum-starved cells compared to serum-stimulated cells. Further investigation 
also revealed that the association between PI3K and calpain increased as serum-starvation 
time progressed (Fig. 4.3.) and that total calpain activity of the cells was also increased upon 
serum-starvation (Fig. 4.4.). 
Having confirmed the association between calpain and class IA PI3K, we next proceeded 
to investigate if PI3K was a substrate for this protease. We isolated PI3K proteins from NIH-
3T3 and RAW 264.7 cells and subjected them to in vitro protease digestion using purified 
calpain 1 and calpain 2. WB analysis of the different PI3K proteins revealed that p110α was 
completely cleaved by both calpain proteins, whereas p110δ and p85 proteins were only 
partially cleaved and p110β was virtually unaffected (Fig. 4.5.). Further investigation 
revealed that calpain-mediated cleavage of p110α resulted in a decrease in lipid kinase 
activity (Fig. 4.6.). We inhibited calpain activity in cells, pharmacologically and genetically, 
and used WB analysis of PI3K proteins to demonstrate that calpain also regulated the 
stability of p110α in vivo (Fig. 4.7.). 
We next investigated the effects of calpain on PI3K/Akt signalling pathway activity. WB 
analysis revealed that pharmacological calpain inhibition affected the kinetics of Akt 
phosphorylation, producing a faster response and reaching a higher peak (Fig. 4.8.). Further 
investigation, using inhibitors, also demonstrated that this increase in Akt phosphorylation 
was dependent on PI3K/mTOR activity (Fig. 4.9.). Subsequent investigations also 
demonstrated that this increase in Akt phosphorylation results in a true increase in Akt 
activity (Fig. 4.10.) and that the signal was effectively propagated downstream to the 
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effector p70 S6K (Fig. 4.11.). These effects of calpain on PI3K/Akt signalling were also 
confirmed using genetic inactivation of calpain by siRNA treatment (Fig. 4.12.). 
We then evaluated if the negative regulation of PI3K/Akt signalling by calpain had any 
functional impact on cell growth and survival. We used an MTS assay to investigate the 
effects of calpain and PI3K inhibition, using inhibitors and siRNA, on the viability of serum-
starved cells. The results of these experiments revealed that calpain inhibition promotes 
survival of cells under serum-starvation in a PI3K/mTOR-dependent manner (Fig. 4.13.). In 
contrast, calpain was not found to have any significant effect on the viability of cells under 
cell culture growth conditions (Fig. 4.14.).  
We next investigated the potential mechanisms for increased cell viability upon calpain 
inhibition in serum-starved cells. FACS cell cycle analysis revealed that, whilst calpain 
inhibition did contribute to cell cycle arrest, this effect was independent of PI3K/mTOR (Fig. 
4.15.). Similarly, FACS analysis of apoptosis failed to identify a role for the PI3K-calpain 
interaction in the regulation of apoptosis (Fig. 4.16.). However, quantification of the 
autophagy marker LC3-II:LC3-I ratio suggested that the interaction of calpain with PI3K may 
have a role in the promotion of autophagy, which is also dependent on PI3K activity (Fig. 
4.17.). 
In summary, we have verified that active calpain heterodimers associate with class IA 
PI3K. Furthermore, this work indicates that calpain has a role in the regulation of PI3K 
protein stability and signalling activity. One of the identified biological outcomes of this 
relationship is that calpain inhibition increases cell viability under serum-starvation, possibly 
through the regulation of autophagy. 
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5. Identification of Phosphorylation Events Downstream of Akt 
5.1. Introduction and aim of study 
Having explored the regulation of PI3K by interaction partners we next focused our 
attention on the investigation of the dynamics of signalling downstream of PI3K. Akt, a 
protein kinase activated downstream of class I PI3K activity, forms part of the critically 
important signalling node: the PI3K/Akt pathway [2, 60]. This pathway plays an essential 
role in the regulation of a wide range of cellular functions including cell survival, growth, 
proliferation, migration and metabolism [2, 60]. 
Akt is recruited to the cell membrane through the binding of its PH domain with PIP3, 
the product of PI3K lipid kinase activity. This translocation permits the phosphorylation of 
Akt at the residue Thr308, by PDK1 [78], and at the residue Ser473, by the mTORC2 complex 
[149], thus activating Akt. The most important regulators of Akt activity are the balance of 
PIP2 and PIP3 at the cell membrane [83] and the activity of protein phosphatases, such as 
PP2A and PHLLP [85, 308]. Phosphorylation of Akt substrates can result in positive or 
negative regulation of protein activity and affects many important cellular processes. Many 
downstream substrates have been well characterized, including but not limited to BAD, 
FOXO, PRAS40, GSK-3 and TSC2 [90, 148, 309-312]. However, there are many more reported 
potential substrates, some of which have not been fully validated in vivo [60]. 
Phosphoproteomics is the area of proteomics that is dedicated to the characterisation 
of protein phosphorylation and the most notable application of this method is in the study 
of signalling pathways, as phosphorylation is a key mechanism in their regulation [200-202]. 
Mass spectrometry based global phosphoproteomics has revolutionized this area of 
research, permitting the large-scale quantitative evaluation of dynamic pathway activity, 
which is not possible using any other method [203, 205]. Understanding the intricacies of 
signalling activity can lead to the identification of novel therapeutic targets and biomarkers. 
Global phosphoproteomics enables the qualitative and quantitative evaluation of 
hundreds, or even thousands, of phosphorylation events in a single analysis. In addition, no 
prior knowledge of a phosphorylation site is necessary and novel sites can be concomitantly 
identified and quantified. However, there remains a key limitation for this technique when 
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used for the investigation of kinase signalling activity: we do not always know the identity of 
the kinase that is phosphorylating a particular site [205]. Thus, our interpretations of the 
signalling dynamics under investigation are hampered. Annotation of the phosphoproteome 
with this important information would enable the advancement of progress in this field. In 
addition, the identification of phosphorylation events that are characteristic of activity of a 
particular pathway may have useful applications as biomarkers [205, 313]. 
The aim of the work presented in this Chapter was to apply our optimised quantitative 
phosphoproteomic approach [232] (Fig. 5.1.) to identify phosphorylation events 
downstream of Akt, thus annotating this fraction of the phosphoproteome. We used two 
complementary strategies, an in vivo cell line model and an in vitro assay, to carry out this 
work and cross-referenced the data to maximise confidence. 
 
 
 
Figure 5.1. Summary of phosphoproteomic approach. Samples were lysed, reduced, alkylated and 
digested with trypsin prior to de-salting by RP chromatography. The solution was then incubated 
with TiO2 beads to enable peptide binding followed by the removal of un-phosphorylated peptides 
by sequential washing with glycolic acid solution, 50% ACN, ammonium acetate solution and 50% 
ACN. Phosphopeptides were then eluted using NH4OH prior to acidification followed by drying and 
reconstitution for LC-MS/MS analysis. Figure reproduced (with modifications) from[232]. 
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The in vivo cell model approach we used applied global phosphoproteomics to the 
MCF10A myrAktER cell line, an immortalised mammary epithelial cell line stably transfected 
with the myrAktER (myristoylated Akt and mutant oestrogen receptor hormone binding 
domain fusion protein) construct (Fig. 5.2. A). This construct contains a constitutively active 
form of Akt which is inducible by treatment with 4-hydroxytamoxifen (4-OHT) [314] (Fig. 5.2. 
B), thus providing a refined system for the investigation of the biochemistry of Akt activity 
and its contribution to the regulation of cell biology. The MCF10A myrAktER cell line was 
generated by Dr Subham Basu and was a kind gift for this project. 
 
 
 
 
Figure 5.2. MCF10A myrAktER cell model. A. Representation of the myrAktER construct designed by 
Kohn et al (figure reproduced from [314]. B. Illustration of the induction of Akt activity using the 
myrAktER construct. The myr tag constitutively targets the myrAktER construct to the cell 
membrane, however the mutant oestrogen receptor hormone binding domain inhibits Akt activity 
by steric hindrance. Upon 4-OHT treatment, the mutant oestrogen receptor hormone binding 
domain binds the drug thereby releasing its inhibitory effect and rendering Akt constitutively active. 
In the in vitro assay approach, we applied global phosphoproteomics in combination 
with an in vitro kinase assay, originally developed by the Cohen group [272, 273], which uses 
intact dephosphorylated proteins as the assay substrate (Fig. 5.3.). In addition to the 
identification of phosphorylation events downstream of Akt, we also developed this strategy 
further to enable the quantification of kinase activity in a global fashion. 
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Figure 5.3. Illustration of the principles of the in vitro kinase assay. Total cell lysate was harvested 
from cells and dephosphorylated using endogenous or exogenous phosphatase activity. The 
dephosphorylated proteins were then used as the substrate for an in vitro kinase assay. Reaction 
products reflect the phosphorylation activity of the kinase under investigation. 
5.2. Characterisation of the MCF10A myrAktER model 
We initially sought to characterise the activity of the myrAktER construct to confirm the 
suitability of this cell line model for the investigation of phosphorylation events downstream 
of Akt. 
5.2.1. Phosphorylation of the myrAktER construct in response to 4-OHT dose and 
treatment time. 
We performed a set of experiments to investigate the phosphorylation of the myrAktER 
construct in response to 4-OHT treatment. Exponentially growing myrAktER cells, in full 
growth medium, were treated with 4-OHT or ethanol control at the indicated dose for the 
given time length. WB analysis was then performed to evaluate the effects of the treatment 
on Akt phosphorylation (Fig. 5.4.). 
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Figure 5.4. 4-OHT treatment enables controlled phosphorylation of the myrAktER construct. 
MCF10A myrAktER cells were treated with A. 0, 30, 50, 100, 300 or 500 nM 4-OHT for 4 h or B. 100 
nM 4-OHT for 0, 1, 2, 4, 8, 24, 48 or 72 h or ethanol (EtOH) control for 4 h. Samples were then 
subjected to WB analysis of Akt phosphorylation. One representative blot of two is shown. 
Results of these experiments showed that myrAktER phosphorylation was not 
completely induced at the lowest doses of 4-OHT treatment (30 nM) (Fig. 5.4. A). However, 
phosphorylation of myrAktER, at Ser473 and Thr308, was observed at all the other doses 
tested (Fig. 5.4.A). myrAktER phosphorylation levels were observed to increase slightly as 
the dose increased and total myrAktER levels were found to be higher for cells where the 
construct was active (Fig. 5.4. A).  
Results also showed that, at a dose of 100 nM, 4-OHT induced the phosphorylation of 
myrAktER, at both at Ser473 and Thr308, within 1 hour (Fig. 5.4. B). This phosphorylation 
was shown to increase considerably over the time-course, up to 72 hours, most likely due to 
the resistance of this Akt construct to normal negative feedback regulatory mechanisms 
(Fig. 5.4. B). Interestingly, total myrAktER was also shown to increase over the time-course 
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(Fig. 5.4. B). The observed increases in total myrAktER upon activation of the construct may 
be due to resistance of myrAktER to normal regulatory feedback  mechanisms, such as 
proteolytic degradation, or may indicate that the myrAktER construct is not detected well by 
the total Akt antibody when in its inactivated conformation. Endogenous Akt 
phosphorylation in treated cells was shown to decrease as myrAktER phosphorylation 
increased (Fig. 5.4. B). These results suggest that negative regulatory mechanisms against 
Akt activity within the cells are active. The data also show that the ethanol vehicle has no 
effect upon the phosphorylation of the myrAktER construct (Fig. 5.4. B). 
These data show that myrAktER phosphorylation can be rapidly induced upon 4-OHT 
treatment. Furthermore, the results of the time course experiment show that the extent of 
Akt phosphorylation can be controlled by treatment time, thus enabling fine-tuned control 
of the model. 
5.2.2. Akt activity in response to 4-OHT dose and treatment time.  
To further investigate the activation of the myrAktER construct by 4-OHT treatment we 
next proceeded to quantify Akt activity in response to different doses and treatment times 
of 4-OHT. Exponentially growing myrAktER cells, in full growth medium, were treated with 
4-OHT or ethanol control at the indicated dose for the given time length. The Aktide assay 
[270, 271] was then performed to quantify Akt pathway activation (Fig. 5.5.). 
 
 
Figure 5.5. 4-OHT treatment enables controlled activation of Akt. MCF10A myrAktER cells were 
treated with A. 0, 30, 50, 100, 300 or 500 nM 4-OHT for 4 h or B. 100 nM 4-OHT for 0, 1, 4, 24, 48 or 
72 h. Samples were then subjected to an Aktide assay for Akt activity (n = 3). Data expressed as 
mean +/- SEM. 
A B
0 30 50 100 300 500nM 4-OHT (4 h): 0 1 4 24 48 72Time (h) 4-OHT (100 nM):
0
50
100
150
200
250
N
o
rm
al
is
e
d
A
kt
id
e
P
h
o
sp
h
o
ry
la
ti
o
n
0
100
200
300
400
N
o
rm
al
is
e
d
A
kt
id
e
 P
h
o
sp
h
o
ry
la
ti
o
n
Chapter 5: Phosphorylation events downstream of Akt 
137 
 
These data show that Akt pathway activation was induced by the treatment with all 
concentrations of 4-OHT (Fig. 5.5. A). In line with the myrAktER phosphorylation data (Fig. 
5.4. A), Akt activity increased slightly as the dose was escalated (Fig. 5.5. A). Akt pathway 
activation was also shown to increase significantly as treatment time was extended, 
reaching a peak of activity after 48 h treatment (Fig. 5.5. B). 
These results support the WB data previously obtained and show that treatment time is 
the most important parameter for controlling Akt activity using the myrAktER model. 
Furthermore, these data also show that the highest levels of Akt activity can be obtained 
with prolonged treatment rather than with higher doses of 4-OHT. 
5.2.3. Phosphorylation of substrates downstream of Akt in response to 4-OHT dose and 
treatment time. 
We also investigated the effects of 4-OHT treatment of the myrAktER MCF10A cells on 
the phosphorylation of downsteam targets of Akt. Exponentially growing myrAktER cells, in 
full growth medium, were treated with 4-OHT or ethanol control at the indicated dose for 
the given time length. WB analysis was then used to evaluate the phosphorylation of 
PRAS40, a direct target of Akt, and S6, a target downstream of mTORC1 which is further 
down in the pathway (Fig. 5.6.). 
 
Figure 5.6. 4-OHT treatment enables the phosphorylation of downstream targets of Akt. MCF10A 
myrAktER cells were treated with A. 0, 30, 50, 100, 300 or 500 nM 4-OHT for 4 h or B. 100 nM 4-OHT 
for 0, 1, 2, 4, 8, 24, 48 or 72 h. Samples were then subjected to WB analysis for phosphorylation of 
the downstream targets PRAS40 and S6. One representative blot of two is shown. 
 
These data showed that phosphorylation of targets downstream of Akt was induced by 
the treatment with all concentrations of 4-OHT (Fig. 5.6. A). Indeed, 4-OHT dose was shown 
to have little effect on the degree of phosphorylation of downstream targets (Fig. 5.6. A) 
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despite previous evidence showing that Akt phosphorylation and activity was variable to 
some degree (Fig. 5.4. A and 5.5. A). In contrast, phosphorylation of targets downstream of 
Akt increased as treatment time was extended (Fig. 5.6. B), reaching a peak of 
phosphorylation at around 48 h of treatment. 
These results further support the myrAktER data previously obtained and show that 
treatment time is the most important parameter for controlling activity of pathway activity 
downstream of Akt. 
5.2.4. Proliferation and survival of cells in response to 4-OHT treatment. 
We finally sought to verify whether activity of the myrAktER construct had an impact on 
the biology of our cell model. MCF10A cells are anchorage-dependent and thus typically 
exhibit anoikis (detachment-induced apoptosis) upon detachment from the extracellular 
matrix (or artificial substitute i.e. tissue culture plastic) [315, 316]. However, increased Akt 
activity has been shown to inhibit apoptosis and thus reduce the incidence of anoikis in 
these cells [315, 316]. We attempted to verify the biological activity of the myrAktER 
construct by assessing the incidence of anoikis in the MCF10A myrAktER cells. 
MCF10A control cells, transfected with the empty vector, (MCF10A ctrl) and MCF10A 
myrAktER cells were plated on 96 well-plates at a density of 2 x 104 cells per well. The wells 
on the plates were either uncoated or coated with poly-HEMA, a cross-linked polymer 
hydrogel which prevents cell attachment. The cells were treated with 100 nM 4-OHT or 
ethanol overnight prior to seeding and during the assay cells were cultured in growth 
medium containing 1% serum and were treated with 100 nM 4-OHT or ethanol as indicated. 
The incidence of anoikis was then assessed in terms of cell viability using an MTS assay (Fig. 
5.7.). 
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Figure 5.7. 4-OHT treatment of MCF10A myrAktER cells protects them from anoikis. MCF10A ctrl 
and MCF10A myrAktER cells were seeded onto 96-well plates where the wells were untreated or 
coated with poly-HEMA. Cells were treated as indicated O/N prior to seeding and were cultured in 
growth medium containing 1% medium and treatment conditions as described. Cell viability was 
then assessed using the MTS assay. A. Cell viability after 72 h treatment expressed as a percentage 
of the ethanol control on untreated wells (n = 3). B. Cell viability after 48 h expressed as a 
percentage of their own ethanol control according to well treatment (n = 3). C. Cell viability after 72 
h as in (A) but expressed as a percentage of their own ethanol control according to well treatment (n 
= 3). Data expressed as mean +/- SEM. *, p<0.05; **, p<0.01. 
The measurement of cell viability after 72 h revealed that cells seeded on poly-HEMA 
treated wells were much less abundant than those seeded on uncoated wells (Fig. 5.7. A). 
These data indicate that MCF10A control and myrAktER cells seeded on poly-HEMA coated 
wells undergo anoikis. 
Measurement of cell viability after 48 h suggested that myrAktER activation by 4-OHT 
treatment induced increased cell proliferation on untreated wells as compared to the 
control samples (Fig. 5.7. B). In addition, the results for the cells plated on poly-HEMA 
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treated wells suggested that 4-OHT treatment was slightly toxic to MCF10A ctrl cells, as 
viability was significantly reduced compared to the control sample (Fig. 5.7. B). In contrast, 
proliferation of MCF10A myrAktER cells treated with 4-OHT was increased compared to the 
ethanol treated sample (Fig. 5.7. B). Measurement of cell viability after 72 h treatment 
showed no significant effect on cell proliferation when cells were plated on untreated wells 
(Fig. 5.7. C). However, when cells were plated on poly-HEMA treated wells, myrAktER 
activation by 4-OHT treatment resulted in significantly increased cell survival compared to 
the control samples (Fig. 5.7. C). 
These results therefore confirmed that phosphorylation of myrAktER has a functional 
consequence for cell viability and therefore that the MCF10A myrAktER cell line is likely to 
be a useful model for the investigation of Akt activity. 
5.3. Phosphoproteomic investigation of the MCF10A myrAktER model 
Having established the suitability of the MCF10A myrAktER model for the investigation 
of Akt activity, we next proceeded to design a phosphoproteomic experiment, using our 
optimised quantitative phosphoproteomic strategy [232] (Fig. 5.1.), to investigate Akt-
dependent phosphorylation events. 
MCF10A myrAktER cells were treated with ethanol for 18 h (minimal Akt activity), 
treated with 100 nM 4-OHT for 1 h (low Akt activity) or treated with 100 nM 4-OHT for 48 h 
(high Akt activity) in full growth medium. Three biological replicates were performed per 
condition, each of which was analyzed in three technical replicates. Cell lysates were then 
harvested and 500 μg of protein were subjected to a phosphoproteomic strategy using 
techniques optimised in our laboratory [232]. In brief, proteins were lysed in a denaturing 
buffer containing 8 M urea and, following reduction and alkylation of proteins, these were 
subjected to in-solution trypsin digestion. The resulting peptide solution was then enriched 
for phosphopeptides using TiO2 affinity chromatography. Samples were subsequently 
analysed by LC-MS/MS on the ThermoFisher LTQ-Orbitrap XL mass spectrometer prior to 
qualitative and quantitative data analysis.  
Our criteria for a confident phosphopeptide identification was a MASCOT Expectation 
value of <0.05. A database was compiled containing 1961 unique phosphopeptide 
identifications across all of the experimental samples. This database was then used by 
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Pescal to quantify every phosphopeptide identified in each of the experimental samples (n = 
27) (Fig. 5.8.).  
 
 
Figure 5.8. Quantitative analysis reveals phosphoproteomic response of 4-OHT treated MCF10A 
myrAktER cells. MCF10A cells were treated with EtOH for 18 h (minimal Akt activity), treated with 
100 nM 4-OHT for 1 h (low Akt activity) or treated with 100 nM 4-OHT for 48 (high Akt activity) in full 
growth medium and subjected to phosphoproteomic analysis. Three biological replicates were 
performed per condition, each of which was analyzed in triplicate (n = 9). Quantification of all 1961 
phosphopeptides identified was represented as a heat map, where phosphopeptide intensity was 
expressed as a percentage of the maximum intensity for that phosphopeptide. 
 
The 1961 phosphopeptides identified in the experiment were quantified in all 27 
experimental samples (3 biological replicates x 3 technical replicates x 3 conditions). The 
heat map representation of the quantitative data generated revealed the presence of a 
small cluster of phosphopeptides where phosphorylation was increased upon 4-OHT 
treatment of the MCF10A myrAktER cells (Fig. 5.8.).  
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ANOVA statistical analysis was performed to identify phosphopeptides that were 
quantitatively altered in one or more conditions and principal component analysis (PCA) was 
performed for the 564 phosphopeptides found to be significantly different (p < 0.05) (Fig. 
5.9.). 
 
 
Figure 5.9. PCA separates 4-OHT treatment of MCF10A myrAktER cells according to their 
phosphoproteomic profile. MCF10A cells were treated with EtOH for 18 h (minimal Akt activity), 
treated with 100 nM 4-OHT for 1 h (low Akt activity) or treated with 100 nM 4-OHT for 48 h (high Akt 
activity) in full growth medium and subjected to phosphoproteomic analysis. Three biological 
replicates were performed per condition, each of which was analyzed in triplicate. PCA was 
performed for quantitative results of the 564 phosphopeptides found by ANOVA analysis to be 
quantitatively different under one or more conditions (n = 9). 
PCA revealed that 4-OHT treatment of MCF10A myrAktER cells clustered together and 
distinctly from the control treated cells on the first principal component, indicating that 
myrAktER activation was the major factor determining variance between sample conditions 
(Fig. 5.9.). The separation of cells treated for 1 h or 48 h with 4-OHT was not complete on 
the second principal component, indicating that treatment time was not a major factor in 
determining variance (Fig. 5.9.). 
We proceeded to define arbitrary criteria for a phosphorylation event to be considered 
dependent on Akt activity and therefore a downstream target. Phosphorylation events were 
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considered to be Akt-dependent if the fold change between either of the 4-OHT treated 
samples and the control sample was a minimum of 2-fold. Furthermore, the fold difference 
was required to be statistically significant (p < 0.05) as assessed by the Student’s t-test (n = 
9). A total of 238 phosphopeptides met these criteria, including some known substrates of 
Akt (Fig. 5.10. – 5.11. and Appendix 2). 
 
 
Figure 5.10. Quantitative analysis identifies phosphorylation events downstream of Akt in MCF10A 
myrAktER cells. MCF10A cells were treated with EtOH for 18 h (minimal Akt activity), treated with 
100 nM 4-OHT for 1 h (low Akt activity) or treated with 100 nM 4-OHT for 48 h (high Akt activity) in 
full growth medium and subjected to phosphoproteomic analysis. Three biological replicates were 
performed per condition, each of which was analyzed in triplicate (n = 9). Phosphorylation events 
were considered to be downstream of Akt if the fold change between either of the 4-OHT treated 
samples and the starved sample was a minimum of 2-fold and statistically significant (p < 0.05) as 
assessed by the student’s t-test. Quantification of the 238 phosphopeptides that met these criteria 
was represented as a heat map, where phosphopeptide intensity was expressed as a percentage of 
the maximum intensity for that phosphopeptide. 
The heat map representation of quantitative data illustrates the increase in 
phosphorylation upon 4-OHT treatment in MCF10A myrAktER cells for candidate 
phosphorylation sites downstream of Akt (Fig. 5.10. and Appendix 2). It is interesting to note 
that for the majority of sites downstream of Akt there is little difference between the 
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28.39114519 35.71142745 43.64765866 2.692173603 0.847126689 1.423931342 2.766940745 1.467112855 1.480031522 53.27457725 52.16390001 55.01886417 1.474235019 2.062582743 5.740133513 1.232846645 71.09422581 38.15917705 82.06993406 100 58.89464101 24.91402415 40.37081114 1.992792903 77.7617853 69.0209511 66.78096443
6.962100448 32.98775466 38.25864756 6.515739377 17.31110581 39.76094406 8.889668617 9.679502445 4.859633252 19.59879308 26.69888472 31.695774 52.91141333 70.80370901 51.56221287 31.80769391 26.88914392 32.40441656 49.23148404 81.36421697 100 44.91832627 31.23621862 30.10901009 46.76153041 45.88217963 53.64565521
20.66180314 20.73227212 18.64984154 38.25005374 24.93668097 34.70382487 32.6773444 42.11426419 30.3881132 60.83942259 85.61198953 100 70.81341671 79.07926282 88.02978569 93.65172746 63.62496444 97.68192811 21.26110713 31.65686701 31.17568891 75.76865808 82.71628398 78.12014697 62.04958125 83.03906244 68.66935649
21.49555589 19.37652336 26.39235599 33.67641698 38.75302576 27.69779604 7.595418469 12.7594238 10.92720889 99.88495992 90.88286411 61.18883594 59.52505081 68.65922955 63.60536621 65.10805699 63.8481022 52.09135108 84.84552244 100 68.49831678 43.66728793 46.06484101 54.47676042 75.4019115 42.32889095 58.24305494
31.06034162 15.23782925 19.36001287 37.79351222 26.81391977 30.32952694 42.02689831 43.08825598 30.2863034 89.22061571 93.31890477 70.55508649 93.54706265 100 97.05343579 61.04095844 62.31118367 58.41302826 54.48264329 29.26094962 29.21551842 46.019688 59.08253818 45.08838276 76.48281203 80.8948011 86.63431669
28.81463633 12.52611285 0.150975327 17.85742489 21.50943168 15.66496532 41.3189593 20.84247201 20.06084961 100 77.85670523 70.10061781 45.45495935 45.62604386 38.74943696 47.60182697 32.22099857 45.98650629 62.5633753 31.64738137 41.71598015 46.81995553 29.32832873 26.24149965 41.04373157 55.73278179 43.06969818
18.4997718 22.19483769 29.86447459 26.43188001 34.7249855 34.53060924 13.30980651 13.55063306 17.57597651 46.36849579 58.94657704 53.31040685 34.00880431 32.69189492 53.98437115 28.62935318 44.05170451 55.89942522 49.58902464 100 70.78375824 39.11286759 43.93793393 51.09449608 44.56588647 60.98087077 49.02969846
1.258198021 0.901231334 4.764941009 10.54594872 1.378818434 0.990650259 0.976580873 1.027604523 2.525621723 45.4874027 57.0833153 100 54.56917495 41.09297618 62.20445322 14.72598011 27.54407731 35.28602321 17.97399821 29.66161057 36.28361217 1.236075896 34.45909744 39.42743778 68.54952354 43.89976248 47.39182783
3.068383687 0.005318845 3.085368871 19.5223349 5.804985686 0.257822154 8.619307635 12.0304973 4.132123594 43.79268538 50.86856542 78.36948727 53.22864512 63.67968821 48.81088864 100 89.18699754 83.53954378 30.94594005 9.444778008 0.00513064 40.83128209 42.26024891 61.52156655 44.72630838 42.6699005 35.67206915
36.86961779 31.2830322 37.17240937 31.93877947 18.69633124 23.18793056 38.47025808 21.76402403 29.97665122 79.12584899 62.27380496 72.70972836 43.17095023 50.37103535 51.64395345 41.70773832 38.64843342 52.38419467 100 83.33789621 93.9495941 49.20771006 35.21734291 46.42736629 50.81371693 44.69087997 45.25672318
45.11761023 56.21569499 28.76140889 23.15337661 18.994741 15.03381009 13.92246081 21.60270028 13.32061899 84.5020999 100 77.79275706 20.0350628 23.76928163 22.89148661 54.36870538 62.08575809 62.74584202 93.28978516 47.47928993 53.37994115 41.53007347 45.65277838 42.97069767 34.38941162 40.92865431 39.83420087
16.84082523 77.44161824 89.54860972 0.952002716 35.33513895 45.74817198 0.722739056 8.599017086 0.835961793 7.679053687 10.2563515 0.327252519 8.63066635 20.25639304 24.32223506 29.21070068 58.80731822 51.99103075 45.11230677 93.5541991 86.94461603 55.2633383 99.4843832 100 25.69556047 32.95124012 29.97021254
55.9824358 42.60522625 62.49345699 10.05224379 6.17679786 9.401576099 1.547634866 0.932502661 0.700017961 39.41399148 44.60137606 46.91140647 38.91975929 38.229474 45.49374408 52.31943337 33.9731203 66.5845743 93.29772099 61.66914232 75.91413375 39.3856405 45.63402947 49.81417533 83.33571405 98.84478123 100
29.70245195 27.42036854 22.5773881 35.10485014 22.245676 19.58746039 44.01473237 42.07471353 47.55818469 95.88386848 59.83746877 66.5044731 100 82.35332408 95.16099191 60.45123095 42.50266682 44.25597245 49.7333037 22.17231472 32.6507844 64.30932215 44.30724155 46.85977145 90.8433683 87.02027921 91.50715243
19.91542867 13.40768988 14.27178507 28.27674653 27.00752751 36.45217847 20.97438104 21.81852947 15.64757474 98.2104652 79.39794073 68.26820002 96.20859619 96.94500583 100 55.19822621 48.82656147 51.60983176 35.08715385 31.44450121 29.27997803 41.77458388 51.199436 46.85133338 69.5589407 76.44884242 69.3487641
47.89043906 35.50824792 35.08146267 29.11522965 25.60346479 21.9551339 8.328191194 7.026894498 6.735676111 51.4493921 44.98103381 52.35087458 18.59042593 23.11799711 20.94288516 48.21016973 51.45925656 44.10028482 64.86790503 100 53.78408009 44.26033552 37.78576408 35.82414816 50.63774914 27.97764208 37.25510021
12.2351488 11.82863598 23.32827555 0.456372392 19.6108679 22.78865502 4.366101626 6.175872237 11.61293083 24.60638022 40.53505079 62.83164291 31.40674743 29.74467414 32.40330908 14.71732867 18.48335848 47.71349129 55.98371036 68.20135745 100 10.66859855 43.78814404 40.4569542 39.86855243 24.09087873 25.81598375
21.44653904 18.06829853 25.43627876 28.87381501 17.8815968 36.32047743 32.52263519 25.59893782 36.60868784 90.86269494 74.2379225 100 62.38115661 55.37824576 49.24750907 38.36738743 34.31810379 30.34320666 71.29330239 47.55281966 55.7544115 51.56995834 28.96748403 32.71539821 47.99922511 55.27037766 51.6079678
33.28749098 23.58236573 37.50839698 29.34164912 18.24582726 28.65918783 3.248727118 8.257636098 3.240622269 45.67264882 54.95572348 53.56046524 54.09782539 49.06303484 63.04166862 46.80793024 38.74390683 38.94766898 78.95568946 42.26871733 85.38539913 45.09813851 26.00138463 48.36184375 100 70.93954865 67.28909315
8.97822105 14.75090622 23.59339503 34.32183713 15.75517501 29.09243621 15.20798013 12.43705281 11.02596193 32.75992323 22.05058806 31.65218472 89.5295268 65.40492144 100 10.08650811 17.69873468 19.9101947 67.1930131 65.49013753 92.56114787 43.62236099 16.67695829 30.08301135 78.60270388 81.21034149 70.099194
15.24169128 19.06504372 19.84726431 14.89378413 13.51120219 14.01133938 40.87162461 45.3841365 48.10639221 79.9211697 49.7364965 86.42682832 59.47196256 51.56547015 65.61709208 39.71183763 30.55540573 37.33772168 100 41.45620709 65.68471276 30.55783907 26.14294668 23.58386083 84.76561065 76.26769816 80.21566513
19.20333433 23.72019918 25.15417042 9.884427492 10.08828305 0.503875524 0.887499428 0.002526044 2.206339752 76.04443827 60.58880781 65.88593119 24.86303833 15.51262998 21.84167892 48.58577814 47.19668262 34.87537848 47.55364693 43.36152241 32.39478018 36.63057003 40.18580527 32.20925243 100 76.65912754 73.81041262
42.89171776 33.45647958 45.93893005 39.49718896 46.19616942 47.16104404 20.85629371 20.41429762 14.88210645 69.88938798 77.63983255 85.66009054 58.50285785 65.88096153 72.98649355 95.40812951 100 91.10461648 37.09834843 84.99663007 67.77687128 47.82732067 81.94828252 70.03741701 90.67824755 61.46159485 62.87488653
0.005465058 0.00681132 3.865790411 2.666078328 0.006776548 4.719893515 12.51128272 8.527089897 5.626091813 100 71.5236327 38.49885767 49.70670262 42.81535235 41.30384522 78.51496892 60.85426285 74.61238636 72.15384391 20.79501167 0.006570305 48.22751763 19.15512498 42.12468027 29.87605694 45.53579927 29.77773638
33.94503137 35.47605168 35.1752315 41.69095134 44.13091934 46.80745041 32.64989437 38.27879215 26.91491099 63.12757843 61.20641345 59.37778618 96.55133355 98.95016429 100 58.88620089 60.74145244 73.01500153 46.26439244 35.34504639 57.98600288 57.26175214 73.07799669 78.23369844 87.99822942 99.13978206 94.22679749
3.328983483 20.66962746 9.365760285 6.794590479 12.90123444 14.91777574 27.18723885 18.41748685 24.45873932 79.41308534 81.27578615 73.12145291 76.08859967 81.43157983 94.99208951 86.41982282 72.17020303 81.44519618 17.99150753 12.60331063 15.9960641 82.362774 57.25881844 67.5460291 100 75.37377334 91.50627842
21.80550264 11.77082843 5.838865775 33.64428122 16.24451836 9.500037209 34.7115236 22.44638386 29.47405239 100 68.6279713 80.26074917 70.63055522 59.65083824 68.38070682 40.25209599 29.90225777 51.09002417 67.31180514 20.24164103 12.92399609 34.88159249 31.15741908 41.4385246 69.07208345 75.38380091 82.79787523
18.41788885 13.90653992 7.94521541 47.20604578 24.61351288 15.97798339 21.92424462 19.44248427 8.439973398 65.42508604 38.83409453 73.08363677 45.18081321 43.86002636 59.44056279 79.55696953 50.62883367 62.63717065 3.678251221 23.94566735 40.78335456 86.13793604 82.27460944 100 64.56838554 65.44647923 50.71253634
28.49457617 34.50295806 55.44711845 50.42029027 48.83948656 62.49635713 20.89955321 29.7092309 30.17439849 81.84167302 82.49380968 95.15122664 60.17672902 78.39992698 76.05179537 99.90211288 91.56582702 100 55.898036 51.30364288 53.75880165 63.71167761 90.60217134 85.96006884 98.82741073 68.28791866 86.7388342
5.813812392 49.30879759 37.94021045 4.483750805 11.75685088 14.05563725 5.947669926 4.23967219 4.405665611 18.93464505 17.07317075 18.31911488 23.0137096 25.40625275 25.76078363 10.94263261 8.502002968 11.14881596 51.87885052 62.51693642 100 7.005192512 15.50049099 27.12021212 40.74240112 43.47967925 34.62857548
28.86419072 43.19484886 19.54946354 21.95798766 24.75299441 16.20435232 8.794768368 13.43044619 13.14997295 82.64806096 79.97512211 100 25.60601799 31.6634407 25.86039155 51.93524989 37.94747523 55.85225416 51.68187463 30.63980493 26.43329251 47.13348702 43.3026184 34.99574486 27.22030741 38.8385105 43.19312045
7.163469515 9.181986071 27.37629783 20.78718924 16.21287008 20.20153804 9.946445056 16.6317309 12.91565249 53.12507949 70.03504466 55.48751474 31.96636199 30.57235298 33.53650041 34.40614537 25.61525798 34.609531 41.61732315 100 96.31694161 32.06424283 38.16337713 37.57621661 34.66162632 41.59829802 33.92940613
18.59672282 25.57382908 26.96377523 21.8592925 21.09881167 28.02610996 6.734272718 8.350557258 12.24790751 49.97548145 66.30268562 77.6071895 24.60504093 34.57683352 34.92931833 23.89994439 30.71539902 40.57765464 73.82308726 66.12175451 100 29.14568648 47.74570144 41.89730969 19.38184908 26.65707301 28.54484375
23.10039414 10.56793627 19.63525539 18.64981307 15.46349441 13.05356933 11.24054775 14.88151402 12.82759329 51.76106264 43.87652119 56.00367526 100 88.33128974 44.5381169 24.50417182 44.67399659 31.80436492 34.31555999 32.75816353 52.15920168 25.0494454 31.29214949 30.99925707 85.12574143 38.27524557 42.74909096
16.1001094 14.07867938 12.38946595 44.28554702 32.90074351 33.25866721 37.80886998 32.9386624 22.90464654 100 70.31078247 87.88794086 45.41704394 50.12405778 33.99967342 85.93583663 73.18212315 51.30645847 47.50695 48.94083075 30.88401822 61.77529656 76.49504329 75.51982999 38.41195183 30.97196632 35.19720648
34.37587475 38.3414173 24.07521098 24.84652624 16.96461857 15.41185833 19.35484987 21.75190044 19.77472121 100 71.61375987 53.02787409 28.54056264 30.31842607 34.05951983 47.07082101 44.32847758 42.25535773 53.36081015 31.80033377 34.90868923 30.01900981 30.16020731 28.57054917 51.23728578 44.05864968 38.60852286
2.794255994 5.248927769 13.19245789 5.12686496 25.49632277 37.26910555 8.215153884 7.791069093 11.69657044 34.25206915 56.89307759 100 41.78634766 36.43381658 26.94810556 16.26218849 37.59244679 72.98117648 0.003684336 28.55991487 24.67924262 12.32914985 80.68277736 61.2237533 37.02624691 32.97665672 29.84226955
22.13265898 25.36410643 44.40906334 4.097806399 13.25585792 14.21401672 21.00550279 10.61680372 13.22847448 44.45728402 78.54904417 100 5.702095127 0.637930667 0.646073634 15.76100652 34.08489721 18.49186907 61.8483904 92.31822485 93.25643676 20.41583772 42.860737 19.28756661 89.66554623 20.91137 19.76536353
0.855291181 13.68454249 15.1760715 4.446083242 8.343631462 3.281582807 0.001296272 6.957944915 3.031495766 11.71700096 18.15046661 18.13809117 29.34412215 40.42001242 36.80213835 8.337668617 6.309665115 8.794540759 27.72320287 51.04594217 100 13.528946 17.91832008 22.06640036 21.16118697 37.87464301 29.91456539
25.59549051 20.8800012 21.1090352 20.55268114 14.79057119 24.72654295 7.693427778 6.466189764 9.943385903 66.73620837 72.74142942 54.29718965 21.87262702 23.19811071 23.65572019 24.27860822 18.29267204 20.67054718 100 62.15593808 78.83541657 31.81821207 32.36847284 36.43076594 24.32917365 25.21682068 26.13407192
10.03690486 11.38788671 14.32361077 13.07362621 20.63746279 21.79866785 11.32932148 19.56633123 17.43198715 52.75541921 74.97765724 77.09768749 40.82711423 36.83312767 42.42040473 35.61976578 50.77864773 42.29304274 76.23807415 100 54.70770974 23.50626385 22.47309294 37.01728843 46.96870572 42.73979135 54.03600993
19.00528514 8.160683788 29.6774778 29.00415675 11.85053507 1.194266761 4.515905915 5.475702606 8.19153896 31.25714258 25.96627936 45.44036108 20.65975484 18.51675856 20.43909099 21.14571145 21.01591596 31.59860765 100 51.88355551 52.48862695 35.3215219 20.45529451 36.33857961 26.34283428 27.86058617 27.2587159
61.88293859 41.20210237 35.94805404 48.54650475 45.81737118 37.57084751 22.31324643 21.90657689 16.81060455 91.16818965 100 93.39043207 63.46035264 66.41506083 66.90053008 66.21631986 82.92172657 50.27146295 54.62301575 92.16458221 96.67741887 46.00767146 72.69290332 61.15184459 50.53897106 59.46415036 55.51271863
57.71521144 46.35853004 14.57797248 2.094748226 36.92780734 20.84530956 2.079722293 3.055281377 1.038455959 7.363444106 52.4013795 39.56906708 9.085413088 12.28925221 21.94509719 62.72032668 61.27578811 63.3419446 80.51036324 100 72.75518486 33.74398963 38.46753283 3.70437066 59.9280152 54.29589031 60.55603181
23.54191342 22.07573875 22.29243622 9.825673523 14.75277498 12.44478957 0.522214287 5.119332274 4.65419994 49.47368602 50.81033409 50.53147567 7.590269275 9.955495897 10.27429365 23.02056847 35.1995223 23.85848339 79.21930836 100 83.26443115 18.31501423 34.56586199 29.24166106 31.329153 16.94528924 15.57033602
25.48824427 29.05901816 27.46486969 24.85350834 48.68840695 40.75267101 27.7286896 31.87397816 25.97147498 66.92967696 87.1491161 100 48.68088373 48.28096453 49.56479577 52.04086367 59.00624651 55.038246 61.09816109 85.49016584 67.64311114 37.06352096 66.66243623 56.17178 28.84863703 43.60889032 37.07332612
1.568021606 0.785153849 1.410930255 0.683794733 1.855933485 0.760801729 2.006644193 1.440058086 1.145455236 29.41812835 44.35691176 100 3.465723681 0.488394969 0.428226991 5.738778542 10.953706 22.13537995 25.99232996 22.88446926 18.97610527 5.71653416 9.796629067 5.770608543 66.05897222 33.41699897 31.77045433
6.628235778 1.938661547 9.550445208 21.41457795 18.04060002 22.25325515 17.381686 19.24378132 26.70372854 62.08531835 100 66.22922217 20.29615089 26.44406481 20.38331324 38.33021892 35.01229351 42.17529489 94.58085147 59.16019799 67.06048345 63.33236303 39.71430805 57.55716774 29.26514717 34.47359973 21.39460099
21.47803596 15.75746588 32.59019439 29.80827087 23.67028985 33.38181983 25.17486138 28.56567105 24.17058008 54.96176972 45.9905873 51.18337683 62.24960415 60.96251563 82.60836784 50.28894119 33.98944776 47.01396583 100 67.34671292 69.33372348 38.96186477 32.58997858 35.21660913 46.42498276 59.61772673 56.01652418
20.84083641 19.39302429 19.64246171 19.33897234 14.03249053 10.73803567 30.80944496 16.87521647 76.11692867 80.71982613 87.16876479 75.52676347 74.13278991 87.67829883 74.47574647 93.44695291 82.15360138 100 43.30947016 46.4693954 37.15416569 65.9607718 11.20132393 63.07136446 64.41617566 66.81451817 70.39911805
44.21985496 29.65009579 59.07731963 36.06086359 19.16578882 23.8845022 14.86518601 6.34104199 19.56911725 61.05769611 55.27074588 86.5288967 100 97.0706423 92.27441035 72.73142234 36.78732409 62.05099907 64.89079716 30.79067802 52.85412505 84.83450035 58.34820212 54.75727383 87.88278965 95.92880977 82.97171878
29.3820114 21.66449411 35.93171829 26.4174895 21.43473466 27.60454572 6.668057334 10.42937748 9.107873212 41.8193265 28.08088641 39.93103523 24.06620991 9.826504638 11.81594332 55.50533974 49.42301321 48.4357607 100 29.44627459 57.75167647 30.01051831 41.0751022 39.38460559 44.22559262 44.77983482 29.22522171
19.78224946 16.56778789 24.38455693 31.33357338 23.75215262 19.03514528 21.01793419 13.45781535 28.51164343 70.44701233 63.97451755 100 24.73479563 27.27335464 31.78395457 37.52328402 49.69615201 43.10729171 35.99791064 36.50410358 16.49395171 61.1445459 55.49855406 50.87028784 36.41919933 27.86983191 29.31549518
29.41217278 19.62278675 19.15941308 24.88352563 22.38014571 15.63291835 11.42607637 17.75568908 12.15503417 62.01609808 100 90.46243345 23.40509533 16.86674728 19.95384357 42.28151084 50.63310533 46.21528963 79.06653788 25.04434 45.5514726 26.65730821 32.69159669 27.83865694 29.16604919 35.92746558 25.08374392
10.96455695 58.31985721 47.0760528 15.42457134 29.44121915 26.15811723 4.176079089 11.15181772 10.54709435 7.403926179 13.99275664 31.77763686 61.69903169 74.77254707 92.55722013 4.104681819 7.414225429 12.62859989 42.62218051 77.30079094 100 9.381453902 36.64781068 30.31626583 48.54245639 70.00331891 68.71754939
43.32268937 45.51620236 40.36287364 41.20357374 35.58161235 31.69076476 18.76684567 16.25104017 16.65075559 49.44876961 42.49670832 38.63157638 60.74004294 61.38601919 67.97826871 59.60948434 57.3586006 62.41644207 64.1614164 37.62566864 41.92200496 83.4124073 59.59935763 61.66484633 100 64.30095624 70.04972853
21.42162496 12.69169104 13.81228305 29.82063302 23.51882833 22.46341425 44.97013974 32.89175051 33.27322315 100 68.93055368 74.29988439 50.06716335 47.65936731 49.14169815 57.8358969 34.33321591 46.04660792 70.37460232 36.27429985 50.25192434 52.51737884 42.29517789 24.50655209 42.42628218 46.46954354 43.42698297
16.74039373 26.43274694 40.15391612 3.393284554 16.19401258 12.12650619 18.57178661 10.02265828 14.12503907 33.87458372 80.1521982 93.06747549 3.037551253 0.689086365 0.603700604 14.85512257 21.20366484 14.05910674 59.88198218 100 97.62704611 11.68230783 37.57209132 18.06908965 68.23065132 17.08862584 20.56156142
17.57778299 24.27465046 29.8785745 55.66294606 30.72655007 36.97509229 16.20447316 12.19452204 12.63668886 97.78451902 95.9634345 100 26.35617835 41.29990662 33.50728851 24.66948725 43.71502648 49.04756086 58.67582622 11.15426781 50.3418141 72.31506559 72.43733032 53.4595028 24.37803525 30.720933 35.92517087
14.78880505 40.04248674 14.91230487 4.24425245 56.56214896 0.921208565 14.50796486 12.93959393 0.001456157 65.91064055 86.61613838 84.69988904 35.67596281 24.17587135 20.4601568 36.97452586 18.43666046 8.339765334 100 85.94886602 88.1260962 12.87570394 47.31811291 57.7415118 29.4917135 31.51968152 34.40765936
34.14732803 12.59339793 41.46058977 15.95828913 9.245537182 28.60279257 28.87302758 42.43654877 36.41006086 39.77000839 71.33363415 93.59394507 33.92667535 39.4835119 45.2040406 24.79673596 60.75298933 12.03743205 39.14885459 100 91.7532736 27.37191017 53.50827299 50.02435911 58.8060968 51.4404175 51.74899706
21.69824759 18.11677974 25.06765663 26.05569074 18.85671897 27.27983817 6.932005682 6.030471886 9.723098598 45.55383789 47.52307902 54.02421983 30.58088836 28.2054174 29.90545082 36.57770344 25.27561364 27.03500652 100 81.36754333 83.46192488 36.54479158 31.71009568 31.05159621 20.86074191 25.66769396 31.89632756
39.18841511 24.79856169 34.49653132 12.62998083 18.8529434 15.0553496 1.785963259 0.82184892 0.810730198 15.80823749 36.59952271 30.30135602 14.46664744 14.48199373 14.79815367 49.09088942 53.03835334 38.36103842 61.84306621 100 60.84071371 31.90115449 27.8068518 24.3491162 10.37631547 13.97935401 32.94620229
9.569702381 5.592265875 1.131883185 5.052472061 1.27009103 4.399264784 8.294010723 9.233455991 16.13899955 67.56429169 83.45587328 100 18.28330664 20.55174412 21.64358312 9.06834838 14.45830373 19.8075356 51.3513615 72.10841412 83.03537635 10.27230125 17.46670957 15.57432759 30.35914875 29.84953081 27.46586362
6.489028143 25.29630341 54.53243909 10.41020854 26.56099423 40.37377629 10.70077248 7.565580857 9.917910822 15.07934286 20.88177356 32.7332915 18.70993265 17.01274239 18.78492861 11.09353804 14.2400206 12.91675542 42.81679753 96.16166969 100 28.39763939 28.45726803 39.17506336 37.82593815 29.09929174 21.65733819
35.02457377 26.76686138 29.15410237 27.62995368 22.54298515 24.91902637 6.308418317 5.66981922 3.903816333 100 49.19144491 36.95121348 11.35007145 12.47978876 8.469110716 34.29319134 29.16778167 25.51025976 97.49140756 78.97819365 68.10927331 23.35079529 48.47038722 28.58748985 39.94330018 18.14486316 11.99027952
21.75487922 20.84162094 15.74305907 32.33846997 20.47114989 24.30702009 59.49582641 44.73674638 41.53705673 75.95066975 77.56463452 49.97581032 96.07217842 100 95.93052741 66.83506113 60.47411319 54.95612161 35.85831659 21.96688895 22.05063705 50.53600991 29.41502765 22.77488865 95.81125524 81.42276244 73.98639274
24.58293478 9.75899171 25.06380922 26.80634211 25.15170186 23.00247505 42.03637985 12.91327511 39.50998745 61.33587192 49.72445982 42.11537807 66.83902006 70.5121827 55.07194172 41.16727727 33.41264844 40.31581551 100 47.3442903 61.1295919 39.11622542 21.16398827 47.70972477 51.90631799 60.77119747 48.7636273
10.06683239 50.9231431 65.71972441 0.784122653 21.74359016 21.57565137 16.84160516 1.250500354 11.95258856 99.48083171 46.09655651 100 7.901347891 1.017903926 0.606683545 32.81876741 64.67612629 38.90626255 76.89688892 58.19030804 83.82917283 23.05642503 58.66344179 28.31946704 97.31348546 6.656683055 40.86537086
23.82003342 25.05649106 38.88576442 3.664623945 11.94592175 13.04753519 21.23596607 10.68572397 13.18432318 41.74839014 72.47052454 83.58858094 3.892433962 0.160159686 0.233976497 12.45940632 41.66743735 14.60726438 56.22570568 100 86.12750231 16.92643633 45.00329354 18.36179331 65.06008869 13.74435749 12.56390442
16.47108468 14.2486782 19.74108334 25.1612844 11.29747922 21.45908378 12.43973149 3.68713647 10.3392238 43.88914323 31.23303628 35.25269367 100 92.41083674 93.30289112 45.86297592 27.55826561 54.32221151 40.60001064 17.95997278 28.4192933 44.95492495 32.40266776 36.26420466 96.06414795 90.41143917 84.11511451
7.760002528 11.11422701 12.91562036 29.02295529 29.13579342 19.45558934 29.43610602 20.62812525 20.24367464 62.86589689 70.48767656 40.18727516 58.76573814 40.59901083 40.90844758 100 94.12964945 59.69901326 7.370091386 27.76758753 23.76120869 56.38539859 60.50131977 56.90996264 29.59112351 28.71687169 26.2667609
13.83080325 37.17114124 38.009748 11.39622075 51.45353789 32.9088552 0.654851083 4.743002145 0.584747001 0.872936149 7.336195636 10.25130679 5.013690176 6.344361466 7.937809511 15.76971694 45.97213475 35.89556277 28.50699014 100 87.53265041 17.03488916 48.70555571 43.70771472 19.93167986 28.2342247 24.09408226
26.36856165 32.01248117 26.75612867 20.62211894 1.209584725 21.78420451 27.12620678 30.60043096 36.18814174 74.95752282 72.50527278 75.42424077 86.90971736 75.25861684 80.1989473 93.80271106 68.340817 55.63098418 43.14755538 16.72260702 22.73929167 82.18982662 37.49792643 47.89598074 92.8354019 100 79.57538297
9.66486997 4.053430855 2.306555571 9.790685835 2.816291776 4.418647418 16.8734395 9.670187641 9.290879556 100 71.49943481 76.93805432 82.91344227 67.47842356 64.78163755 50.99963664 27.78727267 35.33437408 22.58849689 6.789807287 9.484994335 29.40930033 21.02090827 13.31912849 73.72252317 76.36547594 75.20026938
30.27704789 14.26873155 14.73095153 12.68994967 5.404503133 19.7609417 3.228064667 5.967903983 11.07341322 30.26599989 85.61795572 71.92445819 82.40589711 75.90265714 64.32402595 52.67346697 58.70404457 56.09888343 22.04765475 29.49715821 17.8389203 28.00965763 41.43739941 74.02687563 100 89.71759665 90.13653363
11.99527653 5.896033492 9.438594065 27.69128432 13.91967166 15.34770876 8.171201999 5.809100137 5.105211868 33.06371512 26.27826039 27.63039916 24.8030688 22.38399517 22.08233243 25.35732191 19.46310198 15.64772032 100 59.46722836 70.24956877 47.54492998 23.45898972 31.94626519 19.1843528 17.22215984 14.97344334
11.99527653 5.896033492 9.438594065 27.69128432 13.91967166 15.34770876 8.171201999 5.809100137 5.105211868 33.06371512 26.27826039 27.63039916 24.8030688 22.38399517 22.08233243 25.35732191 19.46310198 15.64772032 100 59.46722836 70.24956877 47.54492998 23.45898972 31.94626519 19.1843528 17.22215984 14.97344334
24.90511448 20.91681325 15.69497069 19.43835637 10.44059829 10.87081585 19.1501128 16.58335585 16.82202988 100 58.97720268 52.12791003 53.81402873 46.26354483 49.27541159 47.44476324 32.00639413 39.54232698 47.6069459 20.81669145 29.4920451 27.18872462 20.82869788 22.42499862 89.34185051 69.78748261 62.55717709
2.411319739 13.03914296 15.08135421 2.101461449 2.398381163 16.61334637 59.47220857 2.331194033 1.525829414 100 71.94897224 69.629918 16.68772 2.000231007 6.504616234 38.47925523 49.95543583 45.69869758 27.48880136 77.22754747 71.06758472 3.839789589 58.95971219 39.6138624 66.8460321 1.624354321 13.01655199
25.59549051 20.8800012 21.1090352 20.55268114 14.79057119 24.72654295 7.693427778 6.466189764 9.943385903 66.73620837 72.74142942 54.29718965 21.87262702 23.19811071 23.65572019 24.27860822 18.29267204 20.67054718 100 62.15593808 78.83541657 31.81821207 32.36847284 36.43076594 23.97611606 3.625691682 25.81996579
24.44743584 24.18646204 33.75478754 32.47391115 25.86172838 29.10176663 4.926204718 11.1607747 11.49804276 63.41673165 74.0055324 60.98093952 17.98149204 18.01243952 17.39119223 25.10784947 36.65989129 34.15311583 89.57182469 100 96.18268261 37.05964399 40.83979788 48.52012826 19.86492024 19.4906386 20.58165121
51.05563608 28.58712101 28.65513838 27.98288185 40.40591338 42.56457451 2.990943636 13.11052417 1.81965141 51.85222788 65.09645246 85.40867793 30.26408604 27.44759166 44.03753225 64.03080783 83.66590478 100 35.89959436 68.89848447 58.30826455 37.45283959 47.90069622 49.26952029 37.38825348 57.35100478 42.67559982
29.34732116 7.925939362 21.82587578 51.50891333 12.71166059 29.5385152 34.24413284 21.8194849 33.05690578 73.97568961 52.54524933 82.27156642 65.81144629 67.86847806 69.97930049 45.38379086 36.07981522 44.16430707 75.31314173 20.44169059 19.12036952 55.28374767 25.7427233 38.68669882 100 56.49586808 67.25389055
21.17330775 23.36264333 24.91036155 16.67454325 16.16618128 17.58134766 8.857720005 11.23244326 11.23107231 44.69827619 42.4595643 41.44222633 17.78776079 18.18060894 15.81146191 25.24980549 22.38975662 27.24177808 91.33233559 82.80641785 100 31.2310634 19.4324244 22.89176109 29.01667513 25.39981927 25.66103162
6.908682049 25.62250868 26.80984011 7.039874406 12.46120418 14.50263836 5.262274853 3.17844967 5.685857509 11.03797094 11.5023358 13.09365092 18.67439129 20.17902124 19.579636 7.708453358 8.060606912 8.406072707 37.40685446 72.83707518 100 10.88953032 16.91059791 14.4260149 21.52166464 31.17463249 27.50513096
29.92541513 0.000663213 36.60981251 4.744923366 12.4691309 10.66998074 1.848475805 0.478135761 1.025267853 55.16636643 63.34058052 61.67441956 6.729394212 9.841070787 13.05672156 29.49135967 32.08194177 45.22141245 29.3226915 85.89101898 100 19.67405803 36.87090895 32.67410876 15.98027198 19.22619052 19.2010788
32.26777585 57.84838175 69.70068756 11.82801236 19.96868625 22.26119565 25.99903265 5.822727535 11.19686998 66.78621179 61.53594161 56.55261275 6.504482323 0.235819756 0.346205774 78.45253793 86.06641463 36.68329493 57.96420277 70.38331171 66.86280346 39.5988371 36.56341562 21.76879755 100 80.51707669 55.13729262
14.54874031 23.30554299 16.23681851 21.3808836 29.39183408 25.09029129 2.194700577 8.596178752 0.182643391 51.31230266 62.85131009 47.5896013 19.91814914 26.64048741 27.55219002 42.51883008 54.15732069 73.18255474 63.37780903 100 39.58910803 23.09096765 38.78779525 40.05032186 22.60035685 16.44958317 19.4793345
26.91867057 24.47103904 18.14394819 13.15135512 11.62852124 12.63444089 11.10533287 13.60490878 14.82282343 39.3607395 38.26597463 60.4741035 90.85024498 75.773678 100 52.3788551 27.44986824 69.25470552 24.08063607 22.68486199 29.41721042 35.96283569 39.26412926 38.9416844 99.46503237 77.10177186 82.57516577
13.83864426 1.138722078 12.02800882 1.160408441 22.31263686 3.380695828 16.48342226 2.088402492 3.664911567 27.43920854 19.59948388 34.1889666 7.786270039 0.722741931 11.6515669 38.76035394 68.97503874 57.8660892 14.80984987 100 59.24484055 56.97739217 68.84170985 60.95249324 7.760593614 12.53046571 16.66217527
6.393931054 6.407474187 5.229044304 12.99607935 11.63953993 20.07705597 16.97356116 9.361024382 14.42244374 45.99225773 43.08889652 47.54807393 32.30645658 36.52568749 32.24335106 24.64072536 23.64924102 28.37377774 97.21504077 72.45036083 100 20.92987819 30.88554206 25.12212649 26.97752404 30.1503247 33.95007995
23.66103227 10.69050309 12.59019942 38.24084998 17.08901245 3.795023704 30.52267456 47.40035963 31.12321462 100 69.00363318 69.06717626 34.74464273 32.02418314 34.2774312 51.59417508 48.12195605 49.77330504 64.23862556 8.751642575 13.71430871 68.62149919 31.44192095 24.69484754 52.37880507 43.78606971 45.22383926
5.348796918 0.573205523 3.31760428 23.83476125 0.000482062 0.000533797 30.48386643 6.052130476 0.371668853 100 51.71501319 41.45834465 35.78687752 0.000201915 0.000184718 50.53888085 21.68016643 19.98020927 17.83960511 0.00042594 0.265010391 26.28949076 20.66492571 18.60120113 42.88517591 45.39270338 40.24601959
23.65140723 25.79462846 20.54596875 30.38773937 27.15443321 21.6132969 12.33026681 14.76848329 8.763813656 41.92137018 38.82580288 56.57330713 74.07660252 70.44231448 100 54.05649103 19.61774755 67.62035871 37.05817425 16.25913193 19.38401036 49.34680691 43.480236 62.55482156 64.49181293 90.6748548 84.65175563
17.49374172 17.69668456 22.40065996 16.70694726 16.17784902 20.36148888 12.03661018 11.68444238 14.12196385 56.43089435 62.68141911 68.47781679 25.11550091 29.2677834 26.89740731 22.45155261 23.40308886 35.48093963 94.24209763 71.33812013 100 15.57387181 23.67874684 26.31688507 25.81387611 32.15867594 34.68184182
1.026530208 19.60192534 23.85990295 1.317850869 0.796362322 0.896283886 14.26224558 1.566051883 1.15346972 12.80200557 34.17757198 90.5451691 16.11196936 2.194130069 0.001250626 8.987988934 18.49026447 24.73185195 52.63623902 1.499581524 52.12507316 34.34099828 58.30396193 24.39693762 100 8.818290438 10.13264127
26.66826613 18.84485422 19.76634648 18.03848342 6.250465312 7.107069157 22.72786663 8.266160463 21.90111514 54.45236063 48.36324267 71.65832441 65.50761533 48.52072771 64.99078657 47.00483918 26.87765934 51.24123582 44.64991862 12.24508318 6.216502276 63.92191237 30.62319876 26.63325623 100 95.26402408 96.42054461
51.53000788 28.38624804 33.53741998 43.90046942 38.19873758 42.0067463 8.749053034 8.790851406 6.989805779 82.89409611 90.8838811 84.48025446 36.49331932 34.15322345 37.74568276 69.49489377 58.48789922 67.4370966 100 37.33590701 17.10361928 73.67147314 46.47174544 42.80239821 46.3470342 46.93470514 56.47889676
60.996328 39.37121826 40.65489741 45.37631049 32.96350638 8.490524054 23.58632267 9.589263843 18.15907434 43.48305843 42.74547515 48.02494289 84.77663825 78.5819622 84.3562978 89.36445966 74.19129003 91.0131705 66.40708742 24.14944705 15.82420259 97.18522501 100 65.06114358 80.88041906 86.88949565 83.72684074
20.49924499 14.94008277 11.29866257 37.42697327 26.22249538 23.96620157 30.4333148 38.60703062 31.72012456 100 89.24631799 73.01893064 41.30012228 45.65411413 35.60843259 50.7444521 59.1165418 43.80581084 58.15329295 45.90052305 47.84931369 36.88636367 29.80912381 31.02818953 70.8396194 34.53894211 40.57628154
17.82989735 13.82709978 22.78352353 32.7583043 22.30969699 19.15952967 27.07399989 37.41970581 17.16957083 58.20477149 36.32330575 47.13024792 59.00864132 49.25689796 50.9289893 50.72414905 43.70220012 35.21343533 31.3783424 18.32537013 27.25809984 42.27016538 28.55589366 39.47061464 100 66.3665903 71.60464859
34.37563609 19.43685493 33.09239363 29.16094288 25.66835564 27.4690172 13.40713709 12.69588168 11.13315749 48.1620509 34.34024844 32.08063053 27.28889352 33.30102481 25.33821377 83.40640039 100 66.14241226 25.089796 32.44226281 18.67510276 58.34403192 80.1411226 76.46903983 49.03675303 39.24365793 33.93105163
27.61872081 6.475931872 6.675391371 36.99122359 12.35441028 4.522701854 43.77371405 12.81784044 12.062341 100 57.60073014 56.49315057 66.88848636 62.67345264 51.4367593 64.65102699 23.28182208 18.99628226 43.24878296 13.20362358 12.20831016 47.73294533 14.54846777 10.78298136 54.50744693 60.38702797 56.56239825
41.74300737 10.8365569 3.172117711 62.12574932 22.60789813 10.25962687 30.08821011 24.45483045 29.99772855 100 80.99071274 84.05560603 60.06185368 60.9652353 55.92880778 95.89119761 35.47820643 84.94445962 90.04954304 0.758316943 4.510366287 80.5847947 41.20594437 10.28448639 52.90732317 58.81235855 55.26238264
27.37219237 30.84973367 43.79503661 21.83865365 18.81051674 20.96046178 7.785184664 7.975975559 9.536628953 6.664215152 7.687426889 7.707424978 41.41629169 40.67799006 41.73486188 0.000342682 6.473437656 0.000464521 33.56943506 65.56896731 100 0.000565642 29.31453955 26.66957602 58.00861463 73.14322693 73.44554173
84.51387244 70.30489494 48.61429063 19.0147288 12.31368613 5.690276135 6.352700121 9.001323091 6.802556714 59.00482416 49.4950688 43.82409875 50.29500288 49.46799075 47.41628062 82.51544319 67.05194394 63.12039917 100 37.72680675 40.9159997 86.36185346 48.57178481 46.70892343 92.84649348 88.40309097 79.10281626
18.98641168 23.22994025 18.24937126 28.0869659 34.63034472 29.34750655 30.50245347 33.77599641 32.47520014 93.8191744 97.3856538 99.65672154 50.32682796 55.42653187 53.58530196 56.16552622 52.75727158 58.96842721 100 92.6014901 78.15955513 38.50668767 62.01896359 55.30657473 25.91364742 34.95108544 37.04232635
35.22074334 31.82425438 22.87420724 55.83059028 47.94491978 40.45010688 25.34332514 18.90327176 19.73686115 97.41090467 86.0325719 100 76.16188064 65.01220885 62.87614594 80.02902246 64.49109733 78.72562373 41.93234988 24.5905683 29.43972465 58.06066783 67.22900377 70.45790472 67.6590858 84.88427686 79.59024818
35.22074334 31.82425438 22.87420724 55.83059028 47.94491978 40.45010688 25.34332514 18.90327176 19.73686115 97.41090467 86.0325719 100 76.16176982 65.01220885 62.87614594 80.02902246 64.49109733 78.72562373 41.93234988 24.5905683 29.43972465 58.06066783 67.22900377 70.45790472 67.6590858 84.88427686 79.59024818
39.66338378 26.36726958 36.5295034 23.79413185 15.73385859 1.971323428 38.43148562 36.17299926 38.7963141 85.30288526 52.39613117 41.77222567 100 78.73395016 98.92681458 80.00535184 48.14394203 65.31695628 37.83150222 24.58556588 19.18026749 50.17226338 45.04990643 37.98048026 94.79410887 87.54340608 84.4654973
27.06411614 38.56883979 8.267685296 31.4731788 36.91485197 17.93498226 40.89620698 36.42036439 76.33311303 66.00685483 78.31439456 84.75100055 65.9192121 76.58589654 75.88715473 83.69518797 67.43654201 85.17156832 62.52367574 34.11584414 61.24219442 50.87181441 68.36824069 100 49.24859578 62.58317421 67.30119317
0.002841606 16.81554925 39.02483467 0.003040025 1.708910442 2.953564599 1.225759155 0.508930845 2.574017993 1.320674412 0.002792275 0.003907442 64.41155678 49.7039448 100 4.836562618 5.57775029 23.02431932 16.64105069 35.81325804 41.09715211 11.38530442 3.523248659 17.33372482 68.06588355 96.03322146 90.23239742
16.39065814 14.91120769 18.76382614 6.725779835 0.00229752 0.002544089 22.3775224 26.08482805 1.644370024 77.75598082 65.71573631 60.4220176 99.43723208 100 98.73931142 62.45450999 65.0254386 70.09386593 6.330166277 17.21430934 17.90540949 19.74405287 19.40199837 33.19653332 54.22339265 66.8659934 62.40148768
6.075238763 8.997428751 18.90214478 25.67363974 9.355393772 5.283716112 8.612092703 3.203959056 4.191248993 94.05081488 89.03311276 59.32063034 76.2530954 61.47586611 70.26834988 35.12007921 53.8959096 52.1165992 100 0.008299436 28.79662587 36.38041085 0.455631618 40.85602185 95.67106119 48.89110821 66.22142341
1.466379317 45.20619564 50.7657976 25.87317005 22.94567407 13.62992565 14.4077851 24.56916364 23.87108757 100 65.85140091 44.48290341 47.66249803 46.5324024 58.7023289 67.19033686 48.61937545 61.22531553 78.57171945 36.24134258 47.88772034 42.39850254 36.99586067 28.37301457 52.44882812 58.08623186 56.38010419
25.3936084 1.699562389 7.117668638 22.03593992 1.478047207 6.422296227 32.44443426 1.760958427 16.16703429 38.55720229 4.65241216 17.0268852 100 65.97323391 74.02547017 65.38015826 28.4538983 44.72991971 9.003156747 9.0738997 0.005732252 95.40139668 16.3990004 35.79306308 82.49871469 53.23675498 69.92005936
25.45981114 22.12790827 34.77267947 38.15436685 28.05268109 35.5743545 5.627702294 2.164815586 5.12325966 65.61677074 35.11085691 50.06540879 24.38236655 21.74605637 18.53579427 37.76462198 29.97859567 31.86380499 100 89.41250668 83.95546195 34.25830372 25.61943065 31.34753836 33.71275381 28.79347958 20.34002097
68.36288089 88.33857772 25.13021762 9.489429064 16.40882223 13.21233682 0.002528498 3.916541079 0.00338672 61.28931113 66.43785573 66.58629471 34.44606217 32.70575312 39.66340668 91.84250579 79.05110605 87.79527063 100 50.78857607 11.14291561 73.404633 53.61860587 51.05419135 68.18563461 60.75586783 51.95016031
23.44786824 13.87753036 42.32529649 24.91139699 18.69324587 24.97805669 5.375514088 17.0162217 9.830739214 30.78093438 33.84126795 32.64952447 31.15008731 34.22247879 45.54166026 69.10566256 98.24857369 100 16.23133798 17.7244631 10.95665476 69.65114094 75.84949014 99.28486805 81.85101308 56.05348421 61.15291357
9.702109052 3.064429205 7.615193311 12.52726144 9.633936677 7.320828758 20.77236004 13.80448402 12.68801965 32.69371094 28.25909749 31.64167471 100 81.08818975 86.32353647 47.20660364 22.03718042 36.68921651 11.10655161 6.566248194 5.32876207 19.22642834 16.80091289 23.38822356 62.77201527 59.05984246 59.85921093
5.000031356 67.6511193 72.59403632 2.116441436 24.00173211 23.55259371 7.731090969 4.02480223 2.610224476 18.82203285 19.24172721 27.65107687 1.210940476 2.213172699 0.786911629 5.233377978 75.94426643 76.07744068 17.41895149 58.3057108 73.76239223 3.045538383 73.13204181 42.11148573 100 80.38242089 90.93695319
31.87225835 17.42396084 42.24468757 18.59949113 19.04671819 23.4744106 1.034817414 4.259142514 2.722992949 34.31573175 34.10204813 21.02190476 6.374763516 11.99807182 13.66784342 38.07363268 33.96142615 30.02324183 60.2202097 100 62.86505315 20.44237165 33.61658154 38.52513902 12.93232113 16.61286043 11.04305283
76.18640424 46.9446878 75.63996594 27.78417806 24.65859265 37.96961283 2.331259592 2.791582722 11.71998003 58.59651298 41.44488633 58.17418638 56.55121143 50.33040625 63.40436125 86.46833128 47.66479422 75.30382034 69.23154551 62.04390592 52.11309354 76.10450126 64.39107087 45.9069995 81.61161626 100 90.13432591
0.63206628 0.33405415 0.765221126 0.609864967 0.54564725 1.326506709 0.742165746 1.262937394 0.93286019 46.8897082 0.727229775 100 0.414180182 0.400998779 0.209082903 13.65931185 1.223106034 15.27261666 68.84777258 0.764822361 50.0116496 31.52609986 6.127588469 0.671793928 43.18079646 5.048209902 5.303460673
22.6510497 15.90063613 13.84510481 28.75989036 36.79902968 39.47483637 30.44906171 42.35467296 54.57548246 42.9409715 78.86267266 88.0638203 80.55851594 100 95.27420012 36.22669083 54.31402211 61.90258246 29.52643254 50.0191848 38.25395223 13.73131224 57.5474682 46.17541617 60.85831983 57.73408204 55.32128244
9.239416823 2.535512973 11.49841687 15.60604036 11.72791153 18.72330522 42.70058525 23.99923948 41.54628341 60.72516571 64.26345016 87.93223113 26.73860213 19.19184642 30.63233353 17.19179845 7.753825023 33.25852711 100 85.30734205 95.51082854 26.60168727 29.45649236 44.94377095 30.92330977 38.60266999 41.70640417
35.19785142 25.21185991 22.76548757 18.26887401 27.29536551 17.27240108 0.378504943 0.39029926 0.517856347 55.53681869 31.18937964 39.53975205 4.517064825 6.343629304 2.935567029 19.69415558 22.6051113 21.79861404 69.94259664 100 54.32207317 11.0435586 43.59047766 27.70881541 16.56631637 9.815952277 4.456109375
34.68785538 9.373147063 23.62865949 30.34146418 20.53689717 17.44531062 5.958969629 5.607918482 2.963234721 100 61.27534487 69.19288558 43.66170385 47.48944932 43.21625203 35.83259965 27.48611652 39.69770413 37.54380783 30.11971125 34.91062798 34.73002802 23.81453564 17.05207826 73.07898681 72.52227543 72.55377801
12.02642989 9.661014281 10.51661004 25.1374641 27.06043934 28.3408052 34.10557915 26.19500047 37.60742176 46.12202935 43.74084549 39.94525232 44.23823281 47.2017282 50.4336773 48.495 51.6544275 57.50809013 47.03665514 17.11215531 11.20725302 100 52.57271532 57.02000274 44.96995449 36.35264798 33.56174255
5.304220934 16.62795253 17.47147716 6.892215691 10.57967962 14.43403716 2.355344812 2.179682654 3.042540076 11.04578182 8.184905877 6.900531944 9.631988461 8.826555426 8.351408633 7.48731494 6.616622867 8.830775332 48.48487713 59.93409789 100 12.24774541 15.58751683 18.14261698 13.94094085 12.28176562 10.42129454
39.38633905 0.121397062 18.77504575 21.57827058 28.91223272 37.00458263 14.7664836 21.96524018 43.13854421 16.81185771 48.27746101 78.7317365 61.76796818 38.40834996 47.5694562 44.4571072 41.43296245 55.44325975 100 17.58973943 83.45282318 69.52069911 84.56101172 40.99437992 60.80685054 23.35701255 9.068880657
54.72887824 100 71.09996833 24.9703498 29.13371222 1.672961062 3.292540332 0.893920951 2.13871453 46.66998494 26.67193469 30.62591176 26.29768986 31.74606907 25.41943323 61.91693783 73.03774754 58.06511598 59.10184043 48.74475412 78.7463819 80.94157133 67.46925505 63.30400735 77.32847658 65.79971917 70.20135035
12.01858229 36.92607333 47.11018078 1.49886299 29.44939272 10.10864267 21.96515856 30.74061035 2.799899967 15.49605066 9.449341931 52.73291503 86.75608983 73.57439052 100 23.25255002 35.94183821 76.9316561 1.773302016 57.30394829 25.58830023 22.93454437 40.33248323 62.76957036 94.30763942 79.05460649 83.75125723
18.00842898 24.47787704 8.368895096 2.72418519 10.37691603 6.100547132 2.252139015 9.369831466 1.565485585 14.14479686 12.24430623 20.36941643 17.17255835 15.59271826 6.107909081 8.011391578 15.28536865 16.79418329 98.3489448 80.34095482 100 2.785257051 14.87420613 16.64083235 7.342152847 16.39612174 22.74541979
42.10176095 3.115031757 29.43752618 23.63257089 7.094435397 0.003953602 60.25675519 34.69429668 6.658159933 26.4222664 0.002829441 1.853022899 92.68010838 55.86730645 52.62401544 81.34031622 60.98903389 37.59895835 29.24504936 29.46002499 7.269696347 74.00574157 19.41339462 38.13905528 88.85432409 96.7277126 100
26.24271606 1.561442778 15.58516894 29.2276926 14.90038084 3.531167011 34.99779567 44.75772541 52.14103031 100 87.07315969 84.90931786 34.3972861 43.01054928 45.27877841 23.72457741 39.63669449 23.42912522 42.16865114 40.51887051 38.91004066 7.360761061 37.95097065 28.18928348 44.99090552 52.79817231 59.29386273
52.21259381 43.88529952 23.4083869 13.62078146 13.54901638 2.897597776 27.24646125 27.27002393 23.07447259 49.43940218 61.26495271 75.66690107 99.19810107 52.13643963 76.23420737 91.31166313 69.34216568 75.27461814 50.14531258 9.017895706 20.23713094 61.80265852 47.72579402 62.29118192 100 67.85971311 82.97053532
1.880568296 33.20525286 31.41356669 10.12750196 38.98888695 15.11134227 21.74186696 43.97247206 38.47254073 15.69755364 33.6475005 42.94681361 22.02360259 20.79493029 28.95569816 59.4213029 53.85198786 77.99536705 26.85316397 45.78341625 100 72.94108331 37.76733339 86.8590175 54.83536157 27.52026457 35.36073038
21.40498046 9.797523815 23.28014866 49.82890373 21.10935387 33.65113386 38.4855324 14.4362239 24.62211502 66.60509248 52.10279538 45.45979963 100 75.7040029 53.13006044 43.62676833 18.54943417 30.75421868 78.98906852 48.38567183 41.49247455 34.78692982 19.92736269 19.39626059 70.35926278 74.39220592 69.74554781
34.01975955 46.51180287 39.80490233 21.31467933 23.99784029 26.26195304 9.734680356 10.96999092 8.567092254 48.83470634 54.146099 55.05857568 72.50680128 66.27056138 85.06003747 60.00836351 34.20398561 75.64943625 35.00269341 26.76187152 34.04614565 51.93148641 51.01865295 50.2850764 87.77068482 95.33162205 100
3.859018173 7.104448415 22.3172223 20.82452125 21.50903515 19.11593882 10.33013641 15.63133972 20.4935437 30.10116118 35.55212319 49.68500139 31.52620529 32.68619178 31.08395818 24.01165595 25.58942508 18.75376032 85.97855332 70.84615321 100 26.64616887 29.31391233 25.13837071 20.40609738 22.08836614 21.65233243
18.89116367 31.48341842 18.65362966 12.61016774 31.28424354 27.92813663 27.07015901 27.13160387 36.07093446 68.30689891 83.67593009 82.69915423 25.21518092 39.16079006 37.83140288 26.05300729 30.58605743 43.46813387 92.51100539 99.52897485 100 27.24004094 44.58030764 28.13263826 24.86569213 33.82486777 41.02643356
21.89810231 24.0560101 23.09334825 38.12017619 40.07921357 26.75613842 15.56860015 16.99425484 13.71597101 68.08502761 69.24361076 100 41.93282248 45.65596961 45.05312475 28.88234813 28.18192725 36.3992463 30.91683871 46.22672133 58.63039866 23.50575577 34.51758876 34.52486932 31.87299211 38.70310914 39.45712845
7.045241835 29.51565223 3.318403717 3.546183905 35.07925723 19.24123659 13.26081713 2.407437293 3.289396932 52.70078689 28.14912985 61.23213665 5.090198832 2.383423827 0.001829217 29.08665236 20.59693592 2.601138585 68.44865932 100 96.25709034 7.335635548 51.56609464 35.01387592 14.82160771 7.785730206 0.001437111
13.35689268 8.88704792 28.39973547 0.661975776 9.208003166 26.67999744 4.110233061 7.400920476 20.87749965 23.76819597 58.01957179 100 10.75811895 9.564194598 13.4907995 4.229354216 10.0475621 25.39672468 10.85018643 54.49985369 52.25409346 0.411369231 23.54668578 25.57471656 32.81606996 25.92726698 19.07577445
10.94439379 15.78934739 21.06553824 9.080847279 15.70429919 23.55861322 0.405605558 4.784209798 0.491127832 28.41609045 32.70876091 41.1367519 7.325277702 12.23696444 14.85153155 12.35887383 15.76209747 28.33842893 39.82591335 100 46.13739015 9.82163339 23.41271346 27.33807861 11.22044312 17.65603272 14.76745085
23.27955806 20.99867758 13.8452713 67.78256956 9.137484219 24.5345903 41.56537461 6.746350308 35.52229277 59.85346126 36.1642582 68.54673242 77.32307535 61.4712949 100 21.0492393 51.01209476 60.40042913 57.09139105 26.95801003 32.33915038 41.09846134 11.17354794 47.86286969 63.32435747 55.27218398 74.02963214
50.53964039 39.5945716 40.35744497 9.458804323 27.39343933 13.88701617 3.326617908 18.6533236 24.54837703 100 66.9528522 55.78105861 55.48684126 50.58802154 58.50262807 68.96899217 48.7305179 59.2591195 47.21415185 35.43291405 27.45463928 60.31867487 31.50988686 33.07513976 55.951511 71.70657753 67.92453155
29.9584304 25.058356 41.17634821 27.79754086 26.51243952 25.28943714 28.42167923 32.17303357 31.29616125 58.86231166 45.89207851 56.17711583 80.04801373 100 86.84709426 47.35362048 30.40597316 43.2805175 29.84810012 22.05589277 28.88902679 46.60752009 39.8674789 41.83737105 94.62156153 80.98075347 85.43221274
10.24855802 16.21346805 7.980417522 7.662710702 7.707723867 6.427348208 19.5257599 27.05586409 24.74794287 46.47127272 44.73077984 45.28933752 20.51431984 20.1227307 18.82059714 20.5208019 19.0141482 16.72339336 100 43.54521317 53.60460572 15.54830197 11.57116315 17.75451174 29.04047824 33.18441537 31.08132086
0.003536175 22.51406944 31.81896001 4.123571628 1.745141236 1.519724538 2.136163796 3.703358884 4.44982485 4.883305419 6.807107071 2.372915605 5.363246831 2.933046035 1.91707765 5.017158235 36.40995778 39.96616968 4.915157023 7.237194424 38.95390104 2.141308299 29.7334939 27.61141119 100 60.49854993 85.63971044
44.22322296 34.34389861 23.0281031 2.609174991 32.23768195 19.22493108 59.2127089 24.6657191 15.77549388 94.13546915 58.62281444 60.15667277 63.1136092 38.31507518 67.59415786 83.58855815 48.42070364 45.52504042 50.1152312 43.63096152 43.76482838 27.08105209 32.19177469 32.68352751 52.48049462 100 83.05166545
0.866965901 10.72704321 11.71311978 2.059997513 1.628107088 0.181146107 1.047816256 0.883607561 1.253506468 11.50872594 11.47924965 45.04934676 15.60005234 0.487802844 0.001492496 0.800135914 0.867759398 15.52189032 46.27320989 1.737976592 34.97201328 29.42490575 28.87232291 1.302120144 100 9.062101718 8.777549635
0.001738531 2.933847677 1.783581922 4.093696996 10.15784068 9.211787767 0.001588846 0.001759155 4.13495902 60.84179865 59.04323315 42.91168125 5.92527543 9.257704654 7.440995536 2.291984056 14.2229864 11.73102392 65.2747499 98.26859991 100 15.02316574 18.00326976 16.77163304 7.655839839 1.922707087 4.932006508
9.740633572 29.06572087 23.1753603 8.416699998 11.7482484 8.051959047 3.90239962 3.900449435 3.338999781 21.58279311 30.47265468 30.91047029 3.369434683 6.586197145 7.500624193 14.98746991 14.32356031 21.86721933 73.86700536 100 81.69286267 5.845849317 13.14700754 16.7927689 6.765728736 8.618595579 12.05274722
13.7382081 14.32894035 28.58309648 14.08041631 35.83358834 26.90511928 20.01701025 15.31488446 21.6722358 20.64269304 13.11408805 24.41058737 100 88.55698016 93.52939218 34.2534451 24.29754021 34.63516482 3.099153761 20.22719128 42.73812434 36.50758993 25.07338604 33.95663933 55.46279427 59.43422793 51.2423631
5.562798171 12.94467011 14.71872247 0.478596606 3.997709312 4.053640981 0.501369581 2.742024196 6.387735063 100 42.77291653 75.74612668 2.335837008 0.000244575 0.237840763 3.340580334 14.49131978 13.47316156 0.580441358 45.74276285 34.45238717 0.3405716 15.3415751 9.521242573 61.89104504 18.54751534 9.837389652
23.32523947 22.94889572 36.97234466 50.7150466 22.95445892 23.97785462 30.95923059 18.80259636 19.23670492 75.73602564 96.0093486 100 56.76936231 64.60310607 52.16856721 51.01459382 45.56328688 59.29889871 27.67093609 21.17896248 13.44365655 52.99342008 44.54208878 70.45734992 96.89695977 93.67452903 69.5521196
73.0654691 38.89111872 21.92101255 10.4748218 8.296589368 3.050818438 9.465092278 10.02497487 8.147357603 71.45112237 50.43601478 47.16337827 47.62359518 39.21271062 50.81047902 43.30898811 43.9760818 62.05614375 44.37182328 19.6431676 15.84771416 51.5180167 32.65986518 63.46155207 100 82.00369273 92.2291441
18.80564107 14.4260963 23.63574373 37.72829242 24.80040571 28.04384739 45.87350483 7.193348955 14.47128939 93.3094991 55.05395547 55.22349236 100 58.74768108 64.7461192 66.83919253 28.9680927 24.92293244 20.86392501 35.08053759 28.9250814 28.21957875 35.22566564 27.57757698 65.36188541 59.64996967 51.78648829
9.488505645 21.65203696 12.61080108 8.103511878 17.30205316 12.63682715 35.54462247 24.20602706 28.53962558 50.34669454 50.19181865 38.3259279 47.22784633 60.87076788 61.88693174 40.4325718 32.45563864 49.83612048 31.01019629 7.876254933 12.97068353 29.71353746 11.40493318 20.12423214 99.33658745 96.27353611 100
1.954634149 23.08021517 11.42600855 1.602450905 8.102299922 8.055511745 8.931714231 10.22524904 4.030130329 8.426465525 8.061699974 11.05702516 22.10540082 35.27602656 16.9642823 3.160531766 8.145100733 4.341575926 44.04740056 89.11111796 100 2.903555774 8.206590626 0.224366303 17.52028772 25.7362559 20.10003476
34.47672291 19.44484613 18.36947082 39.58524508 25.18767577 27.95325377 35.21252564 22.39123511 29.49628966 53.2126073 37.20097906 49.23436828 100 75.93339793 84.15473904 77.85631233 36.40521782 68.35716892 24.93612545 10.12309672 8.923738196 72.51935852 42.05844209 47.18738199 61.59001693 68.72078395 64.82391795
15.68685381 10.18208694 13.67981735 19.32105799 8.44196664 13.32509273 38.59747968 21.37338507 25.57815002 44.8067604 25.06878927 33.95062572 68.94549348 63.74371759 55.36657502 51.32817368 48.76688658 35.46692832 17.31237903 6.096504371 9.584011693 24.94547085 19.33460269 20.17377153 100 60.26306663 73.82155051
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phosphorylation response obtained after 1 h treatment compared to 48 h treatment (Fig. 
5.10.) even though differences in Akt activity levels at these time points were clearly 
observed (5.2.1. – 5.2.2.). These results suggest that only low levels of Akt activity are 
required to produce full pathway activation. 
  Some specific examples of phosphorylation sites downstream of Akt in MCF10A 
myrAktER cells are also illustrated (Fig. 5.11.). 
 
 
Figure 5.11. Examples of phosphorylation events downstream of Akt in MCF10A myrAktER cells. 
MCF10A cells were treated with EtOH for 18 h (minimal Akt activity), treated with 100 nM 4-OHT for 
1 h (low Akt activity) or treated with 100 nM 4-OHT for 48 h (high Akt activity) in full growth medium 
and subjected to phosphoproteomic analysis. Three biological replicates were performed per 
condition, each of which was analyzed in triplicate (n = 9). Phosphorylation events were considered 
to be downstream of Akt if the fold change between either of the 4-OHT treated samples and the 
starved sample was a minimum of 2-fold and statistically significant (p < 0.05) as assessed by the 
student’s t-test. Mean phosphopeptide intensity values are illustrated for the named examples from 
proteins A. Proline-rich AKT1 substrate (known substrate of Akt) B. 40S ribosomal protein S6 (known 
to be phosphorylated downstream of Akt). C. Microtubule-actin cross-linking factor 1 isoform 1 (not 
currently linked to Akt pathway). D. Cytoplasmic dynein 1 light intermediate chain 1 (not currently 
linked to Akt pathway). Data expressed as mean +/- SEM (n = 9). 
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5.4. An in vitro kinase assay to identify phosphorylation events downstream 
of Akt1 
In addition to the use of the MCF10A myrAktER cells, an in vitro assay was developed to 
identify phosphorylation events downstream of Akt. In this approach we applied an in vitro 
kinase assay, originally developed by the Cohen group [272, 273], in conjunction with 
shotgun phosphoproteomics to identify in vitro protein substrates of recombinant Akt1. In 
brief, proteins in total cell lysate were dephosphorylated and used as the substrate for an in 
vitro assay using recombinant, active Akt1 as the kinase (Fig. 5.3.). Phosphorylated products 
were then identified and quantified using the phosphoproteomic method previously 
outlined (Fig. 5.1.). Reaction conditions were manipulated and quantitative comparison 
between samples enabled the identification of Akt1-dependent phosphorylation events and, 
furthermore, the quantification of the affinity of Akt1 for each of these sites. 
5.4.1. Identification of phosphorylation events downstream of Akt1 using different 
concentrations of kinase 
In our initial approach we performed the in vitro assay with different concentrations of 
Akt1. Thus, phosphorylation events that were only found to occur in the presence of Akt1 
could be considered to be in vitro downstream substrates. 
Total cell lysate from MCF10A cells was de-phosphorylated by exploitation of the 
endogenous phosphatase activity of the sample. 500 μg of dephosphorylated protein 
substrates were then incubated with 0, 2 or 10 µg of Akt1 and 100 µM of ATP (and relevant 
co-factors) for 5 min at 30oC. The reaction was stopped by denaturation of the proteins 
using 8 M urea and the proteins were subsequently subjected to in-solution digestion. The 
peptide samples were then enriched for phosphopeptides using TiO2 affinity 
chromatography prior to analysis (2 x technical replicates) on a ThermoFisher LTQ-Orbitrap. 
Qualitative and quantitative analysis of the data were then performed.  
561 phosphopeptides were identified, with a minimum MASCOT expectancy < 0.05, 
across all samples in this experiment and were compiled into a database. These 561 
phosphopeptides were quantified in all experimental samples using Pescal (Fig. 5.12.). 
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Figure 5.12. Quantitative analysis reveals phosphoproteomic response in response to Akt1 in an in 
vitro kinase assay. MCF10A cell lysate was de-phosphorylated and incubated in vitro with 0, 2 or 10 
μg of Akt1 and 100 μM ATP for 5 min at 30oC. The resulting phosphorylated proteins were then 
subjected to phosphoproteomic analysis. The quantification of all 561 phosphopeptides was 
represented as a heat map, where phosphopeptide intensity was expressed as a percentage of the 
maximum intensity for that phosphopeptide. 
Quantification of the 561 phosphopeptides identified in this experiment revealed a 
subset of phosphorylation events that were produced in response to the presence of Akt1, 
whilst the majority were found to be unchanged or slightly decreased (Fig. 5.12.).  
PCA was performed for the entire dataset (Fig. 5.13.).  
Normalized Intensity
0 102
μg Akt1
P
h
o
sp
h
o
p
e
p
ti
d
e
s
Chapter 5: Phosphorylation events downstream of Akt 
147 
 
 
Figure 5.13. PCA reveals that Akt1 activity results in a distinct phosphoproteomic profile to that for 
control treatment. MCF10A cell lysate was de-phosphorylated and incubated in vitro with 0, 2 or 10 
μg of Akt1 and 100 μM ATP for 5 min at 30oC. The resulting phosphorylated proteins were then 
subjected to phosphoproteomic analysis. PCA analysis was performed for all 561 phosphopeptides 
identified and quantified in this experiment. 
 
PCA revealed that samples which included active Akt1 in the reaction clustered together 
and distinctly from the control treated cells on the first principle component, indicating that 
Akt1 activity was the major factor determining variance between sample conditions (Fig. 
5.13.). The separation of cells treated with 2 or 10 μg Akt1 on the second principal 
component indicated that Akt1 concentration was also a factor differentiating the samples 
(Fig. 5.13.). 
We proceeded to define arbitrary criteria for a phosphorylation event to be considered 
dependent on Akt1 activity and therefore a downstream target. Phosphorylation events 
were considered to be Akt1-dependent if the fold change between the sample that was 
incubated with 10 μg Akt1 and the control sample was a minimum of 2-fold. 86 
phosphopeptides met these criteria, including some known substrates of Akt (Fig. 5.14. – 
5.15. and Appendix 3). 
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Figure 5.14. An in vitro kinase assay identifies phosphorylation events downstream of Akt1. 
MCF10A cell lysate was de-phosphorylated and incubated in vitro with 0, 2 or 10 μg of Akt1 and 100 
μM ATP for 5 min at 30oC. The resulting phosphorylated proteins were then subjected to 
phosphoproteomic analysis. The quantification of the 86 phosphopeptides that were found to 
increase in response to Akt1 was represented as a heat map, where phosphopeptide intensity was 
expressed as a percentage of the maximum intensity for that phosphopeptide. 
 
The heat map representation of quantitative data illustrated the increase in 
phosphorylation of candidate phosphorylation sites downstream of Akt that occurred in the 
presence of Akt1 in the in vitro reaction (Fig. 5.14.). Candidate sites can be broadly classified 
into two groups: those for which phosphorylation increases proportionally to the 
concentration of Akt1 and those for which phosphorylation increases at the lower dose of 
Akt1 and remains unchanged with the higher dose (Fig. 5.14.).  Some specific examples of 
phosphorylation events found to be dependent on Akt1 by this method are illustrated (Fig. 
5.15.). 
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Figure 5.15. Examples of phosphorylation events downstream of Akt1 identified using an in vitro 
kinase assay. MCF10A cell lysate was de-phosphorylated and incubated in vitro with 0, 2 or 10 μg of 
Akt1 and 100 μM ATP for 5 min at 30oC. The resulting phosphorylated proteins were then subjected 
to phosphoproteomic analysis. The mean normalized peptide intensities (n = 2) are shown for 
representative phosphopeptides that A. Belong to Akt1 (internal control). B. Increase in a linear 
fashion in response to Akt1 concentration. C. Increase rapidly in response to Akt1. Data expressed as 
mean +/- SD (n = 2). 
 
 
Quantitation of the phosphorylation sites on Akt1 itself serve as an internal control for 
the experiment (Fig. 5.15. A). Furthermore, results show that a number of phosphorylation 
sites increase in abundance in the presence of Akt1. Such increases may follow a linear 
pattern in relation to Akt1 (Fig. 5.15. B) or may plateau at when higher concentrations of the 
kinase were included in the reaction (Fig. 5.15. C). 
5.4.2. Identification of phosphorylation events downstream of Akt1 using different 
concentrations of ATP  
We next proceeded to further develop our method to increase the amount of 
information that could be obtained. We reasoned that an improvement over the previous 
strategy (5.4.1.) would be to perform the in vitro kinase reaction with different 
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concentrations of ATP in the presence or absence of Akt1. Thus, we would be able to 
identify Akt1-dependent phosphorylation events as those that occurred only in the presence 
of Akt1. Furthermore, the use of various concentrations of ATP would enable the 
investigation of the dynamics of phosphorylation of each site, thus enabling the 
identification of the most efficient reactions that are more likely to occur in vivo. 
Total cell lysate from MCF10A cells was de-phosphorylated using exogenous lambda 
protein phosphatase. A total of 500 μg of dephosphorylated protein substrates were then 
incubated with 0, 10, 50, 100 or 500 μM ATP in the absence or presence of 2 μg Akt1 (and 
relevant co-factors) for 5 min at 30oC. The reaction was stopped by denaturation of the 
proteins using 8 M urea and the proteins were subsequently subjected to in-solution 
digestion. The peptide samples were then enriched for phosphopeptides using TiO2 affinity 
chromatography prior to analysis (2 x technical replicates) by LC-MS/MS on a ThermoFisher 
LTQ-Orbitrap XL. Qualitative and quantitative analysis of the data were then performed.  
At total of 856 phosphopeptides were identified, with a minimum MASCOT expectancy < 
0.05, across all samples in this experiment and were compiled into a database. These 856 
phosphopeptides were then quantified in all experimental samples using Pescal (Fig. 5.16.). 
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Figure 5.16. Quantitative analysis reveals phosphoproteomic response to an increasing 
concentration of ATP in the presence or absence of Akt1 in an in vitro kinase assay. MCF10A cell 
lysate was de-phosphorylated and incubated in vitro with 0, 10, 50, 100 or 500 μM ATP in the 
absence or presence of 2 μg Akt1 for 5 min at 30oC. The resulting phosphorylated proteins were then 
subjected to phosphoproteomic analysis. The quantification of all 856 phosphopeptides was 
represented as a heat map, where phosphopeptide intensity was expressed as a percentage of the 
maximum intensity for that phosphopeptide. 
Quantification of the 856 phosphopeptides identified in this experiment revealed a 
subset of phosphorylation events that were observed to increase in response to ATP 
concentration only in the presence of Akt1 (Fig. 5.16.). Many other phosphorylation sites 
were found to be unchanged or to decrease only in the presence of Akt1 (Fig. 5.16.).  
PCA was performed for the entire dataset (Fig. 5.17.).  
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Figure 5.17. PCA reveals that the presence of Akt1 in an in vitro reaction confers a distinct 
phosphoproteomic profile. MCF10A cell lysate was de-phosphorylated and incubated in vitro with 0, 
10, 50, 100 or 500 μM ATP in the absence or presence of 2 μg Akt1 for 5 min at 30oC. The resulting 
phosphorylated proteins were then subjected to phosphoproteomic analysis. PCA analysis was 
performed for all 856 phosphopeptides identified and quantified in this experiment. 
 
PCA revealed that samples which included active Akt1 in the reaction clustered together 
and distinctly on the first principle component from those in which no Akt1 was included, 
indicating that the presence of Akt1 in the reaction was the major factor determining 
sample variance between conditions (Fig. 5.17.). In the absence of Akt1, the samples at 
different concentrations of ATP clustered together on the second principal component 
suggesting that ATP concentration did not greatly affect the phosphoproteomic profile 
under these conditions (Fig. 5.17.). In contrast, the samples including Akt1 separated more 
across the second principal component, indicated that ATP concentration was also a factor 
differentiating samples under these conditions (Fig. 5.17.). 
We proceeded to define arbitrary criteria for a phosphorylation event to be considered 
dependent on Akt1 activity and therefore a downstream target. Phosphorylation events 
were considered to be Akt1-dependent if the fold change between the samples incubated 
with 100 μM ATP in the absence or presence of 2 μg Akt1 was a minimum of 2-fold. A total 
of 253 phosphopeptides met these criteria, including some known substrates of Akt (Fig. 
5.18. – 5.19. and Appendix 4). 
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Figure 5.18. An in vitro kinase assay identifies phosphorylation events downstream of Akt1 in the 
presence of different concentrations of ATP. MCF10A cell lysate was de-phosphorylated and 
incubated in vitro with 0, 10, 50, 100 or 500 μM ATP in the absence or presence of 2 μg Akt1 for 5 
min at 30oC. The resulting phosphorylated proteins were then subjected to phosphoproteomic 
analysis. The quantification of the 253 phosphopeptides that were found to increase in response to 
ATP in the presence of Akt1 was represented as a heat map, where phosphopeptide intensity was 
expressed as a percentage of the maximum intensity for that phosphopeptide. 
 
The heat map representation of quantitative data illustrates the increase in 
phosphorylation of candidate phosphorylation sites downstream of Akt that occurred in 
response to increasing concentrations of ATP in the presence of Akt1 in the in vitro reaction 
(Fig. 5.18.).  
  Some specific examples of phosphorylation events found to be dependent on Akt1 by 
this method are illustrated (Fig. 5.19.).  
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Figure 5.19. Examples of phosphorylation events downstream of Akt1 identified using an in vitro 
kinase assay in the presence of different concentrations of ATP. MCF10A cell lysate was de-
phosphorylated and incubated in vitro with 0, 10, 50, 100 or 500 μM ATP in the absence or presence 
of 2 μg Akt1 for 5 min at 30oC. The resulting phosphorylated proteins were then subjected to 
phosphoproteomic analysis. The mean normalized peptide intensities (n = 2) are shown for 
representative phosphopeptides: known to be downstream of Akt1 (A),  Akt1-independent (B), Akt1-
dependent with relatively low affinity for ATP (C) and Akt1-dependent with relatively high affinity for 
ATP (D). 
0
20
40
60
80
100
0 100 200 300 400 500
AKT1 p-S125 (z= 3) + 
oxidation
AKT1S1 p-T247 (z= 2)
RPS6 p-S237 (z= 2)
0
20
40
60
80
100
0 100 200 300 400 500
AKT1 p-S125 (z= 3) + 
oxidation
AKT1S1 p-T247 (z= 2)
RPS6 p-S237 (z= 2)
- Akt1 + Akt1
0
20
40
60
80
100
0 100 200 300 400 500
HSPB1 p-S83 (z= 2)
RIPK2 p-S364 (z= 2)
ABCF1 p-S110 (z= 2)
0
20
40
60
80
100
0 100 200 300 400 500
HSPB1 p-S83 (z= 2)
RIPK2 p-S364 (z= 2)
ABCF1 p-S110 (z= 2)
A
M
ea
n
 N
o
rm
al
iz
ed
 
P
h
o
sp
h
o
p
ep
ti
d
e
In
te
n
si
ty
μM ATP μM ATP
M
ea
n
 N
o
rm
al
iz
ed
 
P
h
o
sp
h
o
p
ep
ti
d
e
In
te
n
si
ty
μM ATP μM ATP
B
0
20
40
60
80
100
0 100 200 300 400 500
EIF2S2 p-T34 (z= 3) + 
oxidation
HNRNPU p-S60 (z= 3) 
+ oxidation
HDGFRP2 p-T608 (z= 
4)
0
20
40
60
80
100
0 100 200 300 400 500
EIF2S2 p-T34 (z= 3) + 
oxidation
HNRNPU p-S60 (z= 3) 
+ oxidation
HDGFRP2 p-T608 (z= 
4)
C
M
ea
n
 N
o
rm
al
iz
ed
 
P
h
o
sp
h
o
p
ep
ti
d
e
In
te
n
si
ty
μM ATP μM ATP
M
ea
n
 N
o
rm
al
iz
ed
 
P
h
o
sp
h
o
p
ep
ti
d
e
In
te
n
si
ty
μM ATP μM ATP
D
0
20
40
60
80
100
0 100 200 300 400 500
MST4 p-T173 (z= 2)
PDHA2 p-S292 (z= 3)
RPS17 p-S116 (z= 2) + 
oxidation
0
20
40
60
80
100
0 100 200 300 400 500
MST4 p-T173 (z= 2)
PDHA2 p-S292 (z= 3)
RPS17 p-S116 (z= 2) + 
oxidation
Chapter 5: Phosphorylation events downstream of Akt 
155 
 
Quantitation of the phosphorylation site S125 on Akt1 itself serves as an internal control 
for the experiment, as levels are undetectable when Akt1 is not added to the reaction mix 
and remain steady and high when Akt1 is present (Fig. 5.19. A). Furthermore, results show 
that the phosphorylation of known Akt1 targets PRAS40 (AKTS1) and S6 (RPS6) increases 
significantly in response to increasing concentrations of ATP in the presence of Akt1 (Fig. 
5.19. A); these positive controls further demonstrate the suitability of this approach to 
identify Akt1 substrates. 
5.4.3. Quantification of Akt1-ATP affinity – a method to evaluate reaction efficiency 
The in vitro Akt1 kinase assay was performed using different concentrations of ATP 
(5.4.2.) as we reasoned that we could use this information to quantify the affinity of Akt1 for 
ATP for each phosphorylation site and thus estimate reaction efficiency and Akt1 affinity for 
that site. The rational for this strategy was that phosphorylation reactions should follow the 
same dynamics as any other enzyme-substrate reaction. Thus, one could apply the 
principles of Michaelis-Menten kinetics to define Akt1-ATP affinity as the ATP concentration 
required to reach 50% of the maximum reaction rate (KATP) and rank novel candidate Akt1 
substrates by reaction efficiency (Fig. 5.20.). 
 
Figure 5.20. Quantification of Akt1-ATP affinity (KATP). The kinetics of phosphorylation efficiency can 
be expressed for each site by plotting substrate concentration (ATP concentration) against the 
reaction rate (phosphopeptide intensity). Using the principles of Michaelis-Menten kinetics, Akt1-
ATP affinity, which is defined as the ATP concentration required to reach 50% of the maximum 
reaction rate, (KATP) can then be calculated using non-linear regression. 
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It should be noted that these in vitro phosphorylation reactions do not adhere to all the 
principles of Michaelis-Menten kinetics, for example substrate source may not be present in 
excess, thus KATP is not equivalent to Km but is a useful estimate of the affinity of Akt1 for 
ATP and thus an approximation of the reaction efficiency for that site that enables ranking 
identified substrates by this value. 
KATP was calculated (as illustrated in Fig. 5.20.) for all phosphorylation events found to be 
Akt-1 dependent using our in vitro strategy (5.4.2. Fig. 5.19.). Reaction kinetics and 
corresponding KATP values are illustrated for some named examples (Fig. 5.21.). 
 
 
Figure 5.21. KATP correlates with reaction efficiency. KATP was calculated (Fig. 5.19.) for 
phosphopeptides found to be dependent on Akt1 activity (Fig. 5.18.). Examples of phosphopeptides 
that showed A. relatively low affinity for ATP and B. relatively high affinity for ATP are shown. 
 
As expected, KATP was found to negatively correlate with reaction efficiency i.e. 
phosphorylation sites that showed relatively low affinity for ATP had higher KATP  values than 
sites that showed higher affinity for ATP (Fig. 5.21.). Thus, KATP values can be used quantify 
reaction efficiency, which may be useful to rank reactions by the likelihood that they truly 
occur in vivo. 
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We used motif analysis to validate the hypothesis that reaction efficiency, as quantified 
by KATP, may be a useful parameter to investigate the likelihood of an Akt1-dependent 
phosphorylation event found using an in vitro reaction to occur in vivo. We grouped 
phosphorylation sites according to their KATP value and quantified the abundance of the 
phosphorylation motifs RXRXXS/XXRXXS, recognised by Akt and its downstream target 
p70S6K [87], and XXDXXS, a control motif (Fig. 5.22.). 
 
 
Figure 5.22. Low KATP indicates enrichment for Akt1 pathway motifs. Phosphorylation sites were 
grouped according to their KATP value and the abundance of the phosphorylation motifs 
RXRXXS/XXRXXS, recognised by Akt and its downstream target p70S6K, and XXDXXS, a control motif 
were evaluated. Motif events were normalized to the total number of peptides per group. 
 
The data showed that the group of phosphorylation sites with the lowest KATP values 
(KATP 0 – 5 µM) were enriched (by approximately 2-fold) for the phosphorylation motifs 
RXRXXS/XXRXXS, which are recognised by Akt and its downstream target p70S6K (Fig. 5.22.). 
In contrast, there was no clear correlation between KATP and the abundance of the control 
motif XXDXXS (Fig. 5.22.). Thus, these data suggest that KATP may be a useful parameter to 
validate in vitro phosphorylation targets as bona fide in vivo substrates. 
5.4.4. Cross-reference of data generated using MCF10A myrAktER model and in vitro 
kinase assay. 
In order to obtain a list of high-confidence phosphorylation events dependent on Akt 
activity we compared the dataset obtained from the in vivo MCF10A myrAktER model (5.3.) 
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with that from the in vitro Akt1 assay (5.4.2.). The overlapping phosphorylation sites are 
listed (Table 5.1.). 
Table 5.1. Akt-dependent phosphorylation events identified using both in vivo and in vitro models. 
Accession Number 
Phosphopeptide 
Identification 
Motif                                          
(*denotates 
phosphorylation site and 
bold indicates 
conformance with Akt/S6 
recognition motif) 
Known Akt 
Substrate 
ABCF1_HUMAN ABCF1 p-S110 (z= 3) LSVPTS*DEEDEV   
AKTS1_HUMAN AKT1S1 p-T247 (z= 2) LNT*SDFQK * 
CALX_HUMAN CANX p-S584 (z= 3) DEILNRS*PR   
CALX_HUMAN CANX p-S565 (z= 4) EDGGTVS*QEEEDR   
CALX_HUMAN CANX p-S555 (z= 3) QKS*DAEEDG   
DAP1_HUMAN DAP p-S52 (z= 3) QEWESPS*PPKPTV   
DC1L2_HUMAN DYNC1LI2 p-S206 (z= 3) GPLTSGS*DEENVA   
DPOD3_HUMAN POLD3 p-S308 (z= 3) VALS*DDETKE   
EF1B_HUMAN EEF1B2 p-S107 (z= 4) DIDLFGS*DDEEES   
HDGF_HUMAN HDGF p-S166 (z= 2) GDLLEDS*PK   
HDGF_HUMAN HDGF p-S134 (z= 3) GNAEGSS*DEEGKL   
HS90A_HUMAN HSP90AA1 p-S264 (z= 3) EIEDVGS*DEEEEK   
HS90A_HUMAN HSP90AA1 p-S253 (z= 3) ES*EDKPEI   
HS90B_HUMAN HSP90AB1 p-S256 (z= 2) IEDVGS*DEEDDS   
HSPB1_HUMAN HSPB1 p-S83 (z= 2) QLS*SGVSEI   
HTSF1_HUMAN HTATSF1 p-S580 (z= 3) DLDEEGS*EKELHE   
KPCD_HUMAN PRKCD p-S665 (z= 2)  SAFAGFS*FVNPK   
MK01_HUMAN MAPK1 p-T186 (z= 3) HTGFLT*EYVATR   
NDRG1_HUMAN NDRG1 p-S331 (z= 2) TAS*GSSVTS   
NP1L4_HUMAN NAP1L4 p-S126 (z= 3) AESEWHS*ENEEEEK   
PGRC1_HUMAN PGRMC1 p-S182 (z= 3) EEPTVYS*DEEEPK   
RS6_HUMAN RPS6 p-S237 p-S241 (z= 2) LSS*LRAS*TSK * 
TPIS_HUMAN TPI1 p-S22 (z= 3) KQS*LGELIG   
 
The list of high-confidence Akt-dependent phosphorylation events using both strategies 
described in this chapter (Table 5.1.) represents around just 10% of phosphosites identified 
in each independent experiment. The majority of the phosphorylation sites have not 
previously been linked directly to Akt activity. It is interesting to note that phosphorylation 
sites for the known Akt substrates and some other candidates conform to the Akt/S6K 
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recognition motif. It should be noted however that downstream candidates may not be 
directly phosphorylated by Akt or S6K and therefore may not adhere to this motif. 
5.5. Conclusions 
The work described in this chapter aimed to identify phosphorylation events 
downstream of Akt, thus potentially enabling further annotation of the phosphoproteome 
and/or identification of possible biomarkers of pathway activity. We used two distinct 
approaches to carry out this work. 
In the first approach, we used a cell line model stably transfected with an inducible, 
constitutively active Akt construct [314] to investigate Akt activity in the human breast 
epithelial cell MCF10A (Fig. 5.2.). Initial work was performed to characterise the cell line and 
evaluate the activity of the MCF10A myrAktER construct. WB and Aktide assay results 
demonstrated that the myrAktER construct was activated in response to 4-OHT treatment 
and, furthermore, that the greater control of activity levels could be obtained by modulating 
treatment time compared to using different doses (Fig. 5.4. – 5.5.). Investigation of the 
phosphorylation of substrates downstream of Akt further supported these results (Fig. 5.6.). 
An assay for anoikis (detachment-induced apoptosis) also demonstrated the biological 
output of the activation of the construct (Fig. 5.7.). 
We then proceeded to perform a phosphoproteomic experiment to evaluate the effects 
of myrAktER activity on the phosphoproteome. MCF10A myrAktER cells treated with EtOH 
overnight (minimal Akt activity), treated for 1 h 4-OHT (low Akt activity) or 48 h 4-OHT (high 
Akt activity) were lysed and subjected to phosphopeptide enrichment prior to shotgun 
phosphoproteomics for peptide identification and quantification. 1961 phosphorylation 
events were identified and heat-map representation of phosphopeptide quantification and 
PCA revealed that activation of the myrAktER construct affected the phosphoproteomic 
profile of cells (Fig 5.8. – 5.9.). Criteria for a phosphorylation event to be considered Akt 
dependent were defined (based upon a statistically-significant increase in phosphorylation 
upon myrAktER activation) and 238 phosphopeptides were classified within this group, 
including some known Akt targets (Fig. 5.10. – 5.11. and Appendix 2). 
Our second strategy for the identification of Akt-dependent phosphorylation events 
coupled a previously described in vitro method for the identification of kinase substrates, 
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which uses de-phosphorylated full-length endogenous proteins as the reaction substrate 
(Fig. 5.3.) [272, 273], with global shotgun phosphoproteomics. Initially we sought to 
investigate if in vitro reaction products were proportional to enzyme activity. De-
phosphorylated proteins were incubated in vitro with different concentrations of 
recombinant, active Akt1 (0, 2 and 10 µg) and a reaction buffer that included ATP and the 
products subjected to shotgun phosphoproteomics. A total of 561 phosphopeptides were 
identified and heat-map representation of peptide quantification and PCA revealed that 
Akt1 activity in the in vitro assay conferred a distinct phosphoproteomic profile (Fig. 5.12. – 
5.13.). Criterium was defined for a phosphorylation event to be considered Akt1-dependent 
(based on an increase in phosphorylation in response to Akt1 presence in the reaction) and 
86 phosphopeptides were classified within this group, including known Akt targets (Fig. 
5.14. – 5.15. and Appendix 3). 
We next further developed the strategy as, in addition to the identification of Akt1-
dependent phosphorylation events, we wished to evaluate phosphorylation efficiency as we 
hypothesized that this may indicate the likelihood of the in vitro reaction occurring in vivo. 
De-phosphorylated proteins were incubated with different concentrations of ATP (0, 10, 50, 
100 or 500 µM) in the presence or absence of 2 µg of recombinant, active Akt1 prior to 
performance of shotgun phosphoproteomics. A total of 856 phosphopeptides were 
identified and heat-map representation of peptide quantification and PCA revealed that the 
presence of Akt1 in the reaction conferred a distinct phosphoproteomic response (Fig. 5.16. 
– 5.17.). Criteria was defined for a phosphorylation site to be considered Akt1-dependent 
(based on phosphorylation increasing in response to increasing ATP concentration only in 
the presence of Akt1) and 253 phosphopeptides were classified within this group, including 
some known Akt substrates (Fig. 5.18. – 5.19. and Appendix 4). 
We next proceeded to use the same data to quantify the affinity of Akt1 for ATP for each 
phosphorylation site, thus providing an estimation of phosphorylation efficiency. Akt1-ATP 
affinity (KATP) was calculated using non-linear regression based on the principles of 
Michaelis-Menten reaction kinetics (Fig. 5.20.). Evaluation of Akt1-dependent 
phosphorylation events revealed that KATP inversely correlated with phosphorylation 
efficiency i.e. low KATP indicates efficient phosphorylation (Fig. 5.21.). These data suggest 
that KATP may be a useful parameter to identify efficient Akt phosphorylation reactions, 
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which may be more likely to occur in vivo. Motif analysis supported this notion as 
phosphopeptides with low KATP were found to be enriched for motifs known to be 
phosphorylated by Akt and its downstream substrate p70S6K (Fig. 5.22.), although this 
correlation was not strong. 
Finally, datasets of phosphopeptides found to be Akt-dependent using the MCF10A 
myrAktER model and the in vitro kinase assay were cross-referenced to produce a short-list 
of high-confidence Akt-dependent phosphorylation events (Table 5.1.). These proteins 
represent potential novel Akt pathway targets of interest for future investigation. 
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6. Global Kinase Activity Profiling (GKAP) 
6.1. Introduction and aim of study 
In the previous chapter we demonstrated the utility of an in vitro assay coupled to 
shotgun phosphoproteomics to investigate the molecular biology of PI3K/Akt signalling. We 
next proceeded to investigate if this strategy could have wider applications for the 
investigation of signalling pathway activities. 
Protein phosphorylation by kinases is a key regulatory mechanism of signalling 
pathway activity [200-202]. Mass-spectrometry based global phosphoproteomics has 
enabled great advances in this field as it provides the unprecedented opportunity to 
perform large-scale, unbiased identification and quantification of phosphorylation events 
[203, 205]. However, although protein phosphorylation levels provide an indication of 
overall pathway activity, they do not necessarily correlate directly with kinase activity as 
there are multiple mechanisms regulating this post-translational modification (Fig. 6.1.) 
[204].  
 
 
Figure 6.1. Regulation of protein phosphorylation. Protein phosphorylation is primarily regulated by 
the balance between kinase and phosphatase activity, and multiple factors affect the outcome of 
this relationship. Figure adapted from [204]. 
There are circumstances where understanding of absolute kinase activity is 
advantageous over measurement of overall pathway activity. For example, small molecule 
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inhibitors exist for many kinases, however they are only likely to be effective as treatment if 
inappropriate pathway activity is attributable to kinase activity itself rather than to other 
factors, for example underactive phosphatases [317]. Evaluation of the contribution of 
kinases to signalling activity can also help in the de-convolution of complex pathways and 
improve our understanding of how they are de-regulated. 
In vitro kinase reaction assays have been available for decades but such methods were 
previously dependent on radioactivity labelling or other indirect detection strategies, such 
as antibodies [318, 319]. More recently, mass-spectrometry has been successfully applied to 
provide a detection method for such reactions. The nature of mass spectrometry is highly 
desirable as a read-out for kinase activity as it enables simultaneous detection and 
quantification of reaction products. In addition, mass-spectrometry can provide information 
that cannot be obtained by other methods, for example the specific localization of a 
phosphorylation site. 
Mass-spectrometry based kinase assays were initially developed using short peptides as 
substrates, the first application of which was in the quantification of PI3K/Akt signalling 
[270, 271]. This approach was then further developed for application to multiple kinases 
[320] and multiplexed, enabling the simultaneous quantification of the activities of several 
kinases using up to 90 peptide substrates [321]. Although these approaches have been 
successful, their application is limited by the use of synthetic purified peptide substrates 
that require specific knowledge of the kinase target site. Such information is not always 
available and thus restricts the application of these methods to well-characterized kinases. 
Another significant limitation in the use of peptide substrates is that substrate recognition 
by some kinases is known to be dependent on conformational interaction between proteins 
in addition to recognition of the short linear phosphorylation motif [322, 323].  
The aim of the work presented in this chapter was to develop a mass-spectrometry 
based in vitro assay for global endogenous kinase activity that used full-length proteins as 
the reaction substrate. We followed on from the kinase assay developed in Chapter 5 to 
develop this novel methodology, which we termed global kinase activity profiling (GKAP). In 
this method, full-length proteins are isolated from cells and incubated in vitro with different 
concentrations of ATP (and co-factors), enabling their phosphorylation by endogenous 
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active kinases. Reaction products are then analyzed using shotgun phosphoproteomics and 
quantitative data is then used to identify and quantify kinase activity (Fig. 6.2.). 
 
 
 
Figure 6.2. Summary of GKAP Strategy. Protein substrates are isolated from total cell lysates and 
incubated in vitro with various concentrations of ATP and necessary co-factors. Kinase activity 
results in protein phosphorylation, which is then detected by phosphoproteomics. Quantitative 
analysis of phosphopeptide intensity before and after incubation with ATP (i.e. kinase activity) is 
used to identify and quantify kinase activity. 
6.2. Detection of phosphopeptide signals using GKAP 
 We initially proceeded to investigate if phosphorylation of full-length proteins as a 
result of in vitro endogenous kinase activity could be detected by mass spectrometry. 
To perform the in vitro reaction, total cell lysate samples from the P31/Fuj cell line 
containing 5, 50 or 100 μg of protein were incubated for 5 min at 30oC with reaction buffer 
containing 10 or 100 μM ATP or not incubated with the reaction mix (baseline). The reaction 
was then stopped by the addition of urea and the reaction protein products were subjected 
to in-solution trypsin digestion. The samples were enriched for phosphopeptides, using TiO2 
affinity chromatography, prior to LC-MS analysis on the LTQ-Orbitrap XL (two technical 
replicates were performed) for qualitative and quantitative phosphoproteomic analysis (Fig. 
6.3. – 6.4.). 
Chapter 6: Global kinase activity profiling 
165 
 
 
Figure 6.3. Quantitative analysis reveals the response of phosphopeptide intensity to ATP 
concentration in an in vitro reaction. Total cell lysate samples from P31/Fuj cells containing 5, 50 or 
100 μg of protein were incubated for 5 min at 30oC with reaction buffer containing 10 or 100 μM 
ATP or were not incubated (0 µM). Reaction products were then subjected to quantitative 
phosphoproteomic analysis. Mean phosphopeptide intensities were normalized as a percentage of 
the maximum value for all conditions and represented on a heat map (n = 2). 
281 phosphopeptides were identified and quantified in this experiment (Fig. 6.3.). The 
data showed that, as expected, phosphopeptide intensities were higher for samples where 
higher amounts of protein were used in the reaction (Fig. 6.3.). Furthermore, the results also 
showed that phosphopeptide intensity increased in response to reaction incubation and was 
proportional to ATP concentration for many phosphopeptides (Fig. 6.3.). These data 
therefore indicate that in vitro phosphorylation of proteins by endogenous kinases is 
detectable by mass spectrometry and that amplification of signal occurs, due to the 
potential for each active kinase molecule to act upon multiple substrate molecules. 
In this experiment, kinase activity was defined as a minimum of a 2-fold increase of 
phosphopeptide signal after incubation with ATP relative to the baseline value. Using 100 μg 
of protein in the reaction mix, 76 kinase activities were detected after incubation with 10 
μM ATP and 195 after incubation with 100 μM ATP.  
The relationship between phosphopeptide intensity and ATP concentration, using 
different amounts of protein in the reaction, was illustrated in greater detail (Fig. 6.4.).  
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Figure 6.4. Phosphopeptide intensities increase upon incubation with ATP in a GKAP reaction. 
Total cell lysate samples from P31/Fuj cells containing 5, 50 or 100 μg of protein were incubated for 
5 min at 30oC with reaction buffer containing  10 or 100 μM ATP or were not incubated (baseline). 
Reaction products were then subjected to quantitative phosphoproteomic analysis. A. Extracted ion 
chromatograms for the example phosphopeptide MST4 p-T173 (z= 2) after no incubation (baseline) 
or incubation with 10 or 100 μM ATP using 5 μg starting material. B. Normalized intensities for the 
same phosphopeptide after no incubation (baseline) or incubation with 10 or 100 μM ATP using 5, 
50 or 100 μg starting material. C. Mean normalized intensities for all phosphopeptides for which 
kinase activity was detected after no incubation (baseline) or incubation with 10 or 100 μM ATP 
using 5, 50 or 100 μg starting material (n = 195). Data is expressed as mean +/- SEM. 
 
The data for the illustrated example demonstrated that phosphopeptide intensity 
increased in proportion to ATP concentration included in the reaction mix, using just 5 μg of 
protein in the reaction (6.4. A). This phenomenon was also found to be true for this 
phosphopeptide when 50 or 100 μg of protein were used in the reaction mix (6.4. B). The 
mean normalized data for all kinase activities detected also illustrated how phosphopeptide 
intensity increased in proportion to ATP present in the reaction mix (Fig. 6.4. C).  
These data show that endogenous kinase activity results in an increase in 
phosphopeptide intensity proportional to ATP concentration, thus following the principles 
of Michaelis-Menten enzyme kinetics, and  that these reaction kinetics are detectable by 
mass spectrometry analysis. Furthermore, these data illustrate that the in vitro reaction 
enables signal amplification that does not appear to be limited by substrate availability. 
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These results suggest that GKAP may be a suitable method for the quantification of 
endogenous kinase activity. 
6.3. Use of GKAP to investigate basal kinase activity in two AML cell lines 
We next proceeded to use GKAP to compare basal kinase activity levels in two acute 
myeloid leukaemia (AML) cell lines with characterised differences in signalling pathway 
activities. P31/Fuj cells are resistant to the effects of MEK, JAK and PI3K inhibitors on cell 
proliferation whereas Kasumi-1 cells are sensitive to these compounds [179]. 
Total cell lysate samples from P31/Fuj and Kasumi-1 cells, under basal growth 
conditions, containing 50 μg of protein were incubated for 5 min at 30oC with reaction 
buffer containing 10, 50 or 500 μM ATP or not incubated with the reaction mix (0 µM). The 
reaction was then stopped by the addition of urea and the reaction protein products were 
subjected to in-solution trypsin digestion. The samples were enriched for phosphopeptides, 
using TiO2 affinity chromatography, prior to LC-MS analysis on the LTQ-Orbitrap XL (two 
technical replicates performed) for qualitative and quantitative phosphoproteomic analysis 
(Fig. 6.5. – 6.7.). 
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Figure 6.5. Quantitative analysis reveals distinct phosphoproteomic responses of P31/Fuj and 
Kasumi-1 cell lines in a GKAP assay. Total cell lysate samples from P31/Fuj and Kasumi-1 cells 
containing 50 μg of protein were incubated for 5 min at 30oC with reaction buffer containing 10, 50 
or 500 μM ATP or were not incubated (0 µM). Reaction products were then subjected to 
quantitative phosphoproteomic analysis. Mean phosphopeptide intensities were normalized as a 
percentage of the maximum value for all conditions and represented on a heat map (n = 2). 
 
A total of 430 phosphopeptides were identified and quantified in this experiment (Fig. 
6.5.). The heat-map analysis of quantitative data revealed the different phosphoproteomic 
responses of the P31/Fuj and Kasumi-1 cell lines to GKAP, indicating differential pathway 
activation (Fig. 6.5.). Kinase activity was again defined as a minimum of a 2-fold increase of 
phosphopeptide signal after incubation with ATP relative to the baseline value. The 
phosphoproteomic dynamics of peptides found to be products of a kinase reaction in either 
cell line were examined in more detail (Fig. 6.6.). 
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Figure 6.6. GKAP analysis reveals differential kinase pathway activation of P31/Fuj and Kasumi-1 
cell lines. Total cell lysate samples from P31/Fuj and Kasumi-1 cells containing 50 μg of protein were 
incubated for 5 min at 30oC with reaction buffer containing  10, 50 or 500 μM ATP or were not 
incubated (0). Reaction products were then subjected to quantitative phosphoproteomic analysis. 
Mean phosphopeptide intensities (n = 2) for phosphopeptides found to be a result of in vitro kinase 
activity were normalized as a percentage of the maximum value for all conditions and represented 
on a heat map. 
Heat-map analysis of phosphopeptide quantification clearly demonstrated that kinase 
activities were distinct and showed little overlap between the P31/Fuj and Kasumi-1 cell 
lines (Fig. 6.6.). A total of 67 and 49 activities were detected in basal P31/Fuj and Kasumi-1 
cells respectively and quantified as area under the kinetic curve (Appendix 5). Some specific 
examples of identified kinase activities are illustrated (Fig. 6.7.). 
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Figure 6.7. GKAP reveals distinct activation of kinases in P31/Fuj and Kasumi-1 cells. Total cell 
lysate samples from P31/Fuj and Kasumi-1 cells containing 50 μg of protein were incubated for 5 min 
at 30oC with reaction buffer containing 10, 50 or 500 μM ATP or were not incubated (0 µM). 
Reaction products were then subjected to quantitative phosphoproteomic analysis. Mean 
phosphopeptide intensities (n = 2) were normalized as a percentage of the maximum value for all 
conditions and expressed as a kinetic curve (left panel) or as AUC, a measure of kinase activity (right 
panel). Examples are shown for A. A kinase active only in Kasumi-1 cells. B. A kinase active only in 
P31/Fuj cells. C. A kinase active in both cell types. 
 
These results show that GKAP can be effectively used to identify differences in basal 
signalling pathway activation in two different cancer cell lines that are known to be 
dependent on distinct kinases for proliferation. Further analysis was performed to verify 
that the kinase activities identified using GKAP were representative of the pathways 
previously found to be active in these cells using traditional global phosphoproteomics. In 
addition to the GKAP experiment already performed, a conventional phosphoproteomic 
experiment was carried out using P31/Fuj and Kasumi-1 cells. Total cell lysate, containing 
500 μg of protein, was harvested and subjected to in-solution trypsin digestion followed by 
phosphopeptide enrichment, using TiO2 affinity chromatography, and LC-MS/MS analysis. A 
list of 44 known phosphorylation motifs was compiled [324] and the incidence of each was 
established for the GKAP and conventional phosphoproteomic datasets (Fig. 6.8.). 
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Figure 6.8. GKAP detects the activity of a broad range of kinases active in P31/Fuj and Kasumi-1 
cells. GKAP and conventional phosphoproteomic experiments were performed using P31/Fuj and 
Kasumi-1 cells. The respective datasets were subjected to motif analysis using in-house software. 
 
The results demonstrated that a broad range of kinase activities were identified using 
GKAP (Fig. 6.8.). Furthermore, the range of represented kinases correlated relatively well 
with those obtained using conventional phosphoproteomic experiments (Fig. 6.8.). These 
results suggest that GKAP is suitable for the detection of global kinase activity in these cells 
as a wide range of kinases were represented in the dataset, including those found by other 
methods to be active. 
6.4. Use of GKAP to investigate signalling pathway activation and inhibition 
We next proceeded to apply GKAP to investigate the activation of signalling pathways by 
growth factor stimulation and the effects of small molecule kinase inhibitors on such a 
response. MCF10A cells were starved of serum and growth factors for 18 h prior to 
stimulation with 100 ng/ml epidermal growth factor (EGF) for 10 min. Where indicated, cells 
were treated with the PI3K inhibitor LY294002 (5 μM) or the MEK inhibitor UO126 (10 μM) 
for 1 h prior to EGF stimulation. Total cell lysate samples from treated cells, containing 50 μg 
of protein, were then incubated for 5 min at 30oC with reaction buffer containing 10, 50, 
100 or 500 μM ATP or not incubated with the reaction mix (0 µM). The reaction was then 
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stopped by the addition of urea and the reaction protein products were subjected to in-
solution trypsin digestion. The samples were enriched for phosphopeptides, using TiO2 
affinity chromatography, prior to LC-MS analysis on the LTQ-Orbitrap XL (two technical 
replicates performed) for qualitative and quantitative phosphoproteomic analysis (Fig. 6.9. – 
6.10.). 
 
 
Figure 6.9. GKAP reveals distinct pathway activation in MCF10A cells stimulated with EGF and 
treated with LY294002 or UO126. MCF10A cells were starved of serum and growth factors for 18 h 
prior to treatment with 100 ng/ml EGF for 10 min. Where indicated, cells were pre-treated with 5 
μM LY294002 or 10 μM UO126 for 1 h prior to stimulation. Total cell lysate samples containing 50 μg 
of protein were incubated for 5 min at 30oC with reaction buffer containing 10, 50, 100 or 500 μM 
ATP or were not incubated (0 µM). Reaction products were then subjected to quantitative 
phosphoproteomic analysis. Mean phosphopeptide intensities were normalized as a percentage of 
the maximum value for all conditions and represented on a heat map (n = 2). 
 
A total of 622 phosphopeptides were identified and quantified in this experiment (Fig. 
6.9.). The heat-map analysis of quantitative data revealed the different phosphoproteomic 
responses of MCF10A cells under the tested treatment conditions, indicating differential 
pathway activation (Fig. 6.9.).  
In this experiment we applied more stringent criteria to define kinase activity to enable 
greater discrimination between the multiple conditions; a minimum of a 2-fold increase of 
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phosphopeptide signal after incubation with 10 μM ATP and a minimum of 3-fold increase 
after incubation with 50, 100 and 500 μM ATP were required relative to the baseline value. 
Following these conditions, 241 kinase activities were detected in untreated cells (Appendix 
6). This number increased to 372 upon EGF stimulation and was decreased by around 30% 
to 246 and 293 by LY294002 or UO126 treatment respectively, thus restoring the number of 
kinase activities detected back to similar levels to that of untreated cells (Appendix 6). Some 
specific examples of identified kinase activities, quantified as AUC, are illustrated (Fig. 6.10.). 
 
 
Figure 6.10. GKAP reveals distinct activation of kinases in MCF10A cells stimulated with EGF and 
treated with LY294002 and UO126. MCF10A cells were starved of serum and growth factors for 18 h 
prior to treatment with 100 ng/ml EGF for 10 min. Where indicated, cells were pre-treated with 5 
μM LY294002 or 10 μM UO126 for 1 h prior to stimulation. Total cell lysate samples containing 50 μg 
of protein were incubated for 5 min at 30oC with reaction buffer containing  10, 50, 100 or 500 μM 
ATP or were not incubated (0 µM). Reaction products were then subjected to quantitative 
phosphoproteomic analysis.  Mean phosphopeptide intensities (n = 2) were normalized as a 
percentage of the maximum value for all conditions and expressed as a kinetic curve (left panel) or 
as AUC, a measure of kinase activity (right panel). Examples are shown for A. A kinase reaction active 
upon EGF stimulation and unaffected by the two inhibitors. B. A kinase reaction active upon EGF 
stimulation and inhibited by LY294002. C. A kinase reaction active upon EGF stimulation and 
inhibited by UO126. D. A kinase reaction active upon EGF stimulation and inhibited by both 
LY294002 and UO126. 
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These results showed that GKAP can be effectively used to identify kinase activity 
following pathway activation by growth factor stimulation and, furthermore, that this 
method can also detect changes to such activities that occur upon inhibitor treatment (Fig. 
6.10). It is also noteworthy that kinase activities inhibited by small molecule treatment 
closely resembled that of the un-stimulated sample, indicating that phosphorylation 
induced by EGF treatment is highly specific and not the result of off-target activity by other 
kinases. 
As before, further analysis was performed to verify that the kinase activities identified 
using GKAP were representative of the pathways previously found to be active in MF10A 
cells using conventional phosphoproteomics. In addition to the GKAP experiment already 
performed, a conventional phosphoproteomic experiment was carried out using MCF10A 
cells that were serum and growth factor starved for 18 h followed by no further treatment 
or stimulation with 100 ng/ml EGF for 10 min. Total cell lysate, containing 500 μg of protein, 
was harvested and subjected to in-solution trypsin digestion followed by phosphopeptide 
enrichment, using TiO2 affinity chromatography, and LC-MS/MS analysis. The incidence of 
common phosphorylation motifs was established for the GKAP and conventional 
phosphoproteomic datasets (Fig. 6.11.). 
 
Figure 6.11. GKAP detects the activity of a broad range of kinases active in EGF-stimulated MCF10A 
cells. GKAP and conventional phosphoproteomic experiments were performed using starved and 
EGF-stimulated MCF10A cells. The respective datasets were subjected to motif analysis. 
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As before, the results demonstrated that a broad range of kinase activities that 
correlated well with those obtained using conventional phosphoproteomics were identified 
using GKAP (Fig. 6.11.). These results further support the notion that GKAP is suitable for the 
detection of global kinase activity in cells as a wide range of kinases were represented in the 
dataset, including those confirmed by other methods to be active. 
6.5. Conclusions 
The aim of the work presented in this chapter was to develop an assay for the 
investigation of endogenous kinase activities on a global scale. We followed on from our 
work in Chapter 5 to develop an assay that coupled an in vitro kinase reaction with shotgun 
phosphoproteomics for the detection of reaction products (Fig. 6.2.). In brief, total cell 
lysates were incubated with reaction buffer containing different concentration of ATP and 
necessary co-factors to allow phosphorylation of full-length protein substrates by 
endogenous kinases. Phosphorylation events were then identified and quantified using 
mass-spectrometry based phosphoproteomic techniques. We termed the technique global 
kinase activity profiling (GKAP). 
We initially sought to investigate if endogenous kinases were active in an in vitro 
reaction and whether such activity could be detected by mass spectrometry. Total cell 
lysates of different total protein composition (5 – 100 μg) were taken from P31/Fuj cells and 
incubated with different concentrations of ATP (0, 10 or 100 μM). Quantitative 
phosphoproteomic analysis revealed that phosphopeptide signal increased as total protein 
in the reaction was increased and, furthermore, that many phosphopeptide signals 
increased as the concentration of ATP in the reaction mix increased, suggesting that kinases 
were phosphorylating targets in vitro (Fig. 6.3.). Closer investigation of kinase activities 
revealed that phosphopeptide intensity appeared to be proportional to ATP concentration 
in the reaction mix, suggesting Michaelis-Menten like reaction dynamics (Fig. 6.4.). 
Having established that the in vitro activities of endogenous kinases could be detected 
by mass spectrometry, we next proceeded to investigate if the GKAP method could be used 
to identify the different levels of kinase activities in two AML cell lines shown to have 
differential activation of signalling pathways under basal conditions [179]. P31/Fuj cells 
(MEK, JAK and PI3K inhibitor resistant) and Kasumi-1 cells (MEK, JAK and PI3K inhibitor 
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sensitive) were lysed and samples containing 50 μg of protein were incubated with reaction 
mix containing 0, 10, 50 or 500 μM ATP. Phosphoproteomic analysis revealed that the two 
cell lines showed distinct responses to GKAP (Fig. 6.5.). More detailed investigation revealed 
distinct, non-overlapping clusters of kinase activity in the two cell lines suggesting 
differential pathway activation (Fig. 6.6. and 6.7.). Motif analysis was performed and 
compared to that of conventional phosphoproteomic experiments to demonstrate that a 
wide range of kinase activities were represented in the GKAP database (Fig. 6.8.).  
We then applied GKAP to MCF10A cells to investigate if the method was suitable for the 
detection of growth factor stimulated pathway activation and small molecule kinase 
inhibition. MCF10A cells were starved of serum and growth factors for 18 h and then 
stimulated with EGF after treatment with the kinase inhibitors LY294002 and UO126 as 
indicated. Cells were lysed and 50 μg of total protein were incubated with reaction buffer 
containing 0, 10, 50, 100 or 500 μM ATP. Phosphoproteomic analysis revealed that the 
treatments resulted in distinct responses to GKAP (Fig. 6.9.). Detailed investigation showed 
that kinase activity induced by EGF treatment (Fig. 6.10.) and inhibition of EGF-induced 
kinase activity by inhibitor treatment were detected (Fig 6.10. B – D). Motif analysis was 
performed and, as before, showed that a wide-range of kinases including those known to be 
active in these cells was represented in the GKAP dataset (Fig. 6.11.). 
These results suggest that GKAP is a useful method for the detection of endogenous 
kinase activities. The use of full-length protein substrates in this assay presents a major 
advantage over existing kinase assays and the GKAP method may therefore prove to be a 
useful tool for future investigation.  
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7. Discussion 
The PI3K/Akt pathway has an essential role in the regulation of key cellular functions in 
health and disease. With this project we used innovative mass spectrometry techniques to 
address some remaining questions about the regulation and activity of this critical cell 
signalling pathway from a proteomics standpoint. 
Mass spectrometry based proteomics is increasingly being applied to advance our 
knowledge in many fields of biochemical research. In addition to being a sensitive, specific 
and quantitative method, its untargeted nature also enables an investigative approach that 
is not possible with more conventional molecular biology techniques. Thus, it enables global 
scale analysis and discovery investigation that was not previously possible with other 
methods. This project applied the discovery potential and global scale analysis qualities of 
mass spectrometry to investigate PI3K/Akt signalling. 
One key area in the field of PI3K/Akt signalling that remained underexplored is the role 
of interacting proteins in the regulation of PI3K activity. Using a rigorous and un-targeted 
AP-MS screen we identified three candidate interaction partners for class IA PI3Ks (Chapter 
3). Furthermore, we were able to validate the interaction between PI3K and calpain, one of 
the identified candidates, and establish a clear role in the regulation of PI3K signalling and 
biological activity (Chapter 4). 
Another aspect of PI3K/Akt signalling that has not been comprehensively investigated is 
the dynamics of signalling activity downstream of Akt. We applied global, quantitative mass-
spectrometry based phosphoproteomics to investigate signalling events downstream of this 
kinase (Chapter 5). We first developed two different strategies for this approach; utilising 
both an in vivo model and an in vitro assay that we developed to identify phosphorylation 
events downstream of Akt (Chapter 5). In addition, as an extension of the utility of the 
approach, we applied our in vitro assay as a novel approach for the quantification of global 
kinase activity (Chapter 6). 
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7.1. AP-MS screen for dynamic interaction partners of class IA PI3K 
PI3K activity is tightly regulated in vivo to enable controlled cell growth and tissue 
homeostasis [60, 111, 325]. As such, a number of mechanisms to regulate PI3K activity have 
been identified and well-characterized (discussed in Chapter 1) [19, 27, 29, 85, 266, 278].  
The regulation of enzymatic activity by protein-protein interactions has been repeatedly 
established [263, 264] and multiple kinases involved in cell signalling are known to be 
regulated by the formation of protein complexes [265-268]. However, the regulation of class 
IA PI3K by interaction partners remains under-explored, most likely due to the lack (until 
recently) of suitable molecular biology techniques for a discovery investigation of transient 
and low affinity protein-protein interactions on a global-scale.  
Another area of interest is the possible role of interaction partners in regulating isoform-
specific activity of class IA PI3Ks. Binding partners have the potential to form isoform-
specific interactions and therefore to regulate PI3K activity, e.g. through cytoplasmic 
localization or by direct interaction with the catalytic subunit, in an isoform-selective way.  
PI3K has previously been shown to interact with a number of proteins [58, 283, 326], 
however a clear mechanism for the regulation of total or isoform-selective PI3K activity has 
not yet been established. Our AP-MS screen for PI3K binding partners aimed to identify 
novel binding partners of PI3K that may have a role in regulating its activity.  
7.1.1. AP-MS strategy for identification of class IA PI3K interaction partners 
7.1.1.1. Principles behind AP-MS strategy 
Affinity purification of protein complexes followed by proteomic analysis by mass 
spectrometry has established itself as the method of choice for the identification of protein-
protein interactions in protein complexes. AP-MS can be used for a global approach and can 
identify multimeric complexes, in contrast to techniques such as Y2H, which only yield 
binary results. 
Crucially for this project, the technique also enables the assessment of endogenous 
binding relationships (without over-expression of the bait) under different growth 
conditions, thus providing valuable information about the dynamic interactions that occur 
during cell signalling events. This aspect was crucial for the success of this project as it can 
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be hypothesized that regulation of PI3K by functional binding partners is most likely to 
involve dynamic interactions as a function of PI3K activation status.  
We designed an AP-MS strategy based on quantitative LC-MS to identify functional 
binding partners of endogenous class IA PI3K (Fig. 3.1.). In this approach, AP-MS is 
performed on cells expressing endogenous levels of proteins under different growth 
conditions. Quantitative analysis of the resulting conditions can be used to identify dynamic 
interactors, which are more likely to be functionally significant, and to identify proteins that 
are unchanged under different states, which are more likely to be non-specific interactors. 
Although alternative AP-MS strategies based on the over-expression or tagging of the 
protein bait are widely used to identify constitutive protein-protein interactions [196, 197] 
we reasoned that this strategy was not suitable for our investigation as subcellular 
localization, physiological responses and functional interactions may be disrupted by 
changes in protein abundance ratios [194, 195]. In addition, dynamic interactions may occur 
through modifications or conformations not identified a priori and therefore not necessarily 
present in over-expressed proteins. Furthermore, false positive results are more likely when 
bait proteins are tagged and expressed at high levels [187].  
Our quantitative AP-MS approach has previously been successfully applied to a 
number of protein interaction studies in mammalian cells [193, 284, 327]. However, to date 
it has not been successfully applied to identify binding partners of PI3K. Factors that may 
have influenced this outcome include the relatively low abundance of PI3K in cells, the 
likelihood that interactions are dynamic, that partners may be present in sub-stochiometric 
levels and the general under-use of mass spectrometry in the field of PI3K investigation. 
7.1.1.2. Technical considerations of AP-MS strategy 
We designed an AP-MS strategy to identify candidate dynamic interaction partners of 
Class IA PI3K (Fig. 3.1.). Our strategy was designed to compare the composition of the PI3K 
protein complex in cells that were serum-starved, resulting in low pathway activity, or 
serum-stimulated, resulting in high pathway activity. We hypothesized that proteins present 
in equal abundance under both conditions were likely to be non-specific interactors or 
constitutive binders, whereas proteins present in different abundance under the two 
conditions were likely to have an active role in signalling. We selected NIH-3T3 mouse 
Chapter 7: Discussion 
180 
 
embryonic fibroblasts (MEFs) as our model cell line as it is a well characterized cell line that 
is widely used as a model experimental system and is easy to work with on the scale 
required for AP-MS investigations. 
The major technical drawbacks of AP-MS relate to the affinity purification stage. When 
using immunoprecipitation to isolate protein complexes, the technique is limited by the 
specificity of the antibody as non-specific interactions will complicate the identification of 
true interaction partners. This problem is particularly significant when “bait” proteins are in 
low abundance, as occurs with signalling enzymes. Another consideration is that interacting 
partners may not be present in equimolar ratios, therefore high amounts of “bait” protein 
may be required to ensure sufficient recovery of binding partners to enable confident 
identification. In addition, dynamic interaction partners, such as those we were hoping to 
identify, are likely to have relatively low binding affinity for their interaction partners. 
In order to overcome these limitations the affinity purification strategy was optimized 
by conducting a series of initial experiments. We showed that the use of 0.3% CHAPS, a mild 
detergent, during IP resulted in the co-purification of a higher number of proteins compared 
to 1% Triton X-100, a stronger detergent (Fig. 3.2.). These results demonstrated, in line with 
the findings of others [268], that, the use of weak detergent for affinity purification 
maximises the retention of weak protein-protein interactions, thus increasing the number of 
potential binding partners. This was of particular importance in our study as our targets of 
interest were likely to be transient, dynamic interactors forming relatively weak interactions 
with PI3K. However, the use of weak detergents also increases the likelihood of non-specific 
interactions between proteins thus potentially generating a more complex dataset with an 
increased incidence of non specific identification. Our quantitative strategy was designed to 
overcome the limitations of low specificity associated with AP-MS and thus the increase in 
non-specific interactions was not considered to be an issue. In addition, in each experiment 
we analyzed a control sample, produced by carrying out a parallel IP with total IgG instead 
of an anti-PI3K antibody as the affinity reagent, and used the data to verify that any 
candidates were not interacting in a non-specific way. 
Further investigations were performed to investigate the effects of the detergents 
CHAPS and Triton X-100 on cell lysis in more detail. Our results showed that, whilst total 
protein yield was inversely proportional to the concentration of either detergent (Fig. 3.3.), 
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the amounts of p85 recovered did not correlate well with detergent type or concentration 
(Fig. 3.4.). These results suggested that the use of low concentration of 0.3% CHAPS in the 
affinity purification process would not negatively impact the recovery of PI3K. These data 
further supported our strategy to use a weak detergent for IP. 
A series of experiments were also performed to identify the optimal antibodies and 
associated conditions for the purification of PI3K complexes by IP. We chose to use 
antibodies with affinity for all isoforms of the p85 regulatory subunit of PI3K (p85 pan) as 
these reagents have previously been demonstrated to be efficient affinity reagents [19]. An 
additional advantage to this approach is that the different isoforms of the p110 catalytic 
subunits expressed in cells will all be isolated by this antibody. Our investigation revealed 
that, whilst both antibodies tested had a high affinity for p85, a combination of the two 
used at a ratio of 1:500 (µl antibody:µg protein) effectively depleted PI3K p85 from the 
sample (Fig. 3.5.). Therefore, these were the antibody IP conditions selected for the AP-MS 
screen. 
It should be noted that it is extremely challenging to comprehensively prevent non-
specific interactions thus appropriate consideration to this matter was given during 
experimental design and data analysis. It should also be taken into consideration that AP-MS 
was used as an initial screening tool to identify potential protein-protein interactions. 
Validation with an alternative method is advocated to confirm AP-MS screen findings. 
7.1.2. AP-MS screen for class IA PI3K protein complexes 
Three independent biological experiments were performed to conduct the AP-MS 
screen. In each, PI3K p85 protein complexes were isolated from NIH-3T3 cells that were 
serum-starved for 18 h (“starved”) or serum-starved for 18 h followed by stimulation with 
10% FBS for 5 min (“stimulated”). SDS-PAGE separation and Colloidal Coomassie blue 
staining revealed the complexity of the IP products isolated and failed to identify any clear 
differences between the samples (Fig. 3.6.). Furthermore, qualitative mass-spectrometry 
analysis did not identify any proteins that were associated with the complex exclusively 
under one condition. However, we anticipated this finding as functional binding partners are 
likely to have a dynamic rather than constitutive association with PI3K. Our initial results 
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supported the requirement for a quantitative mass spectrometry approach to identify 
candidate interaction partners. 
7.1.2.1. Quantitative analysis of class IA PI3K AP-MS screen results 
Mass spectrometry analysis was used to identify and quantify hundreds of proteins 
across the study, however we focused our attention on the 81 proteins that were identified 
in all three replicate experiments (Appendix 1). We employed stringent data quality criteria 
for protein identification and quantification to identify proteins that were interacting 
dynamically with PI3K. Critically, candidates were required to be identified to a high degree 
of confidence in all three experiments and the criteria to be considered quantitatively 
different between the two conditions was for a minimum of a two-fold change in relative 
abundance, which was statistically significant as assessed by the Student’s t-test. The 
selection criteria included proteins with a relatively modest fold change, which we 
hypothesized to be the likely scenario for a dynamic interaction relationship. 
PI3K proteins were found to be present in equal abundance under both conditions in all 
three experiments. Identification of p85α, p85β, p110α and p110β in all the experiments 
confirmed that the affinity purification technique was successful. 
The high number of other proteins also identified illustrated well the challenges 
involved in the identification of PI3K interaction partners. It is technically challenging to 
identify low abundance proteins of potential interest against a high background of non-
specific interactors. A contributing factor is the low abundance of PI3K in cells, thus 
rendering the isolation of significant amounts of the PI3K protein complex technically 
challenging. Another likely complication to this investigation is that interaction partners may 
not be associated with PI3K in an equimolar ratio. Thus, when a modest amount of PI3K is 
isolated the abundance of binding partner in relation to non-specific interactors may be very 
low.  
We considered our approach to mass spectrometry analysis in order to maximize the 
number of protein identifications and, more importantly, to enhance the quality of 
identification data for low abundance proteins. Each independent biological sample set was 
analyzed once and the MS/MS dataset analyzed by MASCOT. These data were then used to 
generate an exclusion list that, when applied to the mass spectrometry method during a 
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second technical replicate analysis, prevented the repeat MS/MS analysis of the same 
peptides thus producing a richer data set. The data from both analyses were then pooled to 
carry out the qualitative analysis. It should be noted that a high number of MS/MS spectra 
were generated during analysis however only a relatively low number (around 10%) were 
assigned by MASCOT to a known peptide. This suggests that the quality of the MS/MS 
spectra generated by these samples was relatively low, which may be due to the presence 
of many proteins in low abundance. 
Despite the technical challenges discussed, three proteins that exhibited a dynamic 
relationship, as assessed using rigorous criteria, with PI3K in response to changes in growth 
conditions were identified. CAPNS1 was found to be more strongly associated with PI3K in 
starved cells whereas FN1 and VIM were found to be more strongly associated with PI3K in 
stimulated cells (Fig. 3.7. - 3.8. and Table 3.1.).  
Our approach was biased towards specificity rather than sensitivity i.e. by using such 
rigorous criteria for accepting protein identification and quantification the risk of false 
positive identification of interaction partners was low but it is likely that other bona fide 
binding partners were excluded for further consideration. For example, we only accepted 
for consideration as potential interaction partners proteins that were identified in all three 
biological replicate experiments. Due to the phenomenon of “under-sampling”, qualitative 
agreement between just two technical replicates is typically around only 60% [193]. Indeed, 
our dataset of 81 proteins identified in all three experiments represented just 27% of the 
total number of proteins identified across all three experiments. Thus, it cannot be excluded 
that more candidate interaction partners could be found within our dataset. 
7.1.2.2. Limitations of class IA PI3K AP-MS screen 
The major factor hampering our quantitative AP-MS investigation was the use of gel 
electrophoresis for the separation of proteins during sample preparation for mass 
spectrometry analysis. Due to inherent physical variabilities during the performance of SDS-
PAGE, the resulting fractions from each of the three experiments were not directly 
comparable; i.e. the same proteins could not be located within the same fraction in every 
experiment. The major problem that this presented was that a distinct database for PESCAL 
quantitation, based on the qualitative data, had to be applied to each fraction for each 
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experiment. The qualitative and quantitative data for all the fractions was then pooled to 
allow comparison between samples. However, only proteins that were identified in all three 
experiments could be quantitatively compared between all biological replicates as the 
qualitative data from one experiment could not be used for quantitation of proteins in 
another. Thus, the quantitative analysis was limited by the qualitative analysis. 
A considerable improvement to this investigation would have been to use a method 
for sample preparation for mass spectrometry that did not involve sample fractionation. A 
number of such methods, including in-gel digestion of un-fractionated samples, filter-aided 
sample preparation and in-solution digestion, were evaluated (data not shown); however 
results were disappointing in our hands as a very low number of peptide identifications 
were obtained and data quality was low. It is likely that the limited success of these 
methods is due to the low abundance of a high number of proteins in our AP-MS samples. 
Thus, mass-spectrometry analysis of the un-fractionated, complex sample resulted in the 
identification of a low number of high abundance peptides. The use of more modern mass 
spectrometers with greater sensitivity and faster (shorter) duty cycles (e.g., new generation 
of orbitrap or Q-TOF mass analysers) could in the future be used to identify additional PI3K 
functional binders. 
7.1.3. Verification of AP-MS screen results 
These results of qualitative and quantitative analysis of mass spectrometry data were 
validated by manual sequencing of representative peptides from candidate interaction 
proteins identified by MASCOT. This analysis confirmed their identification and thus 
supported the proposal that these peptides, and thus the proteins they derived from, 
interact with p85 (Fig. 3.9. – 3.10.). Due to the time-consuming nature of this exercise, it is 
not practical to manually validate the identification of large numbers of peptides; however it 
is a useful tool for the validation of MASCOT data where peptide identification confidence 
values are low and/or numbers of peptide identifications per protein are also low. This was 
not the case for the candidate p85 binding partners in question as a minimum of 4 peptides 
(mean = 9.2) were identified for each protein in each experiment and MASCOT protein 
scores were high (mean = 185) (Appendix 1). 
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The manual quantification (using the vendor software Xcalibur) of a series of peptide 
peaks correlated well with automated quantitation with the in-house program PESCAL (Fig. 
3.11. – 3.13.). Thus we validated the quantitative findings of the AP-MS screen and the 
accuracy of PESCAL. 
7.1.4. Implications of study: candidate class IA PI3K interaction partners 
Our AP-MS strategy was successfully applied to identify the proteins CAPNS1 (calpain 
small subunit 1), FN1 (fibronectin) and VIM (vimentin) as candidate PI3K interaction 
partners. All three of these proteins exhibited a dynamic relationship with p85 PI3K in 
response to changes in growth conditions (which correlates with signalling activity), with 
CAPNS1 found to be more strongly associated with PI3K in starved cells and FN1 and VIM 
found to be more strongly associated with PI3K in stimulated cells (Figs. 3.7. and 3.8. and 
Table 3.1.). To date, there have been no reported observations of interaction between PI3K 
and these three proteins. It should be noted that although the stringency of data quality for 
our AP-MS study was high, we employed this strategy as a screening tool. Thus, we 
undertook further investigation and validation work to confirm one of these candidates as a 
true interaction partner of class IA PI3K and to elucidate the functional significance of such 
associations. 
Calpains are a family of calcium-dependent cysteine proteases that have been shown 
to have key roles in the regulation of important cellular functions including apoptosis, 
autophagy, proliferation and migration [289, 290, 293]. Intriguingly, at the time of 
concluding our AP-MS screen recent studies had reported that calpain negatively regulates 
signalling pathways, including PI3K, in monocytes although the mechanism for this 
phenomenon was not described [288].  
Fibronectin is an extracellular matrix glycoprotein secreted by fibroblasts, such as NIH-
3T3 cells. The protein has been implicated in the stimulation of intracellular signalling 
pathways, including PI3K, and has been linked to the development of lung carcinogenesis 
[328].  Vimentin is an intermediate filament protein, important for cytoskeletal structure 
and has been implicated in cell attachment, migration and signalling through its role in 
regulating cytoplasmic localization of other proteins [329].  
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Our follow-up investigative work from the AP-MS screen (Chapter 4) focused on the 
potential interaction between PI3K p85 and CAPNS1. Although CAPNS1 was not the 
candidate binding partner with the highest fold change, this path was undertaken because 
existing work implicated calpain in the cleavage of other signalling proteins [285] and in the 
regulation of Akt signalling [286-288]. Furthermore, calpain had been extensively implicated 
in a number of key cellular functions that are also regulated by PI3K but the mechanisms by 
which it exhibited control remained poorly understood. Thus, we concluded that a 
functional relationship between class IA PI3K may be a potential explanation for some of 
these reported activities (for which mechanistic insights were lacking) and that the 
relationship between the two proteins may potentially be of great physiological significance. 
However, this does not preclude the possibility that class IA PI3K also interacts with 
fibronectin and/or vimentin and that such functional relationships might be of equal 
biological significance. 
One notable observation of our AP-MS screen results is that we did not identify other 
reported interaction partners of PI3K as candidate dynamic binding partners. For example, 
p85α was reported to bind directly with PTEN, enhancing its lipid phosphatase activity, upon 
EGF stimulation of HeLa cells [52]. One possible explanation for the discrepancy between 
our studies is the difference in ligand stimulation, as Chagpar et al exclusively stimulated 
EGF receptors whereas our use of FBS resulted in a wider response of growth factor 
receptors. An alternative explanation may be found in the observation that the authors 
were unable to co-purify endogenous PTEN-p85-p110 complexes, leading them to suggest 
that it is only free p85 that binds to PTEN [52]. Since the existence of significant amounts of 
free p85 in NIH-3T3 cells has been disputed [19] this may account for the lack of PTEN 
among our candidate binding partners. In addition, this work was performed using human 
HeLa cells whereas we used a mouse fibroblast cell line (NIH-3T3) as the model system; it is 
thus feasible that PI3K interactions may be species, or indeed tissue, specific. 
p85 has also been reported to bind X-box binding protein-1 during periods of ER stress 
and to increase its nuclear translocation thus regulating the unfolded protein response [50, 
51]. Again, these studies were conducted under different growth conditions and in a 
different cell model system and were unable to purify endogenous complexes of X-box 
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binding protein-1 with the PI3K heterodimer; these studies were therefore reliant on the 
“free p85 hypothesis”, which has been disputed [19]. 
Gα16 has also been reported to bind class IA PI3K complexes and to consequentially 
inhibit EGF-induced Akt phosphorylation in haematopoietic cells (i.e. expressing high levels 
of p110δ) [53]. However, the association between these proteins at endogenous levels was 
only investigated under basal conditions and therefore this may not be a dynamic 
association and may be specific to the p110δ PI3K isoform. Furthermore, the investigation 
into effects of the association on signalling was investigated using over-expression of Gα16 
so may be unrepresentative of in vivo signalling dynamics. 
All p110 isoforms have a Ras-binding domain and Ras binding to the p110α subunit is 
known to regulate some PI3K functions [29, 279]. However, the interaction does not survive 
biochemical purification, indicating that it is a weak and transient interaction, and a high 
degree of variability has been demonstrated in the response of PI3K to Ras binding  
depending on the Ras GTPase and p110 isoform investigated [28]. Thus, the contribution of 
Ras in PI3K regulation remains unclear.  
The considerations outlined above (in terms of different approaches in experimental 
design and techniques and the use of different biological models used to identify PI3K 
interactors) provide a rational explanation of why proteins previously shown to associate 
with PI3K were not present in our dataset of potential PI3K protein binders. It should be 
noted that most of the protein binders of PI3K descried previously were identified in a single 
study and for most cases there are not corroborative data from independent laboratories. 
7.2. Regulation of class IA PI3K stability and signalling activity by calpain 
As discussed above, CAPNS1 was consistently found to be more abundant in p85 protein 
complexes isolated from starved cells in all three experiments (Fig. 3.8. B). We next sought 
to validate the interaction between calpain and class IA PI3K and to investigate any potential 
functional significance of such an association. 
7.2.1. Validation of the interaction between calpain and class IA PI3K 
Our initial experiments aimed to confirm the finding from our AP-MS screen that 
CAPNS1 interacts with Class IA PI3K. Furthermore, we sought to investigate if the active 
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calpain heterodimer was part of the PI3K complex as this was likely to be of more functional 
significance. 
We isolated PI3K protein complexes from starved and stimulated NIH-3T3 cells and used 
an in vitro calpain activity assay to confirm the presence of active calpain heterodimers in 
the complex (Fig. 4.2.). Furthermore, we confirmed that the association between PI3K and 
calpain was higher in serum-starved cells compared to serum-stimulated cells (Fig. 4.2.), 
thus validating our AP-MS screen results.  
To further verify the AP-MS study findings, we also isolated calpain protein complexes by 
IP and used an in vitro lipid kinase assay to confirm the presence of PI3K in the protein 
complex (Fig. 4.3.). This approach also verified our AP-MS screen findings and confirmed 
that the association between the proteins was higher in serum-starved cells compared to 
serum-stimulated cells.  
Enzymatic assays were used to investigate the association between calpain and PI3K 
because of the lack of high affinity antibodies available against calpains. Enzymatic assays 
can provide greater sensitivity of detection than WB, which is dependent on antibody 
affinity. The use of enzymatic methods is a well established approach in the field of calpain 
investigation and other groups have used them extensively, for example to verify the 
genetic knockdown of CAPNS1 [301, 305, 306].  Casein zymography [330] was used in the 
examples cited but we chose to use a less-cumbersome commercially available in vitro assay 
to detect calpain activity. An additional benefit of the use of enzymatic assays to validate 
the CAPNS1-p85 interaction is that the data also provided further functional information, 
confirming that both proteins are present in the complex as part of enzymatically active 
heterodimers. 
Further investigation also revealed that the association between PI3K and calpain 
increased as serum-starvation time progressed (Fig. 4.3.). These data suggest that the 
association between PI3K and calpain is an adaptive response to cellular stress caused by 
growth factor starvation. Total calpain activity of NIH-3T3 cells was also shown to be 
increased in serum-starved cells compared to exponentially growing cells (Fig. 4.4.). 
Investigations into the role of calpain in cell survival have revealed discordant results and 
both calpain 1 and 2 have been implicated in pro and anti-apoptotic signals [290, 305, 331]. 
Our discovery that calpain activity and association with PI3K is increased in NIH-3T3 cells 
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during serum starvation would support a role for this protein in the adaptive regulation of 
cell survival during cellular stress. 
Further follow-up work performed by our group has also confirmed that calpain 
interacts with class IA PI3K in human colorectal DLD-1 cancer cells (Appendix 7). The 
association between the two proteins in these cells was found to be higher in starved cells 
compared to insulin stimulated cells, in line with our findings for NIH-3T3 cells (Appendix 7). 
7.2.2. Effects of calpain on PI3K stability and enzymatic activity 
Having confirmed the association between calpain and class IA PI3K, we next proceeded 
to investigate if PI3K was a substrate for this protease as this would be a logical functional 
relationship. We isolated PI3K proteins from NIH-3T3 cells (which highly express p110α and 
p110β PI3K isoforms [19]) and RAW 264.7 cells (which highly express p110δ in addition to 
p110α and p110β PI3K isoforms [75]) and subjected them to in vitro protease digestion 
using purified calpain 1 and calpain 2. WB analysis of the different PI3K isoforms revealed 
that the p110α PI3K isoform was completely cleaved by both calpain proteins, whereas 
p110δ and p85 PI3K subunits were only partially cleaved and p110β was virtually unaffected 
(Fig. 4.5.). These results show that, as hypothesized, PI3K proteins are in vitro substrates of 
calpain. However, we noted that p110β was cleaved to a much lower extent than p110α, 
demonstrating that calpain preferentially cleaves p110α over p110β and p110δ in this assay. 
These results suggest an isoform-specific role for calpain in the regulation of PI3K activity. 
We then proceeded to investigate if cleavage of PI3K proteins by calpain resulted in a 
functional outcome. Results revealed that calpain-mediated cleavage of p110α resulted in a 
decrease in lipid kinase activity in vitro (Fig. 4.6.). These data reveal a key role for calpain in 
the direct regulation of PI3K activity that has not previously been reported. 
To investigate if these exciting in vitro results had any implications for in vivo 
functionality we next proceeded to investigate the effects of calpain activity on PI3K stability 
in vivo. We inhibited calpain activity in cells, pharmacologically and genetically, and used WB 
analysis of PI3K proteins to demonstrate that calpain also regulated the stability of p110α in 
a live context (Fig. 4.7.). From this data we could also infer that calpain inhibits p110α 
activity in vivo. In contrast, p85 and p110β levels were found to be minimally affected by 
calpain activity. 
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We also attempted to investigate the converse response by investigating the effects of 
increased calpain activity on PI3K protein stability. However, calcium ionophore (calpain 
activator) is highly toxic to cells and unsuitable for the longer term treatments (i.e. longer 
than 15 m) required to investigate in vivo protein stability.  
We attempted to identify the cleavage site on p110α targeted by calpain. Calpains are 
thought to cleave proteins at highly-specific recognition sites, however no consensus 
cleavage sequence has been identified and secondary structural features are thought to be 
more important recognition factors for the protease than specific short motifs [285, 293]. 
Several bioinformatic tools have been developed that identify candidate calpain cleavage 
sites based on learned algorithms e.g. GPS-CCD and CaMPDB [332, 333]. We used these 
tools to analyze the sequence of p110α and a number of candidate sites were identified; 
however there was no agreement between the two different prediction models used. 
Furthermore, the p110β sequence was also analyzed in an attempt to identify differences 
between the PI3K isoforms that may indicate the correct site. Agreement of prediction sites 
between p110α and p110β was high for each prediction model suggesting that the correct 
p110α cleavage site could not be identified using the bioinformatics tools currently 
available. 
7.2.3. Effects of calpain on PI3K signalling activity 
Having established that calpain negatively regulates PI3K lipid kinase activity in vitro we 
next proceeded to investigate the effects of calpain activity on PI3K activity in vivo. PI3K 
signalling activity is typically quantified using phosphorylation levels of the downstream 
target Akt as a surrogate marker of activity. Lipid kinase assays can be used to measure PI3K 
activity directly [269] however these methods require purification of PI3K proteins and the 
use of radio-labelling and thus are low throughput and technically cumbersome and are not 
used routinely to investigate signalling. Similarly, assays to measure the levels of PIP3 (the 
product of the PI3K reaction) in cells directly are technically challenging and not routinely 
used, although a mass-spectrometry based method that overcomes many of these 
limitations has recently been described [334].  
Therefore, we proceeded to use WB analysis of Akt phosphorylation to investigate the 
effects of calpain activity in vivo on PI3K signalling activity. WB analysis revealed that 
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pharmacological calpain inhibition resulted in increased PI3K signalling activity, as measured 
by the quantification of Akt phosphorylation (Fig. 4.8.). Thus, we inferred that calpain has a 
role in the negative regulation of PI3K activity in vivo.  
Calpain activity has been previously shown to inhibit Akt phosphorylation in human 
neutrophils and monocytes, although no mechanism was described [287, 288]. 
Haematopoietic cells express p110δ PI3K isoform, which is partially cleaved by calpain, more 
highly than other cell types but they are also dependent on the p110α isoform [75], which is 
completely cleaved by calpain. Calpain activity was also shown to inhibit Akt 
phosphorylation in p110δ-rich rat diaphragm muscle tissue although, again, no mechanism 
was determined [335]. However, in contrast to our findings, another study showed that 
genetic inactivation of calpain in MEFs resulted in a decrease in Akt phosphorylation 
compared to wild type cells when subjected to acute nutrient deprivation [286].  This effect 
was determined to be dependent on the effects of calpain on the Akt phosphatase PP2A 
[286]. Nonetheless, our results indicate that the association between PI3K and calpain 
increases as serum-starvation progresses and therefore the PI3K-mediated effects of calpain 
on Akt phosphorylation that we observed are unlikely to occur during the short starvation 
treatments (up to 20 minutes) used by Bertoli et al [286]. Another study also reported that 
genetic inactivation of calpain in MEFs resulted in decreased Akt phosphorylation in 
response to cell-death stimuli [305]. However, in contrast to other challenges reported, this 
effect was not clear in the data illustrating the effects of serum starvation on Akt 
phosphorylation and the authors do not comment on this phenomenon. These conflicting 
results suggest that the regulation of PI3K/Akt signalling by calpain is likely to be a complex 
relationship that involves the regulation of multiple nodules in this pathway. Furthermore, 
the interacting roles of these two proteins may differ in different organisms and indeed in 
different tissue cell types. 
Further work, using the PI3K inhibitor LY294002, demonstrated that the observed 
increase in Akt phosphorylation upon calpain inhibition was dependent on PI3K/mTOR 
activity (Fig. 4.9.). As occurs with most pharmacological inhibitors, LY294002 has off-target 
effects, including the downstream substrate mTOR [65]; therefore PI3K-dependence of 
calpain effects on signalling could only be fully confirmed by further investigation using 
more specific models, e.g. siRNA inactivation, or inhibitors with different off-target effects. 
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Nonetheless, collectively the data presented in this thesis support the notion that the 
observed increases in Akt phosphorylation upon calpain inhibition are mediated through a 
direct effect on PI3K activity. 
Subsequent investigations also demonstrated the functional significance of the calpain-
PI3K interaction in that the increase in Akt phosphorylation upon calpain inhibition resulted 
in an increase in Akt activity, as measured using an Akt activity assay, (Fig. 4.10.) and that 
the signal was effectively propagated downstream to the effector p70 S6K (Fig. 4.11.). The 
effects of calpain on PI3K/Akt signalling were additionally confirmed using genetic 
inactivation of calpain by siRNA treatment (Fig. 4.12.).These results clearly demonstrated 
that calpain activity has a role in the regulation of downstream events in the PI3K/Akt 
signalling axis, most likely as a result of its interaction with PI3K. 
7.2.4. Effects of calpain in class IA PI3K-dependent cell growth and survival 
We next evaluated if the negative regulation of PI3K/Akt signalling by calpain had any 
functional impact on cell growth and survival. We used an MTS assay to investigate the 
effects of calpain and PI3K inhibition, using inhibitors and siRNA, on the viability of NIH-3T3 
cells.  
Results revealed that calpain inhibition promotes the survival of cells subjected to 
serum-starvation in a PI3K/mTOR-dependent manner, indicating that calpain activity may 
have a role in stress-induced cell death (Fig. 4.13.). In contrast, calpain was not found to 
have any significant effect on the viability of cells under normal growth conditions (Fig. 
4.14.). Our previous data showed that the association between calpain and PI3K increased in 
response to serum-starvation. Therefore, it is unsurprising that an effect of calpain activity 
on cell viability was only observed when cells were deprived of serum. These data further 
support our hypothesis that the association between calpain and PI3K and the resulting 
effects on signalling are a response to cellular stress. 
We attempted to investigate the potential mechanisms for increased cell viability upon 
calpain inhibition in serum-starved cells. Cell cycle arrest is a potential mechanism to 
regulate cell survival in response to cell stress. FACS cell cycle analysis revealed that, whilst 
calpain inhibition did contribute to cell cycle arrest, this effect was independent of 
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PI3K/mTOR (Fig. 4.15.) and therefore unlikely to be the result of the effects of calpain on 
PI3K/Akt signalling. 
Apoptosis is a major mechanism for controlled cell death and thus an increase in 
apoptotic activity might contribute to calpain-dependent cell death in response to cell 
stress. FACS analysis to quantify apoptosis revealed that, contrary to our initial hypothesis, 
apoptosis increased upon inhibition of both calpain and PI3K and that the effects were 
cumulative (Fig. 4.16.). Therefore, increased apoptosis was unlikely to be the mechanism 
through which cell death was mediated by the calpain-PI3K interaction. Previous reports 
suggest a discordant role for calpain in the regulation of apoptosis as both calpain 1 and 2 
have been implicated in pro and anti-apoptotic signals.  [290, 305 , 331]. For example, 
genetic inactivation of calpain in mouse embryonic fibroblast decreased apoptosis induced 
by serum starvation, puromycin, hydrogen peroxide and UV stress but increased apoptosis 
in response to tumour necrosis factor and staurosporine [305]. Thus, calpain is likely to have 
a complex role in the regulation of apoptosis that is unlikely to be regulated primarily 
through PI3K. 
Autophagy is a tightly regulated catabolic process by which cells regulate cell growth and 
is key for the maintenance of essential cellular processes during nutrient starvation. 
However, recent studies have also revealed a role for autophagy in controlled cell death 
[336, 337]. Quantification of the autophagy marker LC3-II:LC3-I ratio suggested that calpain 
may have a PI3K-dependent role in the promotion of autophagy (Fig. 4.17.).  Our findings 
are supported by the findings of Demarchi et al, which showed that genetic inactivation of 
calpain in MEFs resulted in a decrease in autophagic activity as assessed by electron 
microscopy of phagosome formation during serum-starvation [338]. This group 
hypothesized that calpain may be required to break down a cytoskeletal barrier for 
autophagosome formation or may affect the phosphatidylinositol signalling that regulates 
autophagy [290]. However, conflicting reports have also suggested that calpain activity 
results in autophagy impairment through the cleavage of ATG5 and α-subunit of 
heterodimeric G proteins respectively [339, 340]. 
Our findings on the role of calpain in autophagy, although preliminary, suggest that 
calpain may promote cell death in a PI3K-dependent manner during cellular stress by 
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increasing autophagic activity. However, it is clear from the diverse results reported in the 
literature that calpain has a complex, multi-factorial role in autophagy.  
7.2.5. Implication of study and future work 
The discovery that calpain regulates the stability of PI3K proteins has great physiological 
implications due to the implicit link between protein concentration and potential activity 
levels. Basal PI3K levels were thought to be mainly regulated through transcriptional control 
and therefore relatively stable [27]. However, more recently, it has been proposed that 
cellular PI3K levels are dynamic and regulated through a cycle of proteasomal degradation 
and re-synthesis [341]. This process was reported to confer protection to the overall 
MCF10A cell population survival in a culture as the PI3K/Akt pathway is only active in a 
subset of cells at a given time [341]. Our finding that calpain regulates PI3K stability may 
have a role in this dynamic maintenance of PI3K levels or may represent an additional 
mechanism for the regulation of PI3K protein stability under certain circumstances, such as 
during stress. 
The implications of the finding that calpain selectively regulated the stability and activity 
of PI3K p110α remain unclear. Although isoform specific roles have been clearly established 
for different PI3K isoforms [34, 67, 70, 71], it has also been shown that cell key cellular roles 
are not dependent on any single PI3K isoform [72]. Furthermore, this work demonstrated 
that very low levels of activity of a single PI3K isoform are able to sustain proliferation and 
survival [72]. Therefore, the regulation of p110α by calpain is unlikely to be a universal 
mechanism for the control of key cellular functions.  
Although the full implications of the interaction between calpain and class IA PI3K 
remain to be fully explored, we have clearly demonstrated a functional relationship 
between these proteins. The interaction between calpain and PI3K appears to be enhanced 
in response to serum-starvation induced cell stress and the resulting effects on the 
regulation of PI3K/Akt signalling promote cell death. We therefore propose a model that 
describes the calpain-PI3K interaction as a mechanism to reduce growth activity and 
promote death when cells are subjected to environmental stress (Fig. 7.1.).  
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Figure 7.1. Proposed model for a cell death mechanism mediated by the calpain-PI3K interaction. 
Under cell growth conditions, calcium (Ca2+) homeostasis is carefully regulated and intracellular Ca2+ 
is retained within the endoplasmic reticulum (ER). Calpain activity is low. PI3K is recruited to 
activated RTKs and generates PIP3 as a result of its lipid kinase activity resulting in activation of the 
PI3K/Akt signalling pathway. Under cell stress conditions, intracellular Ca2+ is released by the ER 
[342, 343]. PI3K activity is low and PIP2 accumulates at the cell surface membrane. Calpain protease 
activity is activated by intracellular calcium availability and interaction with PIP2 [297, 298]. Active 
calpain interacts with PI3K, resulting in cleavage of the p110α protein and a reduction in lipid kinase 
activity. PI3K/Akt pathway activity is reduced but autophagic activity is enhanced, possibly through a 
reduction in mTOR activity [344]. Disruption of the tight regulation governing autophagy has been 
implicated in cell death [336, 337]. 
Loss of this environmental response mechanism may result in inappropriate cell growth 
and potentially contribute to the development of disease.  
Calpain has been implicated in the pathogenesis of many diseases including cancer, 
neurodegeneration, cataract formation, multiple sclerosis, diabetes type 2, Duchenne’s 
muscular dystrophy, and limb-girdle muscular dystrophy type 2A  [331, 345, 346].  
Cell Stress: e.g. growth factor depletionCell Growth: e.g. growth factor availability
Nucleus Nucleus
ER ER
Ca2+
Ca2+
RTK RTK
PI3K/Akt
Pathway 
Activation
PI3K/Akt
Pathway 
Activation
Calpain
Calpain
Calpain
Calpain
↑Autophagy
Chapter 7: Discussion 
196 
 
Increased expression of calpain or decreased expression of calpastatin, the endogenous 
inhibitor of calpain, has been observed in a variety of solid tumours and linked to poor 
prognosis and reduced response to treatment [290, 331]. In this scenario, calpain is thought 
to promote tumorigenesis through its role in cell migration and apoptosis, mediated by the 
cleavage of FAK and BCL-2 respectively [331, 347]. However, calpain is likely to have a 
complex role in the development of cancer as it has been implicated in the degradation of 
both oncogene gene products, e.g. c-Src (and now PI3K), and tumour suppressors, e.g. p53 
[347].  
Decreased calpain activity has also been implicated in the development of cancers. 
Higher protein expression levels of calpastatin have been found in endometrial carcinoma 
compared to benign endometrial tissue [348]. Calpain 1 protein expression was also shown 
to be reduced in basal cell carcinomas compared to normal tissue [349]. Furthermore, high 
levels of calpain 1 activity have been associated with decreased PI3K/Akt signalling in 
response to insulin in brain tissue of patients suffering from Alzheimer’s or Type 2 diabetes 
[350]. 
The PI3K-calpain interaction may reveal a previously underexplored mechanism for the 
regulation of PI3K/Akt signalling and a potential source of pathogenesis. Reduced calpain 
activity may result in increased PI3K/Akt activity during periods of nutrient depletion, a 
phenomenon that could contribute to tumorigenesis. In contrast, increased calpain activity 
may result in increased cell death and tissue damage during stress. 
Our data have shown that active calpain heterodimers associate with class IA PI3K. 
Furthermore, calpain was shown to have a role in the regulation of PI3K protein stability and 
signalling activity that appeared to be selective for the p110α isoform. One of the identified 
functional outcomes of this relationship was that calpain activity reduces PI3K/Akt signalling 
activity, resulting in increased cell death in response to serum-starvation. 
However, the relationship between calpain and PI3K remains poorly understood and the 
implications of this association are unknown. Future work might attempt to further 
investigate the mechanism of cell death in response to decreased PI3K/Akt signalling upon 
calpain-mediated cleavage of PI3K. Although autophagy has been implicated by our data 
this phenomenon requires further investigation. It would also be of interest to investigate 
the roles of the two major calpain isoforms in the cleavage of PI3K proteins. Both calpain 1 
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and 2 were shown to cleave p110α in vitro however it is unclear whether one or both 
isoforms are involved in vivo. Finally, where calpain activity deregulation has been 
implicated in pathogenesis, it would be of interest to investigate the corresponding PI3K/Akt 
pathway activity to investigate if this is a significant mechanism for the development of 
disease. 
7.3. Identification of phosphorylation events downstream of Akt 
In addition to our investigations into the regulation of PI3K activity by interaction 
partners we also wished to use proteomics to investigate the activity of the PI3K/Akt 
signalling pathway on a global scale. Over 100 proteins have been reported as substrates of 
Akt, however many of these have not been characterized fully in vivo [60]. Substrates that 
have been investigated thoroughly reveal that substrates downstream of Akt have essential 
roles in survival, growth, proliferation, motility and metabolism [60]. Furthermore, evidence 
is increasingly emerging indicating that the three distinct Akt isoforms may regulate specific 
non-redundant functions [60, 104], as is the case for PI3K.  
The identification of phosphorylation events downstream of Akt and quantification of 
PI3K/Akt pathway activity is of great interest due to their important role in normal and 
disease biology. Identification of kinase substrates is arguably the rate-limiting step in 
advancing our knowledge of cell signalling [351] and further characterization of signalling 
pathway dynamics is likely to improve our understanding of signalling in health and disease. 
The most reliable measure of Akt activity is likely to be analysis of phosphorylation 
downstream, a biomarker of PI3K/Akt pathway activation that would be of great interest 
given its importance in tumourogenesis [352]. The finding that the Akt inhibitor A-443654 
inhibits the activity of downstream substrates but hyperphosphorylates Akt [138] further 
supports the use of downstream phosphorylation events as biomarkers of pathway activity.  
In addition, identification of biomarkers for PI3K/Akt pathway activity may be useful for the 
targeted use of pathway inhibitors in the treatment of cancer [139].  
This part of the project aimed to investigate the phosphorylation events downstream 
of Akt using an optimised quantitative global phosphoproteomic approach (Fig. 5.1.). We 
used two complementary strategies, an in vivo cell line model and an in vitro assay that also 
enabled Akt activity quantification, to carry out this work. 
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7.3.1. Phosphoproteomics of the MCF10A myrAktER model 
7.3.1.1. The MCF10A myrAktER model 
In the first approach, we used a cell line model stably transfected with an inducible, 
constitutively active Akt construct [314] to investigate Akt activity in the human breast 
epithelial cell MCF10A (Fig. 5.2.). This model is useful for the investigation of Akt pathway 
dynamics as it enables controlled Akt activation. The myrAktER construct has previously 
been used successfully to investigate Akt activity, for example to identify Akt-regulated 
genes in NIH-3T3 cells using a cDNA array [353]. This study uncovered the possibility of a 
negative feedback action of Akt upon RTK expression [353] which was later demonstrated 
[137]. 
Initial work was performed to characterise the cell line and evaluate the activity of the 
MCF10A myrAktER construct. WB analysis of Akt phosphorylation demonstrated that the 
myrAktER construct was activated in response to 4-OHT treatment (Fig. 5.4.).  Aktide assay 
results, an MS-based method to quantify Akt activity, further demonstrated that the 
construct was enzymatically active following 4-OHT treatment (Fig. 5.5.). These results 
showed that greater control of myrAktER activity levels could be obtained by modulating 
treatment time compared to using different doses (Fig. 5.4. – 5.5.). Total myrAktER was also 
shown to increase over the time-course (Fig. 5.4. B), which may be due to myrAktER’s 
resistance to normal regulatory mechanisms, such as proteolytic degradation, when active 
or may indicate that the myrAktER construct is not detected well by the total Akt antibody 
when in its inactivated conformation. The data also showed that the ethanol vehicle had no 
effect upon the phosphorylation of the myrAktER construct (Fig. 5.4. B). Investigation of the 
phosphorylation of substrates downstream of Akt further demonstrated enzymatic activity 
of the myrAktER construct in response to 4-OHT treatment (Fig. 5.6.). 
MCF10A cells are anchorage-dependent and typically exhibit anoikis (detachment-
induced apoptosis) upon detachment from the extracellular matrix (or artificial substitute 
i.e. tissue culture plastic) [315, 316]. However, increased Akt activity has been shown to 
inhibit apoptosis and thus reduce the incidence of anoikis in these cells [315, 316]. We 
verified the biological activity of the myrAktER construct by assessing the incidence of 
anoikis in the MCF10A myrAktER cells. Results showed that myrAktER activation resulted in 
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protection from anoikis thereby demonstrating the functional output of the myrAktER 
construct (Fig. 5.7.). Taken together these results demonstrated the suitability of the 
myrAktER MCF10A cell line as a refined model for the investigation of Akt-specific 
phosphorylation events. 
7.3.1.2. Phosphoproteomic analysis of the MCF10A myrAktER model 
Having established the suitability of the model for the investigation of Akt activity we 
then proceeded to perform a phosphoproteomic experiment to evaluate the effects of 
myrAktER activity on the phosphoproteome in MCF10A cells.  
MCF10A myrAktER cells were treated with ethanol vehicle control or 4-OHT (to induce 
myrAktER activity) prior to shotgun phosphoproteomics. A high level of analytical replication 
(three independent biological replicates, each analyzed in technical triplicate) was 
undertaken to maximise the quality of results by enabling a greater degree of discrimination 
by statistical tests. The use of an efficient TiO2-affinity phospho-enrichment strategy that 
does not require sample fractionation [232] enables multiple rounds of mass-spectrometry 
analysis as run time per sample is not prohibitively long. In addition, the quantitative 
method PESCAL is not limited by sample number and can be used to quantify large numbers 
of samples per experiment.  
A total of 1961 phosphorylation events were identified across all the samples to the 
standard for confident identification (MASCOT Expectation value <0.05). This identification 
criteria is arbitrary but widely used in phosphoproteomics even though evidence suggests it 
may lead to a high number of false negatives [158]. Qualitative data results were pooled 
across all the samples and conditions to generate a common phosphopeptide database to 
use for quantification. This approach, which is possible due to the nature of PESCAL, 
maximises data mining as a phosphopeptides can be confidently quantified in a sample even 
if it was not identified in that same run. Heat-map representation of phosphopeptide 
quantification and PCA revealed that, as predicted, activation of the myrAktER construct 
affected the phosphoproteomic profile of MCF10A cells (Fig 5.8. – 5.9.). Akt-dependent 
phosphorylation events were arbitrarily defined as those which exhibited a statistically 
significant (p < 0.05 as assessed by the Student’s t-test) increase of a minimum two-fold in 
response to 4-OHT treatment compared to the control sample. Statistical significance was 
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employed in our selection criteria to minimise the number of false positive results. As 
previously mentioned, the use of PESCAL for quantitation permits the analysis of a high 
number of replicate samples to enable this additional level of data selection. A relatively low 
fold change increase was considered significant by our criteria to prevent exclusion of subtle 
phosphoproteomic changes that may be of importance.  
A total of 238 phosphorylation events were defined to be Akt-dependent, including 
some already known to be directly phosphorylated by Akt (e.g. PRAS40 [310] and others 
known to be phosphorylated downstream of Akt activity (e.g. S6 [87]) (Fig. 5.10. – 5.11. and 
Appendix 2). The discovery of phosphorylation events previously shown to be downstream 
of Akt validated our approach. The discovery of a number of previously un-described events 
illustrated that our knowledge of the PI3K/Akt pathway is not comprehensive and that, 
despite extensive research into this field, we have still not fully characterized this signalling 
pathway. However, the limitations of our model also need to be taken into consideration 
when interpreting results. Due to the nature of the experimental design we cannot rule out 
that some of the phosphoproteomic changes may be Akt-independent and induced by the 
4-OHT treatment itself. However, the normal mechanism of action of 4-OHT is the partial 
activation of the endogenous nuclear oestrogen receptor and associated effects on gene 
expression [354] rather than effects on growth factor pathway signalling.  Furthermore, 
MCF10A cells are oestrogen receptor negative cells [355], therefore endogenous effects of 
4-OHT are likely to be minimal. An alternative approach would have been to use 4-OHT 
MCF10A cells that lacked the myrAktER construct as the control, however false positives 
would also be possible with this approach as divergent populations of cells might have 
acquired mutations affecting the phosphoproteomic profile. 
Our dataset may have a number of potential applications. The profile of Akt-dependent 
phosphorylation events, or a subset of those identified, may be a useful phosphoproteomic 
signature for use as a biomarker of Akt activity. Further investigation using a different 
method to affect Akt activity and a different cell model system would be useful to evaluate 
the potential of this application. Phosphorylation events identified as Akt-dependent by our 
study may also have identified novel Akt signalling pathway components that require 
further investigation. However, the findings of this investigation should be validated in a 
different cell system before pursuing extensive follow-up studies. With this consideration in 
Chapter 7: Discussion 
201 
 
mind, we also investigated another strategy for the investigation of phosphorylation 
downstream of Akt (5.4.) and cross-referenced the data sets to identify a list of high-
confidence phosphorylation events dependent on Akt (Table 5.1.). 
7.3.2. In vitro Akt1 assay 
In order to provide further insights on the proteomics of PI3K signalling, we also 
investigated the use of in vitro kinase assays to identify phosphorylation events downstream 
of Akt. In vitro assays have been extensively used in the identification of kinase substrates. 
The classical approach in this strategy is to incubate the kinase of interest with candidate 
substrates, in the presence of radio-labelled ATP, and use the detection of radiation in 
proteins to confirm the relationship. However, this approach is time-consuming, hazardous 
and targeted [356] and therefore unsuitable for a global-scale study.  
A modification of this strategy to an untargeted, more global approach was most notably 
utilised by the Cohen group in a strategy they termed Kinase Substrate Tracking and 
Elucidation (KESTREL) [272, 356]. In this approach, kinases were incubated with total cell 
extracts in the presence of radio-labelled ATP prior to purification of substrates by an 
extensive series of purification steps followed by MS/MS identification [356]. The 
purification of substrates is time-consuming because several rounds of chromatography are 
needed to identify just one potential substrate and often difficult and low-abundance 
proteins are hard to identify by this method. Nevertheless KESTREL was successfully applied 
to identify substrates of many kinases e.g. SGK1, Akt, MAPK and CDK6 [356]. 
Other modifications of the classical approach have also been developed over the years. 
Peptide arrays, in which hundreds or thousands of peptides are spotted onto an array and 
incubated with the kinase under investigation prior to detection of interaction, have been 
widely used [351, 357, 358]. Protein arrays, which utilise the same strategy but use 
thousands of full-length proteins spotted onto chips, have also been developed [359-361]. 
The use of arrays is a considerable innovation in the identification of kinase substrates as 
they are large-scale, relatively fast and require low amounts of kinase material [360]. 
Protein arrays are a preferable option to peptide arrays as the use of full-length protein 
“bait” is likely to result in greater specificity of interactions and reduce the number of false 
positives [360]. Furthermore, bioinformatic modelling can be applied to array data to 
Chapter 7: Discussion 
202 
 
identify phosphorylation motifs and extrapolate to related datasets [351, 360, 362]. 
However, protein arrays are not without practical limitations; recombinant protein 
expression may be challenging and lack required post-translational modifications and 
protein immobilization may obscure phosphorylation sites, denature the protein and alter 
reaction kinetics [360, 363]. 
Other proteomic strategies for the identification of kinase substrates have also been 
developed and a recent innovation involves the use of analog-sensitive kinases. In this 
approach, kinases are genetically engineered so that the active site cannot utilise ATP but 
preferentially uses a labelled ATP analogue [363, 364]. These kinases are incubated with 
protein mixes and then the labelled, modified substrates are affinity purified and identified, 
using a variety of techniques [363]. Although this approach has yielded some success, the 
requirement for the design of an artificial kinase can be costly and time-consuming and can 
be a limiting step as it is estimated that 30% of kinases lose some catalytic activity, and 
resulting functionality, upon the introduction of the analog mutation [363, 365].  
Another untargeted strategy developed for the identification of kinase substrates is the 
use of active catalytic kinase domains as an affinity purification reagent [366]. Proteins 
purified from protein mixes or cell extracts are then identified using mass spectrometry 
[366]. However, a drawback of this approach is that the site of kinase activity on the protein 
cannot be identified as other kinases may have been active in the protein mix. 
Against this backdrop, we attempted to develop an in vitro method which, in 
combination with shotgun proteomics, would enable the un-targeted, global-scale 
identification of kinase substrates. Our strategy was inspired by the KESTREL approach 
[272]. We incubated active recombinant Akt with de-phosphorylated total cell extracts (Fig. 
5.3.) under conditions to enable optimum kinase activity and we then used global 
phosphoproteomics to identify and quantify phosphorylation events. This approach 
encompasses many desirable characteristics of an in vitro kinase assay as it involves a kinase 
reaction with endogenous, full-length proteins and the identification method enables the 
determination of phosphorylation sites [363]. In addition, we developed this in vitro assay 
further to enable the quantification of kinase activity for each phosphorylation site. 
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7.3.2.1. Development of an in vitro assay for the identification of phosphorylation 
events downstream of Akt1 
We applied our in vitro assay to identify phosphorylation events downstream of Akt. 
Total cell extracts from MCF10A cells were de-phosphorylated by exploitation of the 
endogenous phosphatase activity of the sample in the absence of phosphatase inhibitors. 
We used this de-phosphorylation technique as the simple addition of phosphatise inhibitors 
was sufficient to terminate the process thus enabling a simple workflow. Our total cell 
extract substrate was then incubated in vitro with different concentrations of recombinant, 
active Akt1 and a reaction buffer that included ATP.  The quantities of recombinant active 
Akt1 used vastly exceed the in vivo levels of Akt however a short reaction time and a 
relatively low reaction temperature were used as these conditions are likely to minimise 
non-specific kinase reactions [272, 356], a concern as kinases are able to phosphorylate 
proteins in vitro that are not true in vivo substrates [351, 363]. 
The in vitro reaction products were then subjected to our phosphoproteomic protocol. A 
total of 561 phosphopeptides were identified to the required level of confidence (MASCOT 
Expectancy < 0.05) and quantified in this experiment and heat-map representation of the 
peptide quantification and PCA revealed that, as expected, Akt1 activity in the in vitro assay 
conferred a distinct phosphoproteomic profile compared to the control sample (Fig. 5.12. – 
5.13.). 
An arbitrary criterium was defined for a phosphorylation event to be considered Akt1-
dependent: a minimum of a two-fold increase in phosphopeptide intensity in the reaction 
performed with 10 µg Akt1 compared to the control sample. Our control sample, which 
contained no exogenous Akt1 but was subjected to the reaction incubation, accounted for 
any non-Akt endogenous kinase activity in the sample although this should have been low 
due to the de-phosphorylation treatment. Thus, any increases upon incubation with Akt1 
should be specific for the in vitro activity of Akt and kinases activated downstream. 
However, it should be noted that this does not necessarily correlate directly with in vivo 
activity [351, 363]. It was interesting to observe that many phosphopeptide intensities 
decreased as a result of the reaction (Fig. 5.12.), which may indicate the activation of 
phosphatases downstream of Akt activity. The activation of phosphatases downstream of 
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kinase activity remains underexplored in global phosphoproteomics experiments and may 
be an interesting area to explore further for Akt. 
A total of 86 phosphopeptides were identified to be Akt1-dependent (according to our 
criteria) in this reaction, including some known Akt targets thus validating our strategy (Fig. 
5.14. – 5.15. and Appendix 3). However, we wished to further develop our in vitro assay 
strategy to improve the data yield of the approach by investigating the efficiency of the 
measured activities of Akt on their substrates and thus rank the identified substrates 
according to the likelihood that they are physiological  
7.3.2.2. Use of an in vitro assay to identify phosphorylation events downstream of Akt1 
and quantify reaction efficiency 
We reasoned that an improvement to our strategy would be to perform the in vitro 
kinase reaction with different concentrations of ATP in the presence or absence of Akt1. 
Thus, we would be able to identify Akt1-dependent phosphorylation events, as those that 
occurred only in the presence of Akt1, and to investigate the dynamics of the Akt 
phosphorylation reaction, through the use of various concentrations of ATP. Thus, our assay 
would enable the identification of the most efficient reactions that are more likely to occur 
in vivo. An additional improvement to our strategy was the use of exogenous lambda 
protein phosphatase for the de-phosphorylation reaction to improve efficiency as we 
remained vigilant against background kinase activity.  
De-phosphorylated proteins were incubated in an in vitro reaction with different 
concentrations of ATP in the presence or absence of recombinant, active Akt1. It should be 
noted that endogenous ATP was removed from the sample during the size exclusion 
chromatography that forms part of the de-phosphorylation protocol. The concentrations of 
ATP used in the reaction are well within those estimated to be present in the cytoplasm in 
vivo. Intracellular ATP concentrations are dynamically regulated by the cellular adenylate 
pool, which is in turn determined by the balance between energy expenditure and energy 
production [367, 368]. Therefore, intracellular ATP concentration varies widely between 
tissues and even between cells of the same tissue at different stages in differentiation [367]. 
Furthermore, ATP concentrations are also distinct in different intracellular compartments 
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[369]. However, various studies estimate intracellular ATP concentration to be between 1 – 
5 mM, depending on cell type and conditions [368, 370] and the intracellular ATP 
concentration of MCF10A cells has been reported to be 1.2 – 2.7 nmol per 10 million cells, 
which approximates a concentration of 1.2 – 2.7 mM [371]. As previously, a short reaction 
time and a relatively low reaction temperature were used to minimise non-specific kinase 
reactions [272, 356]. 
The reaction products were then subjected to trypsin digestion, phosphopeptide 
enrichment and shotgun phosphoproteomics for peptide identification and quantification. 
As for the previous strategy, samples were analyzed in technical replicate to maximise the 
identification of phosphopeptides and thus the size of the database used by PESCAL for 
quantification.  
A total of 856 phosphopeptides were identified to the required level of confidence 
(MASCOT Expectancy < 0.05) and quantified in the experiment. The heat-map 
representation of peptide quantification and PCA revealed that, as previously observed, the 
presence of active Akt1 in the reaction conferred a distinct phosphoproteomic response 
(Fig. 5.16. – 5.17.). Again, it was interesting to note that the intensity of many 
phosphorylation events decreased in the presence of Akt1. We defined a criterium for 
phosphorylation events to be considered Akt1-dependent: a minimum of a two-fold 
increase in intensity upon incubation with 100 µM ATP in the presence of Akt1 compared to 
in the absence of Akt1. 253 phosphopeptides were classified within this group, including 
some known Akt substrates, which validated this strategy (Fig. 5.18. – 5.19. and Appendix 
4). 
We next proceeded to use the same data to quantify the affinity of Akt1 for ATP for each 
phosphorylation site, thus providing an estimation of phosphorylation efficiency. We 
hypothesized that this data would be useful to discriminate between bona fide in vivo 
substrates, which would be likely to have a high affinity for Akt1, and non-specific reactions, 
which would be likely to have a lower affinity for Akt1. Akt1-ATP affinity (KATP) was 
calculated from the relationship between ATP concentration and phosphopeptide intensity 
using non-linear regression based on the principles of Michaelis-Menten reaction kinetics 
(Fig. 5.20.). It should be noted that phosphorylation reactions do not meet all the principles 
of Michaelis-Menten kinetics, for instance substrate availability was not unlimited, and that 
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a low number of data points were used per reaction so KATP is not equivalent to Km but is a 
useful indicator to rank sites phosphorylated by Akt according to reaction efficiency. 
The evaluation of Akt1-dependent phosphorylation events revealed that KATP inversely 
correlated with phosphorylation efficiency i.e. low KATP indicates efficient phosphorylation 
(Fig. 5.21.). These data support our hypothesis suggesting that KATP may be a useful 
parameter to identify efficient phosphorylation reactions, which may be more likely to occur 
in vivo. Motif analysis further supported this notion as phosphopeptides with low KATP were 
found to be enriched for the motifs known to be phosphorylated by Akt and its downstream 
substrate p70S6K (Fig. 5.22.). Therefore, we can conclude that KATP can be used to predict 
the likelihood of an in vitro substrate being a true in vivo substrate thus providing additional 
information regarding the confidence of results when conducting large-scale studies for the 
identification of kinase substrates. 
As concluded for the myrAktER MCF10A study, our dataset of candidate Akt substrates 
may have a number of potential applications. The profile of Akt-dependent phosphorylation 
events, or a subset of those identified, may be a useful phosphoproteomic signature for use 
as a biomarker of Akt activity. Phosphorylation events identified as Akt-dependent by our 
study may also have identified novel Akt signalling pathway components that require 
further investigation. More exhaustive data analysis and validation would be required to 
establish more clearly the relationship between in vitro KATP and in vivo substrate activity, 
however our strategy and this relationship may enable significant advances in large-scale 
investigations of kinase substrates. 
Finally, the datasets of phosphopeptides found to be Akt-dependent using the MCF10A 
myrAktER model and the in vitro kinase assay were cross-referenced to produce a short-list 
of high-confidence Akt-dependent phosphorylation events (Table 5.1.). Several of the 
phosphorylation sites were known to be targets of Akt activity but the majority have not 
previously been described. These phosphorylation sites are of great potential interest for 
follow-up investigation as they are likely to reveal novel PI3K/Akt pathway components and 
may unveil previously unknown functions of this pathway. 
 
 
Chapter 7: Discussion 
207 
 
7.3.3. Implications of study and future work 
As previously mentioned, following further validation studies the phosphorylation sites 
identified by our investigations may have useful applications as a biomarker 
phosphopeptide signature of Akt activity or may provide leads for future investigation into 
the activity of this pathway. Furthermore, we have established a method to quantify kinase 
activity in vivo that, as demonstrated by Chapter 6, has great potential to advance the 
investigation of signalling pathway activities. Specifically relating to Akt, it would be 
interesting to use this approach to compare the activities of fully phosphorylated Akt 
compared to partially phosphorylated Akt and it would also be interesting to compare the 
different isoforms of Akt to establish their distinct effects upon the phosphoproteome. 
Other large-scale proteomic studies have been used to identify hundreds of downstream 
substrates driven by the Akt pathway [372, 373]. We hope that the addition of our dataset 
may contribute to the detailed mapping of the PI3K/Akt signalling pathway. 
7.4. Global kinase activity profiling 
Quantification of kinase activity is of great interest as it provides information that may 
be useful for the investigation of signalling pathway aberrations, the identification of 
therapeutic targets and as a biomarker for diagnosis and therapeutic monitoring. 
In vitro kinase reaction assays have been available for decades, however such methods 
were previously dependent on cumbersome and hazardous detection methods [318, 319]. 
More recently, mass-spectrometry has been successfully applied to provide a detection 
method for such reactions.  
Mass-spectrometry based kinase assays, which may be multiplexed to measure multiple 
kinase activities, have been developed using short peptides as substrates [270, 271, 320, 
321]. Although these approaches have been successful, their application is limited as the use 
of synthetic purified peptide substrates requires specific knowledge of the kinase target site 
and substrate recognition by some kinases is known to be dependent on conformational 
interaction between proteins in addition to recognition of the short linear phosphorylation 
motif [322, 323, 351].  
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We followed on from the in vitro kinase assay designed in Chapter 5 to develop a novel 
methodology, which we termed global kinase activity profiling (GKAP), to enable the global-
scale quantification of endogenous kinase activity (Fig. 6.2.). 
7.4.1. Development of an assay for the global profiling of endogenous kinase activity 
(GKAP) 
Our GKAP approach exploits the fact that all protein kinases in a cell extract will be 
active upon incubation with ATP and co-factors [356]. We initially investigated whether 
endogenous protein kinase activities responded to an in vitro kinase assay in the same way 
as recombinant Akt1 (5.4.) and whether this activity was detectable using mass 
spectrometry.  
Total cell lysates of different total protein composition were taken from P31/Fuj cells 
and incubated with different concentrations of ATP in a kinase reaction prior to shotgun 
phosphoproteomics. In vitro reaction conditions (5 min incubation at 30oC) were previously 
established and were not modified for GKAP, however it is possible that there is scope for 
optimisation for this modified approach. Results demonstrated that, indeed endogenous 
kinases were active in an in vitro reaction mix and that the level of activity appeared to be 
proportional to ATP concentrations (Fig. 6.3. – 6.4.). The results also illustrated the signal-
amplification inherent to the method as kinase activity was detectable in very small sample 
volumes (5 µg). These preliminary results supported the notion that GKAP is suitable for the 
quantification of endogenous kinase activities. 
7.4.2. Application of GKAP to identify differential pathway activation in two cancer cell 
lines 
Having established that the in vitro activities of endogenous kinases could be detected 
by mass spectrometry, we next proceeded to investigate if the GKAP method could be used 
to detect the different levels of kinase activities in two AML cell lines shown to have 
differential activation of signalling pathways under basal conditions [179]. Analysis revealed 
that the two cell lines showed distinct responses to GKAP (Fig. 6.5.), suggesting differential 
pathway activation (Fig. 6.6.). Kinase activities were quantified as area under the kinetic 
curve (AUC) and data showed differential activation of some kinases between the two cell 
Chapter 7: Discussion 
209 
 
lines (Fig. 6.7.). These results demonstrated that GKAP is a suitable method to discriminate 
between signalling pathways with different levels of basal activation, thus validating our 
hypothesis. Furthermore, motif analysis demonstrated that a wide range of kinase activities 
were represented in the GKAP data (Fig. 6.8.), demonstrating that, in contrast to other in 
vitro kinase assays, it is a truly global method. 
7.4.3. Application of GKAP to detect growth factor induced pathway activation and 
drug mediated kinase inhibition  
We then applied GKAP to MCF10A cells to investigate if the method was suitable for the 
detection of growth factor stimulated pathway activation and small molecule kinase 
inhibition, which would demonstrate the suitability of its use for biomarker monitoring. 
Analysis revealed that, as expected, the various cell treatments resulted in distinct 
responses to GKAP (Fig. 6.9.). Detailed investigation showed that kinase activity induced by 
EGF treatment was detected by GKAP (Fig. 6.10.). Furthermore, inhibition of EGF-induced 
kinase activity by inhibitor treatment was also detected (Fig 6.10. B – D). Therefore, these 
data demonstrate that GKAP is suitable for the detection of signalling pathway activation 
and corresponding inhibition by pharmacological treatment, highlighting an important 
potential application in a biomedical context. Motif analysis was performed and, as before, 
showed that a wide-range of kinases including those known to be active in these cells was 
represented in the GKAP dataset (Fig. 6.11.) as it is a global, unbiased method. 
7.4.4. Implications of study and future work 
These results demonstrate that GKAP is a useful method for the detection of 
endogenous kinase activities. In contrast to alternative kinase assay approaches, GKAP uses 
endogenous, full-length proteins, thereby reducing false positives, and detects global kinase 
activities in an untargeted way. A further advantage of GKAP is that the reaction not only 
takes into account kinase activity but is also affected by substrate availability therefore it is 
a remarkably faithful representation of the in vivo scenario. 
The characteristics of GKAP suggest a wide range of applicability. It is a suitable 
approach for discovery investigations into understanding signal pathway transduction. In 
addition, the technique may have extremely useful applications in the pin-pointing of 
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signalling aberrations in disease. Furthermore, due to the low sample volume requirements 
the method may have an important role in the diagnosis and monitoring of disease in 
patients. 
7.5. Concluding remarks 
The PI3K/Akt pathway is a fundamental signal transduction pathway and as such is 
highly complex; despite extensive research in this field there remains a great deal to 
discover and understand. Mass-spectrometry based proteomics is an exciting field that is 
rapidly developing and is enabling research strategies that were previous not possible. As 
such, the use of proteomics to further our understanding of cell signalling is a necessary and 
exciting prospect. 
We applied emerging proteomic techniques to address two major under-explored areas 
of PI3K/Akt biochemistry: the role of interaction partners in the regulation of PI3K activity 
and characterization of global phosphorylation downstream of its key target Akt. 
Our results have revealed exciting new findings that contribute to our understanding of 
the mechanisms by which the PI3K/Akt pathway operates. Furthermore, they have provided 
leads for further innovative discoveries and have demonstrated the power of mass-
spectrometry based proteomics for the dissection of signalling pathways. 
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Appendix 1 
Summary of AP-MS screen results (Chapter 3). 
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IPI00108939 
Gapdhs 
glyceraldehyde-3-
phosphate 
dehydrogenase, 
spermatogenic 99 3 1.2 0.8 270 6 1.1 0.9 239 5 0.9 1.1 1.1 0.9 1.1 0.2 0.4 0.517 
IPI00110658 
Hba-a2;Hba-a1 
Putative 
uncharacterized 
protein 57 3 0.3 1.7 328 4 0.8 1.2 142 4 0.8 1.2 0.7 1.3 0.5 -1.0 1.0 0.160 
IPI00110753 
Tuba1a Tubulin 
alpha-1A chain 301 3 0.6 1.4 
103
9 3 0.2 1.8 417 3 0.8 1.2 0.5 1.5 0.3 -1.6 1.6 0.122 
IPI00110827 
Acta1 Actin, alpha 
skeletal muscle 532 3 0.9 1.1 218 3 0.9 1.1 493 3 1.0 1.0 0.9 1.1 0.9 -0.2 0.2 0.241 
IPI00110850 
Actb Actin, 
cytoplasmic 1 697 35 1.0 1.0 201 6 1.1 0.9 138 6 1.1 0.9 1.1 0.9 1.2 0.2 0.2 0.230 
IPI00112947 
Krt19 Keratin, type I 
cytoskeletal 19 66 4 1.3 0.7 871 13 1.1 0.9 239 3 1.0 1.0 1.1 0.9 1.3 0.3 0.5 0.347 
IPI00116277 
Cct4 T-complex 
protein 1 subunit 
delta 126 13 1.2 0.8 
144
7 7 1.3 0.7 265 17 0.1 1.9 0.9 1.1 0.8 -0.4 2.5 0.732 
IPI00116281 
Cct6a T-complex 
protein 1 subunit 
zeta 304 16 1.2 0.8 779 16 1.3 0.7 621 17 1.5 0.5 1.3 0.7 2.0 1.0 0.4 0.040 
IPI00116753 
Etfa Electron transfer 
flavoprotein subunit 
alpha, mitochondrial 54 9 1.0 1.0 
127
4 18 1.5 0.5 856 15 1.3 0.7 1.3 0.7 1.7 0.8 0.7 0.190 
IPI00117042 
Gfap Isoform 1 of 
Glial fibrillary acidic 
protein 107 3 0.9 1.1 558 4 0.8 1.2 274 5 0.5 1.5 0.7 1.3 0.6 -0.8 0.6 0.135 
IPI00117063 
Fus RNA-binding 
protein FUS 155 8 0.7 1.3 346 7 0.9 1.1 314 7 1.0 1.0 0.8 1.2 0.7 -0.5 0.4 0.160 
IPI00117159 
Pik3r2 
Phosphatidylinositol 
3-kinase regulatory 
subunit beta 
108
2 46 1.1 0.9 
133
6 25 0.9 1.1 383 9 1.0 1.0 1.0 1.0 1.0 0.0 0.2 0.951 
IPI00117348 
Tuba1b Tubulin 
alpha-1B chain 311 13 0.8 1.2 632 5 0.8 1.2 369 5 0.5 1.5 0.7 1.3 0.5 -0.9 0.6 0.091 
IPI00117352 
Tubb5 Tubulin beta-5 
chain 209 10 0.9 1.1 
103
8 15 1.2 0.8 116 18 1.3 0.7 1.1 0.9 1.3 0.3 0.5 0.365 
IPI00121440 
Etfb Electron transfer 
flavoprotein subunit 
beta 83 3 1.0 1.0 318 6 1.7 0.3 219 5 1.6 0.4 1.4 0.6 2.6 1.4 1.3 0.168 
IPI00121788 
Prdx1 Peroxiredoxin-
1 99 10 0.7 1.3 42 3 0.9 1.1 73 3 0.9 1.1 0.8 1.2 0.7 -0.4 0.5 0.250 
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IPI00123494 
Psmd2 26S 
proteasome non-
ATPase regulatory 
subunit 2 46 5 0.7 1.3 51 4 1.4 0.6 72 5 1.1 0.9 1.0 1.0 1.1 0.1 1.0 0.822 
IPI00123501 
Hnrnpul1 Isoform 1 
of Heterogeneous 
nuclear 
ribonucleoprotein U-
like protein 1 437 39 0.9 1.1 808 15 0.7 1.3 167 19 0.8 1.2 0.8 1.2 0.7 -0.5 0.2 0.041 
IPI00124499 
Krt79 Keratin, type II 
cytoskeletal 79 122 5 1.1 0.9 
122
3 6 0.8 1.2 190 5 1.3 0.7 1.0 1.0 1.1 0.1 0.7 0.753 
IPI00129240 Vtn Vitronectin 107 3 1.3 0.7 58 3 0.4 1.6 92 4 0.5 1.5 0.7 1.3 0.6 -0.8 1.6 0.447 
IPI00129526 
Hsp90b1 
Endoplasmin 404 34 0.8 1.2 296 3 1.0 1.0 125 3 0.9 1.1 0.9 1.1 0.8 -0.3 0.3 0.274 
IPI00130381 
Bat3 Large proline-
rich protein BAT3 187 14 1.1 0.9 661 13 0.5 1.5 326 14 0.5 1.5 0.7 1.3 0.5 -1.0 1.1 0.254 
IPI00130992 
Capns1 Calpain small 
subunit 1 121 8 1.6 0.4 182 7 1.4 0.6 132 6 1.4 0.6 1.5 0.5 2.7 1.4 0.3 0.010 
IPI00131091 
C4b Complement C4-
B 61 4 1.0 1.0 179 4 1.1 0.9 66 4 1.2 0.8 1.1 0.9 1.3 0.3 0.2 0.120 
IPI00131695 Alb Serum albumin 83 3 1.1 0.9 
116
8 6 0.9 1.1 136 5 0.8 1.2 0.9 1.1 0.8 -0.3 0.4 0.363 
IPI00133208 
Hspa1l;ENSMUSG000
00073415;Hspa1a 
Heat shock 70 kDa 
protein 1L 101 3 1.2 0.8 671 3 0.5 1.5 95 3 0.6 1.4 0.8 1.2 0.6 -0.7 1.1 0.364 
IPI00134599 
Rps3 40S ribosomal 
protein S3 116 9 0.9 1.1 143 5 1.2 0.8 140 6 1.2 0.8 1.1 0.9 1.3 0.3 0.5 0.378 
IPI00136110 
Pik3cb 
Phosphatidylinositol-
4,5-bisphosphate 3-
kinase catalytic 
subunit beta isoform 107 7 0.7 1.3 415 13 1.0 1.0 262 11 0.8 1.2 0.8 1.2 0.7 -0.5 0.5 0.239 
IPI00139301 
Krt5 Keratin, type II 
cytoskeletal 5 160 9 1.1 0.9 121 14 0.9 1.1 327 11 0.8 1.2 0.9 1.1 0.9 -0.2 0.5 0.561 
IPI00154054 
Acat1 Acetyl-CoA 
acetyltransferase, 
mitochondrial 76 6 1.0 1.0 76 3 1.3 0.7 83 4 1.2 0.8 1.2 0.8 1.4 0.4 0.3 0.143 
IPI00169463 
Tubb2c Tubulin beta-
2C chain 139 3 0.9 1.1 674 11 1.4 0.6 82 3 1.3 0.7 1.2 0.8 1.5 0.6 0.7 0.271 
IPI00172221 
Dnm1l Isoform 2 of 
Dynamin-1-like 
protein 71 3 1.2 0.8 70 15 0.8 1.2 41 3 0.9 1.1 1.0 1.0 0.9 -0.1 0.6 0.797 
IPI00221528 
Actbl2 Beta-actin-like 
protein 2 216 3 1.3 0.7 45 4 0.7 1.3 112 4 0.7 1.3 0.9 1.1 0.8 -0.3 1.1 0.707 
IPI00222228 
4732456N10Rik 
Putative 
uncharacterized 
protein 91 3 1.1 0.9 854 6 1.0 1.0 142 4 0.8 1.2 1.0 1.0 1.0 -0.1 0.5 0.869 
IPI00225378 
Krt15 Keratin 15, 
isoform CRA_a 40 3 1.0 1.0 940 13 0.8 1.2 161 3 0.9 1.1 0.9 1.1 0.8 -0.3 0.3 0.252 
IPI00226073 
Hnrnpf Isoform 1 of 
Heterogeneous 
nuclear 
ribonucleoprotein F 171 3 1.0 1.0 88 4 0.8 1.2 157 4 0.8 1.2 0.9 1.1 0.7 -0.4 0.4 0.174 
IPI00227140 
Krt14 Keratin, type I 
cytoskeletal 14 64 3 0.9 1.1 
111
5 8 0.6 1.4 223 7 1.0 1.0 0.8 1.2 0.7 -0.5 0.6 0.277 
IPI00227299 Vim Vimentin 107 11 0.5 1.5 340 4 0.0 2.0 218 4 0.3 1.7 0.3 1.7 0.2 -2.6 2 0.031 
IPI00229080 
Hsp90ab1 
MCG18238 570 39 0.9 1.1 920 15 0.8 1.2 132 19 0.8 1.2 0.8 1.2 0.7 -0.5 0.1 0.013 
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IPI00230365 
Krt17 Keratin, type I 
cytoskeletal 17 56 6 1.2 0.8 
137
5 8 0.9 1.1 408 9 1.0 1.0 1.0 1.0 1.0 0.0 0.5 0.950 
IPI00263878 
Pik3r1 
Phosphatidylinositol 
3-kinase regulatory 
subunit alpha 520 37 1.0 1.0 
142
7 31 1.0 1.0 850 19 1.0 1.0 1.0 1.0 1.0 0.0 0.1 0.663 
IPI00273646 
100040053 
Glyceraldehyde-3-
phosphate 
dehydrogenase 530 35 1.1 0.9 
150
6 15 1.5 0.5 294 18 1.5 0.5 1.3 0.7 2.0 1.0 0.7 0.127 
IPI00307837 
Eef1a1 Elongation 
factor 1-alpha 1 175 13 0.9 1.1 243 7 1.1 0.9 49 5 1.0 1.0 1.0 1.0 1.0 0.0 0.3 0.821 
IPI00309224 
Pik3ca 
Phosphatidylinositol-
4,5-bisphosphate 3-
kinase catalytic 
subunit alpha 
isoform 100 8 0.7 1.3 831 23 1.0 1.0 319 11 1.0 1.0 0.9 1.1 0.8 -0.3 0.6 0.445 
IPI00311175 
Tuba8 Tubulin alpha-
8 chain 135 3 0.8 0.9 649 13 0.7 1.3 226 3 1.0 1.0 0.8 1.1 0.8 -0.4 0.6 0.371 
IPI00314950 
Rplp0 60S acidic 
ribosomal protein P0 205 8 1.1 0.9 68 7 1.0 1.0 58 4 0.8 1.2 1.0 1.0 1.0 0.0 0.4 0.865 
IPI00317590 
Rps18 40S ribosomal 
protein S18 178 8 1.0 1.0 68 3 1.0 1.0 114 5 0.8 1.0 0.9 1.0 0.9 -0.1 0.2 0.500 
IPI00317740 
Gnb2l1 Guanine 
nucleotide-binding 
protein subunit beta-
2-like 1 64 7 1.0 1.0 155 4 1.5 0.5 52 3 0.9 1.1 1.1 0.9 1.3 0.4 0.9 0.557 
IPI00319992 
Hspa5 78 kDa 
glucose-regulated 
protein 825 39 1.0 1.0 
260
3 39 2.0 2.0 
119
9 41 2.2 1.8 1.8 1.6 1.1 0.2 0.2 0.385 
IPI00319994 
Ldha L-lactate 
dehydrogenase A 
chain 302 17 1.1 0.9 119 3 0.9 1.1 62 5 0.9 1.1 1.0 1.0 0.9 -0.1 0.4 0.567 
IPI00322867 Itih1 Itih1 protein 58 5 1.1 0.9 65 3 0.7 1.3 47 5 0.9 1.1 0.9 1.1 0.8 -0.3 0.7 0.571 
IPI00323357 
Hspa8 Heat shock 
cognate 71 kDa 
protein 171 34 0.9 1.1 
267
3 35 1.0 1.0 
131
6 36 1.0 1.0 1.0 1.0 0.9 -0.1 0.1 0.177 
IPI00330480 - 35 kDa protein 51 3 1.1 0.9 
124
0 30 0.8 1.2 240 12 1.1 0.9 1.0 1.0 1.0 0.1 0.5 0.853 
IPI00330804 
Hsp90aa1 Heat shock 
protein HSP 90-alpha 514 13 0.8 1.2 571 24 1.3 0.7 40 4 1.1 0.9 1.1 0.9 1.2 0.2 0.6 0.592 
IPI00331174 
Cct7 T-complex 
protein 1 subunit eta 52 7 0.8 1.2 52 5 1.0 1.0 102 4 0.9 1.1 0.9 1.1 0.8 -0.3 0.2 0.097 
IPI00346834 
Krt76 Keratin, type II 
cytoskeletal 2 oral 43 3 1.0 1.0 991 34 1.0 1.0 57 4 1.0 1.0 1.0 1.0 1.0 0.0 0.1 0.818 
IPI00348328 Krt78 keratin Kb40 57 4 0.8 1.2 
155
1 44 1.1 0.9 255 12 1.1 0.9 1.0 1.0 1.0 0.0 0.5 0.943 
IPI00352163 
Fn1 Putative 
uncharacterized 
protein 52 14 0.4 1.6 329 15 0.6 1.4 192 14 0.4 1.6 0.5 1.5 0.3 -1.8 0 0.007 
IPI00406377 
Krt7 Keratin, type II 
cytoskeletal 7 44 3 0.6 1.4 787 33 0.7 1.3 111 9 1.1 0.9 0.8 1.2 0.6 -0.6 0.8 0.277 
IPI00420312 
Krt4 Keratin, type II 
cytoskeletal 4 81 3 0.9 1.1 607 34 0.9 1.1 42 4 0.9 1.1 0.9 1.1 0.8 -0.4 0.0 0.001 
IPI00420363 
Ddx5 Probable ATP-
dependent RNA 
helicase DDX5 71 8 1.0 1.0 128 6 1.0 1.0 57 6 0.8 1.2 0.9 1.1 0.9 -0.2 0.3 0.485 
IPI00420970 
Krt74 Keratin, type II 
cytoskeletal 74 95 3 0.9 1.1 
120
4 23 1.0 1.0 241 3 1.1 0.9 1.0 1.0 1.0 0.0 0.2 0.904 
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IPI00459493 
Tcp1 Isoform 1 of T-
complex protein 1 
subunit alpha B 229 13 1.1 0.9 
141
9 30 1.5 0.5 326 13 1.5 0.5 1.3 0.7 2.0 1.0 0.6 0.100 
IPI00462140 
Krt77 Keratin, type II 
cytoskeletal 1b 122 3 1.2 0.8 
120
8 27 1.1 0.9 446 5 1.1 0.9 1.1 0.9 1.3 0.4 0.2 0.060 
IPI00463573 
Eif3l Eukaryotic 
translation initiation 
factor 3 subunit L 61 6 0.9 1.1 116 4 1.1 0.9 211 4 1.0 1.0 1.0 1.0 1.0 0.0 0.3 0.849 
IPI00468696 
Krt42 Keratin, type I 
cytoskeletal 42 63 4 0.7 1.3 
103
6 45 1.0 1.0 175 5 1.1 0.9 0.9 1.1 0.9 -0.2 0.6 0.641 
IPI00468956 
Krt71 Keratin, type II 
cytoskeletal 71 114 3 1.3 0.7 
120
8 43 0.9 1.1 215 3 0.8 1.2 1.0 1.0 1.0 0.0 0.7 0.976 
IPI00471341 
Ubl4 Ubiquitin-like 
protein 4A 47 3 1.2 0.8 125 4 1.0 1.0 53 3 0.9 1.1 1.0 1.0 1.0 0.0 0.4 0.919 
IPI00473667 
Tuba3b;Tuba3a 
Putative 
uncharacterized 
protein 100 4 1.1 0.9 324 11 1.5 0.5 57 3 1.3 0.7 1.3 0.7 1.8 0.8 0.6 0.120 
IPI00551206 
C4a sex-limited 
protein 72 4 1.1 0.9 179 7 0.5 1.5 82 4 0.7 1.3 0.8 1.2 0.6 -0.7 1.0 0.358 
IPI00555131 
Hbb-
y;LOC100044141 
Hemoglobin subunit 
epsilon-Y2 43 3 0.9 1.1 638 33 1.3 0.7 47 3 1.2 0.8 1.1 0.9 1.3 0.4 0.6 0.316 
IPI00622240 
Krt2 Keratin, type II 
cytoskeletal 2 
epidermal 87 3 1.0 1.0 
110
4 17 0.9 1.1 94 10 0.9 1.1 0.9 1.1 0.9 -0.2 0.2 0.279 
IPI00625729 
Krt1 Keratin, type II 
cytoskeletal 1 121 7 1.2 0.8 
234
9 28 0.9 1.1 425 10 0.9 1.1 1.0 1.0 1.0 0.0 0.5 0.900 
IPI00626132 
Hsd17b10 
Hydroxysteroid (17-
beta) dehydrogenase 
10 44 7 1.1 0.9 40 5 1.1 0.9 51 4 1.0 1.0 1.1 0.9 1.2 0.2 0.2 0.169 
IPI00751677 
640374 similar to 
Glyceraldehyde-3-
phosphate 
dehydrogenase 318 6 1.3 0.7 
110
1 43 0.7 1.3 78 3 0.6 1.4 0.9 1.1 0.8 -0.3 1.1 0.635 
IPI00755181 
Krt10 keratin 
complex 1, acidic, 
gene 10 188 9 1.0 1.0 
293
5 42 1.1 0.9 442 10 1.2 0.8 1.1 0.9 1.2 0.3 0.3 0.221 
IPI00830803 
Fbln2 fibulin 2 
isoform b 155 7 0.7 1.3 233 6 0.8 1.5 132 6 0.8 1.5 0.8 1.4 0.5 -0.9 0.0 0.005 
IPI00875096 Krt2 71 kDa protein 79 6 1.0 1.0 
110
4 36 1.1 0.9 350 16 1.1 0.9 1.1 0.9 1.2 0.3 0.2 0.099 
IPI00880839 
Hspa9 heat shock 
protein 9 55 10 0.8 1.2 
331
2 36 1.3 0.7 668 34 1.3 0.7 1.1 0.9 1.3 0.4 0.8 0.463 
IPI00896727 
Cand1 Cullin-
associated NEDD8-
dissociated protein 1 76 7 1.0 1.0 144 6 1.1 0.9 87 6 1.2 0.8 1.1 0.9 1.3 0.4 0.4 0.217 
IPI00911185 
Ighg;Igh-1a;Igh-1b 
Igh protein 40 3 1.2 0.8 50 3 0.8 1.2 47 4 1.0 1.0 1.0 1.0 1.0 -0.1 0.6 0.866 
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Appendix 2 
Summary of phosphorylation events found to be dependent on Akt by phosphoproteomic 
analysis of MCF10A myrAktER cells (Chapter 5.3.). 
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HS90A_HUMAN HSP90AA1 p-S264 (z= 3) 24.8 43.1 59.4 1.7 2.4 0.081 <0.001   
MACF1_HUMAN MACF1 p-T213 (z= 2) 15.0 87.3 61.3 5.8 4.1 0.000 <0.001   
ZO3_HUMAN TJP3 p-S113 (z= 4) 28.9 79.9 61.9 2.8 2.1 0.002 <0.001   
IF4G1_HUMAN EIF4G1 p-S1233 (z= 2) 16.1 73.1 69.5 4.5 4.3 0.000 <0.001   
CLMN_HUMAN CLMN p-S302 (z= 3) 22.7 51.3 61.2 2.3 2.7 0.050 <0.001   
E41L1_HUMAN EPB41L1 p-S579 (z= 3) 29.3 69.5 55.7 2.4 1.9 0.001 <0.001   
PALLD_HUMAN PALLD p-S894 (z= 2) 24.9 80.8 66.9 3.2 2.7 0.000 <0.001 * 
DC1L1_HUMAN DYNC1LI1 p-S517 (z= 2) 24.4 64.4 45.6 2.6 1.9 0.000 <0.001   
HDGF_HUMAN HDGF p-S166 (z= 2) 26.4 79.2 77.7 3.0 2.9 0.000 <0.001   
FARP1_HUMAN FARP1 p-T25 (z= 2) 8.5 47.5 47.4 5.6 5.6 0.004 <0.001   
RS6_HUMAN RPS6 p-S237 p-S241 (z= 2) 18.9 73.9 57.1 3.9 3.0 0.000 <0.001 * 
ZBT7A_HUMAN ZBTB7A p-S550 (z= 3) 25.1 64.9 46.3 2.6 1.8 0.001 <0.001   
LMO7_HUMAN LMO7 p-S1511 (z= 3) 30.8 65.9 64.1 2.1 2.1 0.010 <0.001   
CALX_HUMAN CANX p-S584 (z= 3) 31.2 75.4 61.4 2.4 2.0 0.000 <0.001   
USO1_HUMAN USO1 p-S943 (z= 4) 28.7 63.1 68.2 2.2 2.4 0.002 <0.001   
RTKN_HUMAN RTKN p-S521 (z= 3) 25.6 65.0 63.7 2.5 2.5 0.002 <0.001   
FAS_HUMAN FASN p-T2205 (z= 2) 11.6 38.2 54.8 3.3 4.7 0.000 <0.001   
RS16_HUMAN RS16 p-Y116 (z= 2) 28.8 74.4 70.7 2.6 2.5 0.000 <0.001   
TR150_HUMAN THRAP3 p-S683 (z= 2) 28.8 74.4 70.7 2.6 2.5 0.000 <0.001   
SRC8_HUMAN CTTN p-S419 (z= 2) 23.4 40.3 57.7 1.7 2.5 0.016 <0.001   
LAD1_HUMAN LAD1 p-S39 (z= 2) 33.3 72.9 71.5 2.2 2.1 0.000 <0.001   
CC64B_HUMAN CCDC64B p-S268 (z= 2) 25.7 52.4 63.8 2.0 2.5 0.000 <0.001   
CI142_HUMAN C9orf142 p-S149 (z= 2) 16.2 76.9 51.2 4.8 3.2 0.000 <0.001   
T132A_HUMAN TMEM132A p-S530 (z= 3) 24.8 81.0 58.8 3.3 2.4 0.000 <0.001   
AHNK_HUMAN AHNAK p-S136 (z= 3) 20.9 74.8 61.8 3.6 3.0 0.000 <0.001   
FAK1_HUMAN PTK2 p-S911 (z= 2) 18.1 69.3 57.8 3.8 3.2 0.000 <0.001   
SL9A1_HUMAN SLC9A1 p-S704 (z= 2) 25.1 51.5 69.5 2.1 2.8 0.008 <0.001   
TRAD1_HUMAN TRAFD1 p-S416 (z= 3) 30.1 62.4 61.8 2.1 2.1 0.011 <0.001   
TPIS_HUMAN TPI1 p-S22 (z= 3) 25.8 68.9 52.5 2.7 2.0 0.001 <0.001   
HSPB1_HUMAN HSPB1 p-S83 (z= 2) 16.9 88.3 58.5 5.2 3.5 0.000 <0.001   
HTSF1_HUMAN HTATSF1 p-S580 (z= 3) 19.0 48.7 50.2 2.6 2.6 0.009 <0.001   
B2L14_HUMAN B2L14 p-S153 (z= 2) 5.4 41.6 48.8 7.8 9.1 0.000 <0.001   
FA63A_HUMAN FAM63A p-S442 (z= 2) 5.4 41.6 48.8 7.7 9.1 0.000 <0.001   
TMM40_HUMAN TMEM40 p-S142 (z= 3) 24.9 72.2 70.4 2.9 2.8 0.000 <0.001   
CHSP1_HUMAN CARHSP1 p-S42 (z= 2) 32.8 67.3 76.5 2.1 2.3 0.002 <0.001 * 
AKTS1_HUMAN AKT1S1 p-T247 (z= 2) 31.3 73.0 73.9 2.3 2.4 0.000 <0.001 * 
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LIMA1_HUMAN LIMA1 p-S491 (z= 3) 29.6 69.5 61.1 2.3 2.1 0.001 <0.001   
ABCF1_HUMAN ABCF1 p-S110 (z= 3) 37.5 76.4 71.5 2.0 1.9 0.000 <0.001   
PGK1_HUMAN PGK1 p-S204 (z= 3) 27.8 57.2 51.6 2.1 1.9 0.004 0.001   
KAPCA_HUMAN PRKACA p-T203 (z= 3) 15.4 70.7 63.3 4.6 4.1 0.001 0.001   
HS90A_HUMAN HSP90AA1 p-S253 (z= 4) 16.3 47.7 69.4 2.9 4.3 0.001 0.001   
MK01_HUMAN MAPK1 p-Y188 (z= 3) 17.7 59.6 45.2 3.4 2.6 0.000 0.001   
MK01_HUMAN MAPK1 p-T186 (z= 3) 17.6 59.5 44.9 3.4 2.5 0.000 0.001   
MAP4_HUMAN MAP4 p-S637 (z= 3) 17.1 42.0 53.3 2.5 3.1 0.001 0.001   
NDRG1_HUMAN NDRG1 p-S331 (z= 2) 16.0 54.8 59.0 3.4 3.7 0.000 0.001   
RD23B_HUMAN RAD23B p-S161 (z= 3) 9.4 61.5 34.5 6.5 3.7 0.000 0.001   
SRRM2_HUMAN SRRM2 p-S324 (z= 4) 21.6 59.6 68.5 2.8 3.2 0.000 0.001   
NP1L4_HUMAN NAP1L4 p-S126 (z= 3) 19.4 39.0 47.7 2.0 2.5 0.000 0.001   
F1142_HUMAN FAM114A2 p-S147 (z= 3) 13.2 31.1 58.0 2.4 4.4 0.049 0.001   
AHNK_HUMAN AHNAK p-S512 (z= 2) + oxidation 18.4 38.3 53.7 2.1 2.9 0.020 0.001   
AHNK_HUMAN AHNAK p-S512 (z= 2) 29.2 82.1 59.4 2.8 2.0 0.000 0.001   
ICAL_HUMAN CAST p-S365 (z= 3) 22.1 69.4 63.7 3.1 2.9 0.000 0.001   
LAD1_HUMAN LAD1 p-S357 (z= 3) 30.7 80.6 56.4 2.6 1.8 0.000 0.001   
TFP11_HUMAN TFIP11 p-S99 (z= 3) 19.9 56.0 42.0 2.8 2.1 0.003 0.001   
NUFP2_HUMAN NUFIP2 p-S630 (z= 3) 23.4 45.3 56.6 1.9 2.4 0.001 0.001   
NIBL1_HUMAN FAM129B p-S634 (z= 3) 2.7 48.7 35.4 18.0 13.1 0.000 0.002   
RFIP1_HUMAN RAB11FIP1 p-S436 (z= 2) 6.3 67.9 34.2 10.8 5.5 0.000 0.002   
ZRAB2_HUMAN ZRANB2 p-S121 (z= 3) 29.9 54.7 61.0 1.8 2.0 0.000 0.002   
HNRPC_HUMAN HNRNPC p-S261 (z= 3) 26.2 56.5 48.8 2.2 1.9 0.002 0.002   
KPCD_HUMAN PRKCD p-S665 (z= 2) + oxidation 30.7 23.5 63.2 0.8 2.1 0.669 0.002   
HS90A_HUMAN HSP90AA1 p-S253 (z= 3) 21.1 45.2 72.0 2.1 3.4 0.035 0.002   
ZO2_HUMAN TJP2 p-S131 (z= 3) 32.3 71.9 58.8 2.2 1.8 0.004 0.002   
NUBPL_HUMAN NUBPL p-S75 (z= 2) 22.0 77.2 50.1 3.5 2.3 0.000 0.002   
1433E_HUMAN YWHAE p-S211 (z= 2) 24.1 39.5 50.3 1.6 2.1 0.055 0.002   
NIBL1_HUMAN FAM129B p-S634 (z= 3) 12.5 33.6 45.4 2.7 3.6 0.001 0.002   
DC1L1_HUMAN DYNC1LI1 p-S208 (z= 3) 27.0 59.5 49.2 2.2 1.8 0.010 0.002   
MAP4_HUMAN MAP4 p-T522 (z= 3) 20.6 49.4 62.7 2.4 3.0 0.000 0.003   
MAP4_HUMAN MAP4 p-S281 (z= 3) + oxidation 18.4 43.2 60.6 2.4 3.3 0.024 0.003   
SEPT2_HUMAN SEPT2 p-S219 (z= 4) 25.7 55.6 58.7 2.2 2.3 0.021 0.003   
AK1C1_HUMAN AKR1C1 p-S233 (z= 3) 10.2 43.9 53.6 4.3 5.3 0.000 0.003   
RICS_HUMAN RICS p-S872 (z= 2) 34.6 79.7 67.2 2.3 1.9 0.001 0.003   
AHNK_HUMAN AHNAK p-S3427 (z= 3) 4.2 62.0 34.2 14.7 8.1 0.000 0.003   
SRC8_HUMAN CTTN p-T402 p-S406 (z= 3) 37.2 74.7 69.9 2.0 1.9 0.000 0.003   
PNCB_HUMAN NAPRT1 p-S538 (z= 2) 15.3 80.7 57.8 5.3 3.8 0.000 0.003   
DPOD3_HUMAN POLD3 p-S308 (z= 3) 20.6 63.2 48.4 3.1 2.3 0.001 0.004   
PKP2_HUMAN PKP2 p-S330 (z= 3) 19.8 57.6 57.5 2.9 2.9 0.001 0.004   
MAVS_HUMAN MAVS p-S223 (z= 2) 40.1 85.1 72.8 2.1 1.8 0.001 0.004   
HNRPC_HUMAN HNRNPC p-S261 (z= 4) + oxidation 15.3 17.7 42.5 1.2 2.8 0.689 0.004   
SYNE2_HUMAN SYNE2 p-S6362 (z= 3) 21.1 54.6 38.2 2.6 1.8 0.004 0.004   
TACC1_HUMAN TACC1 p-S277 (z= 3) 15.6 41.0 50.7 2.6 3.2 0.002 0.004   
RD23B_HUMAN RAD23B p-S161 (z= 3) 18.8 42.6 48.1 2.3 2.6 0.002 0.004   
CALX_HUMAN CANX p-S565 (z= 4) 15.5 53.9 41.4 3.5 2.7 0.001 0.004   
TPIS_HUMAN TPI1 p-S22 (z= 2) 27.4 66.5 49.5 2.4 1.8 0.005 0.004   
EF1D_HUMAN EEF1D p-S163 (z= 3) 23.9 50.1 38.1 2.1 1.6 0.002 0.004   
PLAK_HUMAN JUP p-S666 (z= 2) 13.0 47.0 34.1 3.6 2.6 0.009 0.005   
HNRPK_HUMAN HNRNPK p-T119 (z= 4) 18.7 33.1 51.1 1.8 2.7 0.137 0.005   
STK3_HUMAN STK3 p-S317 (z= 3) + oxidation 6.2 19.8 35.7 3.2 5.8 0.014 0.005   
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RS3_HUMAN RPS3 p-T222 (z= 2) 16.9 36.2 46.4 2.1 2.7 0.014 0.005   
PLEC1_HUMAN PLEC1 p-S4407 (z= 3) 15.5 50.4 50.9 3.2 3.3 0.000 0.005   
K1522_HUMAN KIAA1522 p-S930 (z= 3) 13.0 26.2 42.0 2.0 3.2 0.003 0.005   
CALX_HUMAN CANX p-S555 (z= 3) 36.9 75.6 65.4 2.1 1.8 0.000 0.005   
IF4B_HUMAN EIF4B p-S94 (z= 3) 20.5 36.7 56.0 1.8 2.7 0.255 0.005 * 
DAP1_HUMAN DAP p-S52 (z= 3) 12.8 29.0 45.4 2.3 3.5 0.011 0.005   
PDCD4_HUMAN PDCD4 p-S77 (z= 2) 31.3 63.0 53.7 2.0 1.7 0.003 0.005 * 
NPM_HUMAN NPM1 p-S71 (z= 3) 1.3 24.1 24.5 18.6 18.9 0.066 0.005   
CCD86_HUMAN CCDC86 p-S19 (z= 2) 15.9 45.7 51.8 2.9 3.3 0.028 0.006   
TB182_HUMAN TNKS1BP1 p-S430 (z= 3) 26.1 54.4 56.2 2.1 2.2 0.000 0.006   
SRRM1_HUMAN SRRM1 p-S606 p-S608 (z= 2) 25.3 83.9 52.1 3.3 2.1 0.000 0.006   
AKAP8_HUMAN AKAP8 p-S340 (z= 3) 28.1 73.8 68.1 2.6 2.4 0.000 0.006   
DNJC5_HUMAN DNAJC5 p-S11 (z= 3) 21.0 34.3 46.2 1.6 2.2 0.127 0.006   
STAT3_HUMAN STAT3 p-S728 (z= 3) 22.0 49.8 38.9 2.3 1.8 0.013 0.006   
H1BP3_HUMAN HS1BP3 p-S195 (z= 2) 19.2 50.2 36.3 2.6 1.9 0.014 0.007   
UBP7_HUMAN USP7 p-S19 (z= 3) + oxidation 23.7 34.0 53.7 1.4 2.3 0.403 0.007   
STRN3_HUMAN STRN3 p-S230 (z= 2) 32.1 55.6 64.7 1.7 2.0 0.006 0.007   
ABCF1_HUMAN ABCF1 p-T109 (z= 3) 26.1 58.7 45.4 2.2 1.7 0.006 0.007   
HNRPK_HUMAN HNRNPK p-T119 (z= 5) 17.5 29.1 47.9 1.7 2.7 0.216 0.008   
BA2L1_HUMAN BAT2L1 p-S389 (z= 2) 26.2 56.9 45.5 2.2 1.7 0.041 0.008   
NUMB_HUMAN NUMB p-S426 (z= 3) 17.7 42.4 54.2 2.4 3.1 0.038 0.008   
SYAP1_HUMAN SYAP1 p-S270 (z= 3) 27.7 46.8 58.2 1.7 2.1 0.059 0.009   
COPE_HUMAN COPE p-S100 (z= 2) 17.8 36.1 49.2 2.0 2.8 0.001 0.009   
1433Z_HUMAN YWHAZ p-S208 (z= 2) 16.5 29.7 40.4 1.8 2.5 0.172 0.009   
PGRC2_HUMAN PGRMC2 p-T212 (z= 4) 6.7 39.4 37.5 5.8 5.6 0.027 0.009   
SCRIB_HUMAN SCRIB p-S836 (z= 3) + oxidation 21.3 17.9 47.1 0.8 2.2 0.422 0.009   
PPIL4_HUMAN PPIL4 p-S179 (z= 4) 20.2 34.2 46.1 1.7 2.3 0.148 0.009   
RBM14_HUMAN RBM14 p-T207 (z= 2) 31.2 75.3 48.2 2.4 1.5 0.001 0.009   
PKHA6_HUMAN PLEKHA6 p-T780 (z= 3) 25.4 51.2 53.1 2.0 2.1 0.002 0.009   
HSF1_HUMAN HSF1 p-S321 (z= 3) 22.3 43.5 52.6 1.9 2.4 0.126 0.010   
HNRPK_HUMAN HNRNPK p-T119 (z= 3) 17.9 30.1 46.0 1.7 2.6 0.166 0.010   
NRDC_HUMAN NRD1 p-S95 (z= 3) 15.0 58.2 52.4 3.9 3.5 0.001 0.011   
MACOI_HUMAN TMEM57 p-S332 (z= 2) 20.0 63.1 35.3 3.2 1.8 0.000 0.011   
YAP1_HUMAN YAP1 p-T64 (z= 2) + oxidation 21.2 15.0 44.2 0.7 2.1 0.560 0.011 * 
MK03_HUMAN MAPK3 p-T203 p-Y205 (z= 3) 24.7 75.9 58.1 3.1 2.3 0.000 0.011   
EIF3C_HUMAN EIF3C p-S40 (z= 3) 7.7 64.2 36.4 8.4 4.8 0.000 0.011   
MYH10_HUMAN MYH10 p-S1957 (z= 3) 13.0 64.2 54.7 4.9 4.2 0.000 0.011   
NRG2_HUMAN NRG2 p-Y288 (z= 2) 11.5 24.1 42.7 2.1 3.7 0.001 0.012   
STAM2_HUMAN STAM2 p-Y362 (z= 2) 11.5 24.1 42.7 2.1 3.7 0.001 0.012   
EF1D_HUMAN EEF1D p-S163 (z= 4) 17.2 53.3 43.3 3.1 2.5 0.000 0.012   
MFF_HUMAN MFF p-T139 (z= 4) 12.8 44.5 40.0 3.5 3.1 0.038 0.012   
SCRIB_HUMAN SCRIB p-S1449 (z= 2) 16.9 36.2 43.9 2.1 2.6 0.014 0.012   
LMO7_HUMAN LMO7 p-S989 (z= 3) 21.9 38.6 52.5 1.8 2.4 0.061 0.012   
ESYT2_HUMAN ESYT2 p-S759 (z= 2) 26.4 61.3 48.3 2.3 1.8 0.027 0.012   
MAP4_HUMAN MAP4 p-T283 (z= 3) 26.9 59.8 50.9 2.2 1.9 0.001 0.012   
BCLF1_HUMAN BCLAF1 p-S386 (z= 3) 16.8 28.4 47.5 1.7 2.8 0.005 0.013   
SF3A1_HUMAN SF3A1 p-S330 (z= 3) + oxidation 11.9 13.1 37.0 1.1 3.1 0.701 0.013   
HS90A_HUMAN HSP90AA1 p-S264 (z= 3) 10.9 35.2 39.9 3.2 3.7 0.009 0.013   
MACC1_HUMAN MACC1 p-S75 (z= 3) 28.5 43.7 58.8 1.5 2.1 0.236 0.014   
ICAL_HUMAN CAST p-S365 (z= 2) 15.7 45.1 40.4 2.9 2.6 0.008 0.014   
THUM1_HUMAN THUMPD1 p-S87 p-S89 (z= 4) 16.3 61.5 49.9 3.8 3.1 0.001 0.014   
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STIP1_HUMAN STIP1 p-S17 (z= 2) 8.5 29.7 44.2 3.5 5.2 0.041 0.014   
VNRL4_HUMAN VNRL4 p-T91 (z= 2) 11.5 34.9 48.6 3.0 4.2 0.001 0.015   
SCRIB_HUMAN SCRIB p-S836 (z= 3) 23.9 54.3 39.2 2.3 1.6 0.011 0.016   
TCEA1_HUMAN TCEA1 p-S101 (z= 3) 7.8 35.7 23.6 4.6 3.0 0.023 0.017   
ITPR1_HUMAN ITPR1 p-T277 (z= 2) 20.6 58.1 52.0 2.8 2.5 0.001 0.017 * 
PGRC1_HUMAN PGRMC1 p-S182 (z= 3) 16.5 38.9 47.1 2.4 2.9 0.003 0.017   
DC1L2_HUMAN DYNC1LI2 p-S206 (z= 3) 7.2 23.1 38.0 3.2 5.3 0.054 0.017   
ASAP2_HUMAN ASAP2 p-S702 (z= 3) 16.6 53.2 52.9 3.2 3.2 0.000 0.018   
MAP4_HUMAN MAP4 p-S508 (z= 2) 29.1 62.5 51.9 2.1 1.8 0.011 0.018   
EPN1_HUMAN EPN1 p-S411 (z= 2) 31.0 70.7 68.9 2.3 2.2 0.008 0.019   
XPC_HUMAN XPC p-S95 (z= 3) 26.1 59.8 44.0 2.3 1.7 0.009 0.019   
EPIPL_HUMAN EPPK1 p-S2692 (z= 3) 23.4 47.8 47.2 2.0 2.0 0.000 0.019   
DSG2_HUMAN DSG2 p-S681 (z= 2) 22.9 50.0 45.9 2.2 2.0 0.046 0.019   
EIF3C_HUMAN EIF3C p-S40 (z= 2) 18.1 55.8 34.8 3.1 1.9 0.001 0.019   
SRRM2_HUMAN SRRM2 p-S1180 (z= 2) 26.1 73.1 43.8 2.8 1.7 0.001 0.019   
TMX1_HUMAN TMX1 p-S248 (z= 3) 21.0 16.9 51.1 0.8 2.4 0.580 0.020   
EF1D_HUMAN EEF1D p-S163 (z= 3) 29.2 56.9 69.0 2.0 2.4 0.052 0.020   
AHNK_HUMAN AHNAK p-S136 (z= 2) 27.7 68.7 58.3 2.5 2.1 0.002 0.021   
ALPK3_HUMAN ALPK3 p-S295 (z= 2) 33.1 79.0 58.2 2.4 1.8 0.000 0.021   
CAV1_HUMAN CAV1 p-S38 (z= 2) 33.1 79.0 58.2 2.4 1.8 0.000 0.021   
MK01_HUMAN MAPK1 p-T186 p-Y188 (z= 3) 28.6 72.3 53.5 2.5 1.9 0.003 0.021   
K2C5_HUMAN KRT5 p-S22 (z= 2) 34.9 76.0 61.8 2.2 1.8 0.000 0.022   
TEBP_HUMAN PTGES3 p-S114 (z= 3) + oxidation 7.2 27.7 42.2 3.8 5.9 0.186 0.023   
STK10_HUMAN STK10 p-S439 (z= 2) 11.9 77.7 33.0 6.5 2.8 0.000 0.023   
GPN1_HUMAN GPN1 p-S315 (z= 3) 10.0 65.7 46.4 6.6 4.6 0.000 0.023   
ASML_HUMAN ASMTL p-S240 (z= 3) 24.7 60.0 48.6 2.4 2.0 0.007 0.023   
SLTM_HUMAN SLTM p-S554 (z= 3) 12.7 48.8 41.3 3.8 3.2 0.004 0.024   
SRRM1_HUMAN SRRM1 p-S261 (z= 3) 21.9 35.0 49.7 1.6 2.3 0.097 0.025   
STK39_HUMAN STK39 p-S388 (z= 2) 25.0 62.2 57.9 2.5 2.3 0.025 0.025   
DSG2_HUMAN DSG2 p-S681 (z= 3) 20.1 52.8 54.3 2.6 2.7 0.026 0.026   
YAP1_HUMAN YAP1 p-S110 (z= 3) 10.8 51.8 29.3 4.8 2.7 0.003 0.026 * 
NPM_HUMAN NPM1 p-S71 (z= 3) + oxidation 23.3 25.2 59.9 1.1 2.6 0.897 0.026   
TB182_HUMAN TNKS1BP1 p-S1477 (z= 3) 17.9 24.8 39.6 1.4 2.2 0.352 0.026   
HDGF_HUMAN HDGF p-S134 (z= 3) 34.0 59.8 71.3 1.8 2.1 0.060 0.029   
ZYX_HUMAN ZYX p-S143 (z= 3) 0.8 19.9 23.5 25.0 29.6 0.128 0.029 * 
AHNK_HUMAN AHNAK p-S94 (z= 3) 31.6 70.9 45.5 2.2 1.4 0.003 0.029   
LAD1_HUMAN LAD1 p-T20 (z= 3) 19.7 38.6 54.8 2.0 2.8 0.154 0.029   
PPIL4_HUMAN PPIL4 p-S179 (z= 3) 16.4 22.7 37.5 1.4 2.3 0.317 0.029   
S6A15_HUMAN SLC6A15 p-S676 (z= 3) 16.7 52.0 44.0 3.1 2.6 0.000 0.030   
KLC3_HUMAN KLC3 p-S467 (z= 2) 23.4 47.7 44.4 2.0 1.9 0.000 0.030   
NCRP1_HUMAN NCCRP1 p-S29 (z= 3) + oxidation 8.8 8.4 32.3 1.0 3.7 0.882 0.032   
SRC8_HUMAN CTTN p-T402 p-Y422 (z= 3) 25.1 48.1 54.4 1.9 2.2 0.023 0.032   
OSBP1_HUMAN OSBP p-S352 (z= 3) + oxidation 32.0 42.3 68.0 1.3 2.1 0.539 0.032   
NIBL1_HUMAN FAM129B p-S629 p-T639 (z= 3) 21.4 52.7 52.0 2.5 2.4 0.061 0.032   
HTSF1_HUMAN HTATSF1 p-S677 (z= 3) 9.2 14.0 39.9 1.5 4.3 0.153 0.032   
PROM2_HUMAN PROM2 p-S816 p-S819 (z= 3) 23.0 45.5 53.7 2.0 2.3 0.072 0.034   
MY18A_HUMAN MYO18A p-S1971 (z= 3) 24.8 53.5 39.1 2.2 1.6 0.071 0.034   
HNRPC_HUMAN HNRNPC p-S254 p-S261 (z= 4) 25.2 72.2 55.8 2.9 2.2 0.001 0.035   
LRRF1_HUMAN LRRFIP1 p-S125 (z= 3) 26.1 39.5 54.2 1.5 2.1 0.051 0.035   
DDB2_HUMAN DDB2 p-S27 (z= 3) 26.3 54.0 50.8 2.1 1.9 0.004 0.035   
PGRC1_HUMAN PGRMC1 p-S58 (z= 3) 24.6 61.3 59.1 2.5 2.4 0.001 0.036   
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NCK1_HUMAN NCK1 p-S90 (z= 3) 15.7 31.0 44.7 2.0 2.8 0.002 0.036   
TOIP1_HUMAN TOR1AIP1 p-T221 (z= 3) 25.7 48.6 54.6 1.9 2.1 0.025 0.036   
HNRL2_HUMAN HNRNPUL2 p-S162 (z= 3) 24.5 51.5 37.6 2.1 1.5 0.010 0.037   
ARFG2_HUMAN ARFGAP2 p-S202 (z= 4) 13.0 22.4 42.4 1.7 3.3 0.354 0.039   
HNRPU_HUMAN HNRNPU p-S272 (z= 5) 13.3 28.4 27.2 2.1 2.0 0.135 0.039   
AHNK_HUMAN AHNAK p-T5795 (z= 3) 11.3 21.5 32.2 1.9 2.8 0.038 0.039   
MY18A_HUMAN MYO18A p-S73 (z= 3) 27.0 59.5 45.5 2.2 1.7 0.009 0.039   
NOB1_HUMAN NOB1 p-S202 (z= 2) 25.3 62.7 47.8 2.5 1.9 0.000 0.040   
ATX2L_HUMAN ATXN2L p-S112 (z= 3) 29.7 61.0 52.2 2.1 1.8 0.006 0.040   
EF1B_HUMAN EEF1B2 p-S107 (z= 4) 14.2 28.0 37.3 2.0 2.6 0.043 0.041   
NPM_HUMAN NPM1 p-T76 (z= 4) + oxidation 8.0 11.7 39.6 1.5 5.0 0.599 0.041   
UBP20_HUMAN USP20 p-S135 (z= 3) 28.4 62.2 51.7 2.2 1.8 0.000 0.042   
DC1L2_HUMAN DYNC1LI2 p-S206 (z= 4) 3.4 11.3 28.9 3.3 8.6 0.073 0.044   
LAD1_HUMAN LAD1 p-S65 (z= 4) 3.6 23.7 36.4 6.6 10.1 0.045 0.044   
HTSF1_HUMAN HTATSF1 p-S643 (z= 2) 11.3 16.8 35.4 1.5 3.1 0.078 0.046   
CTNB1_HUMAN CTNNB1 p-S553 (z= 3) + oxidation 21.2 48.2 36.4 2.3 1.7 0.038 0.046 * 
HNRPK_HUMAN HNRNPK p-S117 (z= 4) 5.7 28.0 21.8 4.9 3.8 0.085 0.046   
HPBP1_HUMAN HSPBP1 p-S355 (z= 2) 27.8 66.8 54.5 2.4 2.0 0.001 0.046   
HNRPC_HUMAN HNRNPC p-S261 (z= 4) 20.4 50.7 55.7 2.5 2.7 0.001 0.047   
TXLNA_HUMAN TXLNA p-S515 (z= 3) 23.9 60.9 39.2 2.5 1.6 0.001 0.047   
NPM_HUMAN NPM1 p-S126 (z= 4) 18.9 48.0 45.4 2.5 2.4 0.001 0.048   
SSRP1_HUMAN SSRP1 p-S445 (z= 3) + oxidation 8.6 13.1 34.2 1.5 4.0 0.336 0.048   
CTNB1_HUMAN CTNNB1 p-T557 (z= 3) 28.0 64.7 44.5 2.3 1.6 0.000 0.048 * 
TPIS_HUMAN TPI1 p-S22 (z= 3) 18.5 47.5 36.8 2.6 2.0 0.001 0.055   
LARP1_HUMAN LARP1 p-S767 p-Y778 (z= 2) 25.3 74.3 56.6 2.9 2.2 0.004 0.055   
CTNB1_HUMAN CTNNB1 p-S192 (z= 2) 19.7 57.3 52.4 2.9 2.7 0.002 0.057 * 
FA40A_HUMAN FAM40A p-S336 (z= 3) 23.3 54.1 42.9 2.3 1.8 0.003 0.057   
DOCK8_HUMAN DOCK8 p-S905 (z= 3) 33.3 70.5 52.1 2.1 1.6 0.001 0.058   
SON_HUMAN SON p-S1557 (z= 3) + oxidation 15.5 21.0 38.1 1.4 2.5 0.002 0.059   
ASAP2_HUMAN ASAP2 p-S702 (z= 2) 36.4 74.4 59.5 2.0 1.6 0.000 0.061   
NPM_HUMAN NPM1 p-S126 (z= 3) 16.0 56.0 41.1 3.5 2.6 0.000 0.066   
SFR15_HUMAN SFRS15 p-S155 (z= 4) 20.3 48.5 40.0 2.4 2.0 0.004 0.067   
DDX54_HUMAN DDX54 p-S783 (z= 2) 3.4 11.7 34.2 3.4 10.0 0.003 0.081   
NIBL1_HUMAN FAM129B p-S629 p-S634 (z= 3) 6.4 42.8 28.8 6.7 4.5 0.003 0.101   
ACACA_HUMAN ACACA p-S30 (z= 3) 27.2 69.2 49.9 2.5 1.8 0.001 0.105   
HS90B_HUMAN HSP90AB1 p-S256 (z= 2) 3.7 7.1 32.8 1.9 8.8 0.003 0.106   
DNJC1_HUMAN DNAJC1 p-S480 p-S481 (z= 3) 38.2 78.4 57.6 2.1 1.5 0.003 0.111   
EHD2_HUMAN EHD2 p-S439 (z= 3) 24.2 63.2 53.9 2.6 2.2 0.001 0.151   
PRCC_HUMAN PRCC p-T262 (z= 3) 27.7 74.8 51.4 2.7 1.9 0.001 0.153   
FMNL2_HUMAN FMNL2 p-S172 (z= 2) 26.3 57.6 40.2 2.2 1.5 0.004 0.165   
ZRAB2_HUMAN ZRANB2 p-S154 (z= 2) 13.5 4.4 33.6 0.3 2.5 0.005 0.167   
CTND1_HUMAN CTNND1 p-S350 p-S353 (z= 2) 26.6 66.8 44.6 2.5 1.7 0.003 0.171   
NUCL_HUMAN NCL p-T70 (z= 2) 15.5 52.9 21.9 3.4 1.4 0.004 0.182   
SNTB2_HUMAN SNTB2 p-S111 (z= 3) 27.4 59.6 37.1 2.2 1.4 0.001 0.234   
HNRPC_HUMAN HNRNPC p-S254 p-S261 (z= 3) 28.0 62.0 39.0 2.2 1.4 0.001 0.249   
UBR4_HUMAN UBR4 p-S2720 (z= 2) 42.5 85.9 55.3 2.0 1.3 0.000 0.260   
ARHG6_HUMAN ARHGEF6 p-S489 (z= 2) 37.5 75.7 42.8 2.0 1.1 0.001 0.304   
PR38A_HUMAN PRPF38A p-S194 p-S195 (z= 3) 30.8 70.2 40.4 2.3 1.3 0.000 0.406   
TP53B_HUMAN TP53BP1 p-S1363 (z= 2) 23.9 58.3 24.7 2.4 1.0 0.002 0.849   
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Appendix 3 
Summary of phosphorylation events found to be dependent on Akt1 by an in vitro reaction 
followed by phosphoproteomic analysis in MCF10A cells (Chapter 5.4.1.). 
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AKT1_HUMAN SGSPSDNSGAEEMEVSLAKPK Phospho (ST) 0.4 16.8 100.0 225.3   
AKT1_HUMAN SGSPSDNSGAEEMEVSLAKPK Oxidation (M); Phospho (ST) 0.8 10.9 100.0 132.9   
AKTS1_HUMAN LNTSDFQK Phospho (ST) 0.9 17.1 100.0 113.8 * 
AKT1_HUMAN SGSPSDNSGAEEMEVSLAKPK 3 Phospho (ST) 0.9 29.5 100.0 106.5   
GOGA4_HUMAN TSSFTEQLDEGTPNR Phospho (ST) 1.8 39.9 100.0 55.0   
AKT1_HUMAN SGSPSDNSGAEEMEVSLAKPK 2 Phospho (ST) 2.8 20.5 100.0 36.0   
AHNK_HUMAN SNSFSDER Phospho (ST) 3.6 32.6 100.0 28.0   
AKT1_HUMAN RPHFPQFSYSASGTA Phospho (ST) 3.9 20.2 100.0 25.8   
PURB_HUMAN RGGGSGGGEESEGEEVDED Phospho (ST) 4.1 71.0 100.0 24.6   
HS90B_HUMAN IEDVGSDEEDDSGKDK Phospho (ST) 5.0 75.5 99.8 19.9   
APIP_HUMAN DISGPSPSK Phospho (ST) 6.1 70.2 96.2 15.8   
ITFG3_HUMAN SQENLGNPSK Phospho (ST) 7.3 58.8 100.0 13.7   
WAC_HUMAN QQGHEPVSPR Gln->pyro-Glu (N-term Q); Phospho (ST) 8.8 88.0 100.0 11.4   
CALX_HUMAN SDAEEDGGTVSQEEEDR Phospho (ST) 9.6 94.1 97.1 10.2   
PLEC1_HUMAN SSSVGSSSSYPISPAVSR Phospho (ST) 10.2 30.7 100.0 9.8   
RBM26_HUMAN LNHSPPQSSSR Phospho (ST) 10.6 62.8 100.0 9.4   
TCOF_HUMAN LGAGEGGEASVSPEK Phospho (ST) 9.4 100.0 87.9 9.4   
MAML3_HUMAN SPLNGDQQNGACDGNFSPTSK Phospho (ST) 8.6 82.6 77.9 9.0   
IF4G1_HUMAN AASLTEDR Phospho (ST) 9.9 82.7 88.0 8.9   
APBA1_HUMAN SNSQENVEASHPSQDGK Phospho (ST) 12.1 56.9 100.0 8.2   
PLEC1_HUMAN SDEGQLSPATR Phospho (ST) 11.8 93.3 95.7 8.1   
NUCKS_HUMAN EEDEEPESPPEK Phospho (ST) 12.3 97.7 99.2 8.0   
HS90B_HUMAN EISDDEAEEEK Phospho (ST) 12.8 87.7 100.0 7.8   
DENR_HUMAN LTVENSPK Phospho (ST) 13.4 74.9 100.0 7.4   
TCF20_HUMAN LNASPAAR Phospho (ST) 13.9 17.5 100.0 7.2   
HS90B_HUMAN IEDVGSDEEDDSGKDK Phospho (ST) 11.7 100.0 82.8 7.1   
LA_HUMAN FASDDEHDEHDENGATGPVK Phospho (ST) 15.3 81.6 100.0 6.6   
MARCS_HUMAN VNGDASPAAAESGAK Phospho (ST) 16.2 88.2 100.0 6.2   
Appendix 3 
239 
 
TBCD4_HUMAN LGSVDSFER Phospho (ST) 16.9 30.1 100.0 5.9 * 
HS90B_HUMAN EISDDEAEEEKGEK Phospho (ST) 16.9 87.2 96.2 5.7   
TACC2_HUMAN VQNSPPVGR Phospho (ST) 17.7 87.1 100.0 5.7   
SRRM1_HUMAN AASPSPQSVR Phospho (ST) 17.8 76.1 100.0 5.6   
HTSF1_HUMAN VLDEEGSER Phospho (ST) 16.8 100.0 94.2 5.6   
SRRM1_HUMAN RRTPSPPPR 2 Phospho (ST) 11.9 100.0 66.4 5.6   
HS90B_HUMAN IEDVGSDEEDDSGK Phospho (ST) 18.7 95.7 99.1 5.3   
ACLY_HUMAN TASFSESR Phospho (ST) 18.7 85.0 98.7 5.3   
NUCKS_HUMAN EEDEEPESPPEKK Phospho (ST) 17.8 100.0 91.7 5.2   
CD44_HUMAN KPSGLNGEASK Phospho (ST) 19.5 54.9 100.0 5.1   
SC31A_HUMAN AQGEPVAGHESPK Phospho (ST) 19.6 62.6 100.0 5.1   
NUCKS_HUMAN TPSPKEEDEEPESPPEKK Phospho (ST) 12.3 32.5 62.3 5.1   
MP2K2_HUMAN LNQPGTPTR Phospho (ST) 20.2 86.5 100.0 5.0   
HS90B_HUMAN EKEISDDEAEEEK Phospho (ST) 16.5 89.1 81.6 4.9   
HIRP3_HUMAN EVSDSEAGGGPQGER Phospho (ST) 20.4 70.1 100.0 4.9   
PAXI_HUMAN ISASSATR Phospho (ST) 21.4 74.9 100.0 4.7   
MCM2_HUMAN TDALTSSPGR Phospho (ST) 22.3 87.5 100.0 4.5   
MARCS_HUMAN AEDGATPSPSNETPK Phospho (ST) 22.5 79.6 100.0 4.4   
S10AB_HUMAN ISSPTETER Phospho (ST) 23.5 51.0 100.0 4.3   
SIRT1_HUMAN SPGEPGGAAPER Phospho (ST) 23.5 86.8 100.0 4.3   
MELT_HUMAN DRSLPR Phospho (ST) 23.6 79.0 100.0 4.2   
ZEP2_HUMAN RDLSPR Phospho (ST) 23.6 79.0 100.0 4.2   
ZO3_HUMAN TISEPDEQR Phospho (ST) 23.9 85.6 100.0 4.2   
CALX_HUMAN QKSDAEEDGGTVSQEEEDR Gln->pyro-Glu (N-term Q); 2 Phospho (ST) 24.4 92.3 99.6 4.1   
TGON2_HUMAN DSPSKSSAEAQTPEDTPNK Phospho (ST) 24.8 86.7 100.0 4.0   
LRRF1_HUMAN EILHNTEK Phospho (ST) 25.0 47.4 100.0 4.0   
BCLF1_HUMAN QKSPEIHR Gln->pyro-Glu (N-term Q); Phospho (ST) 25.1 69.9 100.0 4.0   
SMRC2_HUMAN SPSPSPTPEAK Phospho (ST) 25.2 46.5 100.0 4.0   
LAP2B_HUMAN AKTPVTLK Phospho (ST) 25.6 95.6 98.2 3.8   
TCOF_HUMAN KLSGDQPAAR Phospho (ST) 26.3 87.2 100.0 3.8   
TCOF_HUMAN KLSGDQPAAR Phospho (ST) 26.3 87.2 100.0 3.8   
CX026_HUMAN GADSGEEKEEGINR Phospho (ST) 23.7 89.9 89.4 3.8   
EPIPL_HUMAN AEAEAGSPRPDPR Phospho (ST) 26.0 91.9 92.5 3.6   
WRIP1_HUMAN RPAAAAAAGSASPR Phospho (ST) 29.2 83.2 100.0 3.4   
SHRPN_HUMAN SPGNLTER Phospho (ST) 27.0 88.5 91.7 3.4   
PSA3_HUMAN ESLKEEDESDDDNM Phospho (ST) 27.9 95.0 92.2 3.3   
REPS1_HUMAN SSSLDMNR Phospho (ST) 31.0 85.5 100.0 3.2   
YBOX1_HUMAN NEGSESAPEGQAQQR Phospho (ST) 32.5 28.2 100.0 3.1 * 
SRRM1_HUMAN APQTSSSPPPVR Phospho (ST) 33.6 80.5 100.0 3.0   
E41L1_HUMAN DEDGESGGQRSEAEEGEVR Phospho (ST) 29.4 100.0 84.5 2.9   
APIP_HUMAN DISGPSPSKK Phospho (ST) 35.4 67.8 100.0 2.8   
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KC1E_HUMAN IQPAGNTSPR Phospho (ST) 35.9 57.1 100.0 2.8   
CDN1B_HUMAN VSNGSPSLER Phospho (ST) 36.4 87.3 100.0 2.7   
HSPB1_HUMAN QLSSGVSEIR Phospho (ST) 39.1 39.2 100.0 2.6   
LRC47_HUMAN EEGSLSDTEADAVSGQLPDPTTNPSAGK Phospho (ST) 35.1 85.6 88.6 2.5   
CI078_HUMAN VGDTEKPEPERSPPNR Phospho (ST) 41.0 83.0 100.0 2.4   
VINC_HUMAN GQGSSPVAMQK Phospho (ST) 16.2 100.0 39.4 2.4   
NMT1_HUMAN GGLSPANDTGAK Phospho (ST) 37.4 100.0 89.0 2.4   
SSRP1_HUMAN EFVSSDESSSGENK Phospho (ST) 40.3 84.8 94.6 2.4   
F86C1_HUMAN DSSDSELLR Phospho (ST) 39.5 76.5 92.1 2.3   
TB182_HUMAN ASPEPPGPESSSR Phospho (ST) 42.9 74.3 100.0 2.3   
CTND1_HUMAN VGGSSVDLHR Phospho (ST) 42.9 74.6 100.0 2.3   
MRP_HUMAN AAATPESQEPQAK Phospho (ST) 43.9 39.5 100.0 2.3   
TPIS_HUMAN QSLGELIGTLNAAK Phospho (ST) 44.2 37.8 100.0 2.3   
HDGR2_HUMAN ADSDGAKPEPVAMAR Phospho (ST) 44.6 61.1 100.0 2.2   
T22D4_HUMAN NGSPPPGAPSSR Phospho (ST) 46.9 36.2 100.0 2.1   
SET_HUMAN RQSPLPPQK Phospho (ST) 47.3 81.0 100.0 2.1   
TRI16_HUMAN ETEEQDSDSAEQGDPAGEGK Phospho (ST) 49.4 33.4 100.0 2.0   
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Appendix 4 
Summary of phosphorylation events found to be dependent on Akt1 by an in vitro reaction 
followed by phosphoproteomic analysis in MCF10A cells (Chapter 5.4.2.). 
 
    
- Akt1 + Akt1 
    
A
cc
es
si
o
n
 N
u
m
b
er
 
P
h
o
sp
h
o
p
ep
id
e 
Id
en
ti
fi
ca
ti
o
n
 
M
ea
n
 P
e
p
ti
d
e 
In
te
n
si
ty
 0
 μ
M
 A
TP
 
M
ea
n
 P
e
p
ti
d
e 
In
te
n
si
ty
 1
0 
μ
M
 A
TP
 
M
ea
n
 P
e
p
ti
d
e 
In
te
n
si
ty
 5
0 
μ
M
 A
TP
 
M
ea
n
 P
e
p
ti
d
e 
In
te
n
si
ty
 1
00
 μ
M
 A
TP
 
M
ea
n
 P
e
p
ti
d
e 
In
te
n
si
ty
 5
00
 μ
M
 A
TP
 
M
ea
n
 P
e
p
ti
d
e 
In
te
n
si
ty
 0
 μ
M
 A
TP
 
M
ea
n
 P
e
p
ti
d
e 
In
te
n
si
ty
 1
0 
μ
M
 A
TP
 
M
ea
n
 P
e
p
ti
d
e 
In
te
n
si
ty
 5
0
 μ
M
 A
TP
 
M
ea
n
 P
e
p
ti
d
e 
In
te
n
si
ty
 1
00
 μ
M
 A
TP
 
M
ea
n
 P
e
p
ti
d
e 
In
te
n
si
ty
 5
00
 μ
M
 A
TP
 
Fo
ld
 1
00
 +
/-
 
K
n
o
w
n
 A
kt
 S
u
b
st
ra
te
 
NUCKS_HUMAN NUCKS1 p-S59 p-S62 (z= 2) 1.0 1.2 0.5 0.0 2.2 17.0 52.3 13.9 32.6 16.7 697.4   
MOL1A_HUMAN MOBKL1A p-T36 (z= 2) 0.0 0.0 1.3 0.2 0.0 0.0 25.5 59.9 76.5 95.3 509.7   
AKTS1_HUMAN AKT1S1 p-T247 (z= 2) 0.0 0.8 0.6 0.1 0.4 0.0 7.6 24.3 44.2 92.6 469.1 * 
LMNA_HUMAN LMNA p-S637 (z= 2) 0.0 0.0 0.0 0.2 0.0 50.1 93.6 93.8 76.8 84.6 365.3 * 
NSUN2_HUMAN NSUN2 p-S752 (z= 3) 0.0 0.0 0.0 0.3 0.0 0.0 94.7 91.3 98.7 0.0 330.1   
AKT1_HUMAN AKT1 p-S125 (z= 2) 1.9 1.1 0.0 0.2 0.6 90.6 69.2 56.6 48.9 45.3 292.5   
NUCL_HUMAN NCL p-S146 p-S154 (z= 3) 0.0 0.0 0.0 0.2 0.0 9.9 81.3 45.7 41.0 26.4 240.1   
IF2B_HUMAN EIF2S2 p-T32 (z= 3) 0.0 0.0 2.2 0.4 5.1 0.0 46.7 74.0 85.0 91.6 222.8   
HNRPU_HUMAN HNRNPU p-S60 (z= 3) + oxidation 0.0 0.0 0.0 0.4 0.0 0.0 23.7 43.7 77.2 92.8 215.9   
ENPL_HUMAN HSP90B1 p-S65 (z= 2) 0.0 0.0 0.0 0.3 0.0 45.6 48.1 62.9 60.2 99.3 214.5   
TXLNA_HUMAN TXLNA p-S516 (z= 2) 17.0 18.0 12.6 0.3 11.8 74.1 48.0 42.8 51.6 53.4 171.5   
SRRM2_HUMAN SRRM2 p-S2045 p-S2047 (z= 2) 0.0 0.0 0.0 0.3 71.8 0.0 50.0 0.0 39.6 94.4 156.5   
SGIP1_HUMAN SGIP1 p-S161 (z= 2) 0.0 0.0 0.0 0.4 1.4 97.6 67.4 60.3 59.7 71.4 150.4   
HDGR2_HUMAN HDGFRP2 p-T608 (z= 4) 0.0 0.0 0.0 0.6 0.0 0.0 20.6 43.9 76.9 86.3 134.9   
NEK9_HUMAN NEK9 p-S945 (z= 3) 0.0 0.0 0.0 0.6 0.0 46.9 66.5 66.1 80.0 91.3 127.3   
MYH9_HUMAN MYH9 p-S1944 (z= 2) 0.0 0.0 5.6 0.6 0.0 40.0 70.0 71.2 63.3 49.1 112.3   
HS90A_HUMAN HSP90AA1 p-S232 (z= 2) 0.0 3.3 1.6 0.7 2.4 40.9 63.6 46.3 79.5 65.6 110.8   
RLA0L_HUMAN ZRANB2 p-S308 (z= 2) + oxidation 0.0 0.0 0.0 0.9 44.9 7.1 53.4 72.7 94.9 74.9 107.9   
RERE_HUMAN RERE p-S657 (z= 2) 0.0 0.0 0.0 1.1 0.0 36.6 52.3 43.7 95.1 83.6 86.9   
HDGF_HUMAN HDGF p-S133 p-S134 (z= 3) 0.0 12.9 5.5 0.6 8.7 38.7 98.9 71.1 54.7 52.8 84.9   
KPCD_HUMAN PRKCD p-S665 (z= 2) 0.0 0.0 0.0 0.6 1.2 82.9 91.5 85.7 48.6 32.4 84.7   
ODPAT_HUMAN PDHA2 p-S292 (z= 3) 0.0 0.0 0.0 0.9 0.0 33.2 73.2 80.4 71.9 84.4 83.6   
BCKD_HUMAN BCKDK p-T33 (z= 3) + oxidation 15.3 20.7 39.6 1.0 9.9 46.1 57.9 54.5 79.2 87.3 83.3   
LR16A_HUMAN LRRC16A p-S969 (z= 2) 9.5 19.7 22.2 0.7 23.9 88.1 46.4 75.3 60.1 63.4 80.4   
VPS4B_HUMAN VPS4B p-S103 (z= 2) 0.0 0.0 0.0 1.0 0.0 30.6 50.0 20.2 76.1 39.1 75.3   
ARD1A_HUMAN ARD1A p-S187 (z= 2) 0.0 0.0 0.0 1.2 0.0 44.3 52.7 40.1 87.4 72.0 75.3   
G3P_HUMAN GAPDH p-T185 (z= 3) + oxidation 0.0 0.0 0.0 0.4 0.0 24.4 68.6 11.0 28.5 27.8 71.8   
TFAM_HUMAN TFAM p-S125 (z= 2) 0.0 0.0 0.0 1.0 0.0 76.7 51.2 68.2 69.0 97.5 70.3   
RMTL1_HUMAN RNMTL1 p-S64 (z= 2) 0.0 0.0 0.0 1.0 12.1 0.0 17.2 40.8 66.6 86.6 63.9   
Appendix 4 
242 
 
I2BP2_HUMAN IRF2BP2 p-S461 (z= 2) + oxidation 22.9 12.1 9.0 1.3 15.2 47.9 37.9 26.9 83.6 79.2 63.9   
K1C18_HUMAN KRT18 p-S399 (z= 2) 0.0 0.0 0.0 1.4 0.0 0.0 28.0 64.9 84.6 87.4 60.9   
STX4_HUMAN STX4 p-S16 (z= 2) 0.0 0.0 0.0 0.7 0.0 12.9 53.1 14.0 44.6 22.4 60.3   
CD44_HUMAN CD44 p-S698 (z= 2) 0.0 0.0 0.0 0.9 0.0 16.3 39.2 33.9 51.6 50.0 58.7   
NEK9_HUMAN NEK9 p-S945 (z= 3) + oxidation 0.0 0.0 0.0 1.4 0.0 10.2 36.4 77.5 72.0 83.9 50.6   
IF2B_HUMAN EIF2S2 p-T32 p-T37 (z= 3) 0.0 0.0 0.0 1.3 0.0 0.0 8.2 57.3 63.1 98.9 50.2   
I2BP1_HUMAN IRF2BP1 p-S385 (z= 2) 22.4 11.7 0.0 1.2 7.7 83.9 50.8 49.8 55.8 64.5 47.5   
CTR9_HUMAN CTR9 p-S942 (z= 2) 0.0 0.0 0.0 1.7 0.0 50.0 14.1 39.9 80.4 64.8 47.0   
CHRC1_HUMAN CHRAC1 p-S125 (z= 3) 0.0 0.0 0.0 1.5 0.0 46.0 45.4 50.0 69.0 89.9 46.8   
AKT1_HUMAN AKT1 p-S125 (z= 3) 3.2 2.4 1.7 1.5 2.8 99.4 83.2 75.1 60.9 54.4 41.7   
RS6_HUMAN RPS6 p-S237 (z= 2) 0.0 8.9 15.2 0.9 28.0 7.4 9.6 43.0 35.7 94.0 37.9 * 
RL17_HUMAN RPL17 p-S6 (z= 2) 0.0 0.0 0.0 2.5 0.0 17.1 55.7 72.8 91.4 93.9 36.2   
NEK9_HUMAN NEK9 p-S856 p-S869 (z= 3) 0.0 0.0 0.0 2.2 0.0 0.0 44.7 76.3 76.7 87.1 35.6   
RBGP1_HUMAN RABGAP1 p-S43 (z= 2) 27.5 13.8 26.7 1.5 33.1 79.7 60.1 62.6 52.5 63.0 34.3   
VPS4B_HUMAN VPS4B p-S103 (z= 2) 0.0 0.0 0.0 1.2 0.0 26.0 69.1 32.5 38.3 21.9 32.1   
YBOX1_HUMAN YBX1 p-T272 (z= 3) 0.0 0.0 0.0 1.5 0.0 0.0 29.8 44.0 48.5 88.8 32.0 * 
CALX_HUMAN CANX p-S75 (z= 2) 0.0 0.0 0.0 2.2 0.0 0.0 12.2 3.1 66.4 50.0 30.7   
IF2B_HUMAN EIF2S2 p-T37 (z= 3) 0.0 0.0 1.0 2.0 3.2 1.4 38.9 75.0 52.9 82.8 26.6   
AN32B_HUMAN ANP32B p-T245 (z= 2) 0.0 0.0 0.0 2.3 42.9 21.3 77.3 64.6 59.8 41.9 25.6   
HUWE1_HUMAN HUWE1 p-T656 (z= 2) 0.0 2.5 5.4 3.9 3.1 78.3 69.6 94.8 89.6 68.1 23.0   
NUCKS_HUMAN NUCKS1 p-S62 (z= 2) 9.7 11.3 6.8 2.4 7.9 48.1 60.5 34.4 54.5 40.2 23.0   
CD11A_HUMAN CDK11A p-S48 (z= 2) 0.0 9.0 0.0 3.6 14.6 0.0 41.3 55.2 81.4 92.7 22.9   
AKT1_HUMAN AKT1 p-S123 p-S127 (z= 2) 0.0 0.0 0.0 2.4 0.0 42.2 96.4 73.1 50.1 50.8 20.9   
AKT1_HUMAN AKT1 p-S125 (z= 3) + oxidation 0.0 0.0 0.0 4.5 1.9 86.1 78.3 64.5 94.7 73.7 20.9   
FKB15_HUMAN FKBP15 p-S961 (z= 3) 18.0 22.1 5.4 4.3 4.9 93.8 69.3 77.9 79.4 79.2 18.5   
HNRL2_HUMAN HNRNPUL2 p-S186 (z= 3) 0.0 0.0 0.0 4.1 0.0 50.0 40.7 29.9 67.6 55.4 16.3   
MCM2_HUMAN MCM2 p-S42 (z= 2) 17.0 9.6 13.1 5.3 10.0 90.7 75.3 69.9 82.4 82.6 15.4   
SRRM2_HUMAN SRRM2 p-S1500 (z= 2) 13.6 32.7 47.0 1.5 54.8 0.0 35.0 16.6 23.0 49.3 15.0   
HNRPD_HUMAN HNRNPD p-S191 (z= 2) 0.0 50.0 0.0 1.8 82.2 0.0 37.7 0.0 25.5 0.0 14.5   
LIPB1_HUMAN PPFIBP1 p-S795 (z= 2) 24.9 29.0 22.8 6.1 7.8 95.0 69.5 69.8 83.3 82.7 13.8   
EF1B_HUMAN EEF1B2 p-S107 (z= 4) 0.0 3.9 3.9 2.8 8.7 96.1 79.1 55.5 38.2 43.1 13.5   
G3P_HUMAN GAPDH p-T185 (z= 3) 0.0 0.5 0.6 0.6 3.4 36.5 60.7 3.9 7.6 3.6 13.4   
NUCKS_HUMAN NUCKS1 p-S59 (z= 3) 6.0 4.1 3.7 4.0 9.7 47.3 59.1 34.7 51.5 36.9 12.8   
GYS1_HUMAN GYS1 p-S654 (z= 3) 27.1 8.7 8.8 5.5 13.3 59.1 56.4 63.8 70.5 56.3 12.8   
TBB2C_HUMAN TUBB2C p-S96 (z= 3) 17.6 0.0 4.4 7.3 10.1 9.5 62.4 27.6 85.0 82.9 11.6   
PGAM1_HUMAN PGAM1 p-S15 (z= 2) 13.1 11.6 9.2 5.5 19.7 84.8 67.3 58.0 62.6 56.8 11.5   
CIP4_HUMAN TRIP10 p-S297 (z= 2) 0.0 4.9 9.4 4.8 0.0 82.5 48.3 47.4 55.2 51.9 11.4   
SRRM1_HUMAN SRRM1 p-S753 (z= 2) 0.0 0.0 0.0 6.4 14.5 22.9 29.0 39.5 71.8 88.2 11.2   
SRRM2_HUMAN SRRM2 p-S1926 p-T1928 (z= 2) 7.7 4.7 4.6 7.2 18.6 36.0 61.1 59.9 80.7 80.4 11.2   
CC124_HUMAN CCDC124 p-S142 (z= 2) 0.0 0.0 0.0 5.1 13.1 0.0 11.7 27.8 56.2 92.8 11.0   
SLU7_HUMAN SLU7 p-S216 (z= 2) 7.5 0.0 0.0 8.5 12.9 55.0 47.6 40.9 84.1 71.9 9.9   
HNRPU_HUMAN HNRNPU p-S60 (z= 3) 0.0 1.1 4.0 5.3 6.4 0.3 35.0 72.8 46.7 85.9 8.8   
HS90A_HUMAN HSP90AA1 p-S232 (z= 3) 0.0 0.0 0.0 5.6 20.8 49.5 79.3 54.9 46.1 38.6 8.2   
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CQ100_HUMAN C17orf100 p-S55 (z= 2) 60.1 86.3 14.0 2.3 21.7 42.7 15.3 1.7 18.4 91.6 8.1   
HSF1_HUMAN HSF1 p-S315 (z= 3) 0.0 0.0 16.4 9.1 20.2 78.0 0.0 33.7 69.7 14.3 7.7   
IWS1_HUMAN IWS1 p-S238 (z= 3) 37.0 37.1 25.4 9.3 17.3 96.4 79.1 67.1 70.6 53.4 7.6   
CALX_HUMAN CANX p-S584 (z= 2) 18.8 20.6 13.3 9.4 16.8 87.5 66.1 62.8 70.9 76.4 7.5   
MK01_HUMAN MAPK1 p-Y188 (z= 3) 9.5 10.4 11.3 10.2 14.7 82.9 77.8 87.4 75.8 76.2 7.5   
MK01_HUMAN MAPK1 p-T186 (z= 3) 9.5 10.4 11.3 10.2 14.7 82.9 77.8 87.4 75.8 76.2 7.5   
HNRPD_HUMAN HNRNPD p-S83 (z= 3) 26.9 11.6 21.5 11.2 29.9 63.0 76.8 74.4 82.5 92.1 7.4   
RS17_HUMAN RPS17 p-S116 (z= 2) + oxidation 0.0 7.1 22.0 11.1 23.6 5.6 43.2 60.0 81.3 71.0 7.3   
SSH3_HUMAN SSH3 p-S650 (z= 2) 0.0 0.0 0.0 13.7 0.0 23.2 58.8 63.8 98.5 85.3 7.2   
TRI16_HUMAN TRIM16 p-S61 (z= 2) 7.1 0.0 0.0 9.9 24.9 50.0 86.8 79.3 70.3 66.9 7.1   
RRBP1_HUMAN RRBP1 p-S979 (z= 2) 0.0 0.0 0.0 11.1 0.0 0.0 29.0 57.2 78.6 89.8 7.1   
FRIH_HUMAN FTH1 p-S180 (z= 3) 23.4 13.6 17.8 4.9 23.5 50.0 53.1 29.4 34.1 20.5 7.0   
TCOF_HUMAN TCOF1 p-S1411 (z= 2) 14.9 14.6 5.3 11.7 5.9 26.0 30.9 55.0 80.3 94.0 6.9   
PGRC1_HUMAN PGRMC1 p-S182 (z= 3) 11.8 11.3 11.2 8.5 7.8 91.5 82.4 69.3 57.9 60.9 6.8   
PGRC1_HUMAN PGRMC1 p-Y181 (z= 3) 11.8 11.3 11.2 8.5 7.8 91.5 82.4 69.3 57.9 60.9 6.8   
CALX_HUMAN CANX p-S555 (z= 3) 9.8 12.6 16.9 12.0 13.6 99.9 83.1 76.7 81.3 88.7 6.8   
IWS1_HUMAN IWS1 p-S399 (z= 2) 0.0 12.1 12.4 9.6 23.2 92.2 87.2 71.4 64.5 51.7 6.7   
SRRM1_HUMAN SRRM1 p-S563 (z= 2) 52.0 13.5 12.3 2.6 0.0 62.0 35.3 22.6 16.7 0.0 6.4   
DAP1_HUMAN DAP p-S52 (z= 3) 15.0 4.6 10.1 10.7 8.5 84.7 76.2 51.0 66.5 41.5 6.2   
KPCD_HUMAN PRKCD p-S507 (z= 2) 34.3 27.2 27.4 10.9 14.3 84.1 72.0 77.8 66.2 37.3 6.1   
BCLF1_HUMAN BCLAF1 p-S649 (z= 2) 23.1 21.5 35.8 13.1 19.5 48.8 59.8 76.4 76.9 93.2 5.9   
IWS1_HUMAN IWS1 p-S514 (z= 2) 12.7 11.0 8.1 10.5 15.4 52.3 85.0 61.2 61.6 61.8 5.9   
CTR9_HUMAN CTR9 p-S942 (z= 3) 0.0 0.0 0.0 15.5 29.8 50.0 57.1 71.8 90.7 73.3 5.9   
HS90B_HUMAN HSP90AB1 p-S262 (z= 3) 0.0 6.1 17.6 13.0 41.7 76.5 97.0 82.9 73.0 66.9 5.6   
HSP74_HUMAN HSPA4 p-S648 (z= 2) 4.7 3.9 3.1 2.8 3.9 4.3 9.3 4.3 15.3 51.3 5.5   
NP1L4_HUMAN NAP1L4 p-S126 (z= 3) 31.4 39.1 27.3 13.1 27.9 94.1 80.8 78.1 70.4 58.6 5.4   
TIF1B_HUMAN TRIM28 p-S51 (z= 3) 30.2 17.2 7.4 9.2 5.9 88.5 82.5 70.2 49.5 53.5 5.4   
HS90B_HUMAN HSP90AB1 p-S227 (z= 2) 10.5 0.0 0.0 11.8 24.9 71.1 90.5 79.1 62.5 50.1 5.3   
SRRM1_HUMAN SRRM1 p-S798 (z= 2) 89.3 8.8 32.7 7.0 0.0 62.4 40.2 19.4 36.4 27.7 5.2   
MP2K2_HUMAN MAP2K2 p-T395 (z= 2) 9.6 8.4 8.4 7.1 11.2 5.5 64.1 0.0 37.0 50.0 5.2   
PSD3_HUMAN PSD3 p-S339 (z= 2) 15.7 21.8 10.4 13.7 0.0 90.4 90.6 88.8 70.6 48.8 5.2   
TB182_HUMAN TNKS1BP1 p-S1025 (z= 3) 16.3 0.0 11.7 10.9 13.8 90.4 66.5 74.7 55.5 60.3 5.1   
CALX_HUMAN CANX p-S584 (z= 3) 23.9 23.6 18.6 15.5 27.4 85.9 72.7 70.4 77.0 84.8 5.0   
LEO1_HUMAN LEO1 p-S172 (z= 2) 0.0 0.0 0.0 10.7 0.0 66.9 77.3 65.6 52.9 45.2 5.0   
CX026_HUMAN CXorf26 p-S198 (z= 3) 71.2 32.2 46.0 15.7 36.7 96.0 76.7 86.2 75.2 65.3 4.8   
SNX9_HUMAN SNX9 p-S182 (z= 3) 71.2 32.2 46.0 15.7 36.7 96.0 76.7 86.2 75.2 65.3 4.8   
TBA1A_HUMAN TUBA1A p-S49 (z= 2) 0.0 0.0 8.7 17.1 17.8 55.2 74.8 66.3 81.9 97.7 4.8   
SMAP_HUMAN SMAP p-S16 (z= 3) 44.1 47.5 34.5 13.8 33.0 92.1 83.2 76.0 63.2 69.1 4.6   
MARCS_HUMAN MARCKS p-S146 (z= 2) 40.4 19.8 36.4 13.6 28.3 84.5 79.2 58.7 61.6 61.3 4.5   
TCOF_HUMAN TCOF1 p-S1351 (z= 2) 19.5 0.0 13.6 18.5 31.1 55.9 47.7 55.4 82.9 79.3 4.5   
COPB2_HUMAN COPB2 p-T870 (z= 3) 26.4 74.1 63.6 17.5 19.8 34.2 78.6 73.4 77.7 84.9 4.4   
HDGF_HUMAN HDGF p-S133 p-S134 (z= 2) 15.9 26.8 12.8 11.0 17.6 61.5 96.6 71.9 48.2 45.7 4.4   
SRRM1_HUMAN SRRM1 p-S770 p-S776 (z= 3) 10.3 0.0 0.0 11.8 29.1 23.3 90.3 74.8 51.5 46.2 4.4   
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DPOD3_HUMAN POLD3 p-S308 (z= 2) 0.0 36.2 39.6 20.2 46.6 8.2 61.8 71.7 88.0 86.0 4.4   
LA_HUMAN SSB p-S367 (z= 4) 31.5 49.4 53.7 22.3 52.4 85.2 83.5 77.4 96.4 85.7 4.3   
AGM1_HUMAN PGM3 p-S65 (z= 2) 5.5 5.0 8.4 11.7 15.1 84.6 58.7 45.7 50.5 51.1 4.3   
CHSP1_HUMAN CARHSP1 p-S53 (z= 2) 30.0 29.1 19.4 14.3 35.7 38.2 29.3 37.8 61.0 87.4 4.3 * 
SSH3_HUMAN SSH3 p-S38 (z= 2) 6.3 17.0 43.3 17.0 57.3 20.8 37.1 57.5 71.8 99.7 4.2   
RSLBA_HUMAN RSLBA p-S42 (z= 2) + oxidation 6.3 17.0 43.3 17.0 57.3 20.8 37.1 57.5 71.8 99.7 4.2   
HSPB1_HUMAN HSPB1 p-S83 (z= 2) 11.1 19.8 29.1 19.0 69.9 14.1 21.4 41.7 79.0 94.1 4.2   
G3BP1_HUMAN G3BP1 p-S233 (z= 2) 50.3 46.4 40.6 13.9 24.7 96.0 67.5 47.9 57.6 52.0 4.2   
CX026_HUMAN CXorf26 p-S198 (z= 2) 53.8 16.4 32.0 17.5 33.5 88.4 81.0 79.4 72.6 63.7 4.2   
RSRC2_HUMAN RSRC2 p-S31 (z= 2) 36.7 56.2 40.4 16.0 37.8 80.3 60.2 47.8 65.8 68.4 4.1   
ANK1_HUMAN ANK1 p-T15 (z= 2) 2.2 3.0 11.5 10.1 34.9 10.6 14.9 35.5 40.4 94.6 4.0   
BCLF1_HUMAN BCLAF1 p-S178 (z= 2) 49.8 59.9 43.5 18.1 32.5 87.0 65.2 65.8 71.3 71.5 3.9   
E41L1_HUMAN EPB41L1 p-S651 (z= 2) 0.0 28.9 6.9 18.0 28.4 15.2 58.0 97.9 70.6 62.6 3.9   
SRRM1_HUMAN SRRM1 p-S697 (z= 2) 52.1 44.5 59.0 22.6 65.4 87.1 64.5 77.1 88.6 93.2 3.9   
CTR9_HUMAN CTR9 p-T976 (z= 2) 12.4 5.1 3.5 18.9 61.6 36.2 86.5 89.4 73.4 69.0 3.9   
NP1L4_HUMAN NAP1L4 p-S126 (z= 3) 29.0 0.0 31.9 8.6 0.0 88.5 73.7 22.6 33.1 71.2 3.9   
SRRM1_HUMAN SRRM1 p-S598 (z= 2) 50.9 73.5 46.6 13.7 35.7 71.8 47.5 50.5 51.7 59.5 3.8   
HDGF_HUMAN HDGF p-S166 (z= 3) 48.1 55.7 49.8 19.6 44.8 94.1 61.9 56.0 73.6 69.5 3.7   
NIBL1_HUMAN FAM129B p-S653 (z= 3) 0.0 0.0 6.1 2.2 100.0 0.0 0.0 10.0 8.1 12.2 3.7   
MYL9_HUMAN MYL9 p-S21 (z= 2) + oxidation 67.5 52.1 61.2 20.7 34.1 83.1 52.0 54.3 77.3 79.1 3.7   
IWS1_HUMAN IWS1 p-S514 (z= 3) 15.4 7.1 12.3 16.6 24.8 50.0 80.7 62.7 61.5 58.0 3.7   
ZC3HF_HUMAN ZC3H15 p-S382 (z= 2) 0.0 0.0 43.6 21.7 40.0 0.0 15.9 34.2 80.4 93.5 3.7   
PDPK1_HUMAN PDPK1 p-S242 (z= 2) 74.4 66.1 54.1 17.4 37.5 95.3 91.4 74.2 64.4 82.4 3.7   
PEBP1_HUMAN PEBP1 p-S53 (z= 2) 73.7 74.4 52.0 17.5 35.4 91.1 76.6 80.1 64.1 73.5 3.7   
RFIP1_HUMAN RAB11FIP1 p-S235 (z= 3) 0.0 0.0 0.0 23.8 0.0 0.0 0.0 50.0 87.2 0.0 3.7   
MARK2_HUMAN MARK2 p-S572 (z= 2) 0.0 22.9 28.2 21.4 14.7 0.0 36.9 61.2 77.1 91.1 3.6   
E41L1_HUMAN EPB41L1 p-S668 (z= 2) 2.3 1.9 1.5 21.3 3.5 14.6 8.4 58.7 76.6 88.5 3.6   
GFPT1_HUMAN GFPT1 p-S262 (z= 2) 37.3 40.1 41.2 23.4 30.1 90.0 94.1 81.2 83.3 77.9 3.6   
SRRM1_HUMAN SRRM1 p-S739 (z= 2) 44.0 29.6 54.5 24.4 55.9 58.5 74.3 78.6 86.5 90.4 3.5   
I2BP2_HUMAN IRF2BP2 p-S361 (z= 3) 81.2 87.0 87.9 21.9 47.1 79.7 52.7 57.6 77.7 76.0 3.5   
SOX9_HUMAN SOX9 p-S217 (z= 4) 88.8 82.0 36.8 20.5 63.4 24.3 66.9 56.9 72.2 50.0 3.5   
YBOX1_HUMAN YBX1 p-S175 (z= 2) 0.0 0.0 0.0 23.5 66.8 15.5 57.8 84.8 79.6 86.2 3.4 * 
GRLF1_HUMAN GRLF1 p-S976 (z= 3) 47.6 46.5 34.2 19.3 12.0 95.8 66.5 57.6 64.9 54.2 3.4   
HUWE1_HUMAN HUWE1 p-S1908 (z= 2) 28.4 25.2 20.2 13.9 21.7 83.6 59.6 62.1 46.8 53.8 3.4   
DCAF5_HUMAN DCAF5 p-S629 (z= 2) 78.0 65.2 48.4 14.6 45.2 93.4 59.4 44.1 48.5 24.1 3.3   
SFRS7_HUMAN SFRS7 p-S193 (z= 2) 22.5 40.1 37.0 28.5 68.0 34.4 84.4 95.0 94.4 81.2 3.3   
TTL12_HUMAN TTLL12 p-S17 (z= 3) 90.6 79.4 37.5 27.0 61.7 83.4 93.4 81.4 88.3 39.6 3.3   
H90B2_HUMAN HSP90AB2P p-S178 (z= 3) 7.1 3.5 12.7 21.7 65.8 59.7 97.0 87.2 70.7 62.5 3.3   
DC1L2_HUMAN DYNC1LI2 p-S195 (z= 2) 42.7 51.3 27.5 16.5 45.0 93.9 91.1 77.1 53.6 55.5 3.3   
WAC_HUMAN WAC p-S512 (z= 3) 56.7 49.8 40.6 20.0 26.5 73.7 47.9 55.4 64.4 76.8 3.2   
AHNK_HUMAN AHNAK p-S5732 (z= 2) 42.6 72.5 25.2 10.6 23.2 63.4 41.2 30.6 33.9 36.3 3.2   
LMNA_HUMAN LMNA p-S393 (z= 2) 25.1 20.3 38.4 25.8 32.0 45.7 71.4 74.4 82.0 93.8 3.2 * 
AHNK_HUMAN AHNAK p-S217 (z= 2) 79.4 73.0 77.6 29.2 63.4 99.4 73.2 77.1 92.8 92.0 3.2   
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PARVA_HUMAN PARVA p-T37 (z= 2) 0.0 0.0 0.0 21.0 8.5 0.0 8.3 46.5 66.9 92.1 3.2   
PHYD1_HUMAN PHYD1 p-T126 (z= 2) 0.0 0.0 0.0 21.0 8.5 0.0 8.3 46.5 66.9 92.1 3.2   
DOCK3_HUMAN DOCK3 p-S837 (z= 2) 0.0 0.0 0.0 21.0 8.5 0.0 8.3 46.5 66.9 92.1 3.2   
IQGA1_HUMAN IQGA1 p-S815 (z= 2) 0.0 0.0 0.0 21.0 8.5 0.0 8.3 46.5 66.9 92.1 3.2   
G3P_HUMAN GAPDH p-S84 (z= 2) 68.5 33.6 34.5 19.5 35.5 99.7 64.1 26.8 61.7 66.6 3.2   
HDGF_HUMAN HDGF p-S166 (z= 2) 33.1 28.2 20.7 24.1 46.9 93.2 78.2 70.2 75.9 64.6 3.2   
ATX2L_HUMAN ATX2L p-S410 (z= 2) 33.1 28.2 20.7 24.1 46.9 93.2 78.2 70.2 75.9 64.6 3.2   
AKAP3_HUMAN AKAP3 p-S206 (z= 2) 33.1 28.2 20.7 24.1 46.9 93.2 78.2 70.2 75.9 64.6 3.2   
IF2B_HUMAN EIF2S2 p-T34 (z= 3) + oxidation 0.0 0.0 0.0 28.5 0.0 0.0 34.4 50.5 89.4 86.7 3.1   
MCM2_HUMAN MCM2 p-S28 (z= 2) 57.3 56.5 49.3 20.3 50.0 90.5 59.6 55.4 63.6 67.2 3.1   
SRRM1_HUMAN SRRM1 p-S739 p-S741 (z= 2) 6.8 4.9 0.0 17.4 17.4 51.6 65.8 54.9 53.8 51.2 3.1   
RHG12_HUMAN ARHGAP12 p-S241 (z= 3) 20.0 47.2 22.3 26.0 64.2 91.7 75.6 80.7 80.3 71.1 3.1   
LRRF2_HUMAN LRRFIP2 p-S329 (z= 2) 42.9 40.5 32.1 15.7 18.0 94.2 51.6 48.6 48.3 49.0 3.1   
TLE3_HUMAN TLE3 p-S204 (z= 2) 58.8 43.0 28.0 18.4 34.8 95.9 67.3 60.3 56.7 52.0 3.1   
SPTB2_HUMAN SPTBN1 p-S2103 (z= 2) 90.7 68.0 76.5 25.6 62.6 70.6 49.4 68.9 78.6 85.1 3.1   
RS17_HUMAN RPS17 p-S114 (z= 2) 3.1 17.2 28.1 27.5 55.7 4.2 53.6 66.3 84.2 62.0 3.1   
PAXI_HUMAN PXN p-S534 (z= 3) 88.6 98.4 70.7 18.1 41.5 70.7 20.6 38.8 55.5 47.1 3.1   
HDGF_HUMAN HDGF p-S133 p-S134 (z= 3) 24.4 28.4 15.3 17.9 27.5 60.3 98.3 72.9 54.2 49.0 3.0   
TCAL3_HUMAN TCEAL3 p-S122 (z= 2) 82.8 62.6 79.1 21.4 55.9 70.2 70.6 55.2 64.5 58.2 3.0   
AKT1_HUMAN AKT1 p-S125 (z= 2) + oxidation 0.0 0.0 0.0 28.7 0.0 71.7 99.3 76.7 84.7 76.3 3.0   
PYRG1_HUMAN CTPS p-S576 (z= 3) 26.5 39.2 30.4 15.2 9.9 98.1 69.1 50.6 43.0 42.2 2.8   
ADIP_HUMAN SSX2IP p-T7 (z= 3) 0.0 0.0 0.0 28.9 0.0 47.3 17.7 50.0 81.6 71.0 2.8   
APIP_HUMAN APIP p-S88 (z= 2) 52.8 16.2 24.5 31.0 73.0 54.7 69.0 64.1 87.5 79.3 2.8   
NIBL1_HUMAN FAM129B p-S679 (z= 2) 64.6 57.0 49.0 22.4 35.8 98.4 76.8 59.6 63.0 61.2 2.8   
FA40A_HUMAN FAM40A p-S336 (z= 2) 12.0 4.8 11.2 13.9 1.7 91.8 59.4 72.9 38.8 82.3 2.8   
RSRC2_HUMAN RSRC2 p-S33 (z= 2) 55.1 60.4 55.1 28.6 48.6 96.8 66.4 69.8 79.1 78.9 2.8   
ZEP2_HUMAN HIVEP2 p-S2131 (z= 2) 13.5 5.7 0.0 30.0 38.1 55.9 62.4 65.0 81.9 77.8 2.7   
MELT_HUMAN VEPH1 p-S784 (z= 2) 13.5 5.7 0.0 30.0 38.1 55.9 62.4 65.0 81.9 77.8 2.7   
HSPB1_HUMAN HSPB1 p-S84 (z= 2) 6.1 8.0 17.8 15.2 57.4 10.3 13.9 33.1 41.4 90.5 2.7   
NP1L4_HUMAN NAP1L4 p-S126 (z= 3) 49.4 37.3 39.2 21.8 49.5 82.8 86.0 80.1 59.3 60.6 2.7   
COHA1_HUMAN COL17A1 p-S149 (z= 2) 5.8 0.0 0.0 18.6 72.4 8.2 25.7 23.7 50.4 60.4 2.7   
HMGA1_HUMAN HMGA1 p-S100 p-S103 (z= 3) 0.0 0.0 7.6 26.6 6.4 0.0 73.7 93.2 72.2 52.6 2.7   
CHD4_HUMAN CHD4 p-S1536 (z= 2) 50.0 27.1 32.3 28.6 56.9 51.6 68.3 76.7 77.3 93.8 2.7   
SRRM1_HUMAN SRRM1 p-S432 (z= 2) 27.8 17.6 26.3 25.3 78.0 20.4 35.0 63.1 68.1 92.4 2.7   
MYL9_HUMAN MYL9 p-T20 p-S21 (z= 2) 4.6 6.8 17.0 15.4 31.7 36.0 27.6 98.4 40.8 47.6 2.7   
HSF1_HUMAN HSF1 p-S304 (z= 2) 53.7 73.7 49.6 11.5 24.3 43.7 29.3 25.4 30.5 33.9 2.6   
SRRM1_HUMAN SRRM1 p-S561 (z= 2) 8.9 0.0 0.0 3.8 0.0 62.0 20.0 0.0 10.2 0.0 2.6   
F10A1_HUMAN ST13 p-S77 p-S80 (z= 4) 15.8 14.2 18.4 15.0 22.4 50.6 50.0 69.1 39.4 43.4 2.6   
F10A4_HUMAN FAM10A4 p-S73 (z= 4) + oxidation 15.8 14.2 18.4 15.0 22.4 50.6 50.0 69.1 39.4 43.4 2.6   
BL1S3_HUMAN BLOC1S3 p-S28 (z= 2) 20.4 24.4 0.0 16.5 0.0 90.8 54.1 34.9 43.0 27.1 2.6   
SPTA2_HUMAN SPTAN1 p-S1218 (z= 2) 41.1 36.4 37.3 23.8 41.7 87.2 63.2 63.6 61.8 63.5 2.6   
SRF_HUMAN SRF p-S225 (z= 3) 89.8 64.9 67.8 28.9 38.0 91.2 64.3 67.4 74.6 82.8 2.6   
RLA2_HUMAN RPLP2 p-S106 (z= 2) + oxidation 5.1 21.7 23.3 30.1 53.4 15.9 68.0 74.9 77.5 95.7 2.6   
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NDRG1_HUMAN NDRG1 p-S331 (z= 2) 40.7 46.2 30.0 22.1 49.5 38.0 27.9 35.7 56.4 87.5 2.6   
KPCD_HUMAN PRKCD p-S646 (z= 2) 42.6 64.1 40.9 18.6 38.0 80.9 60.6 62.8 47.5 46.0 2.6   
HDGF_HUMAN HDGF p-S134 (z= 3) 68.0 74.6 59.0 24.1 48.6 91.3 61.4 51.6 61.4 62.6 2.5   
BRAF_HUMAN BRAF p-S366 (z= 3) 51.7 61.9 52.6 26.8 29.8 74.7 55.1 50.8 67.1 21.5 2.5 * 
HDGF_HUMAN HDGF p-S134 (z= 3) 85.3 57.5 55.4 27.1 61.5 72.0 63.7 66.5 67.7 58.5 2.5   
ABCF1_HUMAN ABCF1 p-S110 (z= 3) 14.7 69.1 64.2 37.3 91.2 12.6 67.3 84.3 92.9 72.4 2.5   
RBM39_HUMAN RBM39 p-S137 (z= 3) 68.9 77.2 59.6 25.8 40.5 84.2 60.8 65.2 63.9 67.3 2.5   
RS17_HUMAN RPS17 p-S116 (z= 3) 5.8 15.3 28.7 32.4 71.7 4.6 46.8 60.9 79.0 50.1 2.4   
ICAL_HUMAN CAST p-S244 (z= 3) 49.4 35.8 35.1 23.6 29.3 91.5 71.5 52.8 57.5 38.9 2.4   
TB22A_HUMAN TBC1D22A p-S133 (z= 4) 65.3 0.0 0.0 14.7 93.3 35.3 46.1 0.0 35.6 38.6 2.4   
MRP_HUMAN MARCKSL1 p-S23 (z= 2) 98.2 87.3 87.6 18.4 75.5 63.1 44.1 37.9 44.4 44.4 2.4   
BAT3_HUMAN BAT3 p-S114 (z= 4) 95.7 80.7 66.0 27.7 56.3 71.2 58.8 56.6 66.8 54.6 2.4   
OSBP1_HUMAN OSBP p-S194 (z= 3) 14.1 34.0 19.3 21.6 34.9 89.9 87.7 67.6 52.0 49.3 2.4   
ILF3_HUMAN ILF3 p-S383 (z= 3) 48.2 12.3 27.5 20.0 64.9 60.5 67.5 58.4 47.7 45.1 2.4 * 
OGFR_HUMAN OGFR p-S316 (z= 3) 67.5 40.3 44.0 30.2 38.7 85.9 61.5 57.5 71.4 66.7 2.4   
CJ047_HUMAN C10orf47 p-S180 (z= 2) 71.6 84.4 69.8 24.6 43.3 79.0 46.7 47.2 58.1 61.2 2.4   
EMID1_HUMAN EMID1 p-T81 p-Y82 (z= 2) 72.8 55.2 90.6 30.0 86.7 85.9 50.3 62.4 70.1 94.6 2.3   
BRAF_HUMAN BRAF p-S730 (z= 2) 76.6 71.8 55.3 24.8 68.5 89.4 73.4 59.3 57.9 51.5 2.3 * 
SRRM1_HUMAN SRRM1 p-S617 (z= 2) 36.7 53.9 67.4 31.2 89.0 45.7 62.7 63.4 72.6 63.8 2.3   
AHNK_HUMAN AHNAK p-S5732 (z= 2) 62.9 67.5 49.4 27.8 43.6 89.4 63.0 55.7 64.5 67.2 2.3   
NU214_HUMAN NUP214 p-S431 (z= 2) 43.6 62.8 14.3 28.2 0.0 94.6 53.9 57.5 65.5 47.3 2.3   
HTSF1_HUMAN HTATSF1 p-S580 (z= 2) 0.0 0.0 0.0 32.8 5.1 17.3 56.4 22.7 76.0 38.5 2.3   
HEG1_HUMAN HEG1 p-T1083 (z= 2) 93.4 43.2 86.8 15.6 30.2 34.2 56.8 62.5 36.1 37.3 2.3   
ANK3_HUMAN ANK3 p-S1406 (z= 2) 45.9 37.4 46.3 36.7 57.3 58.9 86.6 81.7 84.8 90.4 2.3   
PHC3_HUMAN PHC3 p-S264 (z= 2) 21.3 20.6 21.1 30.1 66.7 46.4 45.0 39.4 69.1 76.4 2.3   
CDR2L_HUMAN CDR2L p-S180 (z= 3) 43.1 45.6 37.8 30.7 42.6 71.6 50.3 44.6 70.3 64.2 2.3   
SRRM2_HUMAN SRRM2 p-S2582 (z= 2) 60.3 68.9 78.5 16.4 39.9 39.9 24.4 29.8 37.4 36.6 2.3   
SFRS2_HUMAN SFRS2 p-S27 (z= 2) 36.1 2.6 16.1 38.6 84.6 50.0 74.4 82.8 87.1 61.3 2.3   
SCRIB_HUMAN SCRIB p-S1310 (z= 3) 97.5 78.8 60.6 30.1 59.2 81.3 80.0 82.4 67.7 65.1 2.3   
SFRS2_HUMAN SFRS2 p-S190 p-S192 (z= 2) 2.2 7.2 4.3 15.4 69.6 19.5 63.6 48.8 34.4 35.2 2.2   
RBM27_HUMAN RBM27 p-S121 (z= 2) 34.0 9.0 13.0 20.6 47.1 56.5 40.0 32.3 45.4 31.1 2.2   
SRRM1_HUMAN SRRM1 p-S875 (z= 2) 10.5 56.8 56.8 39.2 98.3 4.6 63.6 78.3 85.8 84.2 2.2   
LRRF1_HUMAN LRRFIP1 p-S117 (z= 2) 0.0 25.4 57.6 30.3 80.3 2.2 47.1 72.3 65.8 97.7 2.2   
CG055_HUMAN CG055 p-Y30 (z= 2) 82.2 81.3 77.9 32.9 69.0 81.1 61.5 60.6 71.1 81.3 2.2   
HTSF1_HUMAN HTATSF1 p-S454 (z= 3) 72.7 79.7 66.4 28.4 35.1 87.1 51.6 48.5 61.4 67.0 2.2   
NUCKS_HUMAN NUCKS1 p-S205 p-S215 (z= 3) 45.1 50.4 35.0 25.5 57.7 75.9 88.1 68.6 54.9 57.3 2.2   
KAP2_HUMAN PRKAR2A p-S100 (z= 2) 51.7 82.8 59.5 19.7 33.0 65.5 48.5 41.7 42.3 50.8 2.1   
CALX_HUMAN CANX p-S555 (z= 2) 0.0 0.0 0.0 41.9 19.7 74.1 91.1 91.2 89.4 82.6 2.1   
DC1L2_HUMAN DYNC1LI2 p-S195 (z= 3) 58.4 66.1 42.7 22.7 44.1 92.8 83.4 69.7 48.3 48.1 2.1   
ZO3_HUMAN TJP3 p-S361 (z= 2) 0.0 13.4 47.1 37.6 91.0 4.0 56.6 70.7 78.3 83.4 2.1   
NDKB_HUMAN NME2 p-T95 (z= 2) 38.1 34.8 36.3 14.2 31.2 78.9 40.2 37.8 29.4 28.4 2.1   
NPM_HUMAN NPM1 p-S138 (z= 2) 0.0 9.2 9.0 19.8 36.7 8.1 27.0 55.1 40.9 85.9 2.1   
CNTP4_HUMAN CNTNAP4 p-S521 (z= 2) 0.0 9.2 9.0 19.8 36.7 8.1 27.0 55.1 40.9 85.9 2.1   
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ICAL_HUMAN CAST p-S244 (z= 4) 83.2 71.5 46.3 28.5 53.9 59.2 79.8 64.1 58.7 46.3 2.1   
HS90A_HUMAN HSP90AA1 p-S264 (z= 3) 21.4 15.2 14.8 30.2 37.8 71.8 93.2 86.8 62.1 55.0 2.1   
SRRM1_HUMAN SRRM1 p-S714 (z= 3) 62.9 71.2 17.2 16.8 43.6 58.2 28.6 29.2 34.5 40.5 2.1   
ZNRF2_HUMAN ZNRF2 p-S136 (z= 2) 61.8 42.8 42.1 22.9 64.4 31.6 42.2 38.8 46.5 43.7 2.0   
ZO3_HUMAN TJP3 p-S165 (z= 2) 71.3 58.6 44.1 23.5 44.0 86.0 65.5 51.4 47.5 46.0 2.0   
TPIS_HUMAN TPI1 p-S22 (z= 2) 95.7 76.3 98.1 24.7 39.8 68.1 51.3 43.0 49.8 54.1 2.0   
IF2P_HUMAN EIF5B p-S138 (z= 3) + oxidation 18.1 42.6 41.3 43.3 66.1 45.9 89.9 73.1 87.2 67.7 2.0   
MMTA2_HUMAN MMTAG2 p-T216 p-S221 (z= 3) 55.3 34.9 28.1 32.5 76.5 92.0 91.5 93.1 65.4 62.4 2.0   
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Appendix 5 
Summary of kinase activities identified in P31/Fuj and Kasumi-1 cells using GKAP (Chapter 
6.3.). 
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ZCCHV_HUMAN ZC3HAV1 p-S323 (z= 2) 0.01 2.78 35.49 95.89 0.01 0.13 0.27 0.28 134.16 0.70 
RL29_HUMAN RPL29 p-S143 (z= 2) 0.00 17.15 76.67 95.70 0.00 0.38 0.57 0.56 189.52 1.51 
HNRPU_HUMAN HNRNPU p-S60 (z= 3) 0.01 38.62 11.21 29.55 0.01 0.06 0.41 0.35 79.40 0.84 
OSTP_HUMAN SPP1 p-S312 (z= 2) 0.00 13.00 0.01 20.31 0.00 0.01 0.47 0.01 33.33 0.49 
TR150_HUMAN THRAP3 p-S212 (z= 2) 0.05 5.16 0.28 91.57 0.05 0.99 1.82 2.60 97.06 5.46 
PHF6_HUMAN PHF6 p-T359 (z= 2) 0.01 13.84 18.32 89.70 0.01 1.43 2.44 3.37 121.87 7.25 
TAOK3_HUMAN TAOK3 p-T317 (z= 2) 0.05 8.51 0.26 88.51 0.05 3.60 3.99 4.17 97.33 11.80 
TFAM_HUMAN TFAM p-S125 (z= 2) 0.07 28.14 35.15 54.85 0.07 3.02 9.06 9.73 118.21 21.88 
HNRPM_HUMAN HNRNPM p-S482 (z= 2) 4.14 15.00 43.84 77.07 4.14 9.97 12.15 9.10 140.06 35.35 
PRS33_HUMAN PRSS33 p-S100 (z= 2) 4.14 15.00 43.84 77.07 4.14 9.97 12.15 9.10 140.06 35.35 
LIMA1_HUMAN LIMA1 p-S727 (z= 2) 3.00 17.01 14.49 90.35 3.00 0.34 13.71 20.82 124.85 37.88 
ACINU_HUMAN ACIN1 p-T977 (z= 2) 2.66 6.23 18.58 94.60 2.66 6.29 14.13 18.57 122.07 41.66 
HNRPU_HUMAN HNRNPU p-S60 (z= 3) + oxidation 4.45 21.28 54.56 72.80 4.45 7.41 26.06 17.65 153.09 55.56 
ENPL_HUMAN HSP90B1 p-S65 (z= 2) 1.06 6.06 19.87 90.25 1.06 3.23 12.77 28.73 117.25 45.79 
CC124_HUMAN CCDC124 p-S142 (z= 2) 0.21 5.36 37.75 88.64 0.21 7.44 17.52 35.26 131.96 60.43 
NOLC1_HUMAN NOLC1 p-S644 (z= 2) 5.61 16.55 36.92 94.16 5.61 15.41 22.42 40.93 153.23 84.37 
MYL9_HUMAN MYL9 p-T20 (z= 2) + oxidation 13.34 26.61 73.83 29.08 13.34 8.31 43.37 29.87 142.85 94.89 
RCN1_HUMAN RCN1 p-T186 (z= 2) 1.19 3.50 10.07 97.45 1.19 9.07 23.02 46.21 112.20 79.49 
TBA1A_HUMAN TUBA1A p-T335 (z= 2) 2.22 2.69 21.63 99.58 2.22 6.33 25.86 56.68 126.13 91.09 
ACINU_HUMAN ACIN1 p-S329 (z= 2) 8.12 29.02 36.50 93.71 8.12 27.66 54.11 66.21 167.36 156.11 
ZC3HF_HUMAN ZC3H15 p-T349 (z= 2) 0.98 2.97 37.25 96.26 0.98 8.55 51.67 83.47 137.46 144.67 
2A5D_HUMAN PPP2R5D p-S599 (z= 2) 1.84 5.85 12.18 94.11 1.84 10.87 47.41 67.95 113.99 128.07 
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THOC4_HUMAN THOC4 p-S9 (z= 2) + oxidation 0.00 1.05 14.91 72.84 0.00 18.97 19.92 65.46 88.80 104.35 
CALX_HUMAN CANX p-S555 p-T563 (z= 2) 5.65 14.85 20.28 12.23 5.65 45.67 26.37 14.29 53.00 91.98 
PA2G4_HUMAN PA2G4 p-T387 (z= 2) 0.44 4.17 56.45 35.89 0.44 36.34 47.89 97.23 96.94 181.89 
TF2B_HUMAN GTF2B p-S71 (z= 2) 9.28 6.26 30.82 49.62 9.28 7.46 97.55 67.40 95.99 181.69 
HNRPK_HUMAN HNRNPK p-S380 (z= 2) 10.88 13.56 29.38 39.19 10.88 13.28 81.60 92.53 93.01 198.29 
ENPL_HUMAN HSP90B1 p-S747 (z= 2) 0.55 0.33 1.36 62.28 0.55 4.39 36.57 98.94 64.52 140.45 
CALR_HUMAN CALR p-S70 (z= 2) 0.00 2.72 25.06 40.85 0.00 24.47 36.85 92.40 68.63 153.73 
CBX3_HUMAN CBX3 p-S177 (z= 2) 4.80 6.18 21.41 50.34 4.80 18.10 68.75 96.59 82.73 188.23 
NONO_HUMAN NONO p-T374 (z= 2) 0.28 0.67 4.02 44.60 0.28 18.68 55.16 99.03 49.57 173.16 
CCAR1_HUMAN CCAR1 p-S215 (z= 2) 0.00 0.00 9.50 21.59 0.00 16.73 81.01 90.98 31.10 188.73 
RRBP1_HUMAN RRBP1 p-S979 (z= 2) 0.00 0.17 1.99 16.49 0.00 20.48 54.27 95.68 18.65 170.43 
LYRIC_HUMAN MTDH p-S295 (z= 2) 0.00 0.02 0.13 0.24 0.00 32.49 72.05 98.03 0.38 202.57 
TF2B_HUMAN GTF2B p-S71 (z= 2) + oxidation 0.00 0.00 0.06 0.15 0.00 0.83 37.62 83.21 0.21 121.66 
TRM6_HUMAN TRMT6 p-T292 (z= 2) 0.00 0.01 0.02 0.12 0.00 46.58 92.83 76.68 0.15 216.09 
OSTP_HUMAN SPP1 p-S220 (z= 2) 0.01 25.52 0.04 16.24 0.01 0.01 0.49 0.01 41.81 0.52 
ALS2_HUMAN ALS2 p-S493 (z= 2) 0.32 18.36 1.80 46.71 0.32 0.17 0.27 0.23 67.18 0.99 
HNRPM_HUMAN HNRNPM p-S576 (z= 2) 1.10 20.46 54.26 42.60 1.10 1.04 1.20 1.76 118.41 5.09 
STK4_HUMAN STK4 p-T341 (z= 2) 0.50 35.75 9.51 16.27 0.50 0.79 0.79 0.80 62.02 2.88 
NPTX1_HUMAN NPTX1 p-S123 (z= 2) + oxidation 0.65 34.74 5.10 11.09 0.65 0.68 0.58 0.53 51.58 2.45 
REPS1_HUMAN REPS1 p-S563 (z= 2) 0.65 34.74 5.10 11.09 0.65 0.68 0.58 0.53 51.58 2.45 
STK3_HUMAN STK3 p-T175 (z= 2) 1.64 48.15 37.80 4.50 1.64 1.00 2.78 2.03 92.10 7.45 
PRDM8_HUMAN PRDM8 p-S376 (z= 2) 3.99 15.93 39.15 97.27 3.99 4.17 4.57 4.82 156.35 17.55 
FA53B_HUMAN FA53B p-T29 (z= 2) 4.39 14.94 73.36 10.20 4.39 5.57 5.07 3.88 102.90 18.91 
ACLY_HUMAN ACLY p-S456 (z= 2) 20.55 69.94 86.30 63.34 20.55 23.95 8.82 17.21 240.13 70.54 
MST4_HUMAN MST4 p-T173 (z= 2) 13.95 60.09 98.21 66.88 13.95 14.28 22.37 22.13 239.13 72.73 
H90B2_HUMAN HSP90AB2P p-S178 (z= 2) 13.32 46.45 56.13 56.42 13.32 19.42 9.07 14.36 172.33 56.17 
MST4_HUMAN MST4 p-T171 (z= 3) 14.50 47.08 40.16 72.26 14.50 4.19 32.58 12.74 174.00 64.01 
SLU7_HUMAN SLU7 p-S216 (z= 2) 24.49 72.13 55.92 61.29 24.49 21.04 14.02 20.35 213.83 79.90 
NUCL_HUMAN NCL p-S68 (z= 2) 13.56 37.42 27.26 29.02 13.56 11.77 8.38 8.13 107.26 41.85 
HNRPM_HUMAN HNRNPM p-S619 (z= 2) + oxidation 19.19 61.26 41.93 65.45 19.19 16.36 20.05 19.29 187.82 74.89 
PDCD4_HUMAN PDCD4 p-S458 (z= 2) 23.69 60.93 48.11 53.99 23.69 25.33 17.01 17.50 186.71 83.52 
RBM14_HUMAN RBM14 p-S621 (z= 2) 13.50 8.62 46.37 96.68 13.50 9.23 21.01 34.61 165.17 78.36 
TIF1B_HUMAN TRIM28 p-S502 (z= 2) 21.42 46.92 69.37 90.69 21.42 18.12 36.79 39.71 228.40 116.04 
NEUG_HUMAN NRGN p-S37 (z= 2) 29.22 34.54 73.58 69.43 29.22 29.66 25.78 21.08 206.78 105.74 
ASPM_HUMAN ASPM p-S1834 (z= 2) 29.22 34.54 73.58 69.43 29.22 29.66 25.78 21.08 206.78 105.74 
CC106_HUMAN CC106 p-S199 (z= 2) 29.22 34.54 73.58 69.43 29.22 29.66 25.78 21.08 206.78 105.74 
NUCKS_HUMAN NUCKS1 p-S182 (z= 2) 27.32 64.14 61.62 60.03 27.32 41.53 32.63 21.26 213.11 122.75 
MP2K2_HUMAN MAP2K2 p-T395 (z= 2) 32.42 73.42 72.17 69.75 32.42 46.46 36.21 30.19 247.76 145.27 
BIN2_HUMAN BIN2 p-T455 (z= 2) 34.95 67.70 70.92 73.47 34.95 46.76 51.75 39.25 247.04 172.71 
SI1L3_HUMAN SIPA1L3 p-S1502 (z= 2) 18.15 57.12 43.95 72.77 18.15 57.85 19.09 48.70 191.99 143.79 
ZN319_HUMAN ZNF319 p-S329 (z= 2) 18.15 57.12 43.95 72.77 18.15 57.85 19.09 48.70 191.99 143.79 
TCEA3_HUMAN TCEA3 p-S146 (z= 2) 18.15 57.12 43.95 72.77 18.15 57.85 19.09 48.70 191.99 143.79 
KIT_HUMAN KIT p-Y704 (z= 2) 16.90 17.71 39.65 76.87 16.90 21.38 25.56 34.63 151.13 98.48 
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TBA1A_HUMAN TUBA1A p-S49 (z= 2) 41.34 63.43 83.86 96.51 41.34 32.47 80.30 88.23 285.13 242.33 
YBOX1_HUMAN YBX1 p-S314 (z= 2) 24.53 55.12 50.64 95.59 24.53 50.07 46.75 87.86 225.88 209.21 
4EBP1_HUMAN EIF4EBP1 p-S113 (z= 2) 2.24 3.61 0.11 100.00 2.24 4.20 19.67 26.94 105.96 53.06 
SNUT1_HUMAN SART1 p-T431 (z= 2) 3.52 15.67 0.21 94.10 3.52 24.80 52.24 83.04 113.49 163.60 
KCC2G_HUMAN CAMK2G p-S312 (z= 2) 2.79 60.45 0.09 2.40 2.79 27.86 53.45 28.63 65.73 112.71 
HTSF1_HUMAN HTATSF1 p-S617 (z= 2) 12.29 38.93 19.83 31.06 12.29 72.77 42.53 50.66 102.11 178.24 
ZCCHV_HUMAN ZC3HAV1 p-S285 (z= 2) 14.27 16.98 25.55 58.44 14.27 33.84 78.07 98.36 115.24 224.53 
ZCH18_HUMAN ZC3H18 p-S47 (z= 2) 10.88 15.94 12.22 17.93 10.88 43.74 33.74 43.97 56.97 132.33 
IF2P_HUMAN EIF5B p-S67 (z= 2) 15.18 15.43 10.90 28.19 15.18 23.05 69.50 95.58 69.71 203.30 
THOC4_HUMAN THOC4 p-S9 (z= 2) 2.21 9.09 0.15 41.07 2.21 7.56 78.46 68.34 52.52 156.57 
YBOX1_HUMAN YBX1 p-S175 (z= 2) 10.85 12.75 5.73 10.11 10.85 51.42 50.00 70.19 39.45 182.46 
U520_HUMAN SNRNP200 p-S226 (z= 2) + oxidation 0.79 1.18 1.34 1.60 0.79 19.42 6.21 2.14 4.91 28.56 
TBB2A_HUMAN TUBB2A p-T73 (z= 2) 4.29 10.33 0.04 8.92 4.29 5.95 56.70 80.80 23.59 147.74 
KIF4A_HUMAN KIF4A p-S1039 (z= 2) 0.95 0.82 5.38 0.79 0.95 8.37 30.74 26.41 7.95 66.47 
PERM_HUMAN MPO p-T176 (z= 2) 1.83 0.03 0.17 0.03 1.83 9.95 37.67 93.80 2.06 143.25 
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Appendix 6 
Summary of kinase activities identified in MCF10A cells stimulated with EGF and treated 
with the inhibitors  LY294002 or UO126 (Chapter 6.4.). 
 
 
- EGF + EGF + EGF + LY294002 + EGF + UO126 
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YBX1 p-S314 (z= 2) 0 0 0 0 0 0 94 100 74 92 0 0 0 0 0 0 0 0 0 0 1 1 1 
FAM129B p-S680 p-S684 
(z= 2) 25 18 49 41 32 25 30 38 39 53 25 75 45 33 99 37 66 35 61 100 0 0 0 
FAM129B p-S680 p-S684 
(z= 3) 9 9 31 36 17 9 20 31 26 34 9 71 40 33 100 9 38 19 27 52 0 0 0 
EIF4G1 p-S1210 (z= 2) 5 1 2 1 1 5 100 41 18 15 5 2 0 1 0 5 3 2 2 0 1 1 1 
FAM40A p-S336 (z= 2) 18 32 36 31 26 18 100 86 68 54 18 14 9 11 8 23 44 38 37 21 1 1 0 
FASN p-T2205 (z= 2) 47 64 74 68 61 47 92 100 99 70 47 51 46 50 35 58 86 82 83 38 0 1 0 
SEC16A p-S1906 (z= 2) 24 33 45 37 26 24 82 79 77 100 24 28 17 13 23 37 50 36 46 50 0 1 0 
MARCKS p-S146 (z= 2) 32 30 24 31 21 32 100 93 97 60 32 25 28 30 19 16 20 21 22 13 1 1 1 
HDGFRP2 p-S609 (z= 3) 15 10 24 17 30 15 63 64 72 100 15 13 24 10 27 8 27 45 24 38 1 1 0 
CANX p-S584 (z= 2) 13 6 4 2 1 13 100 99 40 35 13 21 5 13 3 13 59 42 49 13 1 1 0 
CANX p-S584 (z= 3) 4 6 4 2 1 4 86 100 35 26 4 34 8 21 4 4 97 69 80 23 0 1 0 
ARHGAP29 p-S356 (z= 2) 0 4 31 6 100 0 0 0 0 0 0 0 0 0 1 0 23 65 19 75 0 1 0 
HUWE1 p-S1396 (z= 2) 27 22 19 18 12 27 100 100 81 57 27 25 16 22 13 12 23 22 22 8 1 1 1 
NADL2 p-Y282 (z= 3) 16 21 31 20 16 16 100 97 97 50 16 48 25 39 20 6 44 33 37 19 1 1 1 
EDC3 p-T61 (z= 2) 2 17 12 12 6 2 10 55 62 31 2 84 74 100 47 0 5 5 6 3 1 0 1 
HDGF p-S166 (z= 2) 46 14 18 11 10 46 100 36 29 23 46 13 5 9 4 40 23 18 19 3 1 1 0 
NSUN2 p-S744 p-S752 (z= 
3) 0 3 29 17 14 0 17 41 40 76 0 21 3 5 14 0 87 48 74 100 0 1 0 
NSUN2 p-S744 (z= 3) 0 3 23 5 3 0 15 33 43 83 0 1 0 0 0 0 59 25 41 100 0 1 0 
PGM1 p-T116 (z= 2) 0 2 27 1 4 0 80 64 55 98 0 32 0 1 5 0 62 33 34 100 1 1 0 
PGM1 p-S118 (z= 3) 0 1 4 1 1 0 51 53 40 46 0 16 1 2 4 0 67 43 46 100 0 1 0 
TMPO p-T209 (z= 2) 88 30 37 33 6 88 9 4 100 86 88 57 17 25 11 26 7 9 9 3 0 1 1 
LRRFIP1 p-S769 (z= 2) 2 22 50 26 44 2 7 6 5 4 2 2 1 1 1 43 100 74 89 61 0 1 0 
C19orf21 p-S395 (z= 2) 21 76 74 44 54 21 70 100 100 86 21 24 24 22 20 30 39 33 32 36 0 1 1 
RNF20 p-S139 (z= 2) 36 51 68 100 61 36 94 92 78 60 36 30 24 27 21 63 94 75 88 65 0 1 0 
DBNL p-S270 (z= 2) 20 0 0 0 0 20 1 12 1 30 20 6 28 5 100 0 0 0 0 0 0 0 1 
DOCK5 p-S1757 (z= 2) 2 4 4 4 3 2 3 4 3 4 2 65 93 70 100 2 2 3 4 4 0 0 1 
EXOSC9 p-S307 (z= 2) 23 24 26 27 20 23 94 100 73 52 23 23 18 18 13 15 38 29 32 16 1 1 1 
SRRM1 p-S697 (z= 2) 23 36 29 30 19 23 83 94 100 76 23 32 29 28 22 10 27 33 31 21 1 1 1 
TRIP10 p-S297 (z= 2) 0 38 62 32 38 0 35 33 35 35 0 9 6 6 6 0 100 81 97 67 0 1 0 
TRIP10 p-S297 (z= 3) 0 16 29 18 15 0 73 75 100 73 0 0 0 0 0 2 35 29 32 28 1 1 1 
SSH3 p-S88 (z= 3) 0 0 0 0 0 0 1 1 1 1 0 0 0 0 0 0 98 82 100 75 0 1 0 
UBAC1 p-S99 (z= 2) 9 22 18 23 14 9 97 96 100 72 9 24 45 31 37 3 15 17 15 10 1 0 1 
FLNA p-S2153 (z= 2) 1 46 66 56 61 1 23 19 28 23 1 8 9 6 8 4 94 100 96 66 0 1 0 
FLNA p-S2153 (z= 3) 0 52 74 76 63 0 18 18 22 17 0 10 10 8 10 1 93 100 91 68 0 1 0 
FLNB p-S2108 (z= 2) 62 27 28 30 26 62 100 72 81 64 62 24 30 20 26 47 28 40 33 31 1 1 0 
CANX p-S75 (z= 2) 0 0 4 0 18 0 1 32 5 100 0 0 0 0 0 0 2 15 1 36 1 1 1 
PSMD2 p-S17 (z= 3) 0 0 0 0 0 0 16 51 92 100 0 47 34 19 52 0 53 41 61 83 1 0 0 
SEC31A p-S800 (z= 2) 1 13 12 8 7 1 71 52 35 23 1 88 78 100 70 0 15 17 15 9 0 0 1 
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SRRM2 p-T1004 (z= 2) 41 32 35 34 23 41 91 74 100 56 41 22 21 22 16 30 43 50 39 19 1 1 0 
ZC3H18 p-S47 (z= 2) 2 3 4 2 3 2 100 51 58 37 2 2 1 1 0 2 5 5 4 3 1 1 1 
CAD p-S1860 (z= 2) 18 60 58 65 66 18 100 82 83 57 18 19 17 19 14 42 74 77 77 38 0 1 0 
API5 p-S463 (z= 2) 0 0 0 0 0 0 43 34 75 100 0 1 1 1 0 0 0 0 0 0 1 1 1 
XPO6 p-S8 (z= 2) 0 31 11 55 58 0 0 33 17 30 0 26 100 24 51 0 8 12 4 33 0 0 0 
STMN1 p-S17 p-S26 (z= 2) 12 1 6 12 5 12 48 74 80 81 12 100 82 81 82 12 60 66 77 62 1 0 0 
STMN1 p-S17 (z= 2) 7 5 7 5 5 7 100 84 87 73 7 7 4 4 3 7 42 45 44 20 1 1 0 
ZC3HAV1 p-S285 (z= 2) 22 12 43 2 22 22 100 98 48 82 22 22 3 5 3 33 65 78 55 57 1 1 0 
IRF2BP1 p-S385 (z= 2) 0 2 1 2 1 0 2 2 4 2 0 74 100 65 40 0 1 1 1 1 0 0 1 
IRF2BPL p-S548 (z= 2) 2 19 13 22 11 2 88 99 100 63 2 9 16 14 11 1 12 9 10 9 1 1 1 
TNKS1BP1 p-S673 (z= 2) 12 30 25 26 18 12 87 100 100 72 12 21 20 21 14 9 22 26 24 14 1 1 1 
DFFA p-S316 (z= 2) 21 30 25 30 21 21 100 78 78 48 21 16 17 17 12 16 23 27 26 13 1 1 1 
PKN2 p-S584 (z= 2) 46 35 72 39 52 46 53 63 48 53 46 42 22 32 23 100 100 89 73 47 0 1 0 
WDPCP p-S20 (z= 2) 2 12 9 12 7 2 100 89 100 49 2 9 8 8 5 2 13 17 18 10 1 1 1 
CHMP2B p-S200 (z= 2) 49 7 10 6 5 49 100 91 52 36 49 14 5 9 4 49 36 24 28 4 1 1 0 
RSL1D1 p-S362 (z= 2) 20 38 34 32 30 20 67 73 100 71 20 19 42 40 27 31 46 62 46 36 1 0 0 
MYL9 p-T20 (z= 2) + 
oxidation 18 1 11 1 5 18 85 86 37 100 18 3 0 0 0 18 23 20 14 24 1 1 1 
MYL9 p-S21 (z= 3) + 
oxidation 9 0 34 0 2 9 89 100 34 92 9 4 0 0 0 9 29 26 15 33 1 1 1 
MYL9 p-T20 (z= 2) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 43 48 21 100 0 1 0 
MYL9 p-S21 (z= 3) 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 36 42 19 100 0 1 0 
SPPL2A p-T203 (z= 2) 0 32 27 23 17 0 100 40 84 56 0 19 13 11 6 1 25 30 27 12 0 1 0 
AHNAK2 p-S295 (z= 3) 5 75 67 67 24 5 100 95 99 57 5 83 56 70 37 1 74 59 62 51 0 0 0 
RRBP1 p-S979 (z= 2) 0 0 0 0 0 0 54 100 31 66 0 0 0 0 0 0 18 38 18 33 1 1 0 
EEF1B2 p-S107 (z= 2) 30 0 9 12 7 30 27 38 100 61 30 41 33 36 20 30 77 70 78 56 1 1 0 
TGBR3 p-S323 (z= 2) 3 100 82 95 75 3 39 41 42 28 3 9 8 12 7 14 74 75 85 59 0 1 0 
RPS3 p-T222 (z= 2) 24 98 75 68 61 24 93 100 95 71 24 31 34 32 24 36 63 51 59 44 0 1 0 
RAPGEFL1 p-S257 (z= 2) 100 14 13 13 31 100 35 36 22 41 100 40 42 34 46 96 16 17 14 30 1 0 0 
DYNC1LI2 p-S195 (z= 2) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 100 98 100 58 0 1 0 
HUWE1 p-S2363 (z= 2) 2 15 12 17 5 2 35 39 41 14 2 64 85 100 53 0 13 9 13 6 0 0 1 
ERGIC3 p-S117 (z= 2) 36 68 58 61 40 36 88 80 100 41 36 38 36 39 30 33 52 43 51 28 0 0 0 
RSRC2 p-S18 (z= 2) 0 98 100 79 69 0 1 0 1 0 0 0 0 0 0 0 90 88 100 55 0 1 0 
AHNAK p-S178 (z= 2) 33 74 47 60 39 33 95 96 100 48 33 49 48 54 31 27 34 28 35 24 1 0 0 
APIP p-S90 (z= 2) 5 27 27 31 19 5 90 59 100 61 5 37 33 33 22 2 25 28 29 19 1 0 1 
APIP p-S90 (z= 2) 16 58 47 49 22 16 23 19 100 62 16 44 36 24 19 4 33 43 41 26 0 0 0 
CHSTD p-S313 (z= 2) 4 78 71 62 56 4 52 48 52 36 4 84 96 100 74 0 66 67 74 41 0 0 0 
HSP90AA1 p-S232 (z= 2) 0 35 48 82 54 0 1 1 2 1 0 1 1 0 0 0 78 90 100 72 0 1 0 
SAMD9L p-T1038 (z= 3) 4 25 17 25 23 4 100 92 51 45 4 19 38 34 17 3 18 16 12 12 1 0 1 
EPB41L1 p-S651 (z= 2) 19 14 30 35 20 19 69 77 100 59 19 26 23 31 19 15 36 31 33 25 1 1 1 
HTATSF1 p-S580 (z= 2) 1 38 43 59 34 1 30 10 100 50 1 64 53 40 24 1 71 83 77 50 0 0 0 
TNKS1BP1 p-S1332 (z= 2) 2 3 12 6 16 2 30 54 30 100 2 1 3 1 10 1 12 18 12 26 1 1 1 
CDK11A p-S272 (z= 2) 13 1 12 17 8 13 39 43 100 50 13 14 17 14 14 13 49 42 49 38 1 1 0 
RGS3 p-S807 (z= 2) 36 100 84 97 54 36 88 79 81 50 36 26 33 35 24 51 82 70 87 44 0 1 0 
HARS2 p-S68 (z= 2) 4 78 71 62 56 4 52 48 52 36 4 84 96 100 74 0 66 67 74 41 0 0 0 
CTTNBP2NL p-S489 (z= 2) 27 81 65 66 47 27 100 89 91 54 27 29 25 28 15 41 57 53 63 30 0 1 0 
MAP4 p-S281 (z= 2) + 
oxidation 42 25 30 29 23 42 100 85 76 59 42 12 9 11 5 67 25 22 26 18 1 1 1 
MAP4 p-S281 (z= 2) 13 29 23 23 14 13 67 59 65 45 13 77 66 100 62 0 21 19 22 16 1 0 1 
MAP4 p-T283 (z= 3) 4 22 18 14 9 4 29 32 28 15 4 86 78 100 58 0 16 13 12 11 0 0 1 
MAP4 p-S508 (z= 2) 5 7 9 2 3 5 27 23 24 19 5 100 27 42 21 0 14 12 15 7 1 0 1 
ARFGAP2 p-S369 (z= 2) 8 2 32 6 55 8 9 44 8 88 8 5 28 6 47 5 16 48 10 100 0 0 0 
EAF1 p-S166 (z= 3) 1 51 86 41 32 1 36 36 43 24 1 19 10 16 8 1 98 94 100 63 0 1 0 
TJP2 p-S987 (z= 2) 3 54 100 76 50 3 66 68 99 97 3 38 30 21 35 3 99 58 92 87 0 1 0 
VCL p-S291 (z= 2) 20 12 26 8 12 20 100 95 87 66 20 24 4 10 5 20 56 54 50 26 1 1 0 
EPS8L1 p-S183 (z= 2) 1 13 12 11 7 1 47 53 79 55 1 27 33 29 20 1 90 90 100 67 1 1 0 
TRMT6 p-S289 (z= 2) 2 29 78 17 49 2 59 97 50 82 2 31 27 28 46 0 74 100 63 77 0 0 0 
SLK p-S778 (z= 2) 60 15 15 17 12 60 93 100 95 32 60 15 13 15 10 39 19 16 17 10 1 1 1 
VATF p-S105 (z= 2) 7 50 19 9 23 7 20 26 5 16 7 100 97 63 84 7 27 58 22 23 0 0 0 
UNC45A p-S494 (z= 2) 7 50 19 9 23 7 20 26 5 16 7 100 97 63 84 7 27 58 22 23 0 0 0 
COPE p-S100 (z= 2) 0 3 3 2 2 0 85 100 96 51 0 16 10 15 6 0 7 4 5 4 1 1 1 
TOP2B p-S1359 (z= 2) 7 50 19 9 23 7 20 26 5 16 7 100 97 63 84 7 27 58 22 23 0 0 0 
PAK4 p-S105 (z= 2) 0 40 37 56 18 0 23 13 100 62 0 42 30 26 19 0 13 21 23 20 0 0 0 
LASP1 p-S147 (z= 2) 0 1 1 1 0 0 6 11 100 61 0 1 1 1 1 0 43 48 34 26 0 1 0 
ZC3H15 p-S352 (z= 2) 1 0 1 0 2 1 32 84 28 96 1 9 24 7 53 1 22 43 19 100 1 0 0 
MAP4 p-T522 (z= 2) 30 31 31 29 16 30 74 72 100 68 30 29 41 30 25 23 24 21 27 23 1 0 1 
MAP4 p-T522 (z= 3) 18 35 38 36 15 18 80 82 100 59 18 49 74 47 42 10 24 22 23 25 1 0 1 
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PTGES3 p-S114 (z= 2) 12 0 2 2 2 12 21 25 34 22 12 28 7 13 6 12 97 78 100 52 0 1 0 
ANK1 p-S16 (z= 2) 100 14 13 13 31 100 35 36 22 41 100 40 42 34 46 96 16 17 14 30 1 0 0 
TUBB2C p-T137 (z= 3) 0 0 0 0 0 0 0 0 0 100 0 1 0 0 0 0 0 0 0 1 0 1 0 
TUBB4Q p-T137 (z= 3) 0 0 0 0 0 0 0 0 0 100 0 1 0 0 0 0 0 0 0 1 0 1 0 
ZKSCAN1 p-S14 (z= 2) 29 23 18 17 13 29 100 75 85 49 29 21 18 21 12 16 19 19 19 11 1 1 1 
PRKAR1A p-S84 (z= 2) 13 64 100 86 57 13 57 55 70 52 13 15 14 13 14 41 76 59 82 73 0 1 0 
SNRNP200 p-S226 (z= 2) 16 31 45 48 28 16 47 63 74 44 16 91 60 100 63 1 75 60 70 42 0 0 0 
NUCKS1 p-S215 (z= 2) 0 44 58 75 53 0 0 0 0 0 0 0 0 0 0 17 72 83 100 57 0 1 0 
NUCKS1 p-S215 (z= 2) 0 17 16 17 11 0 58 56 100 57 0 0 0 0 0 0 3 2 3 2 1 1 1 
NUCKS1 p-S215 (z= 3) 0 18 21 21 13 0 64 65 100 50 0 27 18 27 17 0 24 23 28 18 1 1 1 
HSP90B1 p-S65 (z= 2) 0 1 11 1 33 0 11 29 12 100 0 1 4 1 10 0 6 17 6 40 1 1 0 
GOLGA4 p-S267 (z= 2) 20 31 49 38 31 20 75 63 68 43 20 18 9 13 8 42 100 82 84 45 0 1 0 
ZRANB2 p-S121 (z= 2) 23 23 49 66 42 23 36 43 62 29 23 18 15 22 14 57 97 83 100 56 0 1 0 
SEC62 p-T159 (z= 2) 0 2 3 4 1 0 17 7 100 80 0 65 43 50 32 0 20 26 26 23 0 0 0 
YY1 p-S119 (z= 2) 24 14 22 23 16 24 100 86 97 49 24 21 16 19 9 21 35 25 33 13 1 1 1 
GSTP1 p-S44 (z= 2) 34 8 13 2 11 34 100 50 63 36 34 8 2 4 3 37 33 24 33 16 1 1 0 
NAP1L4 p-S126 (z= 3) 7 0 1 0 0 7 100 34 23 20 7 7 0 0 0 7 43 22 21 9 1 1 0 
PGRMC1 p-S182 (z= 3) 2 9 15 6 6 2 51 52 55 30 2 100 23 57 31 0 19 16 23 10 1 0 1 
TTC21A p-S271 (z= 3) + 
oxidation 3 31 22 20 19 3 92 100 70 30 3 26 28 31 15 0 27 20 21 13 1 0 1 
FOXK2 p-S399 (z= 2) 27 15 21 19 16 27 92 83 100 73 27 15 21 20 18 15 15 9 14 9 1 1 1 
KTN1 p-S78 (z= 2) 8 5 8 1 5 8 91 77 89 88 8 24 4 8 3 8 100 98 91 51 1 1 0 
HSP90AB1 p-S227 (z= 2) 0 51 57 100 57 0 19 21 40 19 0 11 20 16 14 12 85 90 90 61 0 1 0 
HSP90AB1 p-S227 (z= 2) 0 34 45 61 46 0 61 57 100 48 0 1 2 2 1 2 57 56 67 45 0 1 0 
HSP90AB1 p-S227 (z= 3) 0 51 74 100 77 0 3 4 6 3 0 1 1 1 1 0 88 78 86 68 0 1 0 
HSP90AB1 p-S227 (z= 2) 0 57 75 100 73 0 2 2 3 2 0 0 0 0 0 7 81 73 88 62 0 1 0 
EIF5B p-S67 (z= 2) 0 2 9 2 10 0 49 69 39 100 0 6 11 5 23 0 11 25 14 33 1 1 1 
SHC1 p-S427 (z= 2) 5 0 0 0 0 5 51 48 52 51 5 26 7 13 7 5 100 73 76 56 1 1 0 
SHC1 p-Y428 (z= 2) 5 0 0 0 1 5 51 48 52 51 5 26 7 13 7 5 100 73 76 56 1 1 0 
SRRM2 p-S1321 (z= 2) 33 25 22 19 13 33 100 68 65 36 33 17 14 15 8 18 21 20 19 11 1 1 1 
RFC1 p-S191 (z= 2) 1 38 96 15 53 1 74 94 62 64 1 45 29 31 36 0 100 99 95 78 0 1 0 
UBR3 p-S1422 (z= 2) 10 19 19 12 11 10 100 73 62 40 10 13 4 8 3 11 32 19 24 11 1 1 1 
BAG6 p-S974 (z= 2) 17 51 54 53 40 17 95 75 81 49 17 100 84 100 57 1 66 48 62 29 0 0 0 
SRRM2 p-S1330 (z= 2) 49 31 40 27 19 49 83 69 100 57 49 26 35 36 16 43 34 35 41 20 0 0 0 
GEMIN5 p-S779 (z= 2) 8 15 35 17 23 8 28 24 39 25 8 10 4 6 3 29 100 70 76 48 0 1 0 
TCEA1 p-S101 (z= 2) 26 47 40 51 36 26 96 81 100 58 26 29 36 36 25 20 44 40 46 28 1 1 1 
ARHGEF1 p-S787 (z= 2) 0 0 0 0 0 0 0 0 0 1 0 3 4 3 5 0 0 84 55 100 0 1 0 
ESYT2 p-S759 (z= 2) 2 31 68 36 28 2 22 36 48 50 2 13 7 5 15 2 69 46 62 100 0 1 0 
TFAM p-S125 (z= 2) 0 2 6 1 9 0 23 46 24 100 0 1 9 2 11 0 2 6 2 11 1 1 1 
RSRC2 p-S33 (z= 2) 29 24 23 21 13 29 94 95 100 55 29 38 19 30 18 13 25 23 26 11 1 1 1 
ZNF185 p-S469 (z= 2) 3 29 21 37 20 3 50 56 100 39 3 16 34 36 19 2 24 24 21 24 1 0 0 
HSP90AA1 p-S264 (z= 2) 15 25 36 49 38 15 54 43 73 47 15 22 16 21 15 23 100 66 79 52 0 1 0 
HSP90AA1 p-S264 (z= 3) 5 27 38 54 38 5 71 58 84 46 5 32 22 28 22 7 100 61 73 52 0 1 0 
HSP90AA1 p-S264 (z= 3) 1 4 6 4 3 1 40 51 100 60 1 14 12 14 13 1 42 29 41 31 1 1 0 
PSMA3 p-S251 (z= 2) + 
oxidation 0 29 45 56 30 0 1 0 1 0 0 0 0 0 0 10 88 78 100 69 0 1 0 
PSMA3 p-S251 (z= 2) 0 1 1 1 1 0 2 2 3 1 0 91 61 100 60 0 2 1 2 1 0 0 1 
TLE3 p-S204 (z= 2) 22 36 29 32 22 22 91 100 100 59 22 24 23 34 19 15 34 32 38 20 1 1 1 
STMN1 p-S39 (z= 2) 48 65 76 55 36 48 83 83 100 73 48 44 47 43 39 49 49 41 51 38 0 0 0 
LARP1 p-S522 (z= 2) 1 10 8 9 3 1 16 21 100 56 1 70 47 48 30 1 21 18 18 7 0 0 1 
BCLAF1 p-T495 (z= 2) 1 38 30 43 11 1 12 8 91 51 1 100 51 57 36 0 13 13 16 11 0 0 1 
SCAF8 p-S618 (z= 2) 29 36 35 38 27 29 100 82 62 39 29 25 18 21 14 29 43 35 40 19 1 1 0 
ATXN2L p-S595 (z= 2) 25 22 23 9 12 25 80 69 79 48 25 100 59 68 38 1 31 32 38 21 1 0 1 
HSP90AA1 p-S232 (z= 2) 0 2 3 6 4 0 13 10 100 51 0 43 64 42 36 0 41 47 44 40 0 0 0 
HIRIP3 p-S371 (z= 2) 0 29 26 33 15 0 91 88 100 49 0 0 0 0 0 0 29 23 32 12 1 1 1 
CDK11A p-S578 (z= 2) 1 19 15 13 8 1 27 46 47 17 1 100 71 98 52 0 6 6 8 5 0 0 1 
EPRS p-T889 (z= 2) 7 40 66 73 48 7 42 43 48 42 7 11 10 11 10 29 100 70 83 64 0 1 0 
SSB p-S367 (z= 3) 0 45 65 41 23 0 0 0 0 0 0 0 0 0 1 0 77 62 84 100 0 1 0 
CLNS1A p-S103 (z= 3) 8 0 4 0 0 8 49 37 69 46 8 48 2 13 2 8 100 63 94 63 1 1 0 
ACACA p-S30 (z= 2) 10 9 32 21 15 10 62 58 100 70 10 8 5 5 3 14 59 48 51 48 0 1 0 
RRAS2 p-S187 (z= 2) 5 63 100 47 50 5 21 20 31 24 5 7 4 5 3 36 69 73 91 61 0 1 0 
RAB9A p-S72 p-Y78 (z= 2) 0 0 1 5 9 0 3 8 9 4 0 31 100 62 58 0 0 0 0 1 0 0 1 
N4BP1 p-S289 (z= 2) 0 30 29 38 22 0 100 80 72 46 0 1 1 1 1 0 32 29 31 22 1 1 1 
MYO18A p-S141 (z= 2) 34 76 77 60 71 34 100 98 93 72 34 17 17 17 17 58 68 56 56 53 0 1 0 
GTF3C1 p-S1380 (z= 2) 1 27 21 28 20 1 88 93 100 57 1 25 24 30 16 0 20 21 20 15 1 1 1 
PDCD4 p-S458 (z= 2) 100 2 4 3 2 100 81 46 25 47 100 36 9 16 9 100 12 12 6 2 1 0 1 
EPB41L1 p-T687 (z= 2) 40 36 39 37 26 40 76 76 100 58 40 37 29 31 23 6 23 23 30 20 0 1 1 
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CXorf26 p-S198 (z= 2) 0 16 16 16 12 0 34 36 54 33 0 95 80 100 65 0 22 18 24 15 0 0 1 
MYH9 p-S1944 (z= 2) 0 45 40 83 36 0 6 7 19 8 0 71 100 83 58 0 33 38 44 31 0 0 0 
PPP1R7 p-S13 (z= 2) 0 0 0 0 0 0 0 0 0 0 0 39 28 17 100 0 0 0 0 0 0 0 1 
PGRMC1 p-S58 (z= 2) 6 2 44 37 37 6 26 21 37 33 6 12 10 9 15 10 77 74 100 78 0 1 0 
YAP1 p-S62 (z= 2) + 
oxidation 13 2 17 11 12 13 15 15 100 84 13 9 3 1 4 13 49 26 28 73 0 1 0 
YAP1 p-S62 (z= 2) 0 0 0 0 0 0 2 0 29 100 0 1 0 0 0 0 17 7 39 99 0 1 0 
DAB2IP p-S979 (z= 2) 3 24 25 20 16 3 96 85 100 46 3 29 30 34 17 1 14 14 16 9 1 1 1 
PDCD4 p-S77 (z= 2) 44 1 0 10 3 44 20 68 10 67 44 20 58 16 100 46 0 1 0 5 1 0 1 
MARCKSL1 p-S23 (z= 2) 12 30 26 28 18 12 100 85 99 67 12 31 20 27 14 6 28 22 27 15 1 1 1 
MARCKS p-S28 (z= 2) 1 72 68 40 36 1 42 39 54 44 1 42 30 36 28 1 91 77 100 75 0 1 0 
MARCKS p-S102 (z= 2) 49 40 40 45 26 49 32 32 41 33 49 57 73 100 78 41 26 27 36 20 0 0 1 
GSK3A p-Y280 (z= 2) 33 42 56 28 24 33 100 79 71 63 33 27 11 18 11 48 89 69 78 23 0 1 0 
SPTBN1 p-S2139 (z= 2) 26 28 40 18 20 26 89 79 100 65 26 25 12 17 8 29 50 47 53 30 0 1 0 
CSRP1 p-S193 (z= 2) 17 18 28 22 14 17 75 77 100 65 17 17 20 20 11 21 24 29 30 13 1 1 1 
PYGO2 p-T303 (z= 2) 22 20 18 18 11 22 75 79 100 53 22 19 19 23 17 8 13 14 13 8 1 1 1 
NMT1 p-S48 (z= 2) 27 46 36 24 21 27 98 76 100 64 27 27 32 40 23 14 21 30 25 15 1 1 1 
KRT15 p-S23 p-S35 (z= 2) 13 0 4 1 8 13 5 30 15 100 13 2 7 3 17 13 3 8 5 30 1 1 1 
KRT15 p-S35 (z= 2) 90 5 12 5 12 90 51 72 57 100 90 6 9 6 11 90 13 15 13 17 1 1 1 
KRT15 p-S35 (z= 3) 76 12 28 9 23 76 53 100 74 100 76 11 20 12 20 70 24 24 14 30 1 1 1 
AHNAK p-S5732 (z= 2) 19 49 29 25 17 19 79 80 100 44 19 27 27 36 22 10 13 11 13 7 1 1 1 
KRT5 p-S575 (z= 2) 15 11 43 10 44 15 33 79 32 100 15 9 11 6 21 20 32 48 26 60 0 1 0 
TPD52L2 p-S22 (z= 2) 2 0 1 0 0 2 14 9 10 9 2 4 0 0 0 2 100 74 85 51 0 1 0 
MCM2 p-S140 (z= 2) 3 4 64 27 22 3 73 78 100 60 3 47 32 38 24 1 71 57 92 51 0 1 0 
CALR p-S70 (z= 2) 0 12 53 12 22 0 10 14 28 100 0 0 0 0 0 0 18 47 20 20 0 1 0 
LARP1 p-S547 (z= 2) 8 14 42 24 20 8 44 35 100 100 8 13 5 3 10 10 57 38 36 59 0 1 0 
MCM2 p-S28 (z= 2) 53 10 14 5 5 53 100 58 55 39 53 16 4 9 4 53 35 29 31 3 1 1 0 
SNTB2 p-S111 (z= 2) 10 54 48 48 39 10 98 87 100 65 10 19 19 21 15 12 41 47 47 31 0 1 0 
CD2BP2 p-S195 (z= 2) 0 5 6 11 3 0 33 33 100 96 0 67 52 47 38 0 20 34 33 37 1 0 0 
NPM1 p-S244 (z= 2) 7 16 21 16 20 7 60 100 57 78 7 15 23 20 31 3 13 24 12 25 1 1 1 
HSPB1 p-S16 (z= 2) 100 23 30 38 34 100 11 12 14 10 100 52 94 80 73 62 20 20 18 29 0 0 1 
VCL p-S347 (z= 2) 1 1 1 1 1 1 8 6 6 3 1 10 5 9 5 1 99 71 100 25 0 1 0 
TMEM40 p-S138 (z= 2) 7 62 60 100 62 7 27 32 43 20 7 8 14 15 9 21 58 42 58 45 0 1 0 
LRRFIP1 p-S121 (z= 2) 8 64 66 92 65 8 66 58 100 57 8 14 28 25 22 14 84 70 81 67 0 1 0 
HN1L p-S70 (z= 2) 7 29 50 11 69 7 47 65 47 89 7 11 21 7 33 7 51 52 41 100 0 1 0 
HUWE1 p-S1908 (z= 2) 39 51 63 61 43 39 95 100 83 63 39 34 20 30 20 55 96 62 72 38 0 1 0 
NRD1 p-S95 (z= 2) 3 100 82 95 75 3 39 41 42 28 3 9 8 12 7 14 74 75 85 59 0 1 0 
FAM83H p-S937 (z= 2) 29 22 20 15 15 29 98 85 100 69 29 15 14 18 12 18 19 18 20 13 1 1 1 
TJAP1 p-S301 (z= 2) 45 8 15 3 7 45 100 88 96 84 45 29 6 11 6 45 45 45 56 32 1 1 0 
KIAA1522 p-S405 (z= 2) 16 52 54 38 39 16 100 83 77 47 16 19 12 17 10 26 62 53 65 37 0 1 0 
FAM83H p-S882 (z= 2) 7 19 16 16 10 7 69 68 100 53 7 13 13 15 7 7 27 30 30 19 1 1 1 
FAM83H p-S893 (z= 2) 10 65 55 52 40 10 100 90 89 61 10 18 16 20 12 14 63 61 66 39 0 1 0 
CDK12 p-S424 (z= 2) 29 34 52 18 21 29 100 87 71 73 29 22 6 9 4 39 58 43 58 26 0 1 0 
FAM83H p-S915 (z= 2) 6 20 20 19 13 6 58 67 100 59 6 10 12 11 9 5 15 15 16 13 1 1 1 
EWSR1 p-S511 (z= 2) 1 43 47 44 43 1 55 89 100 79 1 7 17 13 19 2 24 35 31 43 0 1 0 
ARFGEF2 p-S277 (z= 2) 24 50 49 53 42 24 100 94 86 61 24 33 32 37 30 24 80 44 50 29 0 1 0 
EGFR p-Y1198 (z= 2) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 95 100 90 23 0 1 0 
LCP1 p-S6 (z= 2) 0 0 0 0 0 0 0 0 0 0 0 100 39 77 35 0 0 0 0 0 0 0 1 
REPS1 p-S144 (z= 2) 0 10 12 8 8 0 100 93 76 56 0 29 31 40 28 0 15 18 18 13 1 0 1 
HNRNPK p-S380 (z= 2) 17 5 47 13 44 17 12 33 22 82 17 6 6 2 21 36 28 55 23 100 0 1 0 
SMN1 p-S29 (z= 2) 16 10 17 20 11 16 64 55 100 51 16 17 19 24 18 14 38 27 38 17 1 1 1 
HDGFRP2 p-T135 (z= 2) 37 52 73 33 32 37 100 94 96 76 37 40 17 30 18 9 94 89 98 62 0 1 0 
ABLIM1 p-S707 (z= 2) 14 14 9 13 9 14 47 29 57 27 14 40 99 100 61 1 10 5 6 5 0 0 1 
PRPSAP2 p-S228 (z= 2) 0 0 0 0 0 0 54 34 100 54 0 1 0 1 1 0 1 1 1 1 1 1 1 
FCHO2 p-S395 (z= 2) 0 1 1 0 0 0 0 0 1 0 0 100 51 47 28 0 1 1 1 0 0 0 1 
TP53I11 p-S15 (z= 2) 7 48 67 33 46 7 71 69 100 82 7 27 26 42 25 4 45 36 40 38 0 1 0 
MAPK14 p-T181 (z= 2) 0 0 58 0 67 0 1 2 1 4 0 1 1 1 1 1 24 44 29 100 0 1 0 
MAPK14 p-Y183 (z= 2) 0 1 58 0 68 0 1 2 1 4 0 1 1 1 1 1 25 44 29 100 0 1 0 
USP11 p-S537 (z= 2) 0 32 28 29 22 0 84 88 100 74 0 0 0 0 0 0 21 24 23 17 1 1 1 
FTH1 p-S180 (z= 2) 1 26 36 32 12 1 10 9 100 51 1 48 21 34 16 0 53 34 45 25 0 0 0 
PALLD p-S894 (z= 2) 16 9 8 9 5 16 19 20 18 22 16 94 100 92 75 9 6 5 5 2 0 0 1 
HSP90AB1 p-S256 (z= 2) 1 48 58 94 56 1 39 36 60 32 1 7 8 8 6 9 100 97 94 62 0 1 0 
HSP90AB1 p-S256 (z= 2) 0 78 75 82 65 0 39 40 49 30 0 2 2 3 2 8 90 97 100 65 0 1 0 
HSP90AB1 p-S256 (z= 3) 0 59 68 76 55 0 89 97 100 57 0 10 11 14 9 0 74 75 75 56 0 1 0 
HSP90AB1 p-S262 (z= 3) 0 24 22 16 8 0 68 81 100 91 0 11 7 8 8 0 36 24 37 35 1 1 1 
SLC9A1 p-S704 (z= 2) 29 26 21 14 17 29 59 65 58 46 29 82 100 83 74 29 35 29 38 27 1 0 1 
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TACC2 p-S2535 (z= 2) 1 2 12 0 16 1 26 70 22 100 1 1 1 0 4 1 12 19 10 21 1 1 1 
PDLIM4 p-S113 (z= 2) 7 100 30 15 15 7 47 42 19 28 7 14 6 7 6 5 34 30 37 16 0 1 0 
PDLIM4 p-S113 (z= 3) 2 20 30 12 13 2 100 91 97 61 2 23 8 14 8 1 30 28 32 11 1 1 1 
RC3H2 p-T454 (z= 2) 19 35 35 19 16 19 100 97 87 64 19 36 16 29 12 9 25 23 24 7 1 1 1 
AKAP9 p-T921 (z= 2) 5 71 67 61 47 5 84 78 100 36 5 51 65 76 41 2 48 52 55 28 0 0 0 
PPP1R13L p-S359 (z= 2) 0 0 0 0 0 0 0 1 0 7 0 0 1 0 5 0 0 12 0 100 0 0 0 
CLIP1 p-S349 (z= 2) 4 8 9 4 5 4 97 100 89 62 4 10 4 8 3 4 19 17 24 11 1 1 1 
PSME3 p-T24 (z= 2) 0 0 2 0 0 0 0 0 4 11 0 0 0 0 0 0 77 62 37 100 0 1 0 
SEPT2 p-S219 (z= 2) 2 2 39 14 25 2 25 22 35 24 2 5 4 5 3 5 100 69 94 81 0 1 0 
SEPT2 p-S219 (z= 3) 32 57 73 52 38 32 67 64 90 70 32 33 30 36 24 37 100 67 64 87 0 1 0 
XRN2 p-S500 p-S502 (z= 
2) 0 0 0 0 0 0 38 65 100 36 0 0 0 0 0 0 0 0 0 0 1 1 1 
BCLAF1 p-S178 (z= 2) 4 33 30 15 15 4 100 94 86 70 4 87 42 62 38 0 40 35 36 15 1 0 1 
IRF2BP1 p-S385 (z= 2) 0 1 1 1 1 0 62 45 100 68 0 1 0 0 0 0 0 0 0 0 1 1 1 
IRF2BPL p-S548 (z= 2) 8 8 10 6 6 8 100 82 96 68 8 4 2 3 2 8 4 4 5 2 1 1 1 
MAP4 p-S637 (z= 2) 20 18 30 2 17 20 100 80 67 69 20 32 2 7 4 12 31 34 34 21 1 1 0 
TJAP1 p-S546 (z= 2) 46 74 66 60 46 46 87 100 98 80 46 24 26 20 26 56 64 60 67 41 0 1 0 
RPLP2 p-S103 p-S106 (z= 
2) 29 0 0 1 0 29 16 26 72 56 29 70 17 34 23 29 27 58 80 100 0 1 0 
RPLP2 p-S103 (z= 2) + 
oxidation 100 0 0 1 0 100 25 46 99 67 100 31 30 42 21 100 23 22 40 31 1 0 1 
RPLP2 p-S106 (z= 2) + 
oxidation 72 0 3 4 4 72 63 100 96 66 72 15 16 22 7 72 20 15 21 11 1 1 1 
RPLP2 p-S106 (z= 2) 10 0 3 2 1 10 21 26 37 29 10 22 10 15 11 10 98 81 100 68 0 1 0 
TCEA1 p-S101 (z= 2) 0 0 0 0 0 0 1 1 1 1 0 1 1 1 1 0 85 90 100 55 0 1 0 
SRRM1 p-T873 (z= 2) 42 35 51 4 24 42 84 97 63 49 42 34 7 13 8 42 77 77 100 47 0 1 0 
PPAP p-S97 (z= 2) 5 58 52 43 47 5 70 67 100 60 5 37 44 49 32 2 26 32 28 20 0 0 1 
MYH9 p-S1944 (z= 2) 0 64 61 65 39 0 12 13 52 33 0 29 18 18 12 0 84 100 100 68 0 1 0 
MYH9 p-S1944 (z= 3) 0 32 35 37 20 0 25 29 100 58 0 50 33 35 23 0 51 54 45 37 0 0 0 
WARS p-S468 (z= 2) 22 29 37 23 19 22 100 98 88 55 22 21 24 35 10 22 37 45 53 11 1 1 0 
EBAG9 p-S37 (z= 2) 21 51 75 57 31 21 46 63 100 87 21 12 18 11 11 37 52 55 59 67 0 1 0 
EBAG9 p-S37 (z= 3) 6 35 52 43 23 6 58 72 100 77 6 10 12 8 9 5 40 30 32 39 0 1 0 
TCOF1 p-S1351 (z= 2) 11 66 65 33 27 11 44 31 73 57 11 100 60 39 27 1 60 73 85 27 0 0 0 
EEF1D p-S163 (z= 3) 4 0 8 0 2 4 45 39 56 48 4 21 0 1 0 4 100 69 75 38 1 1 0 
EHBP1 p-S1059 (z= 2) 1 5 3 4 3 1 6 7 7 6 1 84 100 97 87 0 3 3 3 2 0 0 1 
CD44 p-S698 (z= 2) 3 79 61 56 44 3 38 32 100 56 3 70 82 54 47 1 58 70 55 40 0 0 0 
IRF2BP2 p-S361 (z= 2) 0 0 0 0 0 0 55 67 100 94 0 0 0 0 0 0 1 0 1 1 1 1 1 
DYNC1LI1 p-S517 (z= 2) 30 30 57 17 24 30 55 46 50 40 30 100 34 62 24 15 65 53 65 40 0 0 0 
TPI1 p-S22 (z= 2) 100 3 8 0 0 100 87 34 29 31 100 2 0 0 0 100 34 24 24 1 1 1 0 
TPI1 p-S22 (z= 3) 82 4 10 0 0 82 100 49 32 33 82 3 0 0 0 82 42 28 26 0 1 1 0 
NSFL1C p-S115 (z= 2) 5 2 14 1 2 5 100 76 80 63 5 9 0 1 0 5 60 53 42 15 1 1 0 
CBFA2T2 p-T400 p-T402 
(z= 2) 6 26 15 30 24 6 88 100 36 46 6 10 20 9 14 3 9 18 9 10 1 1 1 
TMX1 p-S248 (z= 3) 0 3 3 2 2 0 71 90 100 61 0 5 2 4 1 0 4 3 4 2 1 1 1 
RPLP2 p-S87 (z= 3) 1 0 1 0 0 1 0 9 9 35 1 0 1 1 100 1 4 4 1 24 0 0 1 
SORBS3 p-S531 (z= 2) 32 34 53 18 22 32 100 74 68 71 32 20 5 8 4 57 40 29 35 13 0 1 0 
TACC2 p-S2318 p-S2322 
(z= 3) 18 14 90 25 16 18 50 80 84 100 18 80 18 18 49 18 20 10 13 25 0 1 1 
CCDC6 p-S241 p-S245 (z= 
2) 93 11 25 13 16 93 100 100 94 92 93 31 12 17 14 93 53 49 50 16 1 1 0 
TNKS1BP1 p-S495 (z= 3) 6 1 9 0 1 6 48 9 56 28 6 2 0 0 0 6 90 35 45 100 0 1 0 
TRAFD1 p-S416 (z= 2) 23 43 46 36 28 23 100 84 81 59 23 19 9 15 8 41 51 48 62 29 0 1 0 
HTATSF1 p-S703 (z= 2) 0 0 0 0 0 0 4 3 100 62 0 0 0 0 0 0 0 0 0 0 1 1 1 
MLLT4 p-S1800 (z= 2) 69 4 13 0 5 69 71 80 48 100 69 42 36 32 63 69 60 43 51 10 1 0 0 
TCOF1 p-S1379 (z= 2) 19 35 28 35 21 19 95 83 100 50 19 26 23 34 19 13 37 31 34 19 1 1 1 
EIF3A p-S883 (z= 2) 1 0 99 0 94 1 0 0 0 8 1 0 0 0 0 1 0 100 0 0 0 1 0 
SEMA4B p-S826 (z= 2) 8 9 10 8 5 8 81 70 49 43 8 33 15 21 13 8 99 89 100 36 0 1 0 
AHNAK p-S136 (z= 2) 7 1 1 1 0 7 20 19 21 21 7 100 93 94 94 7 10 4 3 1 0 0 1 
AHNAK p-S136 (z= 3) 3 8 5 6 3 3 30 31 27 23 3 100 86 91 90 3 0 3 0 3 0 0 1 
KRT18 p-S400 (z= 2) 0 1 1 0 0 0 0 2 0 100 0 0 0 0 0 0 1 7 0 25 0 1 0 
KRT18 p-S402 (z= 3) 0 0 2 1 0 0 0 0 0 3 0 2 0 0 0 0 16 34 4 100 0 1 0 
FAM186B p-S817 (z= 2) 16 62 59 55 47 16 100 69 84 52 16 26 27 19 15 12 42 49 44 37 0 1 0 
SLIRP p-T102 (z= 2) 1 79 78 100 65 1 92 81 84 45 1 44 49 48 34 14 78 96 98 64 0 0 0 
SLIRP p-S103 (z= 2) 0 7 6 8 4 0 50 25 100 63 0 1 2 1 1 0 3 4 4 3 1 1 1 
AHNAK p-S217 (z= 2) 19 72 51 46 29 19 100 99 100 54 19 15 17 18 16 22 33 32 37 20 0 1 1 
DAB2IP p-S703 (z= 2) 7 100 78 92 66 7 26 25 27 19 7 20 23 28 17 27 56 57 61 41 0 1 0 
EPB41L1 p-S541 (z= 2) 26 43 33 42 27 26 77 100 83 72 26 47 66 51 52 17 23 28 23 25 1 0 1 
CTTN p-S419 (z= 2) 60 54 50 29 31 60 100 100 83 52 60 44 27 36 20 48 38 37 44 29 0 1 0 
HNRNPU p-S60 (z= 3) + 
oxidation 1 0 2 0 0 1 40 65 24 100 1 2 0 0 0 1 23 21 19 34 1 1 0 
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HNRNPU p-S60 (z= 3) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 53 44 37 100 0 1 0 
CLCA p-S106 (z= 2) 76 16 14 14 28 76 22 23 13 26 76 26 29 23 33 100 12 15 12 26 0 0 0 
ALDOA p-S47 (z= 2) 60 24 27 23 22 60 100 85 78 51 60 25 14 17 12 53 49 30 35 14 1 1 1 
MYH15 p-Y728 (z= 2) 22 29 37 23 19 22 100 98 88 55 22 21 24 35 10 22 37 45 53 11 1 1 0 
FAM91A1 p-S672 (z= 2) 0 30 39 51 16 0 3 4 100 69 0 53 34 31 27 0 20 24 18 22 0 0 0 
MIPEP p-S326 (z= 2) 30 25 26 20 42 30 79 86 56 100 30 48 33 46 51 13 23 17 16 24 1 0 1 
STK10 p-T953 (z= 2) 54 0 1 0 0 54 100 90 59 74 54 86 39 52 41 54 1 0 0 1 1 0 1 
WRNIP1 p-S76 (z= 2) 1 23 19 24 20 1 88 100 82 53 1 19 27 21 17 0 17 18 16 12 1 1 1 
TCOF1 p-S1351 (z= 2) 0 1 1 1 0 0 14 16 100 59 0 1 2 1 1 0 31 44 44 43 0 1 0 
KRT17 p-S33 (z= 2) 74 28 21 17 13 74 100 72 64 48 74 22 13 17 9 45 24 24 23 11 1 1 1 
LMNA p-S391 p-S393 (z= 
2) 5 17 17 42 11 5 64 81 100 61 5 23 9 18 11 4 23 26 28 21 1 1 1 
LMNA p-S391 (z= 2) 26 26 23 14 9 26 100 90 93 65 26 40 16 21 13 26 39 48 48 16 1 1 0 
SCAMP3 p-S77 (z= 2) 1 18 16 14 11 1 100 87 79 52 1 20 22 24 16 0 8 9 9 5 1 1 1 
BCL2L12 p-S243 (z= 2) 21 39 40 36 23 21 98 100 59 34 21 35 24 29 15 12 34 38 37 12 1 1 0 
MTDH p-S296 (z= 2) 0 17 74 18 48 0 34 55 19 67 0 17 20 7 28 0 63 100 44 44 0 1 0 
CTNNB1 p-S676 (z= 2) 2 3 8 1 2 2 100 77 60 80 2 7 1 1 0 2 32 41 31 9 1 1 0 
ITA2 p-T829 (z= 2) 0 12 5 17 11 0 12 18 7 5 0 39 100 81 64 0 1 2 2 1 0 0 1 
SHAN1 p-T947 (z= 2) 8 33 36 34 25 8 87 89 100 55 8 17 19 21 15 4 21 21 22 16 1 1 1 
WDR44 p-S162 (z= 2) 19 21 25 12 13 19 73 55 100 75 19 6 4 5 4 19 34 28 31 17 1 1 0 
WDR44 p-T164 (z= 3) 12 31 33 19 18 12 87 70 100 74 12 8 6 6 5 21 58 45 48 29 1 1 0 
LEO1 p-S631 (z= 2) 2 42 38 54 31 2 82 76 100 53 2 5 5 6 4 7 51 49 46 31 1 1 0 
CBX3 p-S177 (z= 2) 38 0 14 0 4 38 93 100 20 96 38 4 0 0 0 38 35 49 24 10 1 1 0 
ANXA1 p-S6 (z= 2) 33 94 66 100 56 33 67 77 59 39 33 50 54 46 36 29 68 63 64 40 0 0 0 
SAMM50 p-T4 (z= 2) 34 5 5 5 2 34 100 75 41 28 34 10 6 6 5 34 23 21 25 7 1 1 0 
PRDM5 p-Y6 (z= 3) + 
oxidation 3 30 22 31 21 3 34 53 31 9 3 48 98 100 100 1 25 25 14 14 0 0 1 
AN36A p-S1814 (z= 2) + 
oxidation 5 19 25 24 21 5 59 60 100 49 5 4 4 6 3 12 20 18 21 14 1 1 1 
LIX1 p-S205 (z= 2) + 
oxidation 19 23 23 14 13 19 100 70 86 54 19 20 12 21 10 11 34 29 31 19 1 1 1 
MAP3K7 p-S390 (z= 2) 6 13 20 10 10 6 42 36 34 20 6 100 57 81 55 0 30 24 23 5 0 0 1 
BAD p-S119 (z= 2) 9 32 35 33 31 9 51 45 57 29 9 61 91 100 46 0 69 56 68 23 0 0 0 
ERCC5 p-S385 (z= 2) 34 12 13 3 8 34 88 87 100 61 34 21 6 11 5 34 40 27 38 9 1 1 1 
ADRB2 p-S408 (z= 2) 0 0 0 0 0 0 100 6 0 0 0 0 6 19 4 0 0 0 0 0 0 0 1 
HNRNPD p-S83 (z= 2) 0 56 58 100 33 0 1 1 2 1 0 3 3 3 2 0 67 65 62 37 0 1 0 
YBX1 p-S177 (z= 2) 1 76 71 100 61 1 40 37 68 42 1 4 8 8 6 6 78 68 81 61 0 1 0 
SH3PXD2A p-S1003 (z= 2) 53 14 40 18 43 53 22 36 19 60 53 5 10 8 10 100 30 40 19 50 0 1 0 
TAGLN2 p-S164 (z= 2) 56 23 43 14 40 56 88 93 100 82 56 59 55 54 43 20 86 64 85 41 1 0 0 
EIF5B p-S215 (z= 2) 3 14 16 13 10 3 56 59 92 74 3 37 33 43 30 3 86 69 100 65 1 1 0 
EIF5B p-S215 (z= 3) 1 23 28 27 18 1 52 72 84 59 1 81 72 100 64 0 33 27 37 26 1 0 1 
LSR p-S644 (z= 2) 19 35 35 19 16 19 100 97 87 64 19 36 16 29 12 9 25 23 24 7 1 1 1 
SEC22B p-S138 (z= 2) 72 35 43 23 30 72 73 67 100 77 72 50 43 58 38 61 39 31 38 29 0 0 1 
PTPN12 p-S436 (z= 2) 25 42 50 43 36 25 65 58 55 62 25 80 56 100 74 12 76 64 62 52 0 0 0 
FCHO2 p-S404 (z= 2) 18 17 21 27 14 18 38 41 100 34 18 12 26 26 8 10 12 11 13 7 0 0 1 
LAD1 p-S39 (z= 2) 64 0 0 0 2 64 11 33 13 100 64 22 32 20 80 64 0 0 0 2 1 0 1 
FKBP5 p-S14 (z= 2) 13 44 47 31 31 13 44 42 52 30 13 15 8 15 8 36 100 61 78 34 0 1 0 
PLCG1 p-Y784 (z= 2) 0 0 0 0 0 0 0 0 0 2 0 12 21 4 100 0 0 1 0 2 0 0 1 
BROMI p-T816 p-Y818 (z= 
3) 0 59 68 76 55 0 89 97 100 57 0 10 11 14 9 0 74 75 75 56 0 1 0 
SNX13 p-S337 (z= 2) 1 46 37 32 23 1 100 89 83 48 1 22 19 20 12 0 34 28 29 21 1 1 1 
MEPCE p-S153 (z= 2) 24 30 21 54 17 24 26 39 34 100 24 22 30 20 41 26 16 19 17 15 0 0 1 
SCRIB p-S1221 (z= 2) 11 69 87 48 34 11 48 50 66 34 11 21 11 17 9 27 100 83 96 43 0 1 0 
XRN2 p-S679 (z= 2) 4 56 46 44 37 4 82 88 100 56 4 12 24 23 15 8 35 45 52 24 0 1 0 
PTK2B p-S376 (z= 2) 0 7 21 2 6 0 64 67 75 98 0 33 2 3 7 0 72 42 55 100 1 1 0 
GRLF1 p-S590 (z= 2) 2 2 0 1 0 2 4 4 5 5 2 84 88 100 89 2 6 1 0 1 0 0 1 
SGPP1 p-S113 (z= 2) 3 85 71 100 98 3 34 33 49 29 3 7 11 10 8 13 52 46 52 37 0 1 0 
XRN2 p-S449 (z= 2) 31 24 19 18 15 31 71 66 100 73 31 27 23 33 19 31 41 42 52 30 1 1 0 
ANKRD17 p-S2060 (z= 2) 26 58 67 34 31 26 78 56 100 57 26 27 26 36 21 24 64 61 66 34 0 1 0 
MARK2 p-S487 (z= 2) 6 29 23 22 19 6 48 53 100 57 6 11 13 15 5 5 20 19 19 13 1 1 1 
SSBP3 p-S348 (z= 2) 13 55 63 57 38 13 21 19 27 15 13 4 3 4 2 100 79 50 76 53 0 1 0 
STK11IP p-S773 (z= 2) 1 30 29 24 20 1 56 57 100 54 1 11 9 13 8 0 22 25 26 18 0 1 1 
NUCKS1 p-S59 p-S62 (z= 
2) 0 9 23 42 20 0 1 1 2 1 0 0 0 0 0 0 96 78 100 50 0 1 0 
HN1 p-S88 (z= 2) 3 42 33 53 42 3 41 48 100 36 3 17 44 38 21 4 40 36 43 41 0 0 0 
CDK12 p-S1083 (z= 2) 22 56 60 67 48 22 74 66 100 84 22 22 26 27 18 35 47 46 49 36 0 1 0 
DOCK5 p-S1835 (z= 2) 16 25 35 35 25 16 69 62 100 47 16 13 17 15 10 24 60 40 55 29 0 1 0 
FAM122B p-T53 (z= 2) 27 31 30 26 18 27 86 90 100 71 27 66 62 66 62 3 23 23 26 15 1 0 1 
SPAG9 p-S333 (z= 2) 0 38 38 33 25 0 100 73 86 39 0 11 8 10 6 0 44 44 51 28 0 1 0 
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YAP1 p-T111 (z= 2) 20 75 60 84 42 20 100 92 79 56 20 17 18 18 14 33 63 56 66 34 0 1 0 
MAP3K12 p-S350 (z= 2) 0 89 44 100 41 0 50 41 90 94 0 1 1 0 0 0 42 86 38 20 0 1 0 
SRPK1 p-S312 (z= 2) 6 81 79 67 49 6 44 50 28 27 6 9 8 8 6 47 100 94 78 36 0 1 0 
MACF1 p-S1861 (z= 2) 26 35 28 35 23 26 100 94 65 52 26 16 17 13 10 33 40 38 35 17 1 1 0 
PCBP1 p-S174 (z= 2) 6 0 0 0 0 6 33 11 2 21 6 5 0 0 0 6 100 37 47 29 0 1 0 
PCBP2 p-S174 (z= 2) 5 0 2 0 0 5 51 22 6 26 5 7 0 0 0 5 100 54 57 47 0 1 0 
CANX p-S555 p-S565 (z= 
3) 0 1 17 7 5 0 19 27 100 52 0 48 17 24 12 0 65 35 59 65 0 1 0 
CANX p-S555 p-S565 (z= 
2) 1 5 22 39 30 1 29 47 64 45 1 1 1 1 1 61 95 100 88 58 0 1 0 
CANX p-S555 (z= 2) 1 3 3 3 3 1 83 87 100 65 1 1 1 1 1 1 2 2 2 1 1 1 1 
CANX p-T563 (z= 3) 1 19 18 20 16 1 71 100 77 35 1 4 3 5 3 4 39 39 24 20 1 1 0 
CANX p-S555 (z= 3) 0 20 55 12 17 0 2 2 8 4 0 2 1 2 1 0 89 41 96 100 0 1 0 
CANX p-T563 p-S565 (z= 
3) 1 18 19 10 7 1 24 43 32 34 1 100 30 64 33 0 38 28 38 25 1 0 0 
BCLAF1 p-S649 (z= 2) 0 1 1 0 0 0 3 2 1 1 0 82 81 100 83 0 1 1 1 0 0 0 1 
MYH10 p-S1957 (z= 2) 20 7 15 10 9 20 93 87 100 57 20 15 9 10 4 20 33 41 33 21 1 1 1 
ENSA p-S85 (z= 2) 6 46 45 36 40 6 35 13 25 19 6 100 72 57 30 2 48 34 44 26 0 0 0 
SYNRG p-S753 (z= 2) 29 14 15 19 19 29 84 85 82 100 29 37 45 30 47 15 16 17 15 25 1 0 1 
HSPB1 p-S83 (z= 2) 76 16 14 14 28 76 22 23 13 26 76 26 29 23 33 100 12 15 12 26 0 0 0 
HSPB1 p-S83 (z= 2) 100 3 10 1 5 100 10 5 5 14 100 28 2 13 7 47 11 6 12 5 0 0 0 
MMP28 p-T88 (z= 2) 34 5 5 5 2 34 100 75 41 28 34 10 6 6 5 34 23 21 25 7 1 1 0 
CAPR2 p-T545 (z= 2) 0 35 40 100 30 0 18 12 95 63 0 44 62 49 41 0 9 11 14 16 0 0 1 
EIF3C p-S40 (z= 2) 21 37 27 34 21 21 89 100 77 49 21 19 23 18 14 22 24 26 28 19 1 1 1 
EIF3C p-S40 (z= 3) 0 0 0 0 0 0 0 0 0 0 0 67 34 100 51 0 0 0 0 0 0 0 1 
PEA15 p-S117 (z= 2) 33 94 66 100 56 33 67 77 59 39 33 50 54 46 36 29 68 63 64 40 0 0 0 
KIAA1671 p-T1523 (z= 2) 0 35 40 100 30 0 18 12 95 63 0 44 62 49 41 0 9 11 14 16 0 0 1 
RBM14 p-T207 (z= 2) 26 27 21 28 15 26 60 89 75 100 26 20 32 16 29 27 20 19 19 18 1 1 1 
SFRS18 p-S212 (z= 2) 77 23 23 17 12 77 92 86 48 63 77 14 6 4 5 100 37 27 31 11 1 1 0 
CDK12 p-S304 p-Y306 (z= 
2) 8 12 23 26 14 8 62 71 100 61 8 38 34 46 33 3 24 24 31 19 1 0 1 
TPI1 p-S22 (z= 2) 2 10 16 8 9 2 82 75 81 100 2 5 2 1 2 2 20 26 20 20 1 1 1 
TPI1 p-S22 (z= 2) 1 10 29 5 5 1 37 35 100 73 1 4 3 3 3 1 42 29 36 34 0 1 0 
UTRN p-S834 (z= 2) 5 71 67 61 47 5 84 78 100 36 5 51 65 76 41 2 48 52 55 28 0 0 0 
SET p-S8 (z= 2) 6 77 54 100 48 6 0 0 61 46 6 61 45 38 31 3 51 61 52 40 0 0 0 
CLASP1 p-T652 (z= 2) 14 29 22 34 21 14 52 100 97 61 14 28 47 29 42 7 17 18 20 16 1 0 1 
GL54D p-T154 p-S155 (z= 
2) 6 26 15 30 24 6 88 100 36 46 6 10 20 9 14 3 9 18 9 10 1 1 1 
STK10 p-S439 (z= 2) 9 19 13 14 11 9 100 83 52 44 9 3 2 3 1 20 17 16 14 5 1 1 1 
EPPK1 p-S2717 (z= 2) 51 30 35 22 36 51 63 84 57 100 51 16 11 8 15 73 44 52 55 51 1 1 0 
FAM55D p-Y361 p-S365 
(z= 3) 0 9 7 12 7 0 3 9 22 8 0 26 80 100 87 0 3 2 3 3 0 0 1 
HDGF p-S166 (z= 2) 71 2 6 0 0 71 100 40 26 25 71 14 0 3 0 71 61 38 46 0 1 1 0 
COPE p-S100 (z= 2) 23 25 41 6 17 23 100 75 46 36 23 24 2 9 4 18 48 39 60 10 0 1 0 
ZNF185 p-S466 (z= 2) 55 19 23 9 11 55 94 63 100 50 55 33 14 26 18 26 31 26 27 15 1 1 1 
TNKS1BP1 p-S430 (z= 2) 39 40 70 30 38 39 78 64 100 63 39 23 12 13 11 24 93 70 81 48 0 1 0 
TNKS1BP1 p-S430 (z= 3) 12 45 69 31 36 12 92 78 100 42 12 24 12 23 16 2 92 65 72 45 0 1 0 
MARCKS p-S160 (z= 2) 88 9 36 2 4 88 96 100 37 77 88 12 1 4 2 88 54 70 54 6 1 1 0 
TMEM40 p-S138 (z= 2) 9 14 15 11 8 9 73 66 88 58 9 28 26 31 16 9 95 80 100 42 1 1 0 
TMEM40 p-S138 (z= 3) 0 2 3 2 1 0 16 17 18 10 0 16 13 16 9 0 100 82 87 48 0 1 0 
LRRFIP1 p-S121 (z= 2) 3 19 22 21 16 3 90 73 100 69 3 8 10 10 8 3 33 25 27 19 1 1 1 
LRRFIP1 p-S125 (z= 3) 1 23 32 33 20 1 92 85 100 65 1 25 30 36 29 0 40 29 31 25 1 1 1 
LRRFIP2 p-T332 (z= 3) 14 17 27 25 11 14 44 51 100 56 14 28 37 43 25 7 12 15 14 16 0 0 1 
NRD1 p-S97 (z= 2) 17 11 19 6 4 17 100 73 57 47 17 29 7 17 7 17 86 66 99 15 1 1 0 
EI2BA p-S106 (z= 2) 0 0 0 0 0 0 100 95 62 94 0 0 0 0 0 0 3 3 3 2 1 1 1 
FAM83H p-S1004 (z= 2) 19 23 23 14 13 19 100 70 86 54 19 20 12 21 10 11 34 29 31 19 1 1 1 
ZC3H3 p-S570 (z= 2) 0 0 0 0 0 0 100 95 62 94 0 0 0 0 0 0 3 3 3 2 1 1 1 
RPS6 p-S237 (z= 2) 0 0 0 0 0 0 100 95 62 94 0 0 0 0 0 0 3 3 3 2 1 1 1 
RPS6 p-S237 (z= 2) 0 0 0 0 0 0 100 95 62 94 0 0 0 0 0 0 3 3 3 2 1 1 1 
RUNDC3A p-S140 p-T144 
(z= 2) 4 59 20 100 39 4 13 40 38 17 4 9 76 32 46 3 4 7 7 5 0 0 1 
HN1 p-S88 (z= 2) 27 20 28 12 18 27 100 80 92 60 27 31 16 25 13 20 45 36 41 20 1 1 1 
HN1 p-S89 (z= 3) 16 21 31 20 16 16 100 97 97 50 16 48 25 39 20 6 44 33 37 19 1 1 1 
SPTBN1 p-S2103 (z= 2) 0 8 6 5 3 0 11 9 24 17 0 8 8 6 5 0 88 100 94 66 0 1 0 
PPFIBP1 p-S795 (z= 2) 1 76 90 79 67 1 21 23 28 20 1 19 20 23 15 1 93 100 96 65 0 1 0 
TNKS1BP1 p-S1546 (z= 2) 1 35 29 20 22 1 79 58 100 88 1 81 94 70 79 0 22 34 38 32 0 0 1 
UPF3B p-S326 (z= 2) 3 29 23 29 56 3 18 23 33 38 3 43 70 66 100 1 10 12 12 52 0 0 0 
CCD91 p-S382 (z= 2) 9 49 65 46 34 9 77 79 100 70 9 30 20 31 18 7 74 59 77 34 0 1 0 
RCC1 p-S12 (z= 2) 0 0 0 0 0 0 100 88 91 65 0 24 15 18 11 0 0 0 0 0 1 1 1 
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QSOX2 p-S26 (z= 2) 0 48 37 57 25 0 68 76 100 57 0 25 28 24 14 0 11 20 18 13 1 1 1 
FA47A p-S259 (z= 2) 0 0 0 0 0 0 100 95 62 94 0 0 0 0 0 0 3 3 3 2 1 1 1 
CXorf56 p-T149 (z= 2) 4 21 17 16 12 4 100 89 74 53 4 17 20 17 17 0 16 17 19 10 1 1 1 
SRRM1 p-S726 p-T728 (z= 
3) 0 14 32 16 9 0 25 43 100 83 0 45 13 15 12 0 26 35 42 17 0 1 0 
TNKS1BP1 p-S1667 (z= 2) 3 67 66 65 46 3 31 28 37 23 3 9 8 11 7 36 100 76 76 46 0 1 0 
ARL6IP4 p-S272 (z= 2) 41 11 13 5 13 41 88 100 81 83 41 16 7 16 9 41 42 36 34 32 1 1 1 
LBR p-S100 (z= 2) 13 13 22 6 6 13 11 2 88 100 13 54 13 19 12 13 41 51 55 17 0 1 0 
SMAP p-S18 (z= 2) 43 2 10 0 2 43 100 69 91 64 43 23 0 4 0 43 44 25 41 21 1 1 1 
SMAP p-S18 (z= 3) 23 4 19 0 4 23 90 70 100 52 23 33 0 5 0 23 60 33 52 31 1 1 0 
SLC9A3R1 p-S292 (z= 2) 39 18 32 20 21 39 81 68 100 70 39 23 10 19 10 49 56 42 52 33 1 1 0 
SRRM2 p-S877 (z= 2) 35 71 77 37 34 35 77 69 94 47 35 25 13 25 13 48 100 62 95 30 0 1 0 
EPB41L1 p-S467 (z= 2) 0 24 31 38 29 0 47 24 100 39 0 12 14 9 6 1 40 45 45 30 0 1 0 
HDGFRP2 p-S455 (z= 2) 2 0 1 1 1 2 3 4 2 3 2 50 67 66 100 0 0 0 1 1 0 0 1 
ANKS1A p-S648 (z= 2) 18 13 15 12 7 18 70 76 100 50 18 12 9 13 7 18 32 22 23 13 1 1 1 
CEP110 p-S2163 (z= 2) 29 57 32 57 91 29 80 100 25 65 29 55 67 38 63 25 24 37 20 38 0 0 1 
SLC4A10 p-S239 (z= 2) 0 34 68 40 51 0 46 68 100 79 0 0 0 0 0 0 55 51 40 32 0 1 0 
S4A8 p-S238 (z= 2) 0 34 68 40 51 0 46 68 100 79 0 0 0 0 0 0 55 51 40 32 0 1 0 
SEPT9 p-S31 (z= 2) 75 18 29 12 15 75 99 86 100 80 75 25 12 17 10 75 44 39 50 33 1 1 1 
CCNYL1 p-S345 (z= 2) 100 1 10 1 2 100 65 39 70 56 100 13 4 7 3 100 23 23 26 4 1 1 0 
C10orf47 p-S44 (z= 2) 30 4 6 1 3 30 39 93 42 87 30 44 96 67 100 30 6 6 8 8 1 0 1 
HNRNPUL2 p-S162 (z= 2) 9 16 15 15 10 9 73 63 100 24 9 11 10 11 7 10 18 16 18 10 1 1 1 
CTNND1 p-S921 (z= 2) + 
oxidation 23 14 19 12 14 23 100 86 100 73 23 2 1 2 1 23 3 2 2 2 1 1 1 
CTNND1 p-S921 (z= 2) 9 28 30 21 20 9 88 82 100 61 9 34 19 30 17 1 18 17 21 10 1 1 1 
AGL p-Y970 p-S972 (z= 2) 0 71 66 100 70 0 0 0 0 0 0 0 0 0 0 5 67 71 75 38 0 1 0 
TRIM28 p-S474 (z= 2) 24 61 82 66 56 24 22 22 24 15 24 97 100 94 76 3 68 71 92 45 0 0 0 
ERBB2 p-S1055 (z= 2) 15 0 1 0 0 15 100 39 29 38 15 2 0 0 0 15 18 13 16 8 1 1 0 
MORC1 p-S108 (z= 2) 4 21 17 16 12 4 100 89 74 53 4 18 20 17 17 0 16 17 19 10 1 1 1 
MORC3 p-S109 (z= 2) 4 21 17 16 12 4 100 89 74 53 4 18 20 17 17 0 16 17 19 10 1 1 1 
STMN1 p-S64 (z= 2) 6 46 45 36 40 6 35 13 25 19 6 100 72 57 30 2 48 34 44 26 0 0 0 
ADCY5 p-S729 (z= 2) 7 50 19 9 23 7 20 26 5 16 7 100 97 63 84 7 27 58 17 23 0 0 0 
MAP3K7 p-S440 (z= 2) 19 29 34 35 20 19 72 74 100 54 19 18 16 22 12 18 29 26 35 20 1 1 1 
KRT7 p-S255 (z= 2) 11 10 40 27 27 11 42 54 100 97 11 12 18 9 21 11 23 33 24 43 0 1 0 
KRT8 p-S254 (z= 2) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 73 89 69 100 0 1 0 
GSTA2 p-S213 (z= 2) 0 78 62 100 29 0 2 0 99 59 0 67 65 59 43 0 37 31 30 35 0 0 0 
FHOD1 p-S368 (z= 2) 40 45 34 34 23 40 100 69 99 74 40 53 54 63 36 15 39 34 36 18 1 0 1 
EIF4B p-S446 (z= 2) 11 49 65 81 55 11 38 30 72 31 11 15 23 19 14 34 100 78 81 51 0 1 0 
C18orf34 p-S177 (z= 2) 0 78 62 100 29 0 2 0 99 59 0 67 65 59 43 0 37 31 30 35 0 0 0 
ARHGEF10 p-S380 (z= 2) 0 0 3 0 79 0 0 0 0 4 0 0 0 0 1 0 3 1 1 100 0 1 0 
RIPK2 p-S364 (z= 2) 1 0 1 0 4 1 27 39 19 100 1 2 1 0 3 1 12 16 9 29 1 1 1 
AKT1S1 p-S184 (z= 2) 42 1 9 0 1 42 100 54 49 66 42 9 0 0 0 42 30 21 20 20 1 1 1 
DOCK5 p-S1767 (z= 2) 22 42 58 28 31 22 100 99 86 58 22 85 31 51 26 1 83 64 83 29 0 0 0 
SPTAN1 p-S1218 (z= 2) 32 53 68 32 37 32 100 82 100 51 32 26 20 22 13 40 95 65 75 28 0 1 0 
CBX3 p-S96 (z= 2) 0 12 22 19 11 0 0 0 100 59 0 46 23 27 16 0 55 41 42 37 0 0 0 
F1891 p-S21 (z= 2) 0 0 0 0 0 0 100 95 62 94 0 0 0 0 0 0 3 3 2 2 1 1 1 
NEDD4L p-S449 (z= 2) 15 16 20 15 12 15 61 75 100 91 15 15 22 20 16 15 38 32 43 22 1 1 1 
DNAJC5 p-S11 (z= 2) 1 17 62 22 28 1 13 17 59 31 1 1 1 0 1 13 100 72 56 74 0 1 0 
DNAJC5 p-S11 (z= 3) 1 12 53 17 20 1 19 28 100 53 1 3 1 1 2 4 74 49 38 54 0 1 0 
SLC38A1 p-S53 (z= 2) 5 58 52 43 47 5 70 67 100 60 5 37 44 49 32 2 26 32 28 20 0 0 1 
KRT6A p-S61 (z= 2) 72 8 18 6 18 72 17 23 12 22 72 2 2 2 4 100 9 13 9 15 0 1 0 
KRT5 p-S65 (z= 2) 93 24 50 11 28 93 78 74 41 56 93 11 3 5 5 100 48 51 35 34 0 1 0 
TMPRSS15 p-S848 (z= 2) 7 28 36 27 34 7 67 100 75 83 7 9 10 9 10 5 29 31 23 32 1 1 1 
FKBP4 p-S454 (z= 2) 0 0 0 0 0 0 0 38 31 100 0 0 0 0 0 0 0 0 0 0 1 1 1 
SORBS3 p-S564 (z= 2) 12 31 55 18 25 12 92 69 100 76 12 32 17 27 20 17 47 39 51 37 0 1 0 
TJP3 p-S334 (z= 2) 15 17 19 14 13 15 81 65 100 58 15 26 14 30 14 7 29 23 28 17 1 1 1 
AIM1 p-S534 (z= 2) 15 64 64 78 49 15 60 47 100 60 15 58 66 65 61 14 54 48 55 38 0 0 0 
LIMCH1 p-S719 (z= 2) 22 36 80 59 43 22 55 57 79 89 22 37 21 15 29 41 83 61 76 100 0 1 0 
AHNAK p-S94 (z= 2) 51 89 77 84 47 51 100 88 67 46 51 50 44 48 40 50 60 52 64 30 0 0 0 
ZNF532 p-S315 (z= 2) 27 44 47 56 45 27 62 64 100 47 27 16 21 24 21 30 52 51 61 31 0 1 0 
SIRT1 p-S48 (z= 2) 4 16 16 15 10 4 68 59 100 56 4 27 19 26 15 4 46 44 52 28 1 1 0 
TJP3 p-S165 (z= 2) 21 19 24 20 9 21 76 62 100 68 21 16 19 15 12 18 24 24 26 19 1 1 1 
SRRM2 p-S2133 (z= 2) 22 68 88 66 62 22 62 64 78 65 22 100 83 77 75 2 89 83 93 74 0 0 0 
NCOR2 p-S2270 (z= 2) 28 26 30 26 17 28 87 100 91 79 28 24 28 25 21 21 28 22 32 22 1 1 1 
BICD2 p-S583 (z= 2) 16 47 55 47 35 16 100 84 81 51 16 21 17 22 13 15 40 36 39 26 0 1 0 
DDB2 p-S27 (z= 2) 7 82 78 100 73 7 27 29 42 27 7 10 14 12 10 33 62 71 73 43 0 1 0 
NSFL1C p-S115 (z= 2) 13 4 12 1 4 13 83 66 100 73 13 11 1 2 1 13 43 38 39 38 1 1 0 
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RCC1 p-S12 (z= 2) 13 42 30 33 27 13 63 70 100 58 13 16 23 26 19 12 21 23 23 20 1 1 1 
SH3BP1 p-S551 (z= 2) 0 2 2 1 1 0 3 3 3 2 0 100 29 54 27 0 3 2 3 1 0 0 1 
SSH3 p-S10 (z= 2) 28 20 42 25 22 28 99 98 95 100 28 20 6 6 8 57 91 46 62 49 1 1 0 
MORC2 p-S616 (z= 2) 40 21 43 9 8 40 100 85 88 86 40 27 9 8 7 40 27 23 30 17 0 1 1 
WDR4 p-S392 (z= 2) 1 13 11 16 9 1 4 3 7 5 1 95 100 72 71 0 9 14 12 11 0 0 1 
FAM116A p-S471 (z= 2) 0 1 1 2 0 0 0 0 100 53 0 49 91 63 55 0 13 25 26 40 0 0 0 
C15orf52 p-S202 (z= 2) 15 22 23 21 14 15 86 88 100 58 15 18 20 23 12 8 23 21 24 13 1 1 1 
NCAPH2 p-S285 (z= 2) 19 33 29 25 20 19 100 75 88 52 19 25 22 22 15 11 23 23 27 16 1 1 1 
SYMPK p-S1244 (z= 2) 12 92 100 81 61 12 90 82 100 57 12 61 57 55 50 2 85 72 80 48 0 0 0 
TRIM29 p-S22 (z= 2) 30 29 24 25 15 30 76 86 100 58 30 28 24 29 23 13 20 21 20 13 1 1 1 
KANK4 p-S974 (z= 2) + 
oxidation 4 59 20 100 39 4 13 40 38 17 4 9 76 32 46 3 4 7 7 5 0 0 1 
CTTNBP2NL p-S569 (z= 2) 8 33 36 34 25 8 87 89 100 55 8 17 19 21 15 4 21 21 22 16 1 1 1 
RHG32 p-T955 (z= 2) 5 71 67 61 47 5 84 78 100 36 5 51 65 76 41 2 48 52 55 28 0 0 0 
PML p-S531 (z= 3) 3 11 46 6 15 3 56 58 54 75 3 75 11 15 19 3 100 65 79 100 0 1 0 
C10orf18 p-S445 (z= 2) 0 45 39 38 22 0 100 100 99 74 0 8 9 11 7 0 23 21 28 16 1 1 1 
SRRM2 p-S2450 (z= 2) 35 77 76 77 42 35 62 54 62 44 35 26 25 26 16 61 100 82 97 54 0 1 0 
LSM14A p-S217 (z= 2) 2 16 15 10 6 2 50 55 73 62 2 23 23 23 21 2 100 76 86 62 1 1 0 
LSM14A p-S217 (z= 3) 0 27 29 21 12 0 62 80 100 73 0 38 35 42 36 0 30 21 22 20 1 0 1 
COBLL1 p-S519 (z= 2) 6 1 13 3 8 6 18 21 37 100 6 2 1 0 3 6 13 19 13 41 0 1 0 
TNKS1BP1 p-S837 (z= 2) 58 29 46 41 34 58 27 27 47 23 58 83 68 100 63 48 42 35 47 41 0 0 0 
CLASP1 p-S1197 (z= 2) 6 22 29 22 19 6 79 100 96 79 6 29 33 34 23 1 30 25 25 15 1 1 1 
CD44 p-S707 (z= 2) + 
oxidation 5 19 25 24 21 5 59 60 100 49 5 4 4 6 3 12 20 18 21 14 1 1 1 
CD44 p-S707 (z= 2) 3 87 99 86 59 3 67 67 100 52 3 47 61 83 49 0 66 59 73 37 0 0 0 
CD44 p-S707 (z= 3) 1 89 100 93 56 1 52 58 84 33 1 55 76 97 52 0 70 60 59 41 0 0 0 
ITFG3 p-S22 (z= 2) 5 28 27 33 25 5 66 62 100 43 5 10 12 15 9 7 25 24 28 19 1 1 1 
MAF1 p-S76 (z= 2) 5 0 1 2 16 5 28 25 22 9 5 0 2 4 3 18 0 97 100 27 0 1 0 
PPFIBP1 p-T603 (z= 2) 39 16 32 10 32 39 76 67 75 100 39 48 64 57 78 0 38 37 42 52 1 0 0 
MAST3 p-S886 (z= 2) 37 17 25 23 38 37 10 53 63 100 37 12 54 28 70 14 8 10 8 24 1 0 1 
TJP3 p-S606 (z= 2) 8 33 48 31 29 8 90 99 100 67 8 16 19 22 14 4 34 35 36 21 1 1 1 
TJP1 p-S618 (z= 2) 6 22 26 23 16 6 100 92 97 49 6 23 25 27 16 1 16 15 21 8 1 1 1 
KLC1 p-S522 (z= 2) 9 49 65 46 34 9 77 79 100 70 9 30 20 31 18 7 74 59 77 34 0 1 0 
TMC6 p-S94 (z= 2) 43 3 10 3 4 43 33 79 100 60 43 36 11 22 9 43 32 43 56 11 1 1 0 
ARHGAP9 p-T263 (z= 3)  0 7 6 10 6 0 3 9 22 8 0 26 80 100 87 0 2 2 2 3 0 0 1 
SRRM2 p-S2045 p-S2047 
(z= 2) 14 5 17 15 6 14 43 59 100 50 14 24 18 33 19 14 60 61 69 39 1 1 0 
SRSF2 p-S190 p-S192 (z= 
2) 4 30 49 54 19 4 12 15 100 59 4 26 15 17 14 4 42 48 62 39 0 1 0 
SRRM2 p-S2033 p-T2035 
(z= 2) 8 18 76 72 46 8 38 46 64 32 8 14 15 18 14 18 88 84 100 60 0 1 0 
SGTA p-S306 (z= 2) 0 21 18 17 6 0 6 6 29 19 0 100 49 52 31 0 22 20 21 14 0 0 1 
THRAP3 p-T565 (z= 2) 7 100 77 89 63 7 69 27 60 32 7 26 18 17 10 6 67 64 86 52 0 1 0 
PHF20L1 p-S606 (z= 2) 4 51 29 74 49 4 65 60 37 27 4 48 100 43 55 0 17 38 21 16 0 0 1 
RAB11FIP1 p-S436 (z= 2) 1 1 1 1 1 1 3 2 4 3 1 4 3 4 4 1 100 75 88 55 0 1 0 
KCNT1 p-S94 (z= 2) 0 0 0 0 0 0 100 94 62 93 0 0 0 0 0 0 3 3 3 2 1 1 1 
UBR5 p-S295 (z= 2) 15 7 3 5 2 15 100 67 18 14 15 6 4 4 3 3 3 5 3 1 1 1 1 
LSM14A p-S184 (z= 2) 17 37 73 35 43 17 47 38 41 31 17 8 4 6 3 77 100 69 87 40 0 1 0 
FAM83H p-S926 (z= 2) 15 14 20 15 9 15 56 60 100 52 15 14 13 15 12 15 25 25 27 17 1 1 1 
SLC9A7 p-S694 (z= 2) 1 0 1 0 1 1 6 7 10 9 1 72 100 100 41 1 2 0 0 0 0 0 1 
KIAA1614 p-S1000 p-
S1003 (z= 2) 9 3 7 17 1 9 31 6 12 28 9 79 18 100 27 3 2 4 4 2 0 0 1 
G3BP1 p-S233 (z= 2) 16 21 21 9 11 16 70 52 100 56 16 7 10 9 7 16 42 44 44 24 1 1 0 
G3BP1 p-S232 (z= 3) 5 31 21 12 11 5 75 69 100 54 5 9 15 14 10 5 36 34 31 21 1 1 1 
PHACTR4 p-S118 (z= 2) 21 12 13 8 5 21 100 76 74 42 21 10 8 11 6 21 32 20 26 11 1 1 1 
BDP1 p-S93 (z= 2) 4 51 29 74 49 4 65 60 37 27 4 48 100 43 55 0 17 38 21 16 0 0 1 
C2orf49 p-S92 (z= 2) 3 29 23 29 56 3 18 23 33 38 3 43 70 66 100 1 10 12 12 52 0 0 0 
COG2 p-S106 (z= 2) 3 29 23 29 56 3 18 23 33 38 3 43 70 66 100 1 10 12 12 52 0 0 0 
AIM1 p-T21 (z= 2) 18 18 25 15 14 18 59 64 68 60 18 90 74 100 74 18 15 12 14 9 1 0 1 
PGM3 p-S65 (z= 3) 0 0 2 1 1 0 3 4 4 3 0 100 25 69 98 0 3 2 3 1 0 0 1 
LSR p-S494 (z= 2) 17 11 13 8 8 17 64 79 100 65 17 17 14 17 9 17 23 22 23 14 1 1 1 
ARFGEF1 p-S1570 (z= 2) 10 26 38 31 34 10 88 85 100 68 10 17 24 28 19 3 25 18 25 14 1 1 1 
PTMS p-S6 (z= 2) 21 25 24 35 23 21 100 76 88 47 21 25 24 29 19 12 34 25 28 19 1 1 1 
PI4KB p-S429 (z= 2) 2 67 89 56 47 2 56 52 92 65 2 57 54 55 43 1 99 91 100 67 0 0 0 
PI4KB p-S429 (z= 3) 0 0 0 0 0 0 2 2 3 2 0 0 0 1 0 0 100 93 97 74 0 1 0 
ADCY5 p-S156 (z= 2) 0 3 3 2 2 0 85 100 96 51 0 16 10 15 6 0 5 3 4 3 1 1 1 
YBX1 p-S103 (z= 2) 10 0 0 1 1 10 5 16 7 42 10 57 58 47 100 10 18 5 8 5 0 0 1 
LMNA p-S637 (z= 2) 28 39 61 23 33 28 68 87 100 94 28 17 13 14 18 46 57 50 52 36 0 1 0 
NASP p-S245 (z= 2) 22 36 46 61 44 22 88 61 100 29 22 27 30 31 22 27 72 74 71 45 0 1 0 
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SRSF6 p-S315 p-S317 (z= 
2) 2 12 15 15 5 2 19 23 100 83 2 25 12 16 13 2 9 10 14 9 0 0 1 
KRT8 p-S25 (z= 2) 100 17 29 13 23 100 31 28 48 74 100 32 36 17 33 25 17 28 18 25 0 0 0 
PA2G4 p-T387 (z= 2) 0 0 0 0 0 0 1 1 0 1 0 0 1 1 0 0 97 90 68 100 0 1 0 
CSMD1 p-T412 p-S415 (z= 
2) 1 63 38 39 84 1 19 22 24 25 1 31 100 56 88 0 13 12 10 43 0 0 1 
MCM2 p-S42 (z= 2) 16 18 25 12 10 16 100 67 70 48 16 17 9 14 6 11 23 19 22 5 1 1 1 
SMC4 p-S42 (z= 2) 13 14 20 4 11 13 100 68 98 56 13 16 4 10 3 14 48 34 34 20 1 1 1 
CARHSP1 p-S53 (z= 2) 27 7 12 5 4 27 100 59 70 40 27 18 3 10 5 27 41 31 35 7 1 1 0 
DHTKD1 p-S559 (z= 3) 0 7 6 10 6 0 3 9 22 8 0 26 80 100 87 0 2 2 2 3 0 0 1 
TUBA1A p-T52 (z= 2) 1 9 36 21 72 1 25 48 44 100 1 6 18 8 24 2 37 59 36 87 0 1 0 
KCNH1 p-S870 (z= 2) 0 1 1 1 0 0 1 1 100 57 0 44 36 38 26 0 20 24 28 24 0 0 0 
MTOR p-S1167 (z= 2) 76 16 14 14 28 76 22 23 13 26 76 26 29 23 33 100 12 15 12 26 0 0 0 
GON4L p-S2195 (z= 2) 0 32 28 29 22 0 84 88 100 74 0 0 0 0 0 0 21 24 23 17 1 1 1 
CTNNA1 p-S642 (z= 2) 33 1 11 0 3 33 85 66 100 67 33 19 0 5 0 33 66 43 54 31 1 1 0 
EEF1G p-T47 (z= 2) 1 62 100 73 74 1 5 6 7 4 1 2 3 3 2 9 55 52 62 41 0 1 0 
NCF2 p-T234 (z= 2) 1 62 100 73 74 1 5 6 7 4 1 2 3 3 2 9 55 52 62 41 0 1 0 
SYAP1 p-T249 (z= 2) 8 22 22 23 16 8 69 64 100 42 8 14 17 21 13 4 18 16 17 9 1 1 1 
FAM21A p-S334 (z= 2) 7 22 24 21 21 7 74 81 100 56 7 20 15 18 11 6 37 30 35 25 1 1 1 
RALBP1 p-S30 (z= 2) 17 42 40 43 34 17 83 72 100 55 17 24 26 34 19 14 43 42 43 26 0 1 0 
CTTN p-T400 p-S406 (z= 
2) 55 40 59 61 42 55 46 51 76 59 55 83 83 100 84 55 46 39 57 36 0 0 0 
CTTN p-T402 (z= 2) 19 14 16 12 10 19 67 71 100 65 19 10 10 10 9 19 19 18 23 17 1 1 1 
BRCA2 p-S1633 (z= 2) 1 19 11 21 15 1 12 12 13 5 1 50 100 90 67 0 4 5 6 4 0 0 1 
CTNNB1 p-S553 (z= 2)  14 46 58 46 48 14 83 80 100 54 14 5 5 5 3 88 51 42 49 29 0 1 0 
CTNNB1 p-S553 (z= 2) 4 84 100 66 64 4 41 39 52 32 4 24 20 23 18 2 60 80 78 48 0 1 0 
CTNNB1 p-S553 (z= 3) 0 73 100 37 39 0 0 0 0 0 0 63 68 55 51 0 64 60 38 42 0 0 0 
CIKS p-S404 (z= 2) 76 16 14 14 28 76 22 23 13 26 76 26 29 23 33 100 12 15 12 26 0 0 0 
SRSF2 p-S27 (z= 2) 2 9 10 9 6 2 100 55 92 57 2 21 15 17 8 2 22 21 21 12 1 1 1 
SRRM2 p-S2399 (z= 2) 37 82 95 52 53 37 100 80 99 67 37 27 18 24 14 56 82 76 88 52 0 1 0 
GOLGA4 p-S41 (z= 2) 46 13 48 17 30 46 82 100 56 83 46 21 7 7 9 81 45 49 64 40 1 1 0 
SNCA p-S88 p-T93 (z= 3) 0 9 10 7 6 0 19 19 25 12 0 75 52 100 57 0 8 7 9 6 0 0 1 
RAD50 p-T825 (z= 2) 32 53 68 32 37 32 100 82 100 51 32 26 20 22 13 40 95 65 75 28 0 1 0 
PNMA3 p-T117 (z= 2) 1 16 16 11 9 1 22 25 32 19 1 100 69 97 53 0 15 12 13 8 0 0 1 
NASP p-S452 (z= 2) 0 2 2 3 1 0 24 16 100 91 0 63 26 30 21 0 0 0 0 0 1 0 1 
RERE p-S657 (z= 2) 1 21 18 18 14 1 100 76 64 36 1 73 55 53 26 0 22 23 22 12 1 0 1 
SLK p-S572 (z= 2) 0 23 51 93 52 0 1 1 1 1 0 1 1 1 1 0 92 92 100 69 0 1 0 
GFPT1 p-S262 (z= 2) 16 44 52 35 36 16 79 78 100 51 16 29 24 29 17 18 51 51 53 34 0 1 0 
GAB1 p-Y660 (z= 2) 1 0 0 0 0 1 6 6 7 4 1 100 71 96 53 1 0 33 38 19 0 0 1 
CHTF18 p-S872 (z= 3) 2 10 49 3 12 2 8 8 11 12 2 3 0 0 1 12 78 38 53 100 0 1 0 
ERC1 p-S16 (z= 2) 2 35 28 32 22 2 73 81 100 53 2 18 20 22 14 1 26 25 26 17 1 1 1 
MICALL1 p-S579 (z= 2) 12 9 15 6 5 12 95 77 71 59 12 10 4 5 6 12 100 79 97 26 1 1 0 
PPAN p-S360 (z= 2) 15 38 29 33 20 15 90 86 100 54 15 29 32 48 26 11 36 34 38 22 1 1 1 
CTNND1 p-S269 (z= 2) 100 4 9 4 17 100 22 35 15 54 100 4 9 4 12 34 3 6 3 14 1 1 1 
WDR44 p-S51 (z= 2) 21 16 14 14 10 21 100 92 93 51 21 18 18 21 13 21 34 27 31 14 1 1 1 
MAP4 p-S1074 (z= 2) 2 8 18 9 15 2 32 51 36 100 2 4 5 3 10 2 9 12 8 23 1 1 1 
MAP4 p-S1074 (z= 3) 0 3 6 3 4 0 36 66 40 100 0 2 3 2 6 0 19 30 18 56 1 1 0 
AAK1 p-T621 p-S625 (z= 
2) 33 15 6 18 9 33 49 50 100 65 33 11 7 15 10 33 5 31 26 14 1 1 0 
KRT8 p-S44 (z= 2) 45 6 15 4 21 45 33 54 17 100 45 5 8 3 15 18 7 15 6 15 1 1 1 
HTATSF1 p-S617 (z= 2) 2 6 5 6 4 2 99 86 100 56 2 3 2 3 1 2 4 4 4 2 1 1 1 
RPTOR p-S864 (z= 2) 11 100 83 89 57 11 67 62 70 49 11 13 13 14 11 31 82 76 82 44 0 1 0 
CCDC124 p-S142 (z= 2) 1 4 12 3 13 1 33 66 23 100 1 1 3 1 6 1 12 24 10 23 1 1 1 
LIG1 p-S67 (z= 2) 32 12 39 1 10 32 100 92 75 54 32 26 0 6 1 32 72 56 58 26 1 1 0 
CLASP2 p-S597 (z= 2) 16 61 94 57 36 16 70 51 97 100 16 11 13 7 14 22 93 83 76 67 0 1 0 
CLASP1 p-S798 (z= 2) 10 5 23 3 9 10 34 42 87 100 10 2 1 0 1 10 20 23 14 26 0 1 0 
AARS p-S834 (z= 2) + 
oxidation 0 4 2 4 1 0 1 5 15 3 0 12 100 84 47 0 0 0 0 0 0 0 1 
MARCKS p-S47 (z= 2) 8 19 17 20 10 8 98 90 100 66 8 13 9 11 7 8 15 17 22 11 1 1 1 
RRM2 p-S21 (z= 2) 33 3 34 1 4 33 100 78 63 65 33 11 0 0 2 33 51 15 27 33 1 1 0 
SRRM2 p-S2582 (z= 2) 1 12 11 11 7 1 95 82 100 66 1 9 13 12 8 1 23 29 28 22 1 1 1 
GOLGA4 p-S72 (z= 2) 29 12 10 8 8 29 87 91 100 90 29 10 11 10 7 29 17 16 14 11 1 1 1 
FAM83H p-S648 (z= 2) 5 11 12 12 11 5 67 77 80 100 5 7 7 5 11 5 12 12 14 15 1 1 1 
NACA p-S167 (z= 3) 21 10 21 12 12 21 87 62 100 78 21 33 11 18 12 21 64 42 57 46 1 1 0 
USP24 p-S2048 (z= 2) 30 15 19 8 10 30 100 70 61 56 30 10 3 7 3 30 19 19 21 5 1 1 1 
ASCC3 p-S2196 (z= 2) 0 10 19 4 22 0 90 96 75 100 0 11 14 10 13 0 27 31 26 16 1 1 1 
IFI16 p-S154 (z= 2) 18 85 88 60 68 18 53 49 66 68 18 75 68 45 78 7 76 100 80 56 0 0 0 
AKAP3 p-S206 (z= 2) 71 2 6 0 0 71 100 40 26 25 71 14 0 3 0 71 61 38 46 0 1 1 0 
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PRKACA p-S340 (z= 2) 0 43 41 62 39 0 58 69 100 41 0 14 20 19 14 2 15 23 25 18 0 1 1 
TLE3 p-S264 p-S268 (z= 2) 11 21 28 31 19 11 54 72 100 69 11 24 25 27 19 10 40 37 44 26 1 1 0 
JUP p-S666 (z= 2) 3 12 11 7 5 3 100 83 75 65 3 9 7 8 4 3 22 23 26 9 1 1 1 
PCM1 p-S66 (z= 2) 39 30 30 17 11 39 100 93 92 60 39 48 25 38 24 39 78 78 97 20 1 1 0 
NUCKS1 p-S20 (z= 2) 42 3 30 3 13 42 77 89 100 82 42 28 2 9 2 42 57 43 49 26 1 1 1 
RIOK1 p-S23 (z= 2) 23 22 55 1 28 23 100 100 80 72 23 18 6 8 7 47 94 72 97 48 0 1 0 
NCL p-S68 (z= 2) 88 30 37 33 6 88 9 4 100 86 88 57 17 25 11 26 7 9 9 3 0 1 1 
PTPN11 p-Y585 (z= 2) 0 0 0 2 26 0 1 1 1 2 0 33 24 29 50 0 77 71 72 100 0 0 0 
PAK2 p-S142 (z= 2) 41 26 36 20 14 41 100 78 76 48 41 24 9 15 6 42 33 28 34 11 1 1 1 
AMN1 p-T28 (z= 2) 4 20 15 26 16 4 100 86 63 33 4 15 14 12 8 3 18 11 14 7 1 1 1 
ZRANB2 p-S189 (z= 2) 34 47 52 59 34 34 66 90 100 53 34 25 19 28 17 51 71 62 62 29 0 1 0 
SRRM1 p-S598 (z= 2) 10 26 20 19 14 10 77 100 94 65 10 14 15 17 12 4 12 16 16 9 1 1 1 
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Appendix 7 
Investigation into the association between calpain and class IA PI3K in human DLD1 
colorectal cancer cells. 
 
 
 
 
Figure A9.2. Active calpain heterodimers associate dynamically with Class IA PI3K in human DLD-1 
colorectal cancer cells. The association between calpain and class IA PI3K was investigated in human 
DLD-1 colorectal cancer cells that expressed wild-type p110α (CA) or p110α with an activating 
mutation in exon 9 (EX1-7). PI3K p85 protein complexes (n = 2) were isolated by 
immunoprecipitation from both cell types after serum-starvation for 18 h (0.5% FBS) followed by 
stimulation with 100 ng/ml insulin for 10 min or treatment with PBS vehicle control for 10 min. The 
purified PI3K p85 protein complexes were then subjected to an in vitro protease assay for calpain 
activity. Data expressed as mean+/- SEM (n=2). 
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